Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abducens Nerve Diseases
Isolated diplopia associated with calcineurin inhibitor therapy in a patient with idiopathic membranous nephropathy: a case report.
Acanthoma
Anogenital epidermolytic acanthomas: effective treatment of pruritus with 0.1% tacrolimus ointment.
Acidosis
A kinase-anchoring protein 150 and calcineurin are involved in regulation of acid-sensing ion channels ASIC1a and ASIC2a.
Acidosis
Acid-sensing ion channel 1a mediates acid-induced pyroptosis through calpain-2/calcineurin pathway in rat articular chondrocytes.
Acidosis
Changes in magnesium and potassium homeostasis after conversion from a calcineurin inhibitor regimen to an mTOR inhibitor-based regimen.
Acidosis
Clinical analysis of hyperkalemic renal tubular acidosis caused by calcineurin inhibitors in solid organ transplant recipients.
Acidosis
Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts.
Acidosis
Direct evidence for calcineurin binding to the exon-7 loop of the sodium-bicarbonate cotransporter NBCn1.
Acidosis
Extracellular presence of IL-8 in the astrocyte-rich cultured cerebellar granule cells under acidosis.
Acidosis
Fludrocortisone-a treatment for tubulopathy post-paediatric renal transplantation: A national paediatric nephrology unit experience.
Acidosis
Maximizing growth in children after renal transplantation.
Acidosis
Post-Renal Transplant Metabolic Acidosis: A Neglected Entity.
Acidosis
Posttransplant acidosis and associated disorders of mineral metabolism in patients with a renal graft.
Acidosis
Specific disruption of calcineurin-signaling in the distal convoluted tubule impacts the transcriptome and proteome, and causes hypomagnesemia and metabolic acidosis.
Acidosis
The Calcineurin inhibitor FK506 (Tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport.
Acidosis, Renal Tubular
Clinical analysis of hyperkalemic renal tubular acidosis caused by calcineurin inhibitors in solid organ transplant recipients.
Acidosis, Renal Tubular
Direct evidence for calcineurin binding to the exon-7 loop of the sodium-bicarbonate cotransporter NBCn1.
Acidosis, Renal Tubular
Post-Renal Transplant Metabolic Acidosis: A Neglected Entity.
Acne Vulgaris
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Acquired Hyperostosis Syndrome
Exosomal proteome from the serum, bone marrow, and palm and toe pustular skin tissues of a single patient with SAPHO syndrome.
Acute Coronary Syndrome
Deconvoluting the Dual Antiplatelet Activity of a Plant Extract.
Acute Coronary Syndrome
Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory.
Acute Kidney Injury
Acute Kidney Injury as a Complication of Cardiac Transplantation: Incidence, Risk Factors, and Impact on 1-year Mortality and Renal Function.
Acute Kidney Injury
Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy.
Acute Kidney Injury
Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection.
Acute Kidney Injury
Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
Acute Kidney Injury
Complications of Solid Organ Transplantation: Cardiovascular, Neurologic, Renal, and Gastrointestinal.
Acute Kidney Injury
Development of Focal Segmental Glomerulosclerosis and Thrombotic Microangiopathy in a Liver Transplant Patient on Sorafenib for Hepatocellular Carcinoma: A Case Report.
Acute Kidney Injury
End-stage renal disease after high-dose carboplatinum in preparation of autologous stem cell transplantation.
Acute Kidney Injury
Growth failure associated with sirolimus: case report.
Acute Kidney Injury
Identification of patients best suited for combined liver-kidney transplantation: part II.
Acute Kidney Injury
Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.
Acute Kidney Injury
Long-term results of liver transplantation.
Acute Kidney Injury
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
Acute Kidney Injury
Mini-review of kidney disease following hematopoietic stem cell transplant?.
Acute Kidney Injury
MiRNAs in kidney transplantation: potential role as new biomarkers.
Acute Kidney Injury
Outcomes after liver transplantation: Chronic kidney disease.
Acute Kidney Injury
Post transplant thrombotic microangiopathy causing acute renal failure.
Acute Kidney Injury
Posttransplantation chronic renal damage in nonrenal transplant recipients.
Acute Kidney Injury
Prolonged basiliximab use as an alternative to calcineurin inhibition to allow renal recovery late after heart transplantation.
Acute Kidney Injury
Recent advances in new-onset diabetes mellitus after kidney transplantation.
Acute Kidney Injury
Renal Biopsy in Children-Effect on Treatment Decisions: A Single-Center Experience.
Acute Kidney Injury
Renal-sparing immunosuppressive protocol using OKT3 after liver transplantation: a 19-year single-institution experience.
Acute Kidney Injury
Rho GTPases in kidney physiology and diseases.
Acute Kidney Injury
Tacrolimus Aggravated Tube Feeding Syndrome with Acute Renal Failure in a Pediatric Liver Transplant Recipient.
Acute Kidney Injury
Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?
Acute Lung Injury
miR-21-5p Suppresses Mitophagy to Alleviate Hyperoxia-Induced Acute Lung Injury by Directly Targeting PGAM5.
Adenocarcinoma
Abrogation of DUSP6 by hypermethylation in human pancreatic cancer.
Adenocarcinoma
Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.
Adenocarcinoma
BH-protocadherin-c, a member of the cadherin superfamily, interacts with protein phosphatase 1 alpha through its intracellular domain.
Adenocarcinoma
Chemokine (C-C) motif ligand 20 is regulated by PGF(2?)-F-prostanoid receptor signalling in endometrial adenocarcinoma and promotes cell proliferation.
Adenocarcinoma
Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma.
Adenocarcinoma
Dual specificity phosphatase 1 expression inversely correlates with NF-?B activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
Adenocarcinoma
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
Adenocarcinoma
Dual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17?-estrodial-induced cell growth in endometrial adenocarcinoma cell.
Adenocarcinoma
Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway.
Adenocarcinoma
Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.
Adenocarcinoma
Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
Adenocarcinoma
High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.
Adenocarcinoma
Immunohistochemical expression of dual-specificity protein phosphatase 4 in patients with colorectal adenocarcinoma.
Adenocarcinoma
Increased expression of calcineurin in human colorectal adenocarcinomas.
Adenocarcinoma
Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1.
Adenocarcinoma
Key genes in lung cancer translational research: a meta-analysis.
Adenocarcinoma
Molecular mechanisms of pancreatic carcinogenesis.
Adenocarcinoma
Overexpression of Protein Phosphatase 4 Correlates with Poor Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma.
Adenocarcinoma
Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells.
Adenocarcinoma
Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299.
Adenocarcinoma of Lung
APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP.
Adenocarcinoma of Lung
Combination treatment with triptolide and hydroxycamptothecin synergistically enhances apoptosis in A549 lung adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt signaling pathways.
Adenocarcinoma of Lung
Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma.
Adenocarcinoma of Lung
Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.
Adenocarcinoma of Lung
High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma.
Adenocarcinoma of Lung
miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma.
Adenocarcinoma of Lung
Overexpression of immunoglobulin (CD79a) binding protein1 (IGBP-1) in small lung adenocarcinomas and its clinicopathological significance.
Adenocarcinoma of Lung
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.
Adenocarcinoma of Lung
Survivin mediates self-protection through ROS/cdc25c/CDK1 signaling pathway during tumor cell apoptosis induced by high fluence low-power laser irradiation.
Adenocarcinoma, Clear Cell
Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.
Adenomatous Polyposis Coli
Adenomatous polyposis coli heterozygous knockout mice display hypoactivity and age-dependent working memory deficits.
Adenomatous Polyps
Premature chromosome condensation revisited: a novel chemical approach permits efficient cytogenetic analysis of cancers.
Adenomyosis
Loss of Expressions of Dusp6, Sprouty4, and Sef, Negative Regulators of FGF2/ERK1/2 Signaling, in the Endometrium of Women With Adenomyosis.
African Swine Fever
African swine fever virus A238L inhibitor of NF-kappaB and of calcineurin phosphatase is imported actively into the nucleus and exported by a CRM1-mediated pathway.
African Swine Fever
African swine fever virus protein A238L interacts with the cellular phosphatase calcineurin via a binding domain similar to that of NFAT.
African Swine Fever
Domains involved in calcineurin phosphatase inhibition and nuclear localisation in the African swine fever virus A238L protein.
Agammaglobulinemia
Evolution of immunoglobulin and mannose binding protein levels after renal transplantation: association with infectious complications.
Albuminuria
Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
Albuminuria
Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study.
Albuminuria
Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.
aldehyde dehydrogenase (nad+) deficiency
Aldehyde dehydrogenase 2 knockout accentuates ethanol-induced cardiac depression: Role of protein phosphatases.
Alopecia
Frontal fibrosing alopecia demographics: a survey of 29 patients.
Alopecia
Immunosuppressive treatment for proliferative lupus nephritis.
Alopecia
Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials.
Alopecia
Integration of Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control.
alpha-Thalassemia
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Alzheimer Disease
A pool of beta-tubulin is hyperphosphorylated at serine residues in Alzheimer disease brain.
Alzheimer Disease
A role for calcineurin in Alzheimer's disease.
Alzheimer Disease
A zebrafish model for calcineurin-dependent brain function.
Alzheimer Disease
Activation of glycogen synthase kinase-3 inhibits protein phosphatase-2A and the underlying mechanisms.
Alzheimer Disease
Activation of Protein Phosphatase 2B and Hyperphosphorylation of Tau in Alzheimer's Disease.
Alzheimer Disease
Acute decrease in alkaline phosphatase after brain injury: A potential mechanism for tauopathy.
Alzheimer Disease
Altered expression of insulin-degrading enzyme and regulator of calcineurin in the rat intracerebral streptozotocin model and human apolipoprotein E-?4-associated Alzheimer's disease.
Alzheimer Disease
Alzheimer's Disease, Dendritic Spines, and Calcineurin Inhibitors: A New Approach?
Alzheimer Disease
Calcineurin (phosphatase 2B) is present in neurons containing neurofibrillary tangles and in a subset of senile plaques in Alzheimer's disease.
Alzheimer Disease
Calcineurin immunoreactivity in Alzheimer's disease.
Alzheimer Disease
Calcineurin inhibition rescues early synaptic plasticity deficits in a mouse model of Alzheimer's disease.
Alzheimer Disease
Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models.
Alzheimer Disease
Calcineurin: directing the damage in Alzheimer disease: An Editorial for 'Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain' on doi: 10.1111/jnc.14469.
Alzheimer Disease
Calpain activation in okadaic-acid-induced neurodegeneration.
Alzheimer Disease
Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder.
Alzheimer Disease
Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer's disease.
Alzheimer Disease
Cognitive Decline in Alzheimer's Disease Is Associated with Selective Changes in Calcineurin/NFAT Signaling.
Alzheimer Disease
Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme.
Alzheimer Disease
Cytoskeletal changes in the brains of mice lacking calcineurin A alpha.
Alzheimer Disease
Degradation of regulator of calcineurin 1 (RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways.
Alzheimer Disease
Dehydroevodiamine attenuates calyculin A-induced tau hyperphosphorylation in rat brain slices.
Alzheimer Disease
Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A.
Alzheimer Disease
Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease.
Alzheimer Disease
Deprotonation states of the two active site water molecules regulate the binding of protein phosphatase 5 with its substrate: A molecular dynamics study.
Alzheimer Disease
Differential activation of caspase-3 at two maturational stages during okadaic acid-induced rat neuronal death.
Alzheimer Disease
Dimethyl Fumarate Exerts Neuroprotection by Modulating Calcineurin/NFAT1 and NF?B Dependent BACE1 Activity in a Neuronal Model of Alzheimer's Disease.
Alzheimer Disease
DSCR1(Adapt78)--a Janus gene providing stress protection but causing Alzheimer's disease?
Alzheimer Disease
Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat.
Alzheimer Disease
Elevated protein levels of protein phosphatases PP-2A and PP-2B in astrocytes of Alzheimer's disease temporal cortex.
Alzheimer Disease
Enhanced expression of protein phosphatase 2A associated with hyper-phosphorylation of histone H1 in Alzheimer's disease brain.
Alzheimer Disease
Evidence for colocalization of calcineurin and calcium channels in dorsal root ganglion neurons.
Alzheimer Disease
Expression of calcipressin1, an inhibitor of the phosphatase calcineurin, is altered with aging and Alzheimer's disease.
Alzheimer Disease
Expression of protein phosphatases (PP-1, PP-2A, PP-2B and PTP-1B) and protein kinases (MAP kinase and P34cdc2) in the hippocampus of patients with Alzheimer disease and normal aged individuals.
Alzheimer Disease
Fecal corticosterone levels in RCAN1 mutant mice.
Alzheimer Disease
Fine mapping of calcineurin (PPP3CA) gene reveals novel alternative splicing patterns, association of 5'UTR trinucleotide repeat with addiction vulnerability, and differential isoform expression in Alzheimer's disease.
Alzheimer Disease
Genetic variation in the tau protein phosphatase-2A pathway is not associated with Alzheimer's disease risk.
Alzheimer Disease
Glycogen synthase kinase-3? regulates leucine-309 demethylation of protein phosphatase-2A via PPMT1 and PME-1.
Alzheimer Disease
Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.
Alzheimer Disease
Impairment of phosphatase 2A contributes to the prolonged MAP kinase phosphorylation in Alzheimer's disease fibroblasts.
Alzheimer Disease
Increased production of paired helical filament epitopes in a cell culture system reduces the turnover of tau.
Alzheimer Disease
Inhibition of calcineurin by infusion of CsA causes hyperphosphorylation of tau and is accompanied by abnormal behavior in mice.
Alzheimer Disease
Inhibition of protein phosphatase 2A induces phosphorylation and accumulation of neurofilaments in metabolically active rat brain slices.
Alzheimer Disease
Inhibition of Protein Phosphatase-2A (PP2A) by I1PP2A Leads to Hyperphosphorylation of Tau, Neurodegeneration, and Cognitive Impairment in Rats.
Alzheimer Disease
Inhibition of protein phosphatases induces transport deficits and axonopathy.
Alzheimer Disease
Inhibition of the NFAT pathway alleviates amyloid Beta neurotoxicity in a mouse model of Alzheimer's disease.
Alzheimer Disease
Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine.
Alzheimer Disease
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Alzheimer Disease
Knockdown of microRNA-195 contributes to protein phosphatase-2A inactivation in rats with chronic brain hypoperfusion.
Alzheimer Disease
Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I(2)(PP2A)/SET.
Alzheimer Disease
Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment.
Alzheimer Disease
Memantine mediates astrocytic activity in response to excitotoxicity induced by PP2A inhibition.
Alzheimer Disease
Mitophagy in degenerative joint diseases.
Alzheimer Disease
Neuroimmunomodulation by calcineurin in aging and Alzheimer's disease.
Alzheimer Disease
Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain.
Alzheimer Disease
Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity.
Alzheimer Disease
Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease.
Alzheimer Disease
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Alzheimer Disease
p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease [corrected]
Alzheimer Disease
Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain.
Alzheimer Disease
Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease.
Alzheimer Disease
Phosphoprotein phosphatase activities in Alzheimer disease brain.
Alzheimer Disease
Protein kinase A phosphorylates Down syndrome critical region 1 (RCAN1).
Alzheimer Disease
Proteolysis of calcineurin is increased in human hippocampus during mild cognitive impairment and is stimulated by oligomeric Abeta.
Alzheimer Disease
PTPA activates protein phosphatase-2A through reducing its phosphorylation at tyrosine-307 with upregulation of protein tyrosine phosphatase 1B.
Alzheimer Disease
Q134R: Small chemical compound with NFAT inhibitory properties improves behavioral performance and synapse function in mouse models of amyloid pathology.
Alzheimer Disease
RCAN1 (DSCR1) increases neuronal susceptibility to oxidative stress: a potential pathogenic process in neurodegeneration.
Alzheimer Disease
Reduced Incidence of Dementia in Solid Organ Transplant Patients Treated with Calcineurin Inhibitors.
Alzheimer Disease
Reduction of calcineurin enzymatic activity in Alzheimer's disease: correlation with neuropathologic changes.
Alzheimer Disease
Reduction of mint-1, mint-2, and APP overexpression in okadaic acid-treated neurons.
Alzheimer Disease
Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.
Alzheimer Disease
Regulation of RCAN1 translation and its role in oxidative stress-induced apoptosis.
Alzheimer Disease
Regulator of Calcineurin (RCAN-1) Regulates Thermotaxis Behavior in Caenorhabditis elegans.
Alzheimer Disease
Regulator of calcineurin 1 is a novel RNA-binding protein to regulate neuronal apoptosis.
Alzheimer Disease
Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain.
Alzheimer Disease
Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex.
Alzheimer Disease
Ser9 phosphorylation causes cytoplasmic detention of I(2)(PP2A)/SET in Alzheimer disease.
Alzheimer Disease
Silencing PP2A Inhibitor by Lenti-shRNA Interference Ameliorates Neuropathologies and Memory Deficits in tg2576 Mice.
Alzheimer Disease
Silencing [Formula: see text] Rescues Tau Pathologies and Memory Deficits through Rescuing PP2A and Inhibiting GSK-3? Signaling in Human Tau Transgenic Mice.
Alzheimer Disease
Site-specific regulation of Alzheimer-like tau phosphorylation in living neurons.
Alzheimer Disease
Substituent effect of N-benzylated gramine derivatives that prevent the PP2A inhibition and dissipate the neuronal Ca2+ overload, as a multitarget strategy for the treatment of Alzheimer's disease.
Alzheimer Disease
Tacrolimus Protects against Age-Associated Microstructural Changes in the Beagle Brain.
Alzheimer Disease
The calcineurin inhibitor Sarah (Nebula) exacerbates A?42 phenotypes in a Drosophila model of Alzheimer's disease.
Alzheimer Disease
The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment.
Alzheimer Disease
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Alzheimer Disease
The Neuroprotective Effects of Ginsenosides on Calcineurin Activity and Tau Phosphorylation in SY5Y Cells.
Alzheimer Disease
The new indirubin derivative inhibitors of glycogen synthase kinase-3, 6-BIDECO and 6-BIMYEO, prevent tau phosphorylation and apoptosis induced by the inhibition of protein phosphatase-2A by okadaic acid in cultured neurons.
Alzheimer Disease
The polarity of the amino acid residue 118 of calcineurin B is closely linked to calcineurin enzyme activity.
Alzheimer Disease
The regulator of calcineurin 1 increases adenine nucleotide translocator 1 and leads to mitochondrial dysfunctions.
Alzheimer Disease
Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain.
Alzheimer Disease
Two polymorphisms of RCAN1 gene associated with Alzheimer's disease in the Chinese Han population.
Alzheimer Disease
Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA microarray.
Alzheimer Disease
Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease.
Alzheimer Disease
Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: The Cache County Dementia Progression Study.
Alzheimer Disease
Zinc induces protein phosphatase 2A inactivation and tau hyperphosphorylation through Src dependent PP2A (tyrosine 307) phosphorylation.
Alzheimer Disease
[Expression of protein phosphatase 2AC in the brain of mice and Alzheimer's patients].
Amnesia
Differential expression of molecular markers of synaptic plasticity in the hippocampus, prefrontal cortex, and amygdala in response to spatial learning, predator exposure, and stress-induced amnesia.
Amyloidosis
Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients.
Amyotrophic Lateral Sclerosis
Calcineurin A and calbindin immunoreactivity in the spinal cord of G93A superoxide dismutase transgenic mice.
Amyotrophic Lateral Sclerosis
Impaired Cu-Zn Superoxide Dismutase (SOD1) and Calcineurin (Cn) Interaction in ALS: A Presumed Consequence for TDP-43 and Zinc Aggregation in Tg SOD1
Amyotrophic Lateral Sclerosis
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Amyotrophic Lateral Sclerosis
Overexpressed mutant G93A superoxide dismutase protects calcineurin from inactivation.
Amyotrophic Lateral Sclerosis
Oxidative inactivation of calcineurin by Cu,Zn superoxide dismutase G93A, a mutant typical of familial amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord.
Amyotrophic Lateral Sclerosis
Superoxide dismutase mutations of familial amyotrophic lateral sclerosis and the oxidative inactivation of calcineurin.
Amyotrophic Lateral Sclerosis
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Amyotrophic Lateral Sclerosis
Wild-type p53-induced phosphatase 1 down-regulation promotes apoptosis by activating the DNA damage-response pathway in amyotrophic lateral sclerosis.
Anaphylaxis
Endothelial Regulator of Calcineurin 1 Promotes Barrier Integrity and Modulates Histamine-Induced Barrier Dysfunction in Anaphylaxis.
Anaphylaxis
Successful switch to oral tacrolimus in a patient with hypersensitivity reaction to parenteral vitamin K, cyclosporine, and tacrolimus: A case report.
Anemia
Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state.
Anemia
Early non-immunological post transplant complications: a single center experience.
Anemia
Evolution of glomerular filtration rate, renal injury markers, anemia, and Angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Anemia
Impact of donor-related arteriosclerosis in pretransplant biopsy on long-term outcome of living-kidney transplantation: A propensity score-matched cohort study.
Anemia
Increasing incidence of post-kidney transplant anemia in children.
Anemia
Microcytic anemia associated with mTOR or calcineurin inhibition: An unusual situation after allogeneic hematopoietic stem cell transplantation.
Anemia
Modifiable risk factors of acute kidney injury after liver transplantation: a systematic review and meta-analysis.
Anemia
Mutation of chicken anemia virus VP2 differentially affects serine/threonine and tyrosine protein phosphatase activities.
Anemia
Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil.
Anemia
Severe sirolimus-related inflammatory state anemia in an HIV+ liver transplant patient with calcineurin inhibitor renal insufficiency: a case report.
Anemia
Sofosbuvir Monotherapy for Asymptomatic and Noncirrhotic Hepatitis C Infection in a Renal Retransplantation Recipient: A Case Report.
Anemia
Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
Anemia
[Chronic renal failure after heart, lung, liver, or intestine transplantation]
Anemia, Aplastic
Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia.
Anemia, Aplastic
Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis.
Anemia, Aplastic
Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation.
Anemia, Hemolytic, Autoimmune
Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor.
Anemia, Hypochromic
NH4+ Toxicity, Which Is Mainly Determined by the High NH4+/K+ Ratio, Is Alleviated by CIPK23 in Arabidopsis.
Aneurysm
The elevated serum levels of calcineurin and nuclear factor of activated T-cells 1 in children with Kawasaki disease.
Angina, Stable
Circulating levels of soluble EMMPRIN (CD147) correlate with levels of soluble glycoprotein VI in human plasma.
Angina, Stable
Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy?
Angina, Unstable
Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor.
Angioedema
Angiotensin-converting enzyme inhibitor-induced isolated visceral angioedema in a liver transplant recipient.
Ankylosis
The intracellular protein phosphatase magnesium-dependent 1A negatively regulates osteoclast commitment.
Anthrax
Calyculin A sensitive protein phosphatase is required for Bacillus anthracis lethal toxin induced cytotoxicity.
Anthrax
Regulatory interactions of a virulence-associated serine/threonine phosphatase-kinase pair in Bacillus anthracis.
Aortic Coarctation
Ginsenoside Rg(1) inhibits rat left ventricular hypertrophy induced by abdominal aorta coarctation: involvement of calcineurin and mitogen-activated protein kinase signalings.
Aortic Coarctation
Ginsenoside Rg(1) inhibits rat left ventricular hypertrophy induced by abdominal aorta coarctation: Involvement of calcineurin and mitogen-activated protein kinase signalings.
Aortic Valve Stenosis
Calcineurin in human heart hypertrophy.
Aortic Valve Stenosis
Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin.
Aortic Valve Stenosis
Upregulation of myocardial estrogen receptors in human aortic stenosis.
Arrhythmias, Cardiac
Aberrant sialylation causes dilated cardiomyopathy and stress-induced heart failure.
Arrhythmias, Cardiac
Drug-induced alterations in Mg2+ homoeostasis.
Arrhythmias, Cardiac
Heart-specific deletion of CnB1 reveals multiple mechanisms whereby calcineurin regulates cardiac growth and function.
Arteriolosclerosis
A case of de novo focal segmental glomerulosclerosis occurred one and half years after kidney transplantation supposed to be caused by calcineurin inhibitor.
Arteriosclerosis
Differential impact of belatacept and cyclosporine A on central aortic blood pressure and arterial stiffness after renal transplantation.
Arteriosclerosis
Impact of donor-related arteriosclerosis in pretransplant biopsy on long-term outcome of living-kidney transplantation: A propensity score-matched cohort study.
Arteriosclerosis
Influence of preservation method on histopathological lesions of kidney allografts.
Arteritis
Calcineurin inhibitors exacerbate coronary arteritis via the MyD88 signalling pathway in a murine model of Kawasaki disease.
Arteritis
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis.
Arthritis
Acid-sensing ion channel 1a mediates acid-induced pyroptosis through calpain-2/calcineurin pathway in rat articular chondrocytes.
Arthritis
Amelioration of accelerated collagen induced arthritis by a novel calcineurin inhibitor, ISA(TX)247.
Arthritis
Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis.
Arthritis
Calcineurin is expressed and plays a critical role in inflammatory arthritis.
Arthritis
Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-? Transgenic Mice.
Arthritis
Dual Specificity Phosphatase 1 null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis.
Arthritis
Dual-specificity phosphatase 5 attenuates autoimmune arthritis in mice via reciprocal regulation of the Th17/Treg cell balance and inhibition of osteoclastogenesis.
Arthritis
Regulator of Calcineurin 3 Ameliorates Autoimmune Arthritis by Suppressing Th17 Cell Differentiation.
Arthritis
Specific calcineurin targeting in macrophages confers resistance to inflammation via MKP-1 and p38.
Arthritis, Experimental
Calcineurin is expressed and plays a critical role in inflammatory arthritis.
Arthritis, Rheumatoid
Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus.
Arthritis, Rheumatoid
Cabin1 regulates inflammatory responses and fibroblast-like synoviocytes apoptosis in mice with collagen-induced arthritis.
Arthritis, Rheumatoid
Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis.
Arthritis, Rheumatoid
Calcineurin is expressed and plays a critical role in inflammatory arthritis.
Arthritis, Rheumatoid
Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
Dual Specificity Phosphatase 1 null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis.
Arthritis, Rheumatoid
Gender differences in autoimmune diseases: estrogen increases calcineurin expression in systemic lupus erythematosus.
Arthritis, Rheumatoid
Midterm clinico-radiologic findings of an open label observation study of add-on tacrolimus with biologics or non-biologic DMARDs.
Arthritis, Rheumatoid
Overexpression of miR-101 May Target DUSP1 to Promote the Cartilage Degradation in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study.
Arthritis, Rheumatoid
Protein phosphatase magnesium-dependent 1A induces inflammation in rheumatoid arthritis.
Arthritis, Rheumatoid
Tacrolimus treatment increases bone formation in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis.
Arthritis, Rheumatoid
The Role of Calcium-Calcineurin-NFAT Signaling Pathway in Health and Autoimmune Diseases.
Aspergillosis
Calcineurin-dependent dephosphorylation of the transcription factor CrzA at specific sites controls conidiation, stress tolerance, and virulence of Aspergillus fumigatus.
Aspergillosis
Identification and mutational analyses of phosphorylation sites of the calcineurin-binding protein CbpA and the identification of domains required for calcineurin binding in Aspergillus fumigatus.
Aspergillosis
Impaired calcineurin signaling in myeloid cells results in downregulation of pentraxin-3 and increased susceptibility to aspergillosis.
Aspergillosis
Newer combination antifungal therapies for invasive aspergillosis.
Asthma
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects.
Asthma
Allergic disease after pediatric liver transplantation with systemic tacrolimus and cyclosporine a therapy.
Asthma
Defects of protein phosphatase 2A causes corticosteroid insensitivity in severe asthma.
Asthma
Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients.
Asthma
Effects of variations in access to care for children with atopic dermatitis.
Asthma
Epigenome-wide effects of vitamin D on asthma bronchial epithelial cells.
Asthma
Mast cells as targets of pimecrolimus.
Asthma
MiR-1165-3p Suppresses Th2 Differentiation via Targeting IL-13 and PPM1A in a Mouse Model of Allergic Airway Inflammation.
Asthma
Protein phosphatase 5 mediates corticosteroid insensitivity in airway smooth muscle in patients with severe asthma.
Asthma
Regulator of calcineurin 1 (rcan1) is required for the development of pulmonary eosinophilia in allergic inflammation in mice.
Asthma
Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.
Asthma
Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma.
Asthma
The GPx1-PTP1B-PP2A Axis: A Key Determinant of Airway Inflammation and Alveolar Destruction.
Asthma
[Cross-talk between calcineurin and protein kinases in airway remodeling in asthma]
Astrocytoma
Calcineurin regulates nuclear factor I dephosphorylation and activity in malignant glioma cell lines.
Astrocytoma
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.
Astrocytoma
The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease.
Ataxia
An autosomal recessive cerebellar ataxia syndrome with upward gaze palsy, neuropathy, and seizures.
Ataxia
PLS3 Overexpression Delays Ataxia in Chp1 Mutant Mice.
Ataxia
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
Ataxia Telangiectasia
Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.
Ataxia Telangiectasia
Absence of Wip1 partially rescues Atm deficiency phenotypes in mice.
Ataxia Telangiectasia
Activation of NRF2 by dexamethasone in ataxia telangiectasia cells involves KEAP1 inhibition but not the inhibition of p38.
Ataxia Telangiectasia
Involvement of ATM-mediated Chk1/2 and JNK kinase signaling activation in HKH40A-induced cell growth inhibition.
Ataxia Telangiectasia
Mice lacking protein phosphatase 5 are defective in ataxia telangiectasia mutated (ATM)-mediated cell cycle arrest.
Ataxia Telangiectasia
P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
Ataxia Telangiectasia
Phosphoglycerate mutase 1 (PGAM1) overexpression promotes radio- and chemoresistance in gliomas by activating the DNA damage response.
Ataxia Telangiectasia
r-Tocotrienol inhibits cell proliferation of human gastric cancer by regulating nuclear factor-kB activity.
Ataxia Telangiectasia
The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ataxia Telangiectasia
Utilizing protein phosphatase inhibitors to define PP2A as a regulator of ataxia-telangiectasia mutated.
Ataxia Telangiectasia
Wild-type p53-induced phosphatase 1 down-regulation promotes apoptosis by activating the DNA damage-response pathway in amyotrophic lateral sclerosis.
Atherosclerosis
Association of astragaloside IV-inhibited autophagy and mineralization in vascular smooth muscle cells with lncRNA H19 and DUSP5-mediated ERK signaling.
Atherosclerosis
Association of CnB 5I/5D promoter gene polymorphism and serum calcineurin levels in early onset of coronary artery disease of south Indian cohort.
Atherosclerosis
Cyclosporin A decreases apolipoprotein E secretion from human macrophages via a protein phosphatase 2B-dependent and ATP-binding cassette transporter A1 (ABCA1)-independent pathway.
Atherosclerosis
Effect of Immunosuppressive Treatment on Carotid Atherosclerosis in Renal Transplant Recipients.
Atherosclerosis
Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity.
Atherosclerosis
Protein Phosphatase 5 Contributes to the Overexpression of Epigenetically Regulated T-Lymphocyte Genes in Patients with Lupus.
Atherosclerosis
RCAN1 in cardiovascular diseases: molecular mechanisms and a potential therapeutic target.
Atherosclerosis
Regulation of gene expression by cyclic GMP.
Atherosclerosis
The regulator of calcineurin (RCAN1) an important factor involved in atherosclerosis and cardiovascular diseases development.
Atherosclerosis
Unsaturated fatty acids isolated from human lipoproteins activate protein phosphatase type 2Cbeta and induce apoptosis in endothelial cells.
Atherosclerosis
Wild-type p53-induced phosphatase 1 promotes vascular smooth muscle cell proliferation and neointima hyperplasia after vascular injury via p-adenosine 5'-monophosphate-activated protein kinase/mammalian target of rapamycin complex 1 pathway.
Atherosclerosis
WIP-ing out atherosclerosis with autophagy.
Atherosclerosis
[Current trends in renal transplant immunosuppression]
Atrial Fibrillation
Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation.
Atrial Fibrillation
Calcium- and integrin-binding protein-1 and calcineurin are upregulated in the right atrial myocardium of patients with atrial fibrillation.
Atrial Fibrillation
Calpain-Calcineurin-Nuclear Factor Signaling and the Development of Atrial Fibrillation in Patients with Valvular Heart Disease and Diabetes.
Atrial Fibrillation
Mechanisms underlying pathological Ca2+ handling in diseases of the heart.
Atrial Fibrillation
Serine-threonine protein phosphatase regulation of Cx43 dephosphorylation in arrhythmogenic disorders.
Atrial Fibrillation
[Calpain-2 and calcineurin protein expression in right atrial appendages from patients underwent valve replacement with or without atrial fibrillation].
Atrioventricular Block
Heart block in mice overexpressing calcineurin but not NF-AT3.
Atrioventricular Block
Relevance of calmodulin/CaMKII activation for arrhythmogenesis in the AV block dog.
Atypical Hemolytic Uremic Syndrome
Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor-free immunosuppression regimen.
Autoimmune Diseases
A new cell-permeable peptide allows successful allogeneic islet transplantation in mice.
Autoimmune Diseases
A review and update on orphan drugs for the treatment of noninfectious uveitis.
Autoimmune Diseases
Calcineurin inhibitors: status quo and perspectives.
Autoimmune Diseases
CD44-Positive Glomerular Parietal Epithelial Cells in a Mouse Model of Calcineurin Inhibitors-Induced Nephrotoxicity.
Autoimmune Diseases
Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity.
Autoimmune Diseases
Cyclosporine A disposition, hepatic and renal tolerance in Wistar rat.
Autoimmune Diseases
Fibrosis caused by loss of PTEN expression by fibroblasts is crucially dependent on CCN2.
Autoimmune Diseases
Gender differences in autoimmune diseases: estrogen increases calcineurin expression in systemic lupus erythematosus.
Autoimmune Diseases
Improvement of irregularity of brain vessel walls in systemic lupus erythematosus by tacrolimus.
Autoimmune Diseases
MAP4K Family Kinases and DUSP Family Phosphatases in T-Cell Signaling and Systemic Lupus Erythematosus.
Autoimmune Diseases
New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone.
Autoimmune Diseases
Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis.
Autoimmune Diseases
The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension.
Autoimmune Diseases
The novel calcineurin inhibitor CN585 has potent immunosuppressive properties in stimulated human T cells.
Autoimmune Diseases
The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity.
Autoimmune Diseases
The Role of Calcium-Calcineurin-NFAT Signaling Pathway in Health and Autoimmune Diseases.
Autoimmune Diseases
To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription.
Autoimmune Diseases
Transplantation of the islets of Langerhans: new hope for treatment of type 1 diabetes mellitus.
Autoimmune Diseases
Use of three-carbon chain compounds as biosynthesis precursors to enhance tacrolimus production in Streptomyces tsukubaensis.
Autoimmune Diseases
USP16-mediated deubiquitination of calcineurin A controls peripheral T cell maintenance.
Autoimmune Diseases
YB-1 increases glomerular, but decreases interstitial fibrosis in CNI-induced nephropathy.
Autoimmune Diseases
[Novel action of aldosterone in CsA nephrotoxicity]
Autoimmune Diseases
[Optimal immunosuppressive therapy based on pharmacokinetics and pharmacodynamics of antimetabolites in clinical practice].
Azoospermia
DNA damage in round spermatids of mice with a targeted disruption of the Pp1cgamma gene and in testicular biopsies of patients with non-obstructive azoospermia.
Bacterial Infections
Characterization of calcineurin A and B genes in the abalone, Haliotis diversicolor, and their immune response role during bacterial infection.
Bacterial Infections
European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.2.1 Differential diagnosis of chronic graft dysfunction.
Bacterial Infections
Immunosuppression reduction in kidney transplant recipients during bacterial infection-A retrospective study.
Bacterial Infections
In vivo modulation of innate resistance to Edwardsiella ictaluri with a phosphatase inhibitor.
Balanitis
Anti-inflammatory treatment.
Balanitis
Discordant results with pimecrolimus 1% cream in the treatment of plasma cell balanitis.
Balanitis
Successful treatment of plasma cell cheilitis with topical tacrolimus: Report of two cases.
Balanitis
Tacrolimus 0.1% ointment: is it really effective in plasma cell vulvitis? Report of four cases.
Balanitis
Therapeutic efficacy of topical calcineurin inhibitors in plasma cell balanitis: case series and review of the literature.
beta-Thalassemia
Graft Versus Host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft Versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta Thalassemia Major with Busulfan, Fludarabine, and Thiotepa.
beta-Thalassemia
Imaging findings in a child with calcineurin inhibitor-induced pain syndrome after bone marrow transplant for beta thalassemia major.
beta-Thalassemia
The relation between mitogen activated protein kinase (MAPK) pathway and different genes expression in patients with beta Thalassemia.
Blindness
Prevalence and associated phenotypes of DUSP6, IL17RD and SPRY4 variants in a large Chinese cohort with isolated hypogonadotropic hypogonadism.
Blister
Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
Blister
Identification and biochemical characterization of protein phosphatase 5 from the cantharidin-producing blister beetle, Epicauta chinensis.
Blister
Morphological changes and reorganization of actinfilaments in human myeloid leukemia cells induced by a novel protein phosphatase inhibitor, tautomycin.
Bone Diseases
Calcium-Phosphate Crystals Promote RANKL Expression via the Downregulation of DUSP1.
Bone Diseases
CYP3A4 is a crosslink between vitamin D and calcineurin inhibitors in solid organ transplant recipients: implications for bone health.
Bone Diseases
Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet.
Bone Diseases
Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients.
Bone Diseases
[Effects of kidney transplantation on bone: osteoporosis or other?]
Bone Diseases, Metabolic
Egyptian clinical practice guideline for kidney transplantation.
Bone Diseases, Metabolic
Hepatitis C: liver transplantation.
Bone Resorption
Cellular and molecular consequences of calcineurin A alpha gene deletion.
Bone Resorption
Conditional disruption of calcineurin B1 in osteoblasts increases bone formation and reduces bone resorption.
Bone Resorption
Effects of cyclosporine on osteoclast activity: inhibition of calcineurin activity with minimal effects on bone resorption and acid transport activity.
Bone Resorption
Finely-Tuned Calcium Oscillations in Osteoclast Differentiation and Bone Resorption.
Bone Resorption
Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients.
Bone Resorption
Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease.
Bone Resorption
Inhibitory effect of okadaic acid on bone resorption in neonatal mouse calvaria in vitro. Protein dephosphorylation as an important regulatory mechanism in the bone resorption process.
Bone Resorption
Molecular cloning, expression, and function of osteoclastic calcineurin Aalpha.
Bone Resorption
Protein phosphatase inhibitors and bone resorption: inhibition by okadaic acid and biphasic actions of calyculin-A.
Bradycardia
Heart block in mice overexpressing calcineurin but not NF-AT3.
Brain Death
Oral Preconditioning of Donors After Brain Death With Calcineurin Inhibitors vs. Inhibitors of Mammalian Target for Rapamycin in Pig Kidney Transplantation.
Brain Death
PP2Ac upregulates PI3K-Akt signaling and induces hepatocyte apoptosis in liver donor after brain death.
Brain Death
The effects of brain death and ischemia on tolerance induction are organ-specific.
Brain Diseases
Alternative tacrolimus and sirolimus regimen associated with rapid resolution of posterior reversible encephalopathy syndrome after lung transplantation.
Brain Diseases
Basiliximab for posterior reversible encephalopathy syndrome after lung transplantation.
Brain Diseases
Brain MR imaging abnormalities in kidney transplant recipients.
Brain Diseases
Calcineurin inhibitor encephalopathy can develop years post lung transplantation.
Brain Diseases
Calcineurin inhibitor encephalopathy.
Brain Diseases
Calcineurin inhibitor-free strategies for prophylaxis and treatment of GVHD in children with posterior reversible encephalopathy syndrome after stem cell transplantation.
Brain Diseases
Calcineurin Inhibitors Associated Posterior Reversible Encephalopathy Syndrome in Solid Organ Transplantation: Report of 2 Cases and Literature Review.
Brain Diseases
Clinical and Genetic Study on a Chinese Patient with Infantile Onset Epileptic Encephalopathy carrying a PPP3CA Null Variant: a case report.
Brain Diseases
Early-onset infant epileptic encephalopathy associated with a de novo PPP3CA gene mutation.
Brain Diseases
Evidence for colocalization of calcineurin and calcium channels in dorsal root ganglion neurons.
Brain Diseases
MiR-363-3p attenuates neonatal hypoxic-ischemia encephalopathy by targeting DUSP5.
Brain Diseases
Neurologic complications after liver transplantation.
Brain Diseases
Neurologic complications in renal transplantation.
Brain Diseases
Neurologic Complications of Transplantation.
Brain Diseases
Neurotoxicity including posterior reversible encephalopathy syndrome after initiation of calcineurin inhibitors in transplanted methylmalonic acidemia patients: Two case reports and review of the literature.
Brain Diseases
Novel calcineurin A (PPP3CA) variant associated with epilepsy, constitutive enzyme activation and downregulation of protein expression.
Brain Diseases
Persistent accumulation of unrepaired DNA damage in rat cortical neurons: nuclear organization and ChIP-seq analysis of damaged DNA.
Brain Diseases
Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies.
Brain Diseases
Posterior reversible encephalopathy syndrome after liver transplantation in children: a rare complication related to calcineurin inhibitor effects.
Brain Diseases
Posterior Reversible Encephalopathy Syndrome After Orthotopic Heart Transplantation: A Case Report.
Brain Diseases
Posterior reversible encephalopathy syndrome due to immunosuppressant after living-donor lobar lung transplantation: report of a case.
Brain Diseases
Posterior reversible encephalopathy syndrome in children with kidney disease.
Brain Diseases
Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation.
Brain Diseases
Reversible leukoencephalopathy syndrome associated to leukopenia in a chronic hemodialysis patient.
Brain Diseases
Risk Factor and Long-Term Outcome Analyses for Acute Limbic Encephalitis and Calcineurin Inhibitor-Induced Encephalopathy in Adults following Allogeneic Hematopoietic Cell Transplantation.
Brain Diseases
Seizure treatment in transplant patients.
Brain Diseases
Structure of the gene coding for calcineurin B (PPP3R1) and mapping to D2S358-D2S1778 (chromosomal region 2p15).
Brain Diseases
Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.
Brain Diseases
Tacrolimus-Induced Vision Loss in a Renal Transplant Patient: Posterior Reversible Encephalopathy Syndrome.
Brain Diseases
[Retrospective analysis of posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation]
Brain Edema
A novel PGAM5 inhibitor LFHP-1c protects blood-brain barrier integrity in ischemic stroke.
Brain Infarction
Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury.
Brain Injuries
A Combined Proteomics and Bioinformatics Approach Reveals Novel Signaling Pathways and Molecular Targets After Intracerebral Hemorrhage.
Brain Injuries
A significant increase in both basal and maximal calcineurin activity following fluid percussion injury in the rat.
Brain Injuries
Butylphthalide ameliorates experimental autoimmune encephalomyelitis by suppressing PGAM5-induced necroptosis and inflammation in microglia.
Brain Injuries
Calcium/calcineurin signaling in primary cortical astrocyte cultures: Rcan1-4 and cyclooxygenase-2 as NFAT target genes.
Brain Injuries
MEK/ERK- and calcineurin/NFAT-mediated mechanism of cerebral hyperemia and brain injury following NMDA receptor activation.
Brain Injuries
Proteomic analysis of alterations induced by perinatal hypoxic-ischemic brain injury.
Brain Injuries
Quercetin protects against cerebral ischemia/reperfusion and oxygen glucose deprivation/reoxygenation neurotoxicity.
Brain Injuries
Search for novel gene markers of traumatic brain injury by time differential microarray analysis.
Brain Injuries
TRPM7 Mediates Neuronal Cell Death Upstream of Calcium/Calmodulin-Dependent Protein Kinase II and Calcineurin Mechanism in Neonatal Hypoxic-Ischemic Brain Injury.
Brain Injuries
Variation in PPP3CC Genotype Is Associated with Long-Term Recovery after Severe Brain Injury.
Brain Injuries
WIP1 Phosphatase Plays a Critical Neuroprotective Role in Brain Injury Induced by High-Altitude Hypoxic Inflammation.
Brain Injuries, Traumatic
A persistent change in subcellular distribution of calcineurin following fluid percussion injury in the rat.
Brain Injuries, Traumatic
A significant increase in both basal and maximal calcineurin activity following fluid percussion injury in the rat.
Brain Injuries, Traumatic
EXPRESSION OF PROTEIN PHOSPHATASE 2B (CALCINEURIN) SUBUNIT A ISOFORMS IN RAT HIPPOCAMPUS FOLLOWING A TRAUMATIC BRAIN INJURY.
Brain Injuries, Traumatic
Phosphoglycerate Mutase 5 Knockdown Alleviates Neuronal Injury After Traumatic Brain Injury Through Drp1-Mediated Mitochondrial Dysfunction.
Brain Injuries, Traumatic
Regional calcineurin subunit B isoform expression in rat hippocampus following a traumatic brain injury.
Brain Injuries, Traumatic
The combination of either tempol or FK506 with delayed hypothermia: implications for traumatically induced microvascular and axonal protection.
Brain Injuries, Traumatic
Variation in PPP3CC Genotype Is Associated with Long-Term Recovery after Severe Brain Injury.
Brain Ischemia
Calcineurin activity in children with Mental handicap.
Brain Ischemia
Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder.
Brain Ischemia
Constitutively active calcineurin mediates delayed neuronal death through Fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia.
Brain Ischemia
Generation of constitutively active calcineurin by calpain contributes to delayed neuronal death following mouse brain ischemia.
Brain Ischemia
Ginkgo biloba extract (EGb761) and FK506 preserve energy metabolites in the striatum during focal cerebral ischemia and reperfusion in gerbils monitored by microdialysis.
Brain Ischemia
Interplay between the gamma isoform of PKC and calcineurin in regulation of vulnerability to focal cerebral ischemia.
Brain Ischemia
miR-330 regulates Drp-1 mediated mitophagy by targeting PGAM5 in a rat model of permanent focal cerebral ischemia.
Brain Ischemia
Neuroprotection of gamma-aminobutyric acid receptor agonists via enhancing neuronal nitric oxide synthase (Ser847) phosphorylation through increased neuronal nitric oxide synthase and PSD95 interaction and inhibited protein phosphatase activity in cerebral ischemia.
Brain Ischemia
Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism.
Brain Ischemia
Pathophysiological relevance of forkhead transcription factors in brain ischemia.
Brain Ischemia
Potential role of calcineurin for brain ischemia and traumatic injury.
Brain Ischemia
Protein phosphatase 2A-negative regulation of the protective signaling pathway of Ca2+/CaM-dependent ERK activation in cerebral ischemia.
Brain Ischemia
Protein phosphatase-2A is activated in pig brain following cardiac arrest and resuscitation.
Brain Ischemia
Protein serine/threonine kinases (PKA, PKC and CaMKII) involved in ischemic brain pathology.
Brain Ischemia
[Effects of 3-N-butylphthalide on cortical calcineurin and calpain activities in focal cerebral ischemia rats]
Brain Ischemia
[Involvement of calcineurin A alpha and A beta in neuronal death in a gerbil model of cerebral ischemia]
Brain Neoplasms
Calcineurin as a neuronal marker of human brain tumors.
Brain Neoplasms
Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
Brain Neoplasms
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.
Brain Neoplasms
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Brain Neoplasms
PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1.
Brain Neoplasms
Reversible hyperphosphorylation and reorganization of vimentin intermediate filaments by okadaic acid in 9L rat brain tumor cells.
Breast Neoplasms
A Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells.
Breast Neoplasms
A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
Breast Neoplasms
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Breast Neoplasms
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Breast Neoplasms
Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors.
Breast Neoplasms
Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells.
Breast Neoplasms
Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
Breast Neoplasms
Cloning of a cDNA encoding an isoform of human protein phosphatase inhibitor 2 from vascularized breast tumor.
Breast Neoplasms
Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.
Breast Neoplasms
Delayed mammary gland involution in MMTV-AKT1 transgenic mice.
Breast Neoplasms
Dephosphorylation of Girdin by PP2A inhibits breast cancer metastasis.
Breast Neoplasms
Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720.
Breast Neoplasms
Detectible mosaic truncating PPM1D mutations, age and breast cancer risk.
Breast Neoplasms
Differential Roles for DUSP Family Members in Epithelial-to-Mesenchymal Transition and Cancer Stem Cell Regulation in Breast Cancer.
Breast Neoplasms
Differential up-regulation of MAP kinase phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun converge in the control of the growth arrest versus proliferation response of MCF-7 breast cancer cells to phorbol ester.
Breast Neoplasms
Disruption of the interaction between PMCA2 and calcineurin triggers apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer cells.
Breast Neoplasms
Dual roles for the phosphatase PPM1D in regulating progesterone receptor function.
Breast Neoplasms
DUSP1 promoter methylation in peripheral blood leukocyte is associated with triple-negative breast cancer risk.
Breast Neoplasms
Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer.
Breast Neoplasms
Erratum: Lentivirus-Mediated Short-Hairpin RNA Targeting Protein Phosphatase 4 Regulatory Subunit 1 Inhibits Growth in Breast Cancer.
Breast Neoplasms
Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line.
Breast Neoplasms
Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors.
Breast Neoplasms
Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Breast Neoplasms
High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.
Breast Neoplasms
HUNK suppresses metastasis of basal type breast cancers by disrupting the interaction between PP2A and cofilin-1.
Breast Neoplasms
Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively.
Breast Neoplasms
Identification of differentially expressed genes after PPM1D silencing in breast cancer.
Breast Neoplasms
IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells.
Breast Neoplasms
Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
Breast Neoplasms
Integrative transcriptome and proteome study to identify the signaling network regulated by POPX2 phosphatase.
Breast Neoplasms
Investigation of POPX2 phosphatase functions by comparative phosphoproteomic analysis.
Breast Neoplasms
Investigation of two Wnt signalling pathway single nucleotide polymorphisms in a breast cancer-affected Australian population.
Breast Neoplasms
KEGG-expressed genes and pathways in triple negative breast cancer: Protocol for a systematic review and data mining.
Breast Neoplasms
Knockdown of protein phosphatase 5 (PPP5C) suppresses the growth of leukemic cell line U937.
Breast Neoplasms
Lentivirus-Mediated Short-Hairpin RNA Targeting Protein Phosphatase 4 Regulatory Subunit 1 Inhibits Growth in Breast Cancer.
Breast Neoplasms
Micro-RNA-584 and the protein phosphatase and actin regulator 1 (PHACTR1): New Signaling Route Through Which Transforming Growth Factor-Beta Mediates the Migration and Actin Dynamics of Breast Cancer Cells.
Breast Neoplasms
MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F.
Breast Neoplasms
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
Breast Neoplasms
Mouse 4T1 Breast Cancer Cell-Derived Exosomes Induce Proinflammatory Cytokine Production in Macrophages via miR-183.
Breast Neoplasms
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Breast Neoplasms
Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase.
Breast Neoplasms
Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
Breast Neoplasms
Nuclear factor-kappaB (NF-kappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase.
Breast Neoplasms
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Breast Neoplasms
Older breast cancer survivors may harbor hereditary cancer predisposition pathogenic variants and are at risk for clonal hematopoiesis.
Breast Neoplasms
Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23.
Breast Neoplasms
Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up.
Breast Neoplasms
Plasma membrane calcium ATPase isoform 4 inhibits vascular endothelial growth factor-mediated angiogenesis through interaction with calcineurin.
Breast Neoplasms
POPX2 is a novel LATS phosphatase that regulates the Hippo pathway.
Breast Neoplasms
POPX2 phosphatase regulates apoptosis through the TAK1-IKK-NF-?B pathway.
Breast Neoplasms
PPM1B depletion in U2OS cells supresses cell growth through RB1-E2F1 pathway and stimulates bleomycin-induced cell death.
Breast Neoplasms
PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study.
Breast Neoplasms
PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.
Breast Neoplasms
PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
Breast Neoplasms
Pro-necrotic molecules impact local immunosurveillance in human breast cancer.
Breast Neoplasms
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Breast Neoplasms
Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers.
Breast Neoplasms
Protein phosphatase magnesium-dependent 1? (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma.
Breast Neoplasms
Protein phosphatase Mg2+/Mn2+ dependent 1F promotes smoking-induced breast cancer by inactivating phosphorylated-p53-induced signals.
Breast Neoplasms
Protein phosphatase PP6 is required for homology-directed repair of DNA double-strand breaks.
Breast Neoplasms
PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model.
Breast Neoplasms
Puerarin promotes DUSP1 expression by regulating miR?133a?3p in breast cancer.
Breast Neoplasms
Quercetin inhibits angiogenesis by targeting calcineurin in the xenograft model of human breast cancer.
Breast Neoplasms
Ras and TGF-? signaling enhance cancer progression by promoting the ?Np63 transcriptional program.
Breast Neoplasms
Reduced expression of the regulatory A subunit of serine/threonine protein phosphatase 2A in human breast cancer MCF-7 cells.
Breast Neoplasms
Requirement of protein phosphatase 2A for recruitment of IQGAP1 to Rac-bound beta1 integrin.
Breast Neoplasms
Retraction note to: Lentivirus-Mediated Short-Hairpin RNA Targeting Protein Phosphatase 4 Regulatory Subunit 1 Inhibits Growth in Breast Cancer.
Breast Neoplasms
SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment.
Breast Neoplasms
Silencing of DUSP6 gene by RNAi-mediation inhibits proliferation and growth in MDA-MB-231 breast cancer cells: an in vitro study.
Breast Neoplasms
Small Intestine Posttransplant Lymphoproliferative Disorder in a Kidney Transplant Recipient: A Case Report.
Breast Neoplasms
Sodium cantharidate induces apoptosis in breast cancer cells by regulating energy metabolism via the protein phosphatase 5-p53 axis.
Breast Neoplasms
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
Breast Neoplasms
Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
Breast Neoplasms
Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.
Breast Neoplasms
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.
Breast Neoplasms
Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Breast Neoplasms
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth.
Breast Neoplasms
The 17q23 amplicon and breast cancer.
Breast Neoplasms
The catalytic subunit of protein phosphatase 2A is carboxyl-methylated in vivo.
Breast Neoplasms
The Clinical Significance of PPEF1 as a Promising Biomarker and Its Potential Mechanism in Breast Cancer.
Breast Neoplasms
The Discodermia calyx Toxin Calyculin A Enhances Cyclin D1 Phosphorylation and Degradation, and Arrests Cell Cycle Progression in Human Breast Cancer Cells.
Breast Neoplasms
The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function.
Breast Neoplasms
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Breast Neoplasms
The interaction between endogenous calcineurin and the plasma membrane calcium-dependent ATPase is isoform specific in breast cancer cells.
Breast Neoplasms
The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors.
Breast Neoplasms
The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression.
Breast Neoplasms
The POPX2 phosphatase regulates cancer cell motility and invasiveness.
Breast Neoplasms
The protein phosphatase 4 - PEA15 axis regulates the survival of breast cancer cells.
Breast Neoplasms
The retinoid anticancer signal: mechanisms of target gene regulation.
Breast Neoplasms
The role of calcineurin/NFAT in SFRP2 induced angiogenesis--a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus.
Breast Neoplasms
The role of dual?specificity phosphatase 1 and protein phosphatase 1 in ?2?adrenergic receptor?mediated inhibition of extracellular signal regulated kinase 1/2 in triple negative breast cancer cell lines.
Breast Neoplasms
The role of PPM1D in cancer and advances in studies of its inhibitors.
Breast Neoplasms
The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
Breast Neoplasms
The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer.
Breast Neoplasms
Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells.
Breast Neoplasms
Up-regulation of eukaryotic elongation factor-1 subunits in breast carcinoma.
Breast Neoplasms
Wip1-deficient mice are resistant to common cancer genes.
Bronchiolitis Obliterans
Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation.
Bronchiolitis Obliterans
Everolimus Use for Intolerance or Failure of Baseline Immunosuppression in Adult Heart and Lung Transplantation.
Bronchiolitis Obliterans
Immunosuppression: what's standard and what's new?
Bronchiolitis Obliterans
Long-term use of everolimus in lung transplant patients.
Bronchiolitis Obliterans
Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference.
Bronchitis
Upregulation of DUSP6 impairs infectious bronchitis virus replication by negatively regulating ERK pathway and promoting apoptosis.
Bronchitis, Chronic
Hypothalamic digoxin, hemispheric chemical dominance, and chronic bronchitis emphysema.
Bulbo-Spinal Atrophy, X-Linked
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Burkitt Lymphoma
Caspase-8-mediated cleavage of Bid and protein phosphatase 2A-mediated activation of Bax are necessary for Verotoxin-1-induced apoptosis in Burkitt's lymphoma cells.
Burkitt Lymphoma
Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.
Burkitt Lymphoma
Expression of platelet parameters and platelet membrane glycoproteins in childhood Burkitt lymphoma.
Caliciviridae Infections
Inhibition of calcineurin or IMPDH exerts moderate to potent antiviral activity against norovirus replication.
Candidiasis
Calcineurin is essential for virulence in Candida albicans.
Candidiasis
Comparative analysis of calcineurin signaling between Candida dubliniensis and Candida albicans.
Candidiasis
Ppg1, a PP2A-type protein phosphatase, controls filament extension and virulence in Candida albicans.
Candidiasis
Role of calcineurin in stress resistance, morphogenesis, and virulence of a Candida albicans wild-type strain.
Carcinogenesis
A B56gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A.
Carcinogenesis
A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis.
Carcinogenesis
Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA.
Carcinogenesis
Alterations of the PPP1R3 gene in human cancer.
Carcinogenesis
An unusual cause of cancer mimicry following liver transplantation.
Carcinogenesis
AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer.
Carcinogenesis
Calcineurin homologous protein isoform 2 supports tumor survival via the sodium hydrogen exchanger isoform 1 in non-small cell lung cancer.
Carcinogenesis
Calcineurin signaling as a negative determinant of keratinocyte cancer stem cell potential and carcinogenesis.
Carcinogenesis
Chemopreventive sphingadienes downregulate Wnt signaling via a PP2A/Akt/GSK3? pathway in colon cancer.
Carcinogenesis
Chromosomal aberrations in UVB-induced tumors of immunosuppressed mice.
Carcinogenesis
Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.
Carcinogenesis
Colorectal cancer: Calcineurin drives CRC tumorigenesis.
Carcinogenesis
Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression.
Carcinogenesis
Delivery of the VIVIT Peptide to Human Glioma Cells to Interfere with Calcineurin-NFAT Signaling.
Carcinogenesis
Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
Carcinogenesis
Digital RNA Sequencing of Human Epidermal Keratinocytes Carrying Human Papillomavirus Type 16 E7.
Carcinogenesis
Disruption of serine/threonine protein phosphatase 5 inhibits tumorigenesis of urinary bladder cancer cells.
Carcinogenesis
Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
Carcinogenesis
Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis.
Carcinogenesis
Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.
Carcinogenesis
Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.
Carcinogenesis
Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer.
Carcinogenesis
Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression.
Carcinogenesis
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Carcinogenesis
DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis.
Carcinogenesis
DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
Carcinogenesis
Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway.
Carcinogenesis
DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Carcinogenesis
Dynamic Regulation of ME1 Phosphorylation and Acetylation Affects Lipid Metabolism and Colorectal Tumorigenesis.
Carcinogenesis
Epithelial Calcineurin Promotes Microbiota-Dependent Colorectal Cancer.
Carcinogenesis
Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling.
Carcinogenesis
Functional Roles of Protein Phosphatase 4 in Multiple Aspects of Cellular Physiology: A Friend and A Foe.
Carcinogenesis
Gene amplification and overexpression of protein phosphatase 1alpha in oral squamous cell carcinoma cell lines.
Carcinogenesis
Genetic alterations and expression of the protein phosphatase 1 genes in human cancers.
Carcinogenesis
Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer.
Carcinogenesis
Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6.
Carcinogenesis
iASPP is important for bladder cancer cell proliferation.
Carcinogenesis
Identification of proteins suppressing the functions of oncogenic phosphatase of regenerating liver 1 and 3.
Carcinogenesis
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.
Carcinogenesis
Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a molecularly distinct melanoma subtype.
Carcinogenesis
Loss of endogenous Nfatc1 reduces the rate of DMBA/TPA-induced skin tumorigenesis.
Carcinogenesis
Loss of protein phosphatase 6 in mouse keratinocytes enhances K-rasG12D -driven tumor promotion.
Carcinogenesis
Loss of protein phosphatase 6 in mouse keratinocytes increases susceptibility to ultraviolet-B-induced carcinogenesis.
Carcinogenesis
m6A methyltransferase Wilms' tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation.
Carcinogenesis
Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing.
Carcinogenesis
Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics.
Carcinogenesis
Molecular mechanisms of pancreatic carcinogenesis.
Carcinogenesis
NF-?B gene signature predicts prostate cancer progression.
Carcinogenesis
Okadaic acid activates Wnt/?-catenin-signaling in human HepaRG cells.
Carcinogenesis
Phosphatase activity, trimerization, and the C-terminal polybasic region are all required for PRL1-mediated cell growth and migration.
Carcinogenesis
Phosphatase magnesium-dependent 1 ? (PPM1D), serine/threonine protein phosphatase and novel pharmacological target in cancer.
Carcinogenesis
PP-1? and PP-1? display antagonism and differential roles in tumorigenicity of lung cancer cells.
Carcinogenesis
PP2C? inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response in breast cancer.
Carcinogenesis
PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms.
Carcinogenesis
PPM1D is a prognostic marker and therapeutic target in colorectal cancer.
Carcinogenesis
PPM1D Knockdown Suppresses Cell Proliferation, Promotes Cell Apoptosis, and Activates p38 MAPK/p53 Signaling Pathway in Acute Myeloid Leukemia.
Carcinogenesis
PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
Carcinogenesis
PPM1H is an independent prognostic biomarker of non-small cell lung cancer.
Carcinogenesis
Ppp6c deficiency accelerates K-rasG12D -induced tongue carcinogenesis.
Carcinogenesis
Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis.
Carcinogenesis
PRL-3 activates NF-?B signaling pathway by interacting with RAP1.
Carcinogenesis
PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation.
Carcinogenesis
Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients.
Carcinogenesis
Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53.
Carcinogenesis
Protein phosphatase Mg2+/Mn2+ dependent 1F promotes smoking-induced breast cancer by inactivating phosphorylated-p53-induced signals.
Carcinogenesis
PTEN signaling pathways in melanoma.
Carcinogenesis
PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1.
Carcinogenesis
Redox inhibition of protein phosphatase PP2A: Potential implications in oncogenesis and its progression.
Carcinogenesis
Role of lncRNA-ENST00000412010 in regulating nasopharyngeal cancer cell survival.
Carcinogenesis
Role of PP2C-alpha in cell growth, in radio- and chemosensitivity, and in tumorigenicity.
Carcinogenesis
Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.
Carcinogenesis
Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management.
Carcinogenesis
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth.
Carcinogenesis
The Clinical Significance of PPEF1 as a Promising Biomarker and Its Potential Mechanism in Breast Cancer.
Carcinogenesis
The mechanism of action of the tumour suppressor gene PTEN.
Carcinogenesis
The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
Carcinogenesis
Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis.
Carcinogenesis
Topical tacrolimus in combination with simulated solar radiation does not enhance photocarcinogenesis in hairless mice.
Carcinogenesis
Tripartite motif protein 11 (TRIM11), an oncogene for human lung cancer via the DUSP6-mediated ERK1/2 signaling pathway.
Carcinogenesis
Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
Carcinogenesis
Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Carcinogenesis
TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6.
Carcinogenesis
Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype.
Carcinogenesis
Type-2A protein phosphatase activity is required to maintain death receptor responsiveness.
Carcinogenesis
Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.
Carcinogenesis
Wild-type p53-induced phosphatase 1 promotes vascular smooth muscle cell proliferation and neointima hyperplasia after vascular injury via p-adenosine 5'-monophosphate-activated protein kinase/mammalian target of rapamycin complex 1 pathway.
Carcinogenesis
Wip1 abrogation decreases intestinal tumor frequency in APC(Min/+) mice irrespective of radiation quality.
Carcinogenesis
WIP1 deficiency inhibits HTLV-1 Tax oncogenesis: novel therapeutic prospects for treatment of ATL?
Carcinoma
Absence of PPP2R1A mutations in Wilms tumor.
Carcinoma
Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Carcinoma
Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis.
Carcinoma
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.
Carcinoma
Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-beta1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-beta1.
Carcinoma
Conversion from calcineurin inhibitors to everolimus with low-dose cyclosporine in renal transplant recipients with squamous cell carcinoma of the skin.
Carcinoma
Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
Carcinoma
Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
Carcinoma
Correction: Liu, Y.-S.; et al. Inhibition of Protein Phosphatase 1 Stimulates Noncanonical ER Stress eIF2? Activation to Enhance Fisetin-Induced Chemosensitivity in HDAC Inhibitor-Resistant Hepatocellular Carcinoma Cells. Cancers 2019, 11, 918.
Carcinoma
Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway.
Carcinoma
Differences in association of the serine/threonine protein phosphatase PP-2A with microtubules of metastatic and nonmetastatic tumor cells.
Carcinoma
Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma.
Carcinoma
Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
Carcinoma
DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma.
Carcinoma
Down-regulation of wild-type p53-induced phosphatase 1 (Wip1) plays a critical role in regulating several p53-dependent functions in premature senescent tumor cells.
Carcinoma
Downregulation of calcineurin activity in cervical carcinoma.
Carcinoma
Downregulation of Snail by DUSP1 Impairs Cell Migration and Invasion through the Inactivation of JNK and ERK and Is Useful as a Predictive Factor in the Prognosis of Prostate Cancer.
Carcinoma
Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer.
Carcinoma
DUSP1 is involved in the progression of small cell carcinoma of the prostate.
Carcinoma
DUSP1 phosphatase regulates the proinflammatory milieu in head and neck squamous cell carcinoma.
Carcinoma
DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
Carcinoma
DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma.
Carcinoma
Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2.
Carcinoma
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Carcinoma
Expression of Wip1 in Kidney Carcinoma and its Correlation with Tumor Metastasis and Clinical Significance.
Carcinoma
Gene amplification and overexpression of protein phosphatase 1alpha in oral squamous cell carcinoma cell lines.
Carcinoma
Identification and allelic frequencies of novel single-nucleotide polymorphisms in the DUSP1 and BTG1 genes.
Carcinoma
ILKAP regulates ILK signaling and inhibits anchorage-independent growth.
Carcinoma
Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.
Carcinoma
Inducible expression of catalytically active type 1 serine/threonine protein phosphatase in a human carcinoma cell line.
Carcinoma
Inhibition of protein phosphatase PPM1D enhances retinoic acid-induced differentiation in human embryonic carcinoma cell line.
Carcinoma
Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses.
Carcinoma
Integrated analysis identifies DUSP5 as a novel prognostic indicator for thyroid follicular carcinoma.
Carcinoma
Key genes in lung cancer translational research: a meta-analysis.
Carcinoma
Knockdown of Protein Phosphatase Magnesium-dependent 1 (PPM1D) through Lentivirus-mediated RNA Silencing Inhibits Colorectal Carcinoma Cell Proliferation.
Carcinoma
Long-term maintenance of calcineurin inhibitor monotherapy reduces the risk for squamous cell carcinomas after kidney transplantation compared with bi- or tritherapy.
Carcinoma
Loss of endogenous Nfatc1 reduces the rate of DMBA/TPA-induced skin tumorigenesis.
Carcinoma
MicroRNA-527 Induces Proliferation and Cell Cycle in Esophageal Squamous Cell Carcinoma Cells by Repressing PH Domain Leucine-Rich-Repeats Protein Phosphatase 2.
Carcinoma
Mitochondria-to-nucleus stress signaling in mammalian cells: nature of nuclear gene targets, transcription regulation, and induced resistance to apoptosis.
Carcinoma
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Carcinoma
Multidrug-resistant human KB carcinoma cells are highly resistant to the protein phosphatase inhibitors okadaic acid and calyculin A. Analysis of potential mechanisms involved in toxin resistance.
Carcinoma
Okadaic acid, a phosphatase inhibitor, induces activation and phosphorylation of the Na+/H+ antiport.
Carcinoma
Overexpression of Protein Phosphatase Non-receptor Type 11 (PTPN11) in Gastric Carcinomas.
Carcinoma
Oxidized S100A4 inhibits the activation of protein phosphatase 5 through S100A1 in MKN?45 gastric carcinoma cells.
Carcinoma
PPM1D controls nucleolar formation by up-regulating phosphorylation of nucleophosmin.
Carcinoma
PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Carcinoma
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Carcinoma
PPP1CA contributes to the senescence program induced by oncogenic Ras.
Carcinoma
Ppp6c deficiency accelerates K-rasG12D -induced tongue carcinogenesis.
Carcinoma
Protein phosphatase 2Cbetal regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells.
Carcinoma
Protein phosphatase-2A associates with the cytoskeleton to maintain cell spreading and reduced motility of nonmetastatic Lewis lung carcinoma cells: the loss of this regulatory control in metastatic cells.
Carcinoma
Protein phosphatase-2A association with microtubules and its role in restricting the invasiveness of human head and neck squamous cell carcinoma cells.
Carcinoma
Protein phosphatase-2A is down-regulated in patients within clear cell renal cell carcinoma.
Carcinoma
Protein phosphatase-2A maintains focal adhesion complexes in keratinocytes and the loss of this regulation in squamous cell carcinomas.
Carcinoma
Protein phosphatase-2A modulates the serine and tyrosine phosphorylation of paxillin in Lewis lung carcinoma tumor variants.
Carcinoma
Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants.
Carcinoma
Protein phosphatase-2A restricts migration of Lewis lung carcinoma cells by modulating the phosphorylation of focal adhesion proteins.
Carcinoma
Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma.
Carcinoma
Rapamycin instead of mycophenolate mofetil or azathioprine in treatment of post-renal transplantation urothelial carcinoma.
Carcinoma
Resolution of sirolimus-induced pneumonitis after conversion to everolimus.
Carcinoma
Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants.
Carcinoma
Role of the phosphatase PP4 in the activation of JNK-1 in prostate carcinoma cell lines PC-3 and LNCaP resulting in increased AP-1 and EGR-1 activity.
Carcinoma
Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
Carcinoma
Small Molecules Alter VEGFR and PTEN Expression in HPV-positive and -negative SCC: New Hope for Targeted-therapy.
Carcinoma
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
Carcinoma
Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.
Carcinoma
Squamous cell carcinoma on the lower lip after using topical calcineurin inhibitor.
Carcinoma
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Carcinoma
The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Carcinoma
The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway.
Carcinoma
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma.
Carcinoma
The role of drugs and selected dietary factors in cutaneous squamous cell carcinogenesis.
Carcinoma
Therapeutic Effect of ?-Secretase Inhibition in Kras(G12V)-Driven Non-Small Cell Lung Carcinoma by Derepression of DUSP1 and Inhibition of ERK.
Carcinoma
Tissue-specific gene therapy directed to tumor angiogenesis.
Carcinoma
Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Carcinoma
Urothelial carcinoma in kidney transplant recipients: conversion from calcineurin inhibitor to proliferation signal inhibitor?
Carcinoma
Vitamin D3 and ceramide reduce the invasion of tumor cells through extracellular matrix components by elevating protein phosphatase-2A.
Carcinoma
Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma.
Carcinoma
[Effect of inhibitor-1 of protein phosphatase I on apoptosis of human cervical carcinoma cell line HeLa]
Carcinoma
[Ultraviolet A-induced DNA damage: role in skin cancer].
Carcinoma in Situ
Ppp6c deficiency accelerates K-rasG12D -induced tongue carcinogenesis.
Carcinoma, Basal Cell
Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
Carcinoma, Ductal
Clinicopathological significance of dual-specificity protein phosphatase 4 expression in invasive ductal carcinoma of the breast.
Carcinoma, Ductal
Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
Carcinoma, Ductal
Enhanced expression of PP1 gamma 1, a catalytic subunit isoform of protein phosphatase type 1, in invasive ductal carcinoma of the breast.
Carcinoma, Ehrlich Tumor
Dephosphorylation of the small heat shock protein hsp25 by calcium/calmodulin-dependent (type 2B) protein phosphatase.
Carcinoma, Ehrlich Tumor
Dexamethasone induced expression of phosphatase inhibits generation of reactive oxygen species in Ehrlich ascites tumor cells.
Carcinoma, Ehrlich Tumor
Purification and characterization of butyrate-induced protein phosphatase involved in apoptosis of Ehrlich ascites tumor cells.
Carcinoma, Embryonal
Effects of protein phosphatase inhibition by okadaic acid on the differentiation of F9 embryonal carcinoma cells.
Carcinoma, Hepatocellular
A Genetic Variant of PPP1CB Influences Risk of Hepatitis B Virus-Related Hepatocellular Carcinoma in Han Chinese: A Pathway Based Analysis.
Carcinoma, Hepatocellular
A protein phosphatase is involved in the inhibition of histone deacetylation by sodium butyrate.
Carcinoma, Hepatocellular
Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Activation of protein phosphatase 1alpha promoter in ascites hepatoma cells.
Carcinoma, Hepatocellular
Calcineurin A versus NS5A-TP2/HD domain containing 2: a case study of site-directed low-frequency random mutagenesis for dissecting target specificity of peptide aptamers.
Carcinoma, Hepatocellular
CircSLC3A2 functions as an oncogenic factor in hepatocellular carcinoma by sponging miR-490-3p and regulating PPM1F expression.
Carcinoma, Hepatocellular
Combination of calcineurin B subunit (CnB) and 5-fluorouracil reverses 5-fluorouracil-induced immunosuppressive effect and enhances the antitumor activity in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Correction: Liu, Y.-S.; et al. Inhibition of Protein Phosphatase 1 Stimulates Noncanonical ER Stress eIF2? Activation to Enhance Fisetin-Induced Chemosensitivity in HDAC Inhibitor-Resistant Hepatocellular Carcinoma Cells. Cancers 2019, 11, 918.
Carcinoma, Hepatocellular
Cyclin-dependent kinase-associated protein phosphatase is overexpressed in alcohol-related hepatocellular carcinoma and influences xenograft tumor growth.
Carcinoma, Hepatocellular
Cytosolic protein phosphatases of rat ascites hepatoma AH-13 as compared with those of rat liver: isolation and characterization of a novel protein phosphatase.
Carcinoma, Hepatocellular
Deficiency in calcineurin activity in liver transplantation candidates with alcoholic cirrhosis or hepatocellular carcinoma.
Carcinoma, Hepatocellular
Descriptive Analysis of Everolimus Conversion in Liver Transplant Recipients With Malignant Neoplastic Disease.
Carcinoma, Hepatocellular
Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Carcinoma, Hepatocellular
Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Dual-specificity phosphatases are targets of the Wnt/?-catenin pathway and candidate mediators of ?-catenin/Ras signaling interactions.
Carcinoma, Hepatocellular
Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Carcinoma, Hepatocellular
Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Carcinoma, Hepatocellular
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update.
Carcinoma, Hepatocellular
Expression in hepatomas and chromosomal localization of rat protein phosphatase 5 gene.
Carcinoma, Hepatocellular
Genetically engineered drug rhCNB induces apoptosis and cell cycle arrest in both gastric cancer cells and hepatoma cells.
Carcinoma, Hepatocellular
Hepatocellular carcinoma cell lines from diethylnitrosamine phenobarbital-treated rats. Characterization and sensitivity to endothall, a protein serine/threonine phosphatase-2A inhibitor.
Carcinoma, Hepatocellular
Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway.
Carcinoma, Hepatocellular
High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation.
Carcinoma, Hepatocellular
High PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patients.
Carcinoma, Hepatocellular
Higher intratumor than peritumor expression of DUSP6/MKP-3 is associated with recurrence after curative resection of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Immunosuppressive treatment with everolimus in patients after orthotopic liver transplantation: 4 years of experience.
Carcinoma, Hepatocellular
Impact of recipient age and preoperative fasting blood glucose level as the risk factors of living donor liver transplantation in cirrhotic patients in the recent comprehensive era with knowledge of indications: Recent status in a Japanese single center.
Carcinoma, Hepatocellular
Increases in intracellular calcium dephosphorylate histone H3 at serine 10 in human hepatoma cells: potential role of protein phosphatase 2A-protein kinase CbetaII complex.
Carcinoma, Hepatocellular
Indications and management of everolimus after liver transplantation.
Carcinoma, Hepatocellular
Insulin activates a 70-kDa S6 kinase through serine/threonine-specific phosphorylation of the enzyme polypeptide.
Carcinoma, Hepatocellular
Insulin activation of protein kinase C: a reassessment.
Carcinoma, Hepatocellular
Knockdown of PPP5C inhibits growth of hepatocellular carcinoma cells in vitro.
Carcinoma, Hepatocellular
Knockdown of protein phosphatase 5 (PPP5C) suppresses the growth of leukemic cell line U937.
Carcinoma, Hepatocellular
Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.
Carcinoma, Hepatocellular
Lipin-1 is a novel substrate of protein phosphatase PGAM5.
Carcinoma, Hepatocellular
Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
Carcinoma, Hepatocellular
Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Carcinoma, Hepatocellular
MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase.
Carcinoma, Hepatocellular
miR-149 represses metastasis of hepatocellular carcinoma by targeting actin-regulatory proteins PPM1F.
Carcinoma, Hepatocellular
mRNA levels and enzyme activities of protein phosphatases in drug-resistant rat ascites hepatomas.
Carcinoma, Hepatocellular
Neoplastic alterations in subcellular distribution of type 1 alpha protein phosphatase in rat ascites hepatoma cells.
Carcinoma, Hepatocellular
Overexpression of Protein Phosphatase 1? (PP1?) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Particulate-associated protein phosphatases of rat hepatomas as compared with the enzymes of rat liver.
Carcinoma, Hepatocellular
PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma.
Carcinoma, Hepatocellular
PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3.
Carcinoma, Hepatocellular
Protein phosphatase 2A alpha involvement in granulocytic differentiation of HL-60 cells.
Carcinoma, Hepatocellular
Protein phosphatase 2A-B55? enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
Carcinoma, Hepatocellular
Protein phosphatase inhibitor-1 mRNA expression correlates with neoplastic transformation of epithelial liver cells and progression of hepatocellular carcinomas.
Carcinoma, Hepatocellular
Protein phosphatase magnesium-dependent 1? (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma.
Carcinoma, Hepatocellular
Protein phosphatase magnesium-dependent 1? is a novel tumor marker and target in hepatocellular carcinoma.
Carcinoma, Hepatocellular
PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells.
Carcinoma, Hepatocellular
Reconstitution of human hepatoma endosome-endosome fusion in vitro: potential roles for an endoprotease and a phosphoprotein phosphatase.
Carcinoma, Hepatocellular
Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Regulation of tumor necrosis factor cytotoxicity by calcineurin.
Carcinoma, Hepatocellular
Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Carcinoma, Hepatocellular
Risk factors of recipient receiving living donor liver transplantation in the comprehensive era of indication and perioperative managements.
Carcinoma, Hepatocellular
Selective high expression of protein phosphatase pp1-alpha messenger-RNA in rat poorly differentiated ascites hepatomas.
Carcinoma, Hepatocellular
Selective increases in isoform PP1 alpha of type-1 protein phosphatase in ascites hepatoma cells.
Carcinoma, Hepatocellular
Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria.
Carcinoma, Hepatocellular
Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication.
Carcinoma, Hepatocellular
Suppression of Plasminogen Activators and the MMP-2/-9 Pathway by a Zanthoxylum avicennae Extract to Inhibit the HA22T Human Hepatocellular Carcinoma Cell Migration and Invasion Effects in Vitro and in Vivo via Phosphatase 2A Activation.
Carcinoma, Hepatocellular
Ten years of sirolimus therapy in orthotopic liver transplant recipients.
Carcinoma, Hepatocellular
The competing endogenous circular RNA ADAMTS14 suppressed hepatocellular carcinoma progression through regulating microRNA-572/regulator of calcineurin 1.
Carcinoma, Hepatocellular
Up-regulation of nuclear PP1alpha and PP1delta in hepatoma cells.
Carcinoma, Hepatocellular
Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports.
Carcinoma, Hepatocellular
Zanthoxylum avicennae extract enhances GSK-3? to attenuate ?-catenin via phosphatase 2A to block metastatic effects of HA22T cells and hepatocellular carcinoma xenografted nude mice.
Carcinoma, Hepatocellular
[Overexpression of protein phosphatase 2 regulatory subunit B''? gene effect on proliferation and invasion of hepatoma cells].
Carcinoma, Intraductal, Noninfiltrating
Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
Carcinoma, Intraductal, Noninfiltrating
Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells.
Carcinoma, Lewis Lung
Differences in association of the serine/threonine protein phosphatase PP-2A with microtubules of metastatic and nonmetastatic tumor cells.
Carcinoma, Lewis Lung
Protein phosphatase-2A associates with the cytoskeleton to maintain cell spreading and reduced motility of nonmetastatic Lewis lung carcinoma cells: the loss of this regulatory control in metastatic cells.
Carcinoma, Lewis Lung
Protein phosphatase-2A modulates the serine and tyrosine phosphorylation of paxillin in Lewis lung carcinoma tumor variants.
Carcinoma, Lewis Lung
Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants.
Carcinoma, Lewis Lung
Protein phosphatase-2A restricts migration of Lewis lung carcinoma cells by modulating the phosphorylation of focal adhesion proteins.
Carcinoma, Lewis Lung
Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.
Carcinoma, Lewis Lung
Tissue-specific gene therapy directed to tumor angiogenesis.
Carcinoma, Lewis Lung
Vitamin D3 and ceramide reduce the invasion of tumor cells through extracellular matrix components by elevating protein phosphatase-2A.
Carcinoma, Non-Small-Cell Lung
Altered expression of phosphatase of regenerating liver gene family in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
An okadaic acid fragment analogue prevents nicotine-induced resistance to cisplatin by recovering PP2A activity in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP.
Carcinoma, Non-Small-Cell Lung
Association of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese.
Carcinoma, Non-Small-Cell Lung
Calcineurin homologous protein isoform 2 supports tumor survival via the sodium hydrogen exchanger isoform 1 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Corrigendum to "APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP" [EBioMedicine (2019)].
Carcinoma, Non-Small-Cell Lung
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].
Carcinoma, Non-Small-Cell Lung
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
Carcinoma, Non-Small-Cell Lung
Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy.
Carcinoma, Non-Small-Cell Lung
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Carcinoma, Non-Small-Cell Lung
Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.
Carcinoma, Non-Small-Cell Lung
Involvement of CHP2 in the Development of Non-Small Cell Lung Cancer and Patients' Poor Prognosis.
Carcinoma, Non-Small-Cell Lung
MicroRNA-365b-3p represses the proliferation and promotes the apoptosis of non-small cell lung cancer cells by targeting PPP5C.
Carcinoma, Non-Small-Cell Lung
miR129-1 regulates protein phosphatase 1D protein expression under hypoxic conditions in non-small cell lung cancer cells harboring a TP53 mutation.
Carcinoma, Non-Small-Cell Lung
PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).
Carcinoma, Non-Small-Cell Lung
PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299.
Carcinoma, Non-Small-Cell Lung
Therapeutic Effect of ?-Secretase Inhibition in Kras(G12V)-Driven Non-Small Cell Lung Carcinoma by Derepression of DUSP1 and Inhibition of ERK.
Carcinoma, Non-Small-Cell Lung
Truncating and missense PPM1D mutations in early-onset and/or familial/hereditary prostate cancer patients.
Carcinoma, Ovarian Epithelial
Association of metastin/a G-protein-coupled receptor signaling and Down syndrome critical region 1 in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes.
Carcinoma, Ovarian Epithelial
Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway.
Carcinoma, Ovarian Epithelial
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Carcinoma, Ovarian Epithelial
PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.
Carcinoma, Renal Cell
Current approaches to the use of sirolimus in renal transplantation.
Carcinoma, Renal Cell
Protein phosphatase-2A is down-regulated in patients within clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Resolution of sirolimus-induced pneumonitis after conversion to everolimus.
Carcinoma, Small Cell
DUSP1 is involved in the progression of small cell carcinoma of the prostate.
Carcinoma, Squamous Cell
Calcineurin homologous protein isoform 2 supports tumor survival via the sodium hydrogen exchanger isoform 1 in non-small cell lung cancer.
Carcinoma, Squamous Cell
Characterization of a membrane-associated phosphotyrosyl protein phosphatase from the A431 human epidermoid carcinoma cell line.
Carcinoma, Squamous Cell
Conversion from calcineurin inhibitors to everolimus with low-dose cyclosporine in renal transplant recipients with squamous cell carcinoma of the skin.
Carcinoma, Squamous Cell
Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
Carcinoma, Squamous Cell
Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
Carcinoma, Squamous Cell
Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma.
Carcinoma, Squamous Cell
Downregulation of calcineurin activity in cervical carcinoma.
Carcinoma, Squamous Cell
Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese.
Carcinoma, Squamous Cell
DUSP1 phosphatase regulates the proinflammatory milieu in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.
Carcinoma, Squamous Cell
Induction of apoptosis in human oral squamous carcinoma cell lines by protein phosphatase inhibitors.
Carcinoma, Squamous Cell
Key genes in lung cancer translational research: a meta-analysis.
Carcinoma, Squamous Cell
Long-term maintenance of calcineurin inhibitor monotherapy reduces the risk for squamous cell carcinomas after kidney transplantation compared with bi- or tritherapy.
Carcinoma, Squamous Cell
Loss of endogenous Nfatc1 reduces the rate of DMBA/TPA-induced skin tumorigenesis.
Carcinoma, Squamous Cell
Ppp6c deficiency accelerates K-rasG12D -induced tongue carcinogenesis.
Carcinoma, Squamous Cell
Protein phosphatase-2A association with microtubules and its role in restricting the invasiveness of human head and neck squamous cell carcinoma cells.
Carcinoma, Squamous Cell
Protein phosphatase-2A maintains focal adhesion complexes in keratinocytes and the loss of this regulation in squamous cell carcinomas.
Carcinoma, Squamous Cell
Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
Carcinoma, Squamous Cell
Small Molecules Alter VEGFR and PTEN Expression in HPV-positive and -negative SCC: New Hope for Targeted-therapy.
Carcinoma, Squamous Cell
Squamous cell carcinoma on the lower lip after using topical calcineurin inhibitor.
Carcinoma, Squamous Cell
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Carcinoma, Squamous Cell
The role of drugs and selected dietary factors in cutaneous squamous cell carcinogenesis.
Carcinoma, Squamous Cell
Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Carcinoma, Transitional Cell
Inducible expression of catalytically active type 1 serine/threonine protein phosphatase in a human carcinoma cell line.
Carcinoma, Transitional Cell
Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma.
Carcinosarcoma
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Cardiac Output, Low
[Intracellular disorders in the dog myocardium in low cardiac output syndrome caused by massive hemorrhage, approaches to correction]
Cardiomegaly
A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.
Cardiomegaly
A proteomic interrogation of Cryptococcus neoformans: interaction networks for calcineurin in a heated environment.
Cardiomegaly
A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway.
Cardiomegaly
Activation of calcineurin expression in ischemia-reperfused rat heart and in human ischemic myocardium.
Cardiomegaly
Activation of Serine One-Carbon Metabolism by Calcineurin A?1 Reduces Myocardial Hypertrophy and Improves Ventricular Function.
Cardiomegaly
Activation of transient receptor potential vanilloid 3 channel (TRPV3) aggravated pathological cardiac hypertrophy via calcineurin/NFATc3 pathway in rats.
Cardiomegaly
Adrenergic receptor blockade-induced regression of pressure-overload cardiac hypertrophy is associated with inhibition of the calcineurin/NFAT3/GATA4 pathway.
Cardiomegaly
Analysis of calcineurin activity by capillary electrophoresis with laser-induced fluorescence detection using peptide substrate.
Cardiomegaly
Angiotensin II induced cardiac hypertrophy in vivo is inhibited by cyclosporin A in adult rats.
Cardiomegaly
Angiotensin-converting enzyme inhibitor suppresses activation of calcineurin in renovascular hypertensive rats.
Cardiomegaly
Are calcineurin genes associated with endurance phenotype traits?
Cardiomegaly
AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats.
Cardiomegaly
Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins.
Cardiomegaly
Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex.
Cardiomegaly
Blockade of calcineurin reverses cardiac hypertrophy and induces the down-regulation of JNK mRNA expression in renovascular hypertensive rats.
Cardiomegaly
BMP TYPE I RECEPTOR ALK2 IS REQUIRED FOR ANGIOTENSIN II-INDUCED CARDIAC HYPERTROPHY.
Cardiomegaly
c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling.
Cardiomegaly
Ca(2+) fluxes involvement in gene expression during cardiac hypertrophy.
Cardiomegaly
Calcineurin activation is not necessary for Doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway.
Cardiomegaly
Calcineurin activity in children with Mental handicap.
Cardiomegaly
Calcineurin activity is required for cardiac remodeling in pregnancy.
Cardiomegaly
Calcineurin anchoring and cell signaling.
Cardiomegaly
Calcineurin and cardiac hypertrophy: where have we been? Where are we going?
Cardiomegaly
Calcineurin and electrical remodeling in pathologic cardiac hypertrophy.
Cardiomegaly
Calcineurin and hypertrophic heart disease: novel insights and remaining questions.
Cardiomegaly
Calcineurin and matrix protein expression in cardiac hypertrophy : Evidence for calcineurin B to control excessive hypertrophic signaling.
Cardiomegaly
Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension.
Cardiomegaly
Calcineurin enhances MAPK phosphatase-1 expression and p38 MAPK inactivation in cardiac myocytes.
Cardiomegaly
Calcineurin in human heart hypertrophy.
Cardiomegaly
Calcineurin increases cardiac transient outward K+ currents via transcriptional up-regulation of Kv4.2 channel subunits.
Cardiomegaly
Calcineurin independent development of myocardial hypertrophy in transgenic rats overexpressing the mouse renin gene, TGR(mREN2)27.
Cardiomegaly
Calcineurin inhibition and cardiac hypertrophy: a matter of balance.
Cardiomegaly
Calcineurin inhibition as therapy for cardiac hypertrophy and heart failure: requiescat in pace?
Cardiomegaly
Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
Cardiomegaly
Calcineurin inhibitor attenuates cardiac hypertrophy due to energy metabolic disorder.
Cardiomegaly
Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension.
Cardiomegaly
Calcineurin inhibitors and cardiac hypertrophy.
Cardiomegaly
Calcineurin inhibits Na+/Ca2+ exchange in phenylephrine-treated hypertrophic cardiomyocytes.
Cardiomegaly
Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training.
Cardiomegaly
Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy.
Cardiomegaly
Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy.
Cardiomegaly
Calcineurin signaling in human cardiac hypertrophy.
Cardiomegaly
Calcineurin splicing variant calcineurin A?1 improves cardiac function after myocardial infarction without inducing hypertrophy.
Cardiomegaly
Calcineurin-AKAP interactions: therapeutic targeting of a pleiotropic enzyme with a little help from its friends.
Cardiomegaly
Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure.
Cardiomegaly
Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs.
Cardiomegaly
Calcium signaling regulates ventricular hypertrophy during development independent of contraction or blood flow.
Cardiomegaly
Calcium-calcineurin signaling in the regulation of cardiac hypertrophy.
Cardiomegaly
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.
Cardiomegaly
Calsarcin-3, a novel skeletal muscle-specific member of the calsarcin family, interacts with multiple Z-disc proteins.
Cardiomegaly
CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo.
Cardiomegaly
Carabin Protects Against Cardiac Hypertrophy by Blocking Calcineurin, Ras, and Ca2+/Calmodulin-Dependent Protein Kinase II Signaling.
Cardiomegaly
Carabin: Endogenous calcineurin inhibitor, a potential diagnostic and therapeutic target for cardiac hypertrophy in heart failure.
Cardiomegaly
Cardiac CaM Kinase II genes ? and ? contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy.
Cardiomegaly
Cardiac CaMKII? and Wenxin Keli Prevents Ang II-Induced Cardiomyocyte Hypertrophy by Modulating CnA-NFATc4 and Inflammatory Signaling Pathways in H9c2 Cells.
Cardiomegaly
Cardiac hypertrophy and thyroid hormone signaling.
Cardiomegaly
Cardiac hypertrophy induced by prostaglandin F(2alpha) may be mediated by calcineurin signal transduction pathway in rats.
Cardiomegaly
Cardiac-Specific EPI64C Blunts Pressure Overload-Induced Cardiac Hypertrophy.
Cardiomegaly
Cardiomyocyte calcineurin is required for the onset and progression of cardiac hypertrophy and fibrosis in adult mice.
Cardiomegaly
Cardiovascular effects of an immunosuppressive agent cyclosporin A.
Cardiomegaly
Changes in Cx43 and NaV1.5 expression precede the occurrence of substantial fibrosis in calcineurin-induced murine cardiac hypertrophy.
Cardiomegaly
Choline inhibits angiotensin II-induced cardiac hypertrophy by intracellular calcium signal and p38 MAPK pathway.
Cardiomegaly
Choline Protects Against Cardiac Hypertrophy Induced by Increased After-load.
Cardiomegaly
CIB1 is a regulator of pathological cardiac hypertrophy.
Cardiomegaly
Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3.
Cardiomegaly
Cissampelos pareira Linn. ameliorates thyroxin-induced cardiac hypertrophy in rats.
Cardiomegaly
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Cardiomegaly
Compensatory renal hypertrophy following uninephrectomy is calcineurin-independent.
Cardiomegaly
Constitutively active calcineurin induces cardiac endoplasmic reticulum stress and protects against apoptosis that is mediated by alpha-crystallin-B.
Cardiomegaly
Continuous blockade of L-type Ca2+ channels suppresses activation of calcineurin and development of cardiac hypertrophy in spontaneously hypertensive rats.
Cardiomegaly
Control of cardiac myosin heavy chain gene expression.
Cardiomegaly
Cooperative autoinhibition and multi-level activation mechanisms of calcineurin.
Cardiomegaly
Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy.
Cardiomegaly
Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Facilitates the Development of Cardiac Hypertrophy.
Cardiomegaly
Cyclosporin A regulates sodium-calcium exchanger (NCX1) gene expression in vitro and cardiac hypertrophy in NCX1 transgenic mice.
Cardiomegaly
Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes.
Cardiomegaly
Danshen (Salvia miltiorhiza) inhibits Leu27 IGF-II-induced hypertrophy in H9c2 cells.
Cardiomegaly
Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin.
Cardiomegaly
Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism.
Cardiomegaly
Direct biomechanical induction of endogenous calcineurin inhibitor Down Syndrome Critical Region-1 in cardiac myocytes.
Cardiomegaly
Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy.
Cardiomegaly
Downregulation of Ca2+ signalling proteins in cardiac hypertrophy.
Cardiomegaly
Downregulation of calcineurin activity in cervical carcinoma.
Cardiomegaly
Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy.
Cardiomegaly
Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1.
Cardiomegaly
DUSP5-mediated inhibition of smooth muscle cell proliferation suppresses pulmonary hypertension and right ventricular hypertrophy.
Cardiomegaly
E2/ER ? Enhances Calcineurin Protein Degradation and PI3K/Akt/MDM2 Signal Transduction to Inhibit ISO-Induced Myocardial Cell Apoptosis.
Cardiomegaly
Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca(2+)-ATPase activity in rat cardiac pressure-overload hypertrophy.
Cardiomegaly
Effects of omega-3 fatty acids and metformin combination on diabetic cardiomyopathy in rats through autophagic pathway.
Cardiomegaly
Electrical remodeling in pressure-overload cardiac hypertrophy: role of calcineurin.
Cardiomegaly
Enhanced activity of the myocardial Na+/H+ exchanger NHE-1 contributes to cardiac remodeling in atrial natriuretic peptide receptor-deficient mice.
Cardiomegaly
Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure.
Cardiomegaly
Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin.
Cardiomegaly
Expression of an active LKB1 complex in cardiac myocytes results in decreased protein synthesis associated with phenylephrine-induced hypertrophy.
Cardiomegaly
Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling.
Cardiomegaly
Functional and phenotypic relevance of differentially expressed proteins in calcineurin mutants of Caenorhabditis elegans.
Cardiomegaly
Galactokinase is a novel modifier of calcineurin-induced cardiomyopathy in Drosophila.
Cardiomegaly
GATA4-mediated cardiac hypertrophy induced by d-myo-inositol 1,4,5-tris-phosphate.
Cardiomegaly
Heart block in mice overexpressing calcineurin but not NF-AT3.
Cardiomegaly
High-mobility group box 1 induces calcineurin-mediated cell hypertrophy in neonatal rat ventricular myocytes.
Cardiomegaly
Human Molecular Genetic and Functional Studies Identify TRIM63, Encoding Muscle RING Finger Protein 1, as a Novel Gene for Human Hypertrophic Cardiomyopathy.
Cardiomegaly
In vivo cardiac gene transfer of Kv4.3 abrogates the hypertrophic response in rats after aortic stenosis.
Cardiomegaly
Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles.
Cardiomegaly
Induction of the calcineurin variant CnA?1 after myocardial infarction reduces post-infarction ventricular remodelling by promoting infarct vascularization.
Cardiomegaly
Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality.
Cardiomegaly
Inhibitory molecules in signal transduction pathways of cardiac hypertrophy.
Cardiomegaly
Inorganic arsenic induces sex-dependent pathological hypertrophy in the heart.
Cardiomegaly
iNOS in cardiac myocytes plays a critical role in death in a murine model of hypertrophy induced by calcineurin.
Cardiomegaly
Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes.
Cardiomegaly
Intermedin alleviates pathological cardiac remodeling by upregulating klotho.
Cardiomegaly
Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: endoplasmic reticulum stress as a mediator of pathogenesis.
Cardiomegaly
Into the heart: The emerging role of the ubiquitin-proteasome system.
Cardiomegaly
Involvement of calcineurin in angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibroblast hyperplasia of rats.
Cardiomegaly
Involvement of calcium-sensing receptor in cardiac hypertrophy-induced by angiotensinII through calcineurin pathway in cultured neonatal rat cardiomyocytes.
Cardiomegaly
Isoproterenol activates extracellular signal-regulated protein kinases in cardiomyocytes through calcineurin.
Cardiomegaly
KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin.
Cardiomegaly
Loaded wheel running and muscle adaptation in the mouse.
Cardiomegaly
Long-term administration of pyridostigmine attenuates pressure overload-induced cardiac hypertrophy by inhibiting calcineurin signalling.
Cardiomegaly
Loss of ?-adrenergic-stimulated phosphorylation of CaV1.2 channels on Ser1700 leads to heart failure.
Cardiomegaly
LPS-enhanced IGF-IIR pathway to induce H9c2 cardiomyoblast cell hypertrophy was attenuated by Carthamus tinctorius extract via IGF-IR activation.
Cardiomegaly
Mechanical stress-evoked but angiotensin II-independent activation of angiotensin II type 1 receptor induces cardiac hypertrophy through calcineurin pathway.
Cardiomegaly
Methionine oxidation in the calmodulin-binding domain of calcineurin disrupts calmodulin binding and calcineurin activation.
Cardiomegaly
MicroRNA-22 Regulates Cardiac Hypertrophy and Remodeling in Response to Stress.
Cardiomegaly
MicroRNA-328 as a regulator of cardiac hypertrophy.
Cardiomegaly
miR-155 functions downstream of angiotensin II receptor subtype 1 and calcineurin to regulate cardiac hypertrophy.
Cardiomegaly
Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo.
Cardiomegaly
Molecular and cellular mechanisms of mechanical stress-induced cardiac hypertrophy.
Cardiomegaly
Molecular mechanisms regarding potassium bromate?induced cardiac hypertrophy without apoptosis in H9c2 cells.
Cardiomegaly
Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
Cardiomegaly
Multiple domains of MCIP1 contribute to inhibition of calcineurin activity.
Cardiomegaly
Multiple signaling pathways coordinately mediate reactive oxygen species dependent cardiomyocyte hypertrophy.
Cardiomegaly
MuRF1 Negatively Regulates Pathological Cardiac Hypertrophy Through Downregulation of Calcineurin A.
Cardiomegaly
Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo.
Cardiomegaly
Neurally-mediated increase in calcineurin activity regulates cardiac contractile function in absence of hypertrophy.
Cardiomegaly
NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro.
Cardiomegaly
O-GlcNAc Signaling is Essential for NFAT-Mediated Transcriptional Reprogramming During Cardiomyocyte Hypertrophy.
Cardiomegaly
Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy.
Cardiomegaly
Olmesartan attenuates cardiac hypertrophy and improves cardiac diastolic function in spontaneously hypertensive rats through inhibition of calcineurin pathway.
Cardiomegaly
Overexpression of calcineurin in mouse causes sudden cardiac death associated with decreased density of K+ channels.
Cardiomegaly
Overexpression of calmodulin induces cardiac hypertrophy by a calcineurin-dependent pathway.
Cardiomegaly
Overexpression of prostaglandin EP3 receptors activates calcineurin and promotes hypertrophy in the murine heart.
Cardiomegaly
Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy.
Cardiomegaly
PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2) regulates G-protein-coupled receptor kinase 5 (GRK5)-induced cardiac hypertrophy in vitro.
Cardiomegaly
Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway.
Cardiomegaly
Physical and functional interaction between calcineurin and the cardiac L-type Ca2+ channel.
Cardiomegaly
Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure.
Cardiomegaly
Plasma membrane Ca2+-ATPase isoform 4 antagonizes cardiac hypertrophy in association with calcineurin inhibition in rodents.
Cardiomegaly
Polymorphisms of genes of the cardiac calcineurin pathway and cardiac hypertrophy.
Cardiomegaly
Positive correlations between serum calcineurin activity and left ventricular hypertrophy.
Cardiomegaly
Positive Role for a Negative Calcineurin Regulator in Cardiac Hypertrophy.
Cardiomegaly
Positive Transcription Elongation Factor b Activity in Compensatory Myocardial Hypertrophy is Regulated by Cardiac Lineage Protein-1.
Cardiomegaly
Possible involvement of calcineurin, protein kinase C, and Src-family kinases in angiotensin II-induced tyrosine phosphorylation of p130cas in rat cardiac muscle.
Cardiomegaly
PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart.
Cardiomegaly
Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype?
Cardiomegaly
Prevention of cardiac hypertrophy in mice by calcineurin inhibition.
Cardiomegaly
Prevention of isoproterenol-induced cardiac hypertrophy by eugenol, an antioxidant.
Cardiomegaly
Protein kinase-mediated regulation of calcineurin through the phosphorylation of modulatory calcineurin-interacting protein 1.
Cardiomegaly
Re: Regulation of protein kinase C isozyme and calcineurin expression in isoproterenol-induced cardiac hypertrophy.
Cardiomegaly
Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy.
Cardiomegaly
Recognition of ?-calcineurin by the domains of calmodulin: Thermodynamic and structural evidence for distinct roles.
Cardiomegaly
Recognition of ?-calcineurin by the domains of calmodulin: thermodynamic and structural evidence for distinct roles.
Cardiomegaly
Regulation of gene expression by cyclic GMP.
Cardiomegaly
Regulation of protein kinase C isozyme and calcineurin expression in isoproterenol induced cardiac hypertrophy.
Cardiomegaly
Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition.
Cardiomegaly
Reversal of tacrolimus-related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient.
Cardiomegaly
Reversibility of adverse, calcineurin-dependent cardiac remodeling.
Cardiomegaly
Role of calcineurin in striated muscle: development, adaptation, and disease.
Cardiomegaly
Role of heterotrimeric G protein and calcium in cardiomyocyte hypertrophy induced by IGF-1.
Cardiomegaly
Roles of calcineurin and calcium/calmodulin-dependent protein kinase II in pressure overload-induced cardiac hypertrophy.
Cardiomegaly
Rutaecarpine Ameliorates Pressure Overload Cardiac Hypertrophy by Suppression of Calcineurin and Angiotensin II.
Cardiomegaly
Ryanodine receptor type 2 is required for the development of pressure overload-induced cardiac hypertrophy.
Cardiomegaly
Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy, Fibrosis, and Inflammation.
Cardiomegaly
Separating the good and evil of cardiac growth by CIB1 and calcineurin.
Cardiomegaly
Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy.
Cardiomegaly
Stachydrine hydrochloride suppresses phenylephrine-induced pathological cardiac hypertrophy by inhibiting the calcineurin/nuclear factor of activated T-cell signalling pathway.
Cardiomegaly
Stretch-modulation of second messengers: effects on cardiomyocyte ion transport.
Cardiomegaly
Structures of calcineurin and its complexes with immunophilins-immunosuppressants.
Cardiomegaly
TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NF?B, and Bnip3 Pathways.
Cardiomegaly
Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth.
Cardiomegaly
Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo.
Cardiomegaly
Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function.
Cardiomegaly
Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.
Cardiomegaly
Targeting calcineurin and associated pathways in cardiac hypertrophy and failure.
Cardiomegaly
The ability of phosphodiesterase-5 inhibitors sildenafil and ordonafil to reverse L-NAME induced cardiac hypertrophy in the rabbit: possible role of calcineurin and p38.
Cardiomegaly
The combined inhibition of the CaMKII? and calcineurin signaling cascade attenuates IGF-IIR-induced cardiac hypertrophy.
Cardiomegaly
The essential role of MEKK3 signaling in angiotensin II-induced calcineurin/nuclear factor of activated T-cells activation.
Cardiomegaly
The function of calcineurin and ERK1/2 signal in the antihypertrophic effects of kappa-opioid receptor stimulation on myocardial hypertrophy induced by isoprenaline.
Cardiomegaly
The Nlrp3 Inflammasome promotes myocardial dysfunction in structural cardiomyopathy through IL-1?
Cardiomegaly
The other side of cardiac Ca(2+) signaling: transcriptional control.
Cardiomegaly
The proteasome activator REG? accelerates cardiac hypertrophy by declining PP2Ac?-SOD2 pathway.
Cardiomegaly
The role of modulatory calcineurin-interacting proteins in calcineurin signaling.
Cardiomegaly
Transcriptional upregulation of calcineurin Abeta by endothelin-1 is partially mediated by calcium/calmodulin-dependent protein kinase IIdelta3 in rat cardiomyocytes.
Cardiomegaly
Transient outward potassium channel: a heart failure mediator.
Cardiomegaly
TRPA1 inhibition ameliorates pressure overload-induced cardiac hypertrophy and fibrosis in mice.
Cardiomegaly
TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling.
Cardiomegaly
Ubiquitin-protein ligase E3a (UBE3A) as a new biomarker of cardiac hypertrophy in cell models.
Cardiomegaly
Vascular but not cardiac remodeling is associated with superoxide production in angiotensin II hypertension.
Cardiomegaly
Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways.
Cardiomegaly
Zebrafish hhatla is involved in cardiac hypertrophy.
Cardiomegaly
Zinc inhibits doxorubicin-activated calcineurin signal transduction pathway in H9c2 embryonic rat cardiac cells.
Cardiomegaly
[Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension]
Cardiomegaly
[Cardiac hypertrophy and calcium signaling]
Cardiomegaly
[Functional analysis of calcineurin-mediated signalling pathway using fission yeast as a model system]
Cardiomegaly
[Role of Ca2+/calmodulin-dependent calcineurin signaling pathway in neuropeptide Y-induced cardiac hypertrophy in rats]
Cardiomegaly
[Role of calcineurin in the progression of cardiac hypertrophy in renovascular hypertensive rats]
Cardiomegaly
[Role of valsartan on myocardial Calpain I, calcineurin and Ca/calmodulin-dependent protein kinase II? expression of renovascular hypertensive rats].
Cardiomegaly
[The mutants of calcineurin transgenic mice]
Cardiomyopathies
Aberrant sialylation causes dilated cardiomyopathy and stress-induced heart failure.
Cardiomyopathies
ASK1 Regulates Cardiomyocyte Death but Not Hypertrophy in Transgenic Mice.
Cardiomyopathies
Calcineurin and beyond: cardiac hypertrophic signaling.
Cardiomyopathies
Calcineurin in human heart hypertrophy.
Cardiomyopathies
Cell surface and gene expression regulation molecules in dystrophinopathy: mdx vs. Duchenne.
Cardiomyopathies
Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy.
Cardiomyopathies
Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure.
Cardiomyopathies
Direct and Indirect Involvement of MicroRNA-499 in Clinical and Experimental Cardiomyopathy.
Cardiomyopathies
Elevated dual specificity protein phosphatase 4 in cardiomyopathy caused by lamin A/C gene mutation is primarily ERK1/2-dependent and its depletion improves cardiac function and survival.
Cardiomyopathies
Erratum to: High throughput phenotyping of left and right ventricular cardiomyopathy in calcineurin transgene mice.
Cardiomyopathies
Galactokinase is a novel modifier of calcineurin-induced cardiomyopathy in Drosophila.
Cardiomyopathies
High throughput phenotyping of left and right ventricular cardiomyopathy in calcineurin transgene mice.
Cardiomyopathies
Impaired contractile function and calcium handling in hearts of cardiac-specific calcineurin b1-deficient mice.
Cardiomyopathies
Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure.
Cardiomyopathies
Isoproterenol-Induced Cardiomyopathy in Rats: Influence of Acorus calamus Linn. : A. calamus Attenuates Cardiomyopathy.
Cardiomyopathies
Mechanisms underlying pathological Ca2+ handling in diseases of the heart.
Cardiomyopathies
Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress.
Cardiomyopathies
Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy.
Cardiomyopathies
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.
Cardiomyopathies
Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition.
Cardiomyopathies
The combined inhibition of the CaMKII? and calcineurin signaling cascade attenuates IGF-IIR-induced cardiac hypertrophy.
Cardiomyopathies
The long-term effect of simultaneous heart and kidney transplantation on native renal function.
Cardiomyopathy, Dilated
Activation of calcineurin and stress activated protein kinase/p38-mitogen activated protein kinase in hearts of utrophin-dystrophin knockout mice.
Cardiomyopathy, Dilated
Calcineurin Protects the Heart in a Murine Model of Dilated Cardiomyopathy.
Cardiomyopathy, Dilated
Galactokinase is a novel modifier of calcineurin-induced cardiomyopathy in Drosophila.
Cardiomyopathy, Dilated
Increased COUP-TFII expression in adult hearts induces mitochondrial dysfunction resulting in heart failure.
Cardiomyopathy, Dilated
Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure.
Cardiomyopathy, Dilated
Molecular mechanisms of reduced sarcoplasmic reticulum Ca(2+) uptake in human failing left ventricular myocardium.
Cardiomyopathy, Dilated
Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo.
Cardiomyopathy, Dilated
Pathogenesis of dilated cardiomyopathy: molecular, structural, and population analyses in tropomodulin-overexpressing transgenic mice.
Cardiomyopathy, Dilated
Polymorphisms of genes of the cardiac calcineurin pathway and cardiac hypertrophy.
Cardiomyopathy, Dilated
Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice.
Cardiomyopathy, Dilated
The CnB1 p.D102A variant is linked to dilated cardiomyopathy via impaired Calcineurin activity.
Cardiomyopathy, Hypertrophic
Calcineurin in human heart hypertrophy.
Cardiomyopathy, Hypertrophic
Pathogenesis of Hypertrophic Cardiomyopathy Caused by Myozenin 2 Mutations Is Independent of Calcineurin Activity.
Cardiomyopathy, Hypertrophic
Progressive Left Ventricular Hypertrophy after Heart Transplantation: Insights and Mechanisms Suggested by Multimodal Images.
Cardiomyopathy, Hypertrophic
Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart.
Cardiomyopathy, Hypertrophic
Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.
Cardiotoxicity
Aldehyde dehydrogenase 2 ameliorates acute cardiac toxicity of ethanol: role of protein phosphatase and forkhead transcription factor.
Cardiotoxicity
Cissampelos pareira Linn. ameliorates thyroxin-induced cardiac hypertrophy in rats.
Cardiotoxicity
Current methods of the analysis of immunosuppressive agents in clinical materials: A review.
Cardiotoxicity
Dexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation.
Cardiotoxicity
Phloretin Alleviates Arsenic Trioxide-Induced Apoptosis of H9c2 Cardiomyoblasts via Downregulation in Ca2+/Calcineurin/NFATc Pathway and Inflammatory Cytokine Release.
Cardiotoxicity
Protection against tacrolimus-induced cardiotoxicity in rats by olmesartan and aliskiren.
Cardiotoxicity
[The Role of Laboratory Medicine in Hematopoietic Stem Cell Transplantation "Echocardiogram"].
Cardiovascular Diseases
Aortic valve replacement performed twice through ministernotomy 15 years after lung transplantation.
Cardiovascular Diseases
Association of a Change in Immunosuppressive Regimen with Hemodynamic and Inflammatory Markers of Cardiovascular Disease After Kidney Transplantation.
Cardiovascular Diseases
Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies).
Cardiovascular Diseases
Calcineurin suppresses AMPK-dependent cytoprotective autophagy in cardiomyocytes under oxidative stress.
Cardiovascular Diseases
Clinical application of mTORi based immunosuppression for renal transplantation in India.
Cardiovascular Diseases
DUSP1 Is a Potential Marker of Chronic Inflammation in Arabs with Cardiovascular Diseases.
Cardiovascular Diseases
Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Cardiovascular Diseases
Effects of Calcineurin Inhibitors on Paraoxonase and Arylesterase Activity After a Kidney Transplant.
Cardiovascular Diseases
Enhanced platelet responsiveness due to chilling and its relation to CD40 ligand level and platelet-leukocyte aggregate formation.
Cardiovascular Diseases
Extracellular vesicles from patients with Acute Coronary Syndrome impact on ischemia-reperfusion injury.
Cardiovascular Diseases
From cyclosporine to the future.
Cardiovascular Diseases
Influence of dual-specificity protein phosphatase 5 on mechanical properties of rat cerebral and renal arterioles.
Cardiovascular Diseases
Is a flavonoid-rich diet with steamer cooking safe during calcineurin inhibitors therapy?
Cardiovascular Diseases
Massive Analysis of cDNA Ends (MACE) and miRNA expression profiling identifies proatherogenic pathways in chronic kidney disease MACE and miRNA profiling in CKD.
Cardiovascular Diseases
Neutrophil Gelatinase-Associated Lipocalin: Ready for Routine Clinical Use? An International Perspective.
Cardiovascular Diseases
PHACTR1 Gene Polymorphism Is Associated with Increased Risk of Developing Premature Coronary Artery Disease in Mexican Population.
Cardiovascular Diseases
Prolonged Subcutaneous Administration of Oxytocin Accelerates Angiotensin II-Induced Hypertension and Renal Damage in Male Rats.
Cardiovascular Diseases
Scutellarin exerts its anti-hypertrophic effects via suppressing the Ca2+-mediated calcineurin and CaMKII signaling pathways.
Cardiovascular Diseases
The evolving role of alemtuzumab (Campath-1H) in renal transplantation.
Cardiovascular Diseases
The regulator of calcineurin (RCAN1) an important factor involved in atherosclerosis and cardiovascular diseases development.
Cardiovascular Diseases
Therapeutic potential of VIVIT, a selective peptide inhibitor of nuclear factor of activated T cells, in cardiovascular disorders.
Cataract
Human Aqueous Humor Phosphatase Activity in Cataract and Glaucoma.
Cataract
Ocular complications in a young pediatric population following bone marrow transplantation.
Cataract
Spectrum and range of oxidative stress responses of human lens epithelial cells to H2O2 insult.
Cataract
Strategies to reduce toxicities and improve outcomes in renal transplant recipients.
Catatonia
Catatonia After Liver Transplantation.
Celiac Disease
A possible mechanism behind autoimmune disorders discovered by genome-wide linkage and association analysis in celiac disease.
Central Nervous System Diseases
Seizure treatment in transplant patients.
Central Nervous System Infections
Pathophysiology and Management of Hyperammonemia in Organ Transplant Patients.
Cerebellar Ataxia
Cerebellar ataxia in a patient receiving calcineurin inhibitors after living donor liver transplantation: a case report.
Cerebellar Diseases
Analysis of the cerebellar proteome in a transgenic mouse model of inherited prion disease reveals preclinical alteration of calcineurin activity.
Cerebellar Diseases
Unusual cerebral white matter change in a Chinese family with Spinocerebellar ataxia type 12.
Cerebral Infarction
[Effect of electro-needling at acupoints of the yangming meridian on the expression of PAC-1 and lower limb functions in acute cerebral infarction patients].
Cerebrovascular Disorders
Neuroimaging and neurologic complications after organ transplantation.
Cerebrovascular Disorders
Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients.
Chagas Disease
A preliminary study of platelet hyperactivity in the chronic indeterminate phase of Chagas' disease.
Cheilitis
Plasma cell cheilitis successfully treated with topical calcineurin inhibitors.
Cheilitis
Successful treatment of plasma cell cheilitis with topical calcineurin inhibitors.
Cheilitis
Successful treatment of plasma cell cheilitis with topical tacrolimus: Report of two cases.
Cherubism
SH3BP2 mutations potentiate osteoclastogenesis via PLC?.
Cherubism
The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism.
Cholangiocarcinoma
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
Cholangiocarcinoma
Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma.
Cholangitis, Sclerosing
Identification of novel loci for pediatric cholestatic liver disease defined by KIF12, PPM1F, USP53, LSR, and WDR83OS pathogenic variants.
Cholelithiasis
Prevalence of cholecystolithiasis and its management among kidney/pancreas-transplanted type 1 (insulin-dependent) diabetic patients.
Cholera
Calcineurin mediates calcium-induced potentiation of adenylyl cyclase activity in dispersed chief cells from guinea pig stomach. Further evidence for cross-talk between signal transduction pathways that regulate pepsinogen secretion.
Cholera
Comparison of the immunogenicity of Dukoral® oral cholera vaccine between renal transplant recipients on either a calcineurin inhibitor or mycophenolate - A controlled trial.
Cholera
Regulation of the transmodulated epidermal growth factor receptor by cholera toxin and the protein phosphatase inhibitor okadaic acid.
Cholestasis
Calcineurin inhibitor-related cholestasis complicating lung transplantation.
Cholestasis
Plasma miR-218a-5p as a biomarker for acute cholestatic liver injury in rats and investigation of its pathophysiological roles.
Cholestasis, Intrahepatic
Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis.
Chondroma
Selective increase in expression of isoform PP1 gamma 1 of type-1 protein phosphatase in chondrosarcoma cells.
Chondrosarcoma
Enhanced expression of PP1gamma1, a catalytic subunit isoform of protein phosphatase type1 and expression of telomerase activity in Ewing's sarcoma cells.
Chondrosarcoma
Selective increase in expression of isoform PP1 gamma 1 of type-1 protein phosphatase in chondrosarcoma cells.
Choriocarcinoma
A protein kinase C-independent pathway leading to c-Jun-dependent expression of 100-kDa Ras GTPase-activating protein in JEG-3 human choriocarcinoma cells.
Choriocarcinoma
Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma.
Choriocarcinoma
Long noncoding RNA H19 controls DUSP5/ERK1/2 axis in cardiac fibroblast proliferation and fibrosis.
Chronic Traumatic Encephalopathy
Transcriptome analyses of chronic traumatic encephalopathy show alterations in protein phosphatase expression associated with tauopathy.
Chronic Urticaria
Calcineurin inhibitors in chronic urticaria.
Chronic Urticaria
Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria.
Chronic Urticaria
Omalizumab is efficacious for management of recalcitrant, antihistamine-resistant chronic urticaria.
Clostridium Infections
Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus.
Coccidiosis
A novel serine/threonine protein phosphatase type 5 from second-generation merozoite of Eimeria tenella is associated with diclazuril-induced apoptosis.
Coinfection
Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways.
Coinfection
Reduction of I(to) causes hypertrophy in neonatal rat ventricular myocytes.
Colitis
An approach to acute severe ulcerative colitis.
Colitis
Calcineurin inhibition by polaprezinc in rats with experimentally-induced colitis.
Colitis
Calcineurin inhibitors in steroid and anti-TNF-alpha refractory immune checkpoint inhibitor colitis.
Colitis
Cytomegalovirus colitis in inflammatory bowel disease and after haematopoietic stem cell transplantation: diagnostic accuracy, predictors, risk factors and disease outcome.
Colitis
Dual-specificity phosphatase 6 deletion protects the colonic epithelium against inflammation and promotes both proliferation and tumorigenesis.
Colitis
Dual-specificity phosphatase 6 regulates CD4+ T-cell functions and restrains spontaneous colitis in IL-10-deficient mice.
Colitis
DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis.
Colitis
FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression.
Colitis
Hyperosmotic stress contributes to mouse colonic inflammation through the methylation of protein phosphatase 2A.
Colitis
Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion.
Colitis
Tacrolimus ameliorates dextran sulfate sodium-induced colitis in mice: implication of interferon-? and interleukin-1? suppression.
Colitis
Where are we going with ulcerative colitis management?
Colitis, Ulcerative
A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis.
Colitis, Ulcerative
Amelioration of murine experimental colitis using biocompatible cyclosporine A lipid carriers.
Colitis, Ulcerative
Calcineurin inhibition in severe ulcerative colitis: Lost in translation?
Colitis, Ulcerative
Calcineurin inhibitors or anti-TNF-? agents in severe ulcerative colitis: available options and limitations.
Colitis, Ulcerative
Changes in the rate of and trends in colectomy for ulcerative colitis during the era of biologics and calcineurin inhibitors based on a Japanese nationwide cohort study.
Colitis, Ulcerative
Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy.
Colitis, Ulcerative
Comparing guidelines for the treatment of inflammatory bowel disease.
Colitis, Ulcerative
Current surgical practice in pediatric ulcerative colitis: A systematic review.
Colitis, Ulcerative
Editorial: calcineurin inhibitors as a bridge to vedolizumab for severe ulcerative colitis.
Colitis, Ulcerative
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.
Colitis, Ulcerative
Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination with Vedolizumab in Patients With Refractory Ulcerative Colitis.
Colitis, Ulcerative
EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Colitis, Ulcerative
Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients.
Colitis, Ulcerative
Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus.
Colitis, Ulcerative
Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis.
Colitis, Ulcerative
Optimizing conventional therapy for inflammatory bowel disease.
Colitis, Ulcerative
Pediatric ulcerative colitis: current treatment approaches including role of infliximab.
Colitis, Ulcerative
Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery.
Colitis, Ulcerative
Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors.
Colitis, Ulcerative
Prognostic factors for colectomy in refractory ulcerative colitis treated with calcineurin inhibitors.
Colitis, Ulcerative
Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis.
Colitis, Ulcerative
Readministration of calcineurin inhibitors for ulcerative colitis.
Colitis, Ulcerative
Recent trends and future directions for the medical treatment of ulcerative colitis.
Colitis, Ulcerative
Risk Factors of Colectomy in Patients With Refractory Ulcerative Colitis Under Calcineurin Inhibitors Combined With Vedolizumab.
Colitis, Ulcerative
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
Colitis, Ulcerative
Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis.
Colitis, Ulcerative
Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland.
Colitis, Ulcerative
Tacrolimus for the Treatment of Ulcerative Colitis.
Colitis, Ulcerative
Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review.
Colitis, Ulcerative
The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis.
Colitis, Ulcerative
The efficacy of oral tacrolimus in patients with moderate/severe ulcerative colitis not receiving concomitant corticosteroid therapy.
Colitis, Ulcerative
Therapy of ulcerative colitis.
Colitis, Ulcerative
Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.
Colitis, Ulcerative
[Current management of toxic megacolon].
Colonic Neoplasms
Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway.
Colonic Neoplasms
DUSP1 is controlled by p53 during the cellular response to oxidative stress.
Colonic Neoplasms
Dysregulated CRTC1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth.
Colonic Neoplasms
Elevated expression of the cdc25A protein phosphatase in colon cancer.
Colonic Neoplasms
Fibroblast-derived CXCL12 regulates PTEN expression and is associated with the proliferation and invasion of colon cancer cells via PI3k/Akt signaling.
Colonic Neoplasms
INPP4B is an oncogenic regulator in human colon cancer.
Colonic Neoplasms
Ligand modulates VDR-Ser/Thr protein phosphatase interaction and p70S6 kinase phosphorylation in a cell-context-dependent manner.
Colonic Neoplasms
LncRNA ROR1-AS1 promotes colon cancer cell proliferation by suppressing the expression of DUSP5/CDKN1A.
Colonic Neoplasms
New Acetohydrazides Incorporating 2-Oxoindoline and 4-Oxoquinazoline: Synthesis and Evaluation of Cytotoxicity and Caspase Activation Activity.
Colonic Neoplasms
Protein expression profiles that underpin the preventive and therapeutic potential of Moringa oleifera Lam against azoxymethane and dextran sodium sulfate-induced mouse colon carcinogenesis.
Colonic Neoplasms
Protein phosphatase 1H, overexpressed in colon adenocarcinoma, is associated with CSE1L.
Colonic Neoplasms
Silencing of PPMD1 inhibits proliferation of human colon cancer cells via induction of apoptosis and cell cycle arrest.
Colonic Neoplasms
Synergistic cytotoxic effect between serine-threonine phosphatase inhibitors and 5-fluorouracil: a novel concept for modulation of cytotoxic effect.
Colonic Neoplasms
The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 Inhibition.
Colonic Neoplasms
Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
Colonic Neoplasms
[Effects of phosphatase of regenerating liver cell-3 gene silence by RNA interference on the expression of matrix metalloproteinases-2,-9 in human colon cancer cells]
Colorectal Neoplasms
Association between PPP2CA expression and colorectal cancer prognosis Tumour Marker Prognostic Study.
Colorectal Neoplasms
Autocrine BMP-4 Signaling Is a Therapeutic Target in Colorectal Cancer.
Colorectal Neoplasms
Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer.
Colorectal Neoplasms
Calmodulin-binding proteins: A journey of 40 years.
Colorectal Neoplasms
Colorectal cancer: Calcineurin drives CRC tumorigenesis.
Colorectal Neoplasms
Correlation of PRL3 expression with colorectal cancer progression.
Colorectal Neoplasms
Cyclosporine A inhibits colorectal cancer proliferation probably by regulating expression levels of c-Myc, p21(WAF1/CIP1) and proliferating cell nuclear antigen.
Colorectal Neoplasms
Dual-specificity phosphatase 6 deletion protects the colonic epithelium against inflammation and promotes both proliferation and tumorigenesis.
Colorectal Neoplasms
DUSP10 gene polymorphism and risk of colorectal cancer in the Han Chinese population.
Colorectal Neoplasms
DUSP10 Is a Regulator of YAP1 Activity Promoting Cell Proliferation and Colorectal Cancer Progression.
Colorectal Neoplasms
DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
Colorectal Neoplasms
Epithelial Calcineurin Promotes Microbiota-Dependent Colorectal Cancer.
Colorectal Neoplasms
Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
Colorectal Neoplasms
High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.
Colorectal Neoplasms
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
Colorectal Neoplasms
Increased Calcineurin A Expression Is Associated with a Lower Relapse-Free Survival Rate after Colorectal Cancer Surgery.
Colorectal Neoplasms
Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
Colorectal Neoplasms
Inhibition of protein phosphatase 5 (PP5) suppresses survival and growth of colorectal cancer cells.
Colorectal Neoplasms
Knockdown of Protein Phosphatase Magnesium-dependent 1 (PPM1D) through Lentivirus-mediated RNA Silencing Inhibits Colorectal Carcinoma Cell Proliferation.
Colorectal Neoplasms
KRAS mutation leads to decreased expression of regulator of calcineurin 2, resulting in tumor proliferation in colorectal cancer.
Colorectal Neoplasms
Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Colorectal Neoplasms
Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells.
Colorectal Neoplasms
Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.
Colorectal Neoplasms
Polymorphisms in the DUSP10 gene are associated with sex-specific colorectal cancer risk in a Han population.
Colorectal Neoplasms
PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer.
Colorectal Neoplasms
PP4C facilitates lung cancer proliferation and inhibits apoptosis via activating MAPK/ERK pathway.
Colorectal Neoplasms
PPM1D is a prognostic marker and therapeutic target in colorectal cancer.
Colorectal Neoplasms
PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers.
Colorectal Neoplasms
Premature chromosome condensation revisited: a novel chemical approach permits efficient cytogenetic analysis of cancers.
Colorectal Neoplasms
The Comparison Between Molecular Tumour Profiling in Microdissected and Surgical Tissue Samples.
Colorectal Neoplasms
The critical role of calcineurin/NFAT (C/N) pathways and effective antitumor prospect for colorectal cancers.
Colorectal Neoplasms
The phosphatase of regenerating liver 3 (PRL-3) promotes cell migration via Arf-activity dependent stimulation of integrin alpha5 recycling.
Colorectal Neoplasms
The ratio of thioredoxin/Keap1 protein level is a predictor of distant metastasis in colorectal cancer.
Colorectal Neoplasms
Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
Colorectal Neoplasms
Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Colorectal Neoplasms
Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner.
Colorectal Neoplasms
[Expression of cancerous inhibitor of protein phosphatase 2A in tissue microarray of colorectal cancer and its clinical significance].
Common Cold
DUSP10 Negatively Regulates the Inflammatory Response to Rhinovirus through Interleukin-1? Signaling.
Communicable Diseases
CD28 confers CD4+ T cells with resistance to cyclosporin A and tacrolimus but to different degrees.
Communicable Diseases
Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings.
Communicable Diseases
Interactions between anti-infective agents and immunosuppressants-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Confusion
DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs.
Conjunctivitis
Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis.
Conjunctivitis, Allergic
Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis.
Conjunctivitis, Allergic
Phase II drugs under investigation for allergic conjunctivitis.
Conjunctivitis, Allergic
[New strategy in the treatment of vernal keratoconjunctivitis by calcineurin inhibitor eye drops].
Connective Tissue Diseases
The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases.
Corneal Neovascularization
Loss of Down Syndrome Critical Region-1 Mediated-Hypercholesterolemia Accelerates Corneal Opacity Via Pathological Neovessel Formation.
Corneal Opacity
Loss of Down Syndrome Critical Region-1 Mediated-Hypercholesterolemia Accelerates Corneal Opacity Via Pathological Neovessel Formation.
Coronary Artery Disease
ACP1 Genetic Polymorphism and Coronary Artery Disease: Evidence of Effects on Clinical Parameters of Cardiac Function.
Coronary Artery Disease
Association of CnB 5I/5D promoter gene polymorphism and serum calcineurin levels in early onset of coronary artery disease of south Indian cohort.
Coronary Artery Disease
Circulating levels of soluble EMMPRIN (CD147) correlate with levels of soluble glycoprotein VI in human plasma.
Coronary Artery Disease
Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab.
Coronary Disease
[Changes and significance of P-selectin and PAC-1 in coronary heart disease before and after stenting].
Coronary Disease
[Expression profile of calcineurin pathway genes in myocardium tissues in relation to ischemic heart remodeling in humans].
Coronary Vasospasm
Detection of platelets activated during acetylcholine-induced coronary vasospasm.
COVID-19
Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy.
COVID-19
Calcineurin Inhibitors and COVID-19.
COVID-19
Calcineurin inhibitors revisited: A new paradigm for COVID-19?
COVID-19
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).
COVID-19
COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm?
COVID-19
COVID-19 infection in a kidney transplant recipient-special emphasis on pharmacokinetic interactions: A case report.
COVID-19
Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection.
COVID-19
Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients.
COVID-19
Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.
COVID-19
Immunosuppression practices during the COVID-19 pandemic: A multinational survey study of transplant programs.
COVID-19
Kidney transplantation and COVID-19 renal and patient prognosis.
COVID-19
Pharmacotherapeutic considerations in solid organ transplant patients with COVID-19.
COVID-19
Resurgence of BK virus following Covid-19 in kidney transplant recipients.
COVID-19
SARS-CoV-2 attenuates corticosteroid sensitivity by suppressing DUSP1 expression and activating p38 MAPK pathway.
COVID-19
Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options.
Craniosynostoses
Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development.
Crohn Disease
Comparing guidelines for the treatment of inflammatory bowel disease.
Crohn Disease
Differences between treatment guidelines--Germany.
Crohn Disease
Newer Therapies for Inflammatory Bowel Disease.
Crohn Disease
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
Cryptococcosis
A Mechanosensitive Channel Governs Lipid Flippase-Mediated Echinocandin Resistance in Cryptococcus neoformans.
Cryptococcosis
Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis.
Cryptococcosis
Evaluation of host immune responses to pulmonary cryptococcosis using a temperature-sensitive C. neoformans calcineurin A mutant strain.
Cryptococcosis
Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression.
Cryptococcosis
Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent.
Cryptococcosis
T11TS immunotherapy potentiates the repressed Calcineurin-NFAT signaling pathway of T cells in Cryptococcus neoformans infected rats: A cue towards T cell activation for antifungal immunity.
Cryptogenic Organizing Pneumonia
BOOP is common in cardiac transplant recipients switched from a calcineurin inhibitor to sirolimus.
Cryptorchidism
Prevalence and associated phenotypes of DUSP6, IL17RD and SPRY4 variants in a large Chinese cohort with isolated hypogonadotropic hypogonadism.
Cystic Fibrosis
Association of cystic fibrosis transmembrane conductance regulator and protein phosphatase 2C.
Cystic Fibrosis
Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis.
Cystic Fibrosis
Protein phosphatase 2C dephosphorylates and inactivates cystic fibrosis transmembrane conductance regulator.
Cystic Fibrosis
Regulation of CFTR by protein phosphatase 2B and protein kinase C.
Cystic Fibrosis
The molecular basis of chloride channel dysregulation in cystic fibrosis.
Cystinosis
Excellent long-term outcome of renal transplantation in cystinosis patients.
Cystinuria
A recessive contiguous gene deletion of chromosome 2p16 associated with cystinuria and a mitochondrial disease.
Cystitis
Effects of herpes simplex virus vectors encoding poreless TRPV1 or protein phosphatase 1? in a rat cystitis model induced by hydrogen peroxide.
Cystitis
The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.
Cysts
Protein phosphatase 1ß limits ring canal constriction during Drosophila germline cyst formation.
Cysts
Protein phosphatase 2A, a potential regulator of actin dynamics and actin-based organelle motility in the green alga Acetabularia.
Cysts
Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma.
Cytomegalovirus Infections
A single-center experience of overseas kidney transplant for immunologically high-risk patients.
Cytomegalovirus Infections
A single-centre comparison of the clinical outcomes at 6 months of renal transplant recipients administered Adoport(®) or Prograf(®) preparations of tacrolimus.
Cytomegalovirus Infections
Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
Cytomegalovirus Infections
Cellular serine/threonine phosphatase activity during human cytomegalovirus infection.
Cytomegalovirus Infections
Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study.
Cytomegalovirus Infections
CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
Cytomegalovirus Infections
Comparison of long-term actual renal allograft survival in mycophenolate mofetil and azathioprine-based triple drug immunosuppression protocols.
Cytomegalovirus Infections
Cyclosporine Versus Tacrolimus: Which Calcineurin Inhibitor Has Influence on Cytomegalovirus Infection in Cardiac Transplantation?
Cytomegalovirus Infections
Deep vein thrombosis and pulmonary embolism after solid organ transplantation: an unresolved problem.
Cytomegalovirus Infections
Does the calcineurin inhibitor have influence on cytomegalovirus infection in heart transplantation?
Cytomegalovirus Infections
High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
Cytomegalovirus Infections
Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients.
Cytomegalovirus Infections
Incidence, Risk Factors, and Outcomes of Stroke Following Cardiac Transplantation.
Cytomegalovirus Infections
New-Onset Diabetes after Kidney Transplantation.
Cytomegalovirus Infections
New-onset diabetes mellitus after kidney transplantation: Current status and future directions.
Cytomegalovirus Infections
Outcomes of kidney transplantation over a 16-year period in Korea: An analysis of the National Health Information Database.
Cytomegalovirus Infections
RECENT ADVANCES IN MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR USE IN HEART AND LUNG TRANSPLANTATION.
Cytomegalovirus Infections
Sirolimus-based therapy for kidney transplantation from expanded criteria donors.
Cytomegalovirus Infections
The aetiology and pathogenesis of chronic allograft nephropathy.
Cytomegalovirus Infections
Urinary granzyme A mRNA is a biomarker to diagnose subclinical and acute cellular rejection in kidney transplant recipients.
De Lange Syndrome
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Deafness
Mutations in CDC14A, Encoding a Protein Phosphatase Involved in Hair Cell Ciliogenesis, Cause Autosomal-Recessive Severe to Profound Deafness.
Deafness
Taperin (c9orf75), a mutated gene in nonsyndromic deafness, encodes a vertebrate specific, nuclear localized protein phosphatase one alpha (PP1?) docking protein.
Death, Sudden, Cardiac
Galactokinase is a novel modifier of calcineurin-induced cardiomyopathy in Drosophila.
Death, Sudden, Cardiac
Overexpression of calcineurin in mouse causes sudden cardiac death associated with decreased density of K+ channels.
Deglutition Disorders
Eosinophilic esophagitis in children following cardiac transplantation: association with post-transplant lymphoproliferative disorder and other transplant outcomes.
Dehydration
An abscisic acid-AtNAP transcription factor-SAG113 protein phosphatase 2C regulatory chain for controlling dehydration in senescing Arabidopsis leaves.
Dehydration
Chronic interstitial nephritis in agricultural communities is a toxin-induced proximal tubular nephropathy.
Dehydration
Intra-specific variations in expression of stress-related genes in beech progenies are stronger than drought-induced responses.
Dehydration
Physiological and molecular responses for long term salinity stress in common fig (Ficus carica L.).
Dehydration
The root-colonizing endophyte Pirifomospora indica confers drought tolerance in Arabidopsis by stimulating the expression of drought stress-related genes in leaves.
Delirium
Pathophysiology and Management of Hyperammonemia in Organ Transplant Patients.
Dementia
Calcineurin Inhibition and Protein Kinase A Activation Limits Cognitive Dysfunction and Histopathological Damage in a Model of Dementia of the Alzheimer's Type.
Dementia
Calcineurin inhibitors improve memory loss and neuropathological changes in mouse model of dementia.
Dementia
Calcium phosphatase calcineurin influences tau metabolism.
Dementia
Generation and characterization of a laforin nanobody inhibitor.
Dementia
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Dementia
Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy.
Dementia
Reduced Incidence of Dementia in Solid Organ Transplant Patients Treated with Calcineurin Inhibitors.
Dementia
The 6th International Lafora Epilepsy Workshop: Advances in the search for a cure.
Dementia, Vascular
Knockdown of microRNA-195 contributes to protein phosphatase-2A inactivation in rats with chronic brain hypoperfusion.
Demyelinating Diseases
Calcineurin Activity Is Increased in Charcot-Marie-Tooth 1B Demyelinating Neuropathy.
Demyelinating Diseases
In vivo and in vitro models of demyelinating disease: a phosphoprotein phosphatase in host cell endosomes dephosphorylating the nucleocapsid protein of coronavirus JHM.
Dental Plaque
Characterization of a small plasmid determining resistance to erythromycin, lincomycin, and vernamycin Balpha in a strain of Streptococcus sanguis isolated from dental plaque.
Dermatitis
A Practical Guide to Patch Testing.
Dermatitis
Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis.
Dermatitis
Calcineurin inhibitors in the treatment of allergic dermatitis.
Dermatitis
Diagnosis and management of common dermatoses in children: atopic, seborrheic, and contact dermatitis.
Dermatitis
Evidence-based Danish Guidelines for the Treatment of Malassezia-related Skin Diseases.
Dermatitis
Granuloma Glutaeale Infantum: A Re-emerging Complication of Diaper Dermatitis.
Dermatitis
JAAD Game Changers: Topical calcineurin inhibitors for pediatric periorificial dermatitis.
Dermatitis
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Dermatitis
Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial.
Dermatitis
Port-wine-stain-associated dermatitis: implications for cutaneous vascular laser therapy.
Dermatitis
Red Ginseng Inhibits Scratching Behavior Associated With Atopic Dermatitis in Experimental Animal Models.
Dermatitis
Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience.
Dermatitis
Tacrolimus ointment in the treatment of hormone-dependent dermatitis: A protocol of systematic review.
Dermatitis
Tacrolimus-induced rosacea-like dermatitis: a clinical analysis of 16 cases associated with tacrolimus ointment application.
Dermatitis
The IKK-2/Ikappa Balpha /NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in Ikappa Balpha -deficient mice.
Dermatitis
Topical calcineurin inhibitors for pediatric periorificial dermatitis.
Dermatitis
Treatment of pediatric periorificial dermatitis with topical calcineurin inhibitor and topical/oral metronidazole.
Dermatitis
[Allergic contact eczema].
Dermatitis
[Cutaneous Malassezia infections and Malassezia associated dermatoses: An update].
Dermatitis, Allergic Contact
Discovery of Topical Calcineurin Inhibitors and Pharmacological Profile of Pimecrolimus.
Dermatitis, Allergic Contact
Human skin safety test of green tea cell extracts in condition of allergic contact dermatitis.
Dermatitis, Allergic Contact
Successful treatment of nodular actinic reticuloid with tacrolimus ointment.
Dermatitis, Allergic Contact
Tacrolimus modulates dendritic cell activation in the sensitization phase of allergic contact dermatitis.
Dermatitis, Atopic
A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030.
Dermatitis, Atopic
A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis.
Dermatitis, Atopic
A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis.
Dermatitis, Atopic
Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial.
Dermatitis, Atopic
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects.
Dermatitis, Atopic
Advances in allergic skin diseases.
Dermatitis, Atopic
Allergy in patients under fourteen years of age in Alergológica 2005.
Dermatitis, Atopic
Association Between Malignancy and Topical Use of Pimecrolimus.
Dermatitis, Atopic
Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis.
Dermatitis, Atopic
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.
Dermatitis, Atopic
Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns.
Dermatitis, Atopic
Atopic dermatitis in children, part 2: treatment options.
Dermatitis, Atopic
Atopic dermatitis: a review of topical nonsteroid therapy.
Dermatitis, Atopic
Atopic dermatitis: a review of topical treatment options.
Dermatitis, Atopic
Atopic dermatitis: an overview.
Dermatitis, Atopic
Atopic Dermatitis: Managing the Itch.
Dermatitis, Atopic
Atopic dermatitis: understanding the disease and its management.
Dermatitis, Atopic
Atopic eczema.
Dermatitis, Atopic
Attrition of topical calcineurin inhibitor use over time in patients with atopic dermatitis.
Dermatitis, Atopic
Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate.
Dermatitis, Atopic
Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application.
Dermatitis, Atopic
Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis.
Dermatitis, Atopic
Breaking the Itch-Scratch Cycle: Topical Options for the Management of Chronic Cutaneous Itch in Atopic Dermatitis.
Dermatitis, Atopic
Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology.
Dermatitis, Atopic
Calcineurin inhibitors for the treatment of atopic dermatitis.
Dermatitis, Atopic
Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence.
Dermatitis, Atopic
Calcineurin inhibitors in the treatment of allergic dermatitis.
Dermatitis, Atopic
Calcineurin inhibitors: a novel approach to canine atopic dermatitis.
Dermatitis, Atopic
Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
Dermatitis, Atopic
Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis
Dermatitis, Atopic
Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
Dermatitis, Atopic
CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults.
Dermatitis, Atopic
Cutaneous nocardiosis in two dogs receiving ciclosporin therapy for the management of canine atopic dermatitis.
Dermatitis, Atopic
Determination of the effect of calcineurin inhibitors on the rat's immune system after KLH immunisation.
Dermatitis, Atopic
Differences in therapeutic effects of topically applied corticosteroid and tacrolimus on atopic dermatitis-like symptoms in NC/Nga mice.
Dermatitis, Atopic
Differential effects of topical corticosteroid and calcineurin inhibitor on the epidermal tight junction.
Dermatitis, Atopic
Editorial comments on this issue of the Journal.
Dermatitis, Atopic
Effects of cyclosporin A and cilomilast on activated canine, murine and human keratinocytes.
Dermatitis, Atopic
Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Dermatitis, Atopic
Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials.
Dermatitis, Atopic
Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial.
Dermatitis, Atopic
Efficacy of topical calcineurin inhibitors in psoriasis.
Dermatitis, Atopic
Emerging systemic therapies for atopic dermatitis: oral small molecules and targeted topical agents.
Dermatitis, Atopic
Evaluation of Cancer Risk Related to Atopic Dermatitis and Use of Topical Calcineurin Inhibitors.
Dermatitis, Atopic
Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis.
Dermatitis, Atopic
Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis.
Dermatitis, Atopic
Glucocorticoids Inhibit Double-Stranded RNA-Induced Thymic Stromal Lymphopoietin Release from Keratinocytes in an Atopic Cytokine Milieu More Effectively than Tacrolimus.
Dermatitis, Atopic
Guidelines for the Management of Atopic Dermatitis in Singapore.
Dermatitis, Atopic
Health plan budget impact analysis for pimecrolimus.
Dermatitis, Atopic
How clinically relevant are treatment comparisons of topical calcineurin inhibitor trials for atopic eczema?
Dermatitis, Atopic
Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Dermatitis, Atopic
Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis.
Dermatitis, Atopic
Improving the management of atopic eczema in primary care.
Dermatitis, Atopic
Inhibition of calcineurin by cyclosporine A exerts multiple effects on human melanoma cell lines HT168 and WM35.
Dermatitis, Atopic
Innovative therapeutics in pediatric dermatology.
Dermatitis, Atopic
Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle.
Dermatitis, Atopic
Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults.
Dermatitis, Atopic
Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.
Dermatitis, Atopic
Long-Term Treatment of Atopic Dermatitis.
Dermatitis, Atopic
Maintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo-Controlled Study.
Dermatitis, Atopic
Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.
Dermatitis, Atopic
Management of atopic dermatitis in the pediatric population.
Dermatitis, Atopic
Management of atopic dermatitis: nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema.
Dermatitis, Atopic
Management of patients with atopic dermatitis: the role of emollient therapy.
Dermatitis, Atopic
Mechanism of action and clinical benefits of colloidal oatmeal for dermatologic practice.
Dermatitis, Atopic
Mechanisms of action of topical therapies and the rationale for combination therapy.
Dermatitis, Atopic
Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis.
Dermatitis, Atopic
Modulation of Lymphocyte Function In Vivo via Inhibition of Calcineurin or Purine Synthesis in Patients with Atopic Dermatitis.
Dermatitis, Atopic
Monitoring of therapy in atopic dermatitis - observations with the use of high-frequency ultrasonography.
Dermatitis, Atopic
New and emerging trends in the treatment of atopic dermatitis.
Dermatitis, Atopic
Off-label Uses of Topical Pimecrolimus.
Dermatitis, Atopic
Pediatric atopic dermatitis: a review of the medical management.
Dermatitis, Atopic
Periorbital dermatitis: Causes, differential diagnoses and therapy.
Dermatitis, Atopic
Personalized Immunomodulatory Therapy for Atopic Dermatitis: An Allergist's View.
Dermatitis, Atopic
Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.
Dermatitis, Atopic
Phosphodiesterase 4 inhibitors.
Dermatitis, Atopic
Pimecrolimus , a topical calcineurin inhibitor used in the treatment of atopic eczema.
Dermatitis, Atopic
Pimecrolimus in dermatology: atopic dermatitis and beyond.
Dermatitis, Atopic
Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
Dermatitis, Atopic
Pimecrolimus reduces eosinophil activation associated with calcium mobilization.
Dermatitis, Atopic
Pimecrolimus: a review of its use in atopic dermatitis.
Dermatitis, Atopic
Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro.
Dermatitis, Atopic
Position statement: topical calcineurin inhibitors in atopic dermatitis.
Dermatitis, Atopic
Potential new indications of topical calcineurin inhibitors.
Dermatitis, Atopic
Practical algorithm to inform clinical decision-making in the topical treatment of atopic dermatitis.
Dermatitis, Atopic
Prescriptions for atopic dermatitis: oral corticosteroids remain commonplace.
Dermatitis, Atopic
Recent advances in treatment strategies for atopic dermatitis.
Dermatitis, Atopic
Recent developments in the treatment of adult atopic dermatitis.
Dermatitis, Atopic
Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment.
Dermatitis, Atopic
Research Waste in Atopic Eczema Trials-Just the Tip of the Iceberg.
Dermatitis, Atopic
Review of Atopic Dermatitis and Topical Therapies.
Dermatitis, Atopic
Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum.
Dermatitis, Atopic
Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis.
Dermatitis, Atopic
Role of the epidermal barrier in atopic dermatitis.
Dermatitis, Atopic
Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy.
Dermatitis, Atopic
Role of topical calcineurin inhibitors on atopic dermatitis of children.
Dermatitis, Atopic
Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
Dermatitis, Atopic
Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
Dermatitis, Atopic
Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Dermatitis, Atopic
Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence.
Dermatitis, Atopic
Sclareol attenuates the development of atopic dermatitis induced by 2,4-dinitrochlorobenzene in mice.
Dermatitis, Atopic
Sdz asm 981.
Dermatitis, Atopic
Short-term efficacy of tacrolimus ointment and impact on quality of life.
Dermatitis, Atopic
Steroids versus other immune modulators in the management of allergic dermatoses.
Dermatitis, Atopic
Successful treatment of nodular actinic reticuloid with tacrolimus ointment.
Dermatitis, Atopic
Suppression of T cell activation by Hirsutenone, isolated from the bark of Alnus japonica, and its therapeutic advantages for atopic dermatitis.
Dermatitis, Atopic
Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience.
Dermatitis, Atopic
Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.
Dermatitis, Atopic
Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis.
Dermatitis, Atopic
Systemic therapy of atopic dermatitis.
Dermatitis, Atopic
Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis.
Dermatitis, Atopic
Tacrolimus for the management of psoriasis: clinical utility and place in therapy.
Dermatitis, Atopic
Tacrolimus ointment: a new therapy for atopic dermatitis--review of the literature.
Dermatitis, Atopic
Tacrolimus suppresses atopic dermatitis-associated cytokines and chemokines in monocytes.
Dermatitis, Atopic
The diagnosis and graded therapy of atopic dermatitis.
Dermatitis, Atopic
The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes.
Dermatitis, Atopic
The frequency and intensity of topical pimecrolimus treatment in children with physician-confirmed mild to moderate atopic dermatitis.
Dermatitis, Atopic
The ins and outs of an 'outside-in' view of allergies: atopic dermatitis and allergy prevention.
Dermatitis, Atopic
The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis.
Dermatitis, Atopic
The role of topical calcineurin inhibitors in atopic dermatitis.
Dermatitis, Atopic
The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review.
Dermatitis, Atopic
The show must go on: an update on clinical experiences and clinical studies on novel pharmaceutical developments for the treatment of atopic dermatitis.
Dermatitis, Atopic
The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.
Dermatitis, Atopic
The US FDA 'Black Box' Warning for Topical Calcineurin Inhibitors : An Ongoing Controversy.
Dermatitis, Atopic
Therapeutic Perspectives in Atopic Dermatitis.
Dermatitis, Atopic
Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.
Dermatitis, Atopic
Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.
Dermatitis, Atopic
Topical calcineurin inhibitors compromise stratum corneum integrity, epidermal permeability and antimicrobial barrier function.
Dermatitis, Atopic
Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks.
Dermatitis, Atopic
Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations.
Dermatitis, Atopic
Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis.
Dermatitis, Atopic
Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use.
Dermatitis, Atopic
Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues.
Dermatitis, Atopic
Topical calcineurin inhibitors in systemic lupus erythematosus.
Dermatitis, Atopic
Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues.
Dermatitis, Atopic
Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence.
Dermatitis, Atopic
Topical Corticosteroids and Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis: Focus on Percutaneous Absorption.
Dermatitis, Atopic
TOPICAL CORTICOSTEROIDS BUT NOT CALCINEURIN INHIBITORS INDUCED ATROPHY AFTER FOUR WEEKS.
Dermatitis, Atopic
Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.
Dermatitis, Atopic
Topical pimecrolimus and tacrolimus do not accelerate photocarcinogenesis in hairless mice after UVA or simulated solar radiation.
Dermatitis, Atopic
Topical pimecrolimus in the treatment of vitiligo.
Dermatitis, Atopic
Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Dermatitis, Atopic
Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy.
Dermatitis, Atopic
Treatment of pruritic diseases with topical calcineurin inhibitors.
Dermatitis, Atopic
Treatment strategies for atopic dermatitis: optimizing the available therapeutic options.
Dermatitis, Atopic
Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial.
Dermatitis, Atopic
Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
Dermatitis, Atopic
Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review.
Dermatitis, Atopic
Use of a home-visit nursing service to manage severe atopic dermatitis in a child with difficult family environment.
Dermatitis, Atopic
Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas.
Dermatitis, Atopic
What Is the Risk of Harm Associated With Topical Calcineurin Inhibitors?
Dermatitis, Atopic
What's new in the topical treatment of allergic skin diseases.
Dermatitis, Atopic
[Allergic contact eczema].
Dermatitis, Atopic
[Antipruritic effects of pimecrolimus and tacrolimus]
Dermatitis, Atopic
[Basis for the treatment of eczematous diseases in otorhinolaryngology].
Dermatitis, Atopic
[Calcineurin inhibitors in treatment of atopic dermatitis. Topical corticoids now only in severe outbreaks? ]
Dermatitis, Atopic
[Current aspects of the therapy with topical calcineurin inhibitors]
Dermatitis, Atopic
[How I treat ... atopic dermatitis by topical pimecrolimus (Elidel). The emerging paradigm of calcineurin inhibitors]
Dermatitis, Atopic
[Local treatment of atopic dermatitis with calcineurin inhibitors]
Dermatitis, Atopic
[Long term management of childhood atopic dermatitis with calcineurin inhibitors]
Dermatitis, Atopic
[New immune suppressants: topical immunomodulatory agents]
Dermatitis, Atopic
[Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life]
Dermatitis, Atopic
[Safety of topical tacrolimus and pimecrolimus in children with atopic dermatitis]
Dermatitis, Atopic
[The treatment of atopic dermatitis in adults with topical calcineurin inhibitors]
Dermatitis, Atopic
[Therapy of atopic dermatitis.]
Dermatitis, Atopic
[Therapy of atopic eczema with calcineurin inhibitors]
Dermatitis, Atopic
[Topical calcineurin inhibitors in atopic eczema -- contra]
Dermatitis, Atopic
[Topical calcineurin inhibitors in atopic eczema -- pro]
Dermatitis, Contact
Abnormal epidermal barrier in the pathogenesis of contact dermatitis.
Dermatitis, Contact
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Dermatitis, Contact
Pimecrolimus and tacrolimus differ in their inhibition of lymphocyte activation during the sensitization phase of contact hypersensitivity.
Dermatitis, Contact
Signal transducer and activator of transcription 1 decoy oligodeoxynucleotide suppression of contact hypersensitivity.
Dermatitis, Contact
Specific calcineurin targeting in macrophages confers resistance to inflammation via MKP-1 and p38.
Dermatitis, Exfoliative
Omenn syndrome: therapeutic effects of cyclosporin.
Dermatitis, Seborrheic
Clinical efficacies of topical agents for the treatment of seborrheic dermatitis of the scalp: a comparative study.
Dermatitis, Seborrheic
Maintenance Therapy of Facial Seborrheic Dermatitis with 0.1% Tacrolimus Ointment.
Dermatitis, Seborrheic
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Dermatitis, Seborrheic
Optimizing treatment approaches in seborrheic dermatitis.
Dermatitis, Seborrheic
Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy.
Dermatitis, Seborrheic
Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults.
Dermatitis, Seborrheic
Topical Anti-inflammatory Agents for Seborrheic Dermatitis of the Face or Scalp: Summary of a Cochrane Review.
Dermatomycoses
Clinical and mycological analysis of twenty-one cases of tinea incognita in the aegean region of Turkey: a retrospective study.
Dermatomycoses
Tinea Incognita following the Use of an Antipsoriatic Gel.
Dermatomycoses
[A tinea incognito case caused by Trichophyton rubrum with clinical and mycological cure and review of the literature]
Dermatomyositis
Effective Use of Calcineurin Inhibitor in Combination Therapy for Interstitial Lung Disease in Patients With Dermatomyositis and Polymyositis.
Dermatomyositis
Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
Diabetes Insipidus, Nephrogenic
Loss of calcineurin Aalpha results in altered trafficking of AQP2 and in nephrogenic diabetes insipidus.
Diabetes Mellitus
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
Diabetes Mellitus
A Rationale for Age-Adapted Immunosuppression in Organ Transplantation.
Diabetes Mellitus
Adiponectin and leptin gene polymorphisms in patients with post-transplant diabetes mellitus.
Diabetes Mellitus
Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Diabetes Mellitus
Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
Diabetes Mellitus
Atorvastatin Alleviates Experimental Diabetic Cardiomyopathy by Regulating the GSK-3?-PP2Ac-NF-?B Signaling Axis.
Diabetes Mellitus
Axillary Artery Dissection After Ultrasound-Guided Infraclavicular Brachial Plexus Block: A Case Report.
Diabetes Mellitus
Benefit-risk assessment of sirolimus in renal transplantation.
Diabetes Mellitus
Calcineurin inhibition and new-onset diabetes mellitus after transplantation.
Diabetes Mellitus
Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation.
Diabetes Mellitus
Calcineurin inhibitor-associated new-onset diabetes mellitus in chronic kidney disease treatment: a 4-year single-center cross-sectional study in China.
Diabetes Mellitus
Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers.
Diabetes Mellitus
Calcineurin inhibitors in renal transplantation: what is the best option?
Diabetes Mellitus
Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus.
Diabetes Mellitus
Calcineurin/NFAT signaling in the beta-cell: From diabetes to new therapeutics.
Diabetes Mellitus
CCL2 gene polymorphism is associated with post-transplant diabetes mellitus.
Diabetes Mellitus
Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant.
Diabetes Mellitus
Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus.
Diabetes Mellitus
Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report.
Diabetes Mellitus
Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells.
Diabetes Mellitus
Deciphering Tacrolimus-Induced Toxicity in Pancreatic ? Cells.
Diabetes Mellitus
Early non-immunological post transplant complications: a single center experience.
Diabetes Mellitus
Early-Onset Pneumonia After Liver Transplant: Microbial Causes, Risk Factors, and Outcomes, Mansoura University, Egypt, Experience.
Diabetes Mellitus
Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia.
Diabetes Mellitus
Excellent long-term outcome of renal transplantation in cystinosis patients.
Diabetes Mellitus
Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
Diabetes Mellitus
Glucocorticoids use in kidney transplant setting.
Diabetes Mellitus
HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.
Diabetes Mellitus
Hypertension and hepatitis C virus infection are strong risk factors for developing late renal dysfunction after living donor liver transplantation: significance of renal biopsy.
Diabetes Mellitus
Impaired glucose transport and protein kinase B activation by insulin, but not okadaic acid, in adipocytes from subjects with Type II diabetes mellitus.
Diabetes Mellitus
Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients.
Diabetes Mellitus
Influence of long chain polyunsaturated fatty acids and ornithine concentrations on complications after renal transplant.
Diabetes Mellitus
KCNJ11 and KCNQ1 Gene Polymorphisms Are Not Associated with Post-Transplant Diabetes Mellitus in Kidney Allograft Recipients Treated with Tacrolimus.
Diabetes Mellitus
Necrobiosis lipoidica with rapid response to doxycycline.
Diabetes Mellitus
New onset diabetes after transplantation (NODAT): an overview.
Diabetes Mellitus
New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis.
Diabetes Mellitus
New-onset diabetes mellitus after solid organ transplantation.
Diabetes Mellitus
Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study.
Diabetes Mellitus
Post-transplant diabetic ketoacidosis--a possible consequence of immunosuppression with calcineurin inhibiting agents: a case series.
Diabetes Mellitus
Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
Diabetes Mellitus
Predictors of decline in renal function after lung transplantation.
Diabetes Mellitus
Proteasomal degradation of IRS-2, but not IRS-1 by calcineurin inhibition: attenuation of insulin-like growth factor-I-induced GSK-3beta and ERK pathways in adrenal chromaffin cells.
Diabetes Mellitus
Regulation of dual leucine zipper kinase activity through its interaction with calcineurin.
Diabetes Mellitus
Risk factors for acute renal injury in living donor liver transplantation: evaluation of the RIFLE criteria.
Diabetes Mellitus
Serum calcineurin activity in relation to oxidative stress and glycemic control in type II diabetes mellitus.
Diabetes Mellitus
The defective protein level of myosin light chain phosphatase (MLCP) in the isolated saphenous vein, as a vascular conduit in coronary artery bypass grafting (CABG), harvested from patients with diabetes mellitus (DM).
Diabetes Mellitus
The role and value of sirolimus administration in kidney and liver transplantation.
Diabetes Mellitus
The year in review--ATC 2002.
Diabetes Mellitus
Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases.
Diabetes Mellitus
[Calcineurin inhibitors and mechanisms that are responsible for the appearance of post-transplant diabetes mellitus]
Diabetes Mellitus
[Chronic renal failure after heart, lung, liver, or intestine transplantation]
Diabetes Mellitus
[Late complications following renal transplantation]
Diabetes Mellitus
[New immunosuppressive drugs and diabetes]
Diabetes Mellitus, Experimental
[Effect of trihydroxyoctadecadiene acids from Bryonia alba L. on the activity of glycogen metabolism enzymes in alloxan diabetes]
Diabetes Mellitus, Type 1
Atorvastatin Alleviates Experimental Diabetic Cardiomyopathy by Regulating the GSK-3?-PP2Ac-NF-?B Signaling Axis.
Diabetes Mellitus, Type 1
Calcineurin Inhibitor-Free Immunosuppressive Regimen in Type 1 Diabetes Patients Receiving Islet Transplantation: Single-Group Phase 1/2 Trial.
Diabetes Mellitus, Type 1
Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients.
Diabetes Mellitus, Type 2
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Abnormal myosin phosphatase targeting subunit 1 phosphorylation and actin polymerization contribute to impaired myogenic regulation of cerebral arterial diameter in the type 2 diabetic Goto-Kakizaki rat.
Diabetes Mellitus, Type 2
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
Diabetes Mellitus, Type 2
Cytoprotective regulation of the mitochondrial permeability transition pore is impaired in type 2 diabetic Goto-Kakizaki rat hearts.
Diabetes Mellitus, Type 2
Dysfunction of insulin mediator protein kinase FA in lymphocytes of patients with NIDDM.
Diabetes Mellitus, Type 2
Effect of insulin on protein phosphatase 2A expression in muscle in type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Egr-1 transcriptionally activates protein phosphatase PTP1B to facilitate hyperinsulinemia-induced insulin resistance in the liver in type 2 diabetes.
Diabetes Mellitus, Type 2
Exendin-4 stimulates autophagy in pancreatic ?-cells via the RAPGEF/EPAC-Ca2+-PPP3/calcineurin-TFEB axis.
Diabetes Mellitus, Type 2
HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.
Diabetes Mellitus, Type 2
Hypomethylation of the promoter of the catalytic subunit of protein phosphatase 2A in response to hyperglycemia.
Diabetes Mellitus, Type 2
Insulin Requirement After a Renal Transplant in Patients With Type 2 Diabetes: The Choice of Calcineurin Inhibitors.
Diabetes Mellitus, Type 2
Is a flavonoid-rich diet with steamer cooking safe during calcineurin inhibitors therapy?
Diabetes Mellitus, Type 2
Magnesemia in renal transplant recipients: relation with immunosuppression and posttransplant diabetes.
Diabetes Mellitus, Type 2
Mutational analysis of the coding regions of the genes encoding protein kinase B-alpha and -beta, phosphoinositide-dependent protein kinase-1, phosphatase targeting to glycogen, protein phosphatase inhibitor-1, and glycogenin: lessons from a search for genetic variability of the insulin-stimulated glycogen synthesis pathway of skeletal muscle in NIDDM patients.
Diabetes Mellitus, Type 2
New-Onset Diabetes after Kidney Transplantation.
Diabetes Mellitus, Type 2
New-onset diabetes after renal transplantation.
Diabetes Mellitus, Type 2
The B55alpha-containing PP2A holoenzyme dephosphorylates FOXO1 in islet beta cells under oxidative stress.
Diabetes Mellitus, Type 2
Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus.
Diabetic Angiopathies
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
Diabetic Cardiomyopathies
Leukocytic toll-like receptor 2 knockout protects against diabetes-induced cardiac dysfunction.
Diabetic Nephropathies
Calcineurin is activated in diabetes and is required for glomerular hypertrophy and ECM accumulation.
Diabetic Nephropathies
Cluster analysis and phylogenetic relationship in biomarker identification of type 2 diabetes and nephropathy.
Diabetic Nephropathies
Differential expression of calcineurin A isoforms in the diabetic kidney.
Diabetic Nephropathies
DUSP1 overexpression attenuates renal tubular mitochondrial dysfunction by restoring Parkin-mediated mitophagy in diabetic nephropathy.
Diabetic Nephropathies
DUSP1 recuses diabetic nephropathy via repressing JNK-Mff-mitochondrial fission pathways.
Diabetic Nephropathies
DUSP26 regulates podocyte oxidative stress and fibrosis in a mouse model with diabetic nephropathy through the mediation of ROS.
Diabetic Nephropathies
FK506 ameliorates renal injury in early experimental diabetic rats induced by streptozotocin.
Diabetic Nephropathies
FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats.
Diabetic Nephropathies
Inhibition of calcineurin/NFAT pathway plays an essential role in renoprotective effect of tropisetron in early stage of diabetic nephropathy.
Diabetic Nephropathies
Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat.
Diabetic Nephropathies
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
Diabetic Neuropathies
Downregulation of calcineurin activity in cervical carcinoma.
Diabetic Retinopathy
Expression of wild-type p53-induced phosphatase 1 in diabetic epiretinal membranes.
Diabetic Retinopathy
Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation.
Diffuse Intrinsic Pontine Glioma
Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Diffuse Intrinsic Pontine Glioma
Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Diplopia
Isolated diplopia associated with calcineurin inhibitor therapy in a patient with idiopathic membranous nephropathy: a case report.
DNA Virus Infections
Dephosphorylation of cGAS by PPP6C impairs its substrate binding activity and innate antiviral response.
Down Syndrome
A calcineurin inhibitory protein overexpressed in Down's syndrome interacts with the product of a ubiquitously expressed transcript.
Down Syndrome
A conserved family of calcineurin regulators.
Down Syndrome
A low-risk ZnT-8 allele (W325) for post-transplantation diabetes mellitus is protective against cyclosporin A-induced impairment of insulin secretion.
Down Syndrome
A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling.
Down Syndrome
A single extra copy of Down syndrome critical region 1-4 results in impaired hepatic glucose homeostasis.
Down Syndrome
A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis.
Down Syndrome
A zebrafish model for calcineurin-dependent brain function.
Down Syndrome
Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test.
Down Syndrome
Arsenic Trioxide Inhibits the Metastasis of Small Cell Lung Cancer by Blocking Calcineurin-Nuclear Factor of Activated T Cells (NFAT) Signaling.
Down Syndrome
Association Between Sequence Variations in RCAN1 Promoter and the Risk of Sporadic Congenital Heart Disease in a Chinese Population.
Down Syndrome
c-Jun Inhibits Thapsigargin-Induced ER Stress Through Up-Regulation of DSCR1/Adapt78.
Down Syndrome
Calcineurin activity in children with Mental handicap.
Down Syndrome
Confirmed rare copy number variants implicate novel genes in schizophrenia.
Down Syndrome
Covalent NEDD8 conjugation increases RCAN1 protein stability and potentiates its inhibitory action on calcineurin.
Down Syndrome
Creation and characterization of BAC-transgenic mice with physiological overexpression of epitope-tagged RCAN1 (DSCR1).
Down Syndrome
CREB activates proteasomal degradation of DSCR1/RCAN1.
Down Syndrome
CREB-mediated Bcl-2 expression contributes to RCAN1 protection from hydrogen peroxide-induced neuronal death.
Down Syndrome
Cyclosporin A Promotes Tumor Angiogenesis in a Calcineurin-Independent Manner by Increasing Mitochondrial Reactive Oxygen Species.
Down Syndrome
Degradation of regulator of calcineurin 1 (RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways.
Down Syndrome
Differential expression of members of the RCAN family of calcineurin regulators suggests selective functions for these proteins in the brain.
Down Syndrome
Direct biomechanical induction of endogenous calcineurin inhibitor Down Syndrome Critical Region-1 in cardiac myocytes.
Down Syndrome
Division of labor in the growth cone by DSCR1.
Down Syndrome
Down syndrome candidate region 1 increases the stability of the IkappaBalpha protein: implications for its anti-inflammatory effects.
Down Syndrome
Down syndrome candidate region 1-like 1 (DSCR1-L1) mimics the inhibitory effects of DSCR1 on calcineurin signaling in endothelial cells and inhibits angiogenesis.
Down Syndrome
Down syndrome critical region 1 enhances the proteolytic cleavage of calcineurin.
Down Syndrome
Down syndrome critical region-1 is a transcriptional target of nuclear factor of activated T cells-c1 within the endocardium during heart development.
Down Syndrome
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.
Down Syndrome
DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways.
Down Syndrome
Fecal corticosterone levels in RCAN1 mutant mice.
Down Syndrome
Histone deacetylase 3 promotes RCAN1 stability and nuclear translocation.
Down Syndrome
Identification and analysis of human RCAN3 (DSCR1L2) mRNA and protein isoforms.
Down Syndrome
Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans.
Down Syndrome
Interaction of calcineurin with substrates and targeting proteins.
Down Syndrome
Lycopene inhibits regulator of calcineurin 1-mediated apoptosis by reducing oxidative stress and down-regulating Nucling in neuronal cells.
Down Syndrome
Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) Targets Down Syndrome Candidate Region 1 (DSCR1/RCAN1) to control Neuronal Differentiation.
Down Syndrome
Protein kinase A phosphorylates Down syndrome critical region 1 (RCAN1).
Down Syndrome
Raf-1 is a binding partner of DSCR1.
Down Syndrome
RCAN1 (DSCR1) increases neuronal susceptibility to oxidative stress: a potential pathogenic process in neurodegeneration.
Down Syndrome
RCAN1 links impaired neurotrophin trafficking to aberrant development of the sympathetic nervous system in Down syndrome.
Down Syndrome
RCAN1 Mutation and Functional Characterization in Children with Sporadic Congenital Heart Disease.
Down Syndrome
RCAN1 overexpression promotes age-dependent mitochondrial dysregulation related to neurodegeneration in Alzheimer's disease.
Down Syndrome
Regulation of Down Syndrome Critical Region 1 expression by Nuclear Factor of Activated T cells in megakaryocytes.
Down Syndrome
Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.
Down Syndrome
Regulation of RCAN1 translation and its role in oxidative stress-induced apoptosis.
Down Syndrome
Regulator of Calcineurin (RCAN): Beyond Down Syndrome Critical Region.
Down Syndrome
Regulator of Calcineurin (RCAN-1) Regulates Thermotaxis Behavior in Caenorhabditis elegans.
Down Syndrome
Regulator of calcineurin 1 is a novel RNA-binding protein to regulate neuronal apoptosis.
Down Syndrome
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth.
Down Syndrome
The Caenorhabditis elegans homologue of Down syndrome critical region 1, RCN-1, inhibits multiple functions of the phosphatase calcineurin.
Down Syndrome
The calcineurin inhibitor Sarah (Nebula) exacerbates A?42 phenotypes in a Drosophila model of Alzheimer's disease.
Down Syndrome
The neuronal and endocrine roles of RCAN1 in health and disease.
Down Syndrome
The regulator of calcineurin (RCAN1) an important factor involved in atherosclerosis and cardiovascular diseases development.
Down Syndrome
The regulator of calcineurin 1 (RCAN1/DSCR1) activates the cAMP response element-binding protein (CREB) pathway.
Down Syndrome
The transcription factor STAT2 enhances proteasomal degradation of RCAN1 through the ubiquitin E3 ligase FBW7.
Down Syndrome
Trisomy of the Dscr1 gene suppresses early progression of pancreatic intraepithelial neoplasia driven by oncogenic Kras.
Down Syndrome
VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis?
Drug Resistant Epilepsy
A novel compound heterozygous EPM2A mutation in a Chinese boy with Lafora disease.
Drug Resistant Epilepsy
De Novo Mutations in PPP3CA Cause Severe Neurodevelopmental Disease with Seizures.
Drug Resistant Epilepsy
Early-onset infant epileptic encephalopathy associated with a de novo PPP3CA gene mutation.
Drug Resistant Epilepsy
Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy.
Drug Resistant Epilepsy
PPP3CA truncating variants clustered in the regulatory domain cause early-onset refractory epilepsy.
Drug-Related Side Effects and Adverse Reactions
A model of prediction system for adverse cardiovascular reactions by calcineurin inhibitors among patients with renal transplants using gene-based single-nucleotide polymorphisms.
Drug-Related Side Effects and Adverse Reactions
Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling.
Drug-Related Side Effects and Adverse Reactions
Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
Drug-Related Side Effects and Adverse Reactions
Idiosyncratic drug reactions and membranous glomerulopathy.
Drug-Related Side Effects and Adverse Reactions
Immunosuppressive agents in organ transplantation: past, present, and future.
Drug-Related Side Effects and Adverse Reactions
Liver transplantation and liver cell transplantation.
Drug-Related Side Effects and Adverse Reactions
Mycophenolate sodium: tolerability and efficacy in transplantation in the rat.
Drug-Related Side Effects and Adverse Reactions
Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies.
Drug-Related Side Effects and Adverse Reactions
The influence of immunomodulatory diets on transplant success and complications.
Dry Eye Syndromes
Calcineurin Inhibitor Voclosporin Preserves Corneal Barrier and Conjunctival Goblet Cells in Experimental Dry Eye.
Ductus Arteriosus, Patent
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Dwarfism
Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development.
Dysautonomia, Familial
Calcineurin and synaptophysin in the human spinal cord of normal individuals and patients with familial dysautonomia.
Dyslexia
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Dyslipidemias
A retrospective analysis of ezetimibe treatment in renal transplant recipients.
Dyslipidemias
Calcineurin Antagonizes AMPK to Regulate Lipolysis in Caenorhabditis elegans.
Dyslipidemias
Characteristics and Outcomes of Kidney Transplant Recipients with a Functioning Graft for More than 25 Years.
Dyslipidemias
Cyclosporin A inhibits apolipoprotein AI gene expression.
Dyslipidemias
mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?
Dyslipidemias
New onset diabetes after transplantation (NODAT): an overview.
Dyslipidemias
Nutritional and metabolic issues in solid organ transplantation: targets for future research.
Dyslipidemias
Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia.
Dyslipidemias
[Chronic renal failure after heart, lung, liver, or intestine transplantation]
Dyspnea
Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.
Eclampsia
Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin.
Eclampsia
Elucidating the mechanism of posterior reversible encephalopathy syndrome: a case of transient blindness after central venous catheterization.
Eczema
A multi-centre, parallel group superiority trial of silk therapeutic clothing compared to standard care for the management of eczema in children (CLOTHES Trial): study protocol for a randomised controlled trial.
Eczema
A Practical Guide to Patch Testing.
Eczema
Atopic dermatitis: skin care and topical therapies.
Eczema
Atopic dermatitis: the updated practice parameter and beyond.
Eczema
Challenges in assessing rare risks associated with topical calcineurin inhibitors for the treatment of eczema.
Eczema
Common Skin Conditions in Children: Noninfectious Rashes.
Eczema
Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness.
Eczema
Health plan budget impact analysis for pimecrolimus.
Eczema
Incidence Trends of Atopic Dermatitis in Infancy and Early Childhood in a Nationwide Prescription Registry Study in Norway.
Eczema
Management of atopic dermatitis: nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema.
Eczema
National Eczema Association and topical calcineurin inhibitor labeling.
Eczema
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Eczema
Potential new indications of topical calcineurin inhibitors.
Eczema
Predictors of Basal Cell Carcinoma in High-Risk Patients in the VATTC (VA Topical Tretinoin Chemoprevention) Trial.
Eczema
Skin conditions: new drugs for managing skin disorders.
Eczema
Topical calcineurin inhibitors in eczema and cancer association: A cohort study.
Eczema
Treatment of childhood eczema.
Eczema
Treatment policy for psoriasis and eczema: a survey among dermatologists in the Netherlands and Belgian Flanders.
Eczema
Use of Complementary and Alternative Therapies in Outpatients with Atopic Dermatitis from a Dermatological University Department.
Eczema
[Development of calcineurin blocking non-steroid topical immunosuppressants for effective management of eczema]
Eczema
[Evidence-based treatment options for allergic diseases in otolaryngology: an update].
Eczema
[New and rarley used treatment options for refractory hand eczema: local UVA-1 phototherapy, retinoids, calcineurin inhibitors]
Eczema
[Off-label indications for topical tacrolimus].
Eczema
[The treatment of atopic dermatitis in adults with topical calcineurin inhibitors]
Eczema, Dyshidrotic
Pompholyx: what's new?
Edema, Cardiac
VEGF-C/VEGFR-3 axis protects against pressure-overload induced cardiac dysfunction through regulation of lymphangiogenesis.
Embolic Stroke
Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury.
Embolism
Comparison of denovo sirolimus vs. Calcineurin inhibitor immunosuppression regarding incidence of deep venous thrombosis and pulmonary embolism following renal transplantation.
Encephalitis
Human herpesvirus 6 encephalitis in patients administered mycophenolate mofetil as prophylaxis for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Encephalitis
Posterior reversible encephalopathy syndrome concurrent with human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation.
Encephalomyelitis
Butylphthalide ameliorates experimental autoimmune encephalomyelitis by suppressing PGAM5-induced necroptosis and inflammation in microglia.
Encephalomyelitis, Autoimmune, Experimental
Butylphthalide ameliorates experimental autoimmune encephalomyelitis by suppressing PGAM5-induced necroptosis and inflammation in microglia.
Encephalomyelitis, Venezuelan Equine
Protein Phosphatase 1? Interacts with Venezuelan Equine Encephalitis Virus Capsid Protein and Regulates Viral Replication through Modulation of Capsid Phosphorylation.
End Stage Liver Disease
A comprehensive review of immunosuppression used for liver transplantation.
Endometrial Hyperplasia
Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Endometrial Neoplasms
Analysis of methylation profiling data of hyperplasia and primary and metastatic endometrial cancers.
Endometrial Neoplasms
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
Endometrial Neoplasms
Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
Endometrial Neoplasms
Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Endometrial Neoplasms
Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway.
Endometrial Neoplasms
Identification and allelic frequencies of novel single-nucleotide polymorphisms in the DUSP1 and BTG1 genes.
Endometrial Neoplasms
Infrequent methylation of the DUSP6 phosphatase in endometrial cancer.
Endometrial Neoplasms
Membrane-associated serine/threonine protein phosphatase in endometrial cancer.
Endometrial Neoplasms
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Endometrial Neoplasms
[MicroRNA-145-5p over-expression suppresses proliferation, migration and invasion and promotes apoptosis of human endometrial cancer cells by targeting dual specific phosphatase 6].
Endometriosis
Administration of betaHCG leads to dose-dependent changes of gene expression signature of endometriotic stromal cells.
Endometriosis
Elevated phosphatase of regenerating liver 3 (PRL-3) promotes cytoskeleton reorganization, cell migration and invasion in endometrial stromal cells from endometrioma.
Endometriosis
Endometrial ILKAP expression among patients with endometriosis and its association with clinical characteristics.
Endotoxemia
Calcineurin regulates myocardial function during acute endotoxemia.
Eosinophilia
Regulator of calcineurin 1 (rcan1) is required for the development of pulmonary eosinophilia in allergic inflammation in mice.
Epilepsies, Myoclonic
A novel nonsense mutation of the EPM2A gene in Northwest Greece causing myoclonic epilepsy.
Epilepsies, Myoclonic
A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.
Epilepsies, Myoclonic
Are there errors in glycogen biosynthesis and is laforin a repair enzyme?
Epilepsies, Myoclonic
Biophysical characterization of laforin-carbohydrate interaction.
Epilepsies, Myoclonic
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
Epilepsies, Myoclonic
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Epilepsies, Myoclonic
Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy.
Epilepsies, Myoclonic
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
Epilepsy
A bioassay for Lafora disease and laforin glucan phosphatase activity.
Epilepsy
A chloroplast-localized dual-specificity protein phosphatase in Arabidopsis contains a phylogenetically dispersed and ancient carbohydrate-binding domain, which binds the polysaccharide starch.
Epilepsy
Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.
Epilepsy
Altered patterns of Ca2+/calmodulin-dependent protein kinase II and calcineurin immunoreactivity in the hippocampus of patients with temporal lobe epilepsy.
Epilepsy
Assessing the Biological Activity of the Glucan Phosphatase Laforin.
Epilepsy
Astrocytes and neurons produce distinct types of polyglucosan bodies in Lafora disease.
Epilepsy
Burden analysis of rare microdeletions suggests a strong impact of neurodevelopmental genes in genetic generalised epilepsies.
Epilepsy
Calmodulin-binding proteins: A journey of 40 years.
Epilepsy
De Novo Mutations in PPP3CA Cause Severe Neurodevelopmental Disease with Seizures.
Epilepsy
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
Epilepsy
Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling.
Epilepsy
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Epilepsy
Glycogen phosphorylation and Lafora disease.
Epilepsy
High level calcineurin activity predisposes neuronal cells to apoptosis.
Epilepsy
Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.
Epilepsy
Hyperphosphorylation of glucosyl C6 carbons and altered structure of glycogen in the neurodegenerative epilepsy Lafora disease.
Epilepsy
Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product.
Epilepsy
Incorporation of phosphate into glycogen by glycogen synthase.
Epilepsy
Isolation and characterization of mouse homologue for the human epilepsy gene, EPM2A.
Epilepsy
Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.
Epilepsy
Mutations in NHLRC1 cause progressive myoclonus epilepsy.
Epilepsy
Myristoyltransferase and calcineurin: novel molecular therapeutic target for epilepsy.
Epilepsy
Novel calcineurin A (PPP3CA) variant associated with epilepsy, constitutive enzyme activation and downregulation of protein expression.
Epilepsy
Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy.
Epilepsy
Polyglucosan body structure in Lafora disease.
Epilepsy
Prolonged infusion of inhibitors of calcineurin or L-type calcium channels does not block mossy fiber sprouting in a model of temporal lobe epilepsy.
Epilepsy
Similar protein phosphatases control starch metabolism in plants and glycogen metabolism in mammals.
Epilepsy
Spatiotemporal expression of RCAN1 and its isoform RCAN1-4 in the mouse hippocampus after pilocarpine-induced status epilepticus.
Epilepsy
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
Epilepsy
Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.
Epilepsy
The 6th International Lafora Epilepsy Workshop: Advances in the search for a cure.
Epilepsy
The Emerging Roles of the Calcineurin-Nuclear Factor of Activated T-Lymphocytes Pathway in Nervous System Functions and Diseases.
Epilepsy
Traumatic Brain Injury Causes a Tacrolimus-Sensitive Increase in Non-Convulsive Seizures in a Rat Model of Post-Traumatic Epilepsy.
Epilepsy
Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the malin-laforin E3-ubiquitin ligase complex.
Epilepsy, Frontal Lobe
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
Epilepsy, Post-Traumatic
Traumatic Brain Injury Causes a Tacrolimus-Sensitive Increase in Non-Convulsive Seizures in a Rat Model of Post-Traumatic Epilepsy.
Epilepsy, Temporal Lobe
Altered patterns of Ca2+/calmodulin-dependent protein kinase II and calcineurin immunoreactivity in the hippocampus of patients with temporal lobe epilepsy.
Epilepsy, Temporal Lobe
Prolonged infusion of inhibitors of calcineurin or L-type calcium channels does not block mossy fiber sprouting in a model of temporal lobe epilepsy.
Epilepsy, Temporal Lobe
Spatiotemporal expression of RCAN1 and its isoform RCAN1-4 in the mouse hippocampus after pilocarpine-induced status epilepticus.
Epiretinal Membrane
Expression of wild-type p53-induced phosphatase 1 in diabetic epiretinal membranes.
Erectile Dysfunction
[Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction]
Erythema
Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus.
Erythema
Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
Erythema
The UV erythema test as a model to investigate the anti-inflammatory potency of topical preparations--reevaluation and optimization of the method.
Esophageal Achalasia
Chest pain in a heart transplant recipient: A case report.
Esophageal Neoplasms
PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
MicroRNA-527 Induces Proliferation and Cell Cycle in Esophageal Squamous Cell Carcinoma Cells by Repressing PH Domain Leucine-Rich-Repeats Protein Phosphatase 2.
Esophageal Squamous Cell Carcinoma
PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Esthesioneuroblastoma, Olfactory
Calcineurin, a calcium/calmodulin-regulated protein phosphatase, in mammalian neuroendocrine cells and neoplasms.
Eye Diseases
Immunosuppression for the Uveitides.
Eye Infections
Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis.
Facial Dermatoses
[Steroid-aggravated rosacea: successful therapy with pimecrolimus]
Fanconi Anemia
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Fatty Liver
Calcineurin inhibitor attenuates cardiac hypertrophy due to energy metabolic disorder.
Fatty Liver
Pediatric post-transplant metabolic syndrome: New clouds on the horizon.
Fibroadenoma
Effect of Converting From Calcineurin Inhibitor- to Sirolimus-Based Immunosuppressant Regimen on Breast Fibroadenoma Among Kidney Transplant Patients.
Fibroadenoma
Enhanced expression of PP1 gamma 1, a catalytic subunit isoform of protein phosphatase type 1, in invasive ductal carcinoma of the breast.
Fibrocystic Breast Disease
Enhanced expression of PP1 gamma 1, a catalytic subunit isoform of protein phosphatase type 1, in invasive ductal carcinoma of the breast.
Fibroma
Loss of alpha 2-macroglobulin and epidermal growth factor surface binding induced by phenothiazines and naphthalene sulfonamides.
Food Hypersensitivity
Allergic disease after pediatric liver transplantation with systemic tacrolimus and cyclosporine a therapy.
Food Hypersensitivity
Management of tacrolimus-associated food allergy after liver transplantation.
Frontotemporal Dementia
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Frontotemporal Dementia
Tau pathology in Alzheimer disease and other tauopathies.
Frontotemporal Dementia
The phosphatase calcineurin regulates pathological TDP-43 phosphorylation.
Fungemia
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis.
Gallbladder Neoplasms
DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system.
Gallbladder Neoplasms
DUSP1 inhibits cell proliferation, metastasis and invasion and angiogenesis in gallbladder cancer.
Gallbladder Neoplasms
Protein phosphatase PHLPP induces cell apoptosis and exerts anticancer activity by inhibiting Survivin phosphorylation and nuclear export in gallbladder cancer.
Gastrointestinal Stromal Tumors
Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.
Gastroparesis
Impaired contractile responses and altered expression and phosphorylation of Ca(2+) sensitization proteins in gastric antrum smooth muscles from ob/ob mice.
Genetic Diseases, Inborn
Calcineurin A alpha (PPP3CA), calcineurin A beta (PPP3CB) and calcineurin B (PPP3R1) are located on human chromosomes 4, 10q21-->q22 and 2p16-->p15 respectively.
Genetic Diseases, Inborn
Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles.
Genetic Diseases, Inborn
NHLRC1 homozygous dodecamer expansion in a Newfoundland dog with Lafora disease.
Gestational Trophoblastic Disease
[Expression and significance of LMP2 and PPM1A in gestational trophoblastic disease].
Giant Cell Arteritis
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis.
Gingival Overgrowth
Gingival overgrowth in renal transplant recipients: a study concerning prevalence, severity, periodontal, and predisposing factors.
Gingival Overgrowth
Mechanism of drug-induced gingival overgrowth revisited: a unifying hypothesis.
Gingival Overgrowth
Periodontal Microbiological Status Influences the Occurrence of Cyclosporine-A and Tacrolimus-Induced Gingival Overgrowth.
Gingival Overgrowth
Poor oral hygiene enhances gingival overgrowth caused by calcineurin inhibitors.
Gitelman Syndrome
Transplantation of a Gitelman Syndrome Kidney Ameliorates Hypertension: A Case Report.
Glaucoma
Calcineurin cleavage is triggered by elevated intraocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucoma.
Glaucoma
Calpain activation in experimental glaucoma.
Glaucoma
Human Aqueous Humor Phosphatase Activity in Cataract and Glaucoma.
Glaucoma, Open-Angle
Human Aqueous Humor Phosphatase Activity in Cataract and Glaucoma.
Glioblastoma
Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma.
Glioblastoma
Activation of DNA-PK by ionizing radiation is mediated by protein phosphatase 6.
Glioblastoma
Adding perphenazine to increase effectiveness of standard glioblastoma chemoirradiation.
Glioblastoma
AEG-1 expression correlates with CD133 and PPP6c levels in human glioma tissues.
Glioblastoma
Calcineurin regulates nuclear factor I dephosphorylation and activity in malignant glioma cell lines.
Glioblastoma
Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma.
Glioblastoma
Cordycepin inhibits migration of human glioblastoma cells by affecting lysosomal degradation and protein phosphatase activation.
Glioblastoma
Corrigendum: Decreased DUSP26 Expression Promotes Malignant Behavior in Glioblastoma Cells via Deregulation of MAPK and Akt Signaling Pathway.
Glioblastoma
Cyclosporin A attenuating morphine tolerance through inhibiting NO/ERK signaling pathway in human glioblastoma cell line: the involvement of calcineurin.
Glioblastoma
Decreased DUSP26 Expression Promotes Malignant Behavior in Glioblastoma Cells via Deregulation of MAPK and Akt Signaling Pathway.
Glioblastoma
Dual-specificity phosphatase (DUSP6) in human glioblastoma: epithelial-to-mesenchymal transition (EMT) involvement.
Glioblastoma
Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53.
Glioblastoma
Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas.
Glioblastoma
Expression Profiling of the MAP Kinase Phosphatase Family Reveals a Role for DUSP1 in the Glioblastoma Stem Cell Niche.
Glioblastoma
Glioblastomas on the move.
Glioblastoma
ILKAP, ILK and PINCH1 control cell survival of p53-wildtype glioblastoma cells after irradiation.
Glioblastoma
Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.
Glioblastoma
Inhibitory effects of cyclosporin A on calcium mobilization-dependent interleukin-8 expression and invasive potential of human glioblastoma U251MG cells.
Glioblastoma
Protein phosphatase Dusp26 associates with KIF3 motor and promotes N-cadherin-mediated cell-cell adhesion.
Glioblastoma
Proteome profile changes that are differentially regulated by lipid and protein phosphatase activities of tumor suppressor PTEN in PTEN-expressing U-87 MG human glioblastoma cells.
Glioblastoma
Serine/threonine protein phosphatase 6 modulates the radiation sensitivity of glioblastoma.
Glioblastoma
STAT3-iNOS Signaling Mediates EGFRvIII-Induced Glial Proliferation and Transformation.
Glioblastoma
Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN.
Glioblastoma
Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.
Glioma
AEG-1 expression correlates with CD133 and PPP6c levels in human glioma tissues.
Glioma
Calcineurin involvement in the regulation of high-threshold Ca2+ channels in NG108-15 (rodent neuroblastoma x glioma hybrid) cells.
Glioma
Calcineurin regulates nuclear factor I dephosphorylation and activity in malignant glioma cell lines.
Glioma
Calmodulin-dependent phosphatases of PC12, GH3, and C6 cells: physical, kinetic, and immunochemical properties.
Glioma
Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity.
Glioma
Ceramide activates heterotrimeric protein phosphatase 2A.
Glioma
Cloning of a highly conserved human protein serine-threonine phosphatase gene from the glioma candidate region on chromosome 19q13.3.
Glioma
Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.
Glioma
Cyclic AMP induces activity increase of kinase FA (a transmembrane signal of insulin) during NG108-15 hybrid cell differentiation.
Glioma
Cyclosporin A-sensitive signaling pathway involving calcineurin regulates survival of reactive astrocytes.
Glioma
Decreased DUSP26 Expression Promotes Malignant Behavior in Glioblastoma Cells via Deregulation of MAPK and Akt Signaling Pathway.
Glioma
Disease relevance of T11TS-induced T-cell signal transduction through the CD2-mediated calcineurin-NFAT pathway: Perspectives in glioma immunotherapy.
Glioma
Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.
Glioma
Glucose deprivation affects the expression of genes encoding cAMP-activated protein kinase and related proteins in U87 glioma cells in ERN1 dependent manner.
Glioma
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.
Glioma
Impact of calcineurin inhibitors on rat glioma cells viability.
Glioma
Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
Glioma
Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Glioma
Inhibitory effects of cyclosporin A on calcium mobilization-dependent interleukin-8 expression and invasive potential of human glioblastoma U251MG cells.
Glioma
Mechanisms of hypoosmotic volume regulation in glioma cells.
Glioma
MicroRNA?216b inhibits cell proliferation and invasion in glioma by directly targeting metadherin.
Glioma
Modulation by calcineurin of 5-HT3 receptor function in NG108-15 neuroblastoma x glioma cells.
Glioma
MTDH promotes glioma invasion through regulating miR-130b-ceRNAs.
Glioma
Nuclear factor of activated T cells (NFAT) as a new component of the signal transduction pathway in glioma cells.
Glioma
Open Data for Differential Network Analysis in Glioma.
Glioma
Over-expression of Wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas.
Glioma
P68 RNA helicase promotes invasion of glioma cells through negatively regulating DUSP5.
Glioma
PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma.
Glioma
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Glioma
PPM1D silencing by lentiviral-mediated RNA interference inhibits proliferation and invasion of human glioma cells.
Glioma
Protein phosphatase 1? regulates the proliferation of human glioma via the NF-?B pathway.
Glioma
Protein phosphatase 4 catalytic subunit is overexpressed in glioma and promotes glioma cell proliferation and invasion.
Glioma
Protein phosphatase activity of PTEN inhibited the invasion of glioma cells with epidermal growth factor receptor mutation type III expression.
Glioma
Protein phosphatase Dusp26 associates with KIF3 motor and promotes N-cadherin-mediated cell-cell adhesion.
Glioma
Protein Phosphatase Magnesium-Dependent 1? (PPM1D) Expression as a Prognostic Marker in Adult Supratentorial Diffuse Astrocytic and Oligodendroglial Tumors.
Glioma
Proteomics reveals protein phosphatase 1? as a biomarker associated with Hippo signal pathway in glioma.
Glioma
PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity.
Glioma
Retraction Note to: uPAR and cathepsin B downregulation induces apoptosis by targeting calcineurin A to BAD via Bcl-2 in glioma.
Glioma
Serine/Threonine Protein Phosphatase-5 Accelerates Cell Growth and Migration in Human Glioma.
Glioma
Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma.
Glioma
Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.
Glioma
Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Glioma
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
Glioma
The regulator of calcineurin 1 (RCAN1) inhibits nuclear factor kappaB signaling pathway and suppresses human malignant glioma cells growth.
Glioma
uPAR and cathepsin B downregulation induces apoptosis by targeting calcineurin A to BAD via Bcl-2 in glioma.
Glomerulonephritis
Accompanying renal injuries did not impact graft survival in patients with transplant glomerulopathy.
Glomerulonephritis
Acute transplant glomerulopathy is associated with antibody-mediated rejection and poor graft outcome.
Glomerulonephritis
Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus.
Glomerulonephritis
Change in glomerular volume and its clinicopathological impact after kidney transplantation.
Glomerulonephritis
Chronic allograft nephropathy: current concepts and future directions.
Glomerulonephritis
Clinical Significance of Renal Allograft Protocol Biopsies: A Single Tertiary Center Experience in Malaysia.
Glomerulonephritis
Egyptian clinical practice guideline for kidney transplantation.
Glomerulonephritis
Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.
Glomerulonephritis
Kidney Complications of Hematopoietic Stem Cell Transplantation.
Glomerulonephritis
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
Glomerulonephritis
Posterior Reversible Encephalopathy Syndrome in Henoch-Schonlein Purpura and Hemolytic Uremic Syndrome.
Glomerulonephritis
Protein Phosphatase 2A Enables Expression of Interleukin 17 (IL-17) through Chromatin Remodeling.
Glomerulonephritis
Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy.
Glomerulonephritis
Synergistic impact of pre-diabetes and immunosuppressants on the risk of diabetes mellitus during treatment of glomerulonephritis and renal vasculitis.
Glomerulonephritis
The pathobiology of chronic allograft nephropathy: immune-mediated damage and accelerated aging.
Glomerulonephritis
The serine/threonine protein phosphatase 2A controls autoimmunity.
Glomerulonephritis
The value of long-term protocol biopsies after kidney transplantation.
Glomerulonephritis
[Late complications following renal transplantation]
Glomerulonephritis
[Use of rituximab in primary and secondary glomerulonephritis].
Glomerulonephritis, IGA
Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis.
Glomerulonephritis, IGA
The effect of calcineurin inhibitors in the treatment of IgA nephropathy: A systematic review and meta-analysis (PRISMA).
Glomerulonephritis, Membranoproliferative
Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients.
Glomerulonephritis, Membranoproliferative
Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation.
Glomerulonephritis, Membranous
Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy.
Glomerulonephritis, Membranous
Calcineurin B1 subunit in human peripheral blood mononuclear cells and its role in idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials.
Glomerulonephritis, Membranous
Chronic renal failure and end-stage renal disease are associated with a high rate of mortality after heart transplantation.
Glomerulonephritis, Membranous
Endoplasmic Reticulum Stress Predicts Clinical Response to Cyclosporine Treatment in Primary Membranous Nephropathy.
Glomerulonephritis, Membranous
Immunosuppressive regimens based on Cyclophospamide or Calcineurin inhibitors: Comparison of their effect in the long term outcome of Primary Membranous Nephropathy.
Glomerulonephritis, Membranous
Isolated diplopia associated with calcineurin inhibitor therapy in a patient with idiopathic membranous nephropathy: a case report.
Glomerulonephritis, Membranous
Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients.
Glomerulonephritis, Membranous
Kidney Pathology after Hematologic Cell Transplantation-A Single-Center Observation Study of Indication Biopsies and Autopsies.
Glomerulonephritis, Membranous
Membranous Nephropathy: Core Curriculum 2021.
Glomerulonephritis, Membranous
Overcoming calcineurin dependence in membranous nephropathy: is rituximab the answer?
Glomerulonephritis, Membranous
Response Predictors to Calcineurin Inhibitors in Patients with Primary Membranous Nephropathy.
Glomerulonephritis, Membranous
Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.
Glomerulonephritis, Membranous
Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients.
Glomerulonephritis, Membranous
Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
Glomerulonephritis, Membranous
Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes.
Glomerulonephritis, Membranous
The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4.
Glomerulonephritis, Membranous
The calcineurin regulatory subunit polymorphism and the treatment efficacy of tacrolimus for idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy.
Glomerulonephritis, Membranous
Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.
Glomerulosclerosis, Focal Segmental
A case of de novo focal segmental glomerulosclerosis occurred one and half years after kidney transplantation supposed to be caused by calcineurin inhibitor.
Glomerulosclerosis, Focal Segmental
A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis.
Glomerulosclerosis, Focal Segmental
Calcineurin inhibitors in the treatment of primary focal segmental glomerulosclerosis: A protocol of systematic review and meta-analysis of randomized controlled trials.
Glomerulosclerosis, Focal Segmental
Calcineurin Inhibitors in the Treatment of Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis of the Literature.
Glomerulosclerosis, Focal Segmental
Calcineurin Inhibitors With Reduced-Dose Steroids as First-Line Therapy for Focal Segmental Glomerulosclerosis.
Glomerulosclerosis, Focal Segmental
Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant.
Glomerulosclerosis, Focal Segmental
Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial.
Glomerulosclerosis, Focal Segmental
Influence of preservation method on histopathological lesions of kidney allografts.
Glomerulosclerosis, Focal Segmental
Loss of Subpodocytic Space Predicts Poor Response to Tacrolimus in Steroid-Resistant Calcineurin Inhibitor-Naïve Adult-Onset Primary Focal Segmental Glomerulosclerosis.
Glomerulosclerosis, Focal Segmental
Persistent CD-19 Depletion by Rituximab is Cost-effective in Maintaining Remission in Calcineurin-inhibitor Dependent Podocytopathy.
Glomerulosclerosis, Focal Segmental
Renal transplantation: basic concepts and evolution of therapy.
Glomerulosclerosis, Focal Segmental
Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.
Glomerulosclerosis, Focal Segmental
Standard immunosuppresive therapy of immune-mediated glomerular diseases.
Glomerulosclerosis, Focal Segmental
Successful treatment of recurrent focal segmental glomerulosclerosis combined with calcineurin inhibitor nephrotoxicity four yr after kidney transplantation.
Glomerulosclerosis, Focal Segmental
Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistance to corticosteroids and calcineurin inhibitors.
Glucose Intolerance
Conversion to sirolimus in solid organ transplantation: a single-center experience.
Glucose Intolerance
Dual specificity phosphatase 6 deficiency is associated with impaired systemic glucose tolerance and reversible weight retardation in mice.
Glucose Intolerance
Glucocorticoids use in kidney transplant setting.
Glucose Intolerance
How to assess for impaired glucose tolerance before transplantation and should these results influence the choice of calcineurin inhibitors?
Glucose Intolerance
HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.
Glucose Intolerance
Involvement of AMPK in alcohol dehydrogenase accentuated myocardial dysfunction following acute ethanol challenge in mice.
Glucose Intolerance
New onset diabetes after transplantation (NODAT): an overview.
Glucose Intolerance
Nutritional and metabolic issues in solid organ transplantation: targets for future research.
Glucose Metabolism Disorders
DUSP1 recuses diabetic nephropathy via repressing JNK-Mff-mitochondrial fission pathways.
Glucose Metabolism Disorders
Effects of non-steroid immunosuppressive drugs on insulin secretion in transplantation.
Glucose Metabolism Disorders
Glucose metabolism disorders in children with refractory nephrotic syndrome.
Glycogen Storage Disease
The 6th International Lafora Epilepsy Workshop: Advances in the search for a cure.
Glycosuria
Increase in liver protein phosphatase-1 in spontaneously diabetic Chinese hamsters.
Gout
Gout Due to Tacrolimus in a Liver Transplant Recipient.
Gout
Hyperuricemia and gout in solid-organ transplant: update in pharmacological management.
Gout
Managing new-onset gout in pediatric renal transplant recipients: when, how, to what extent.
Gout
Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature.
Gout
[A case of gout secondary to primary myelofibrosis].
Gout
[Research on relationship of syndrome type and parameters of hemorheology and platelet activation in patients with acute gout arthritis of dampness-heat blockage type and stasis-heat accumulate type]
Graft vs Host Disease
A BMT CTN phase II trial of unrelated donor marrow transplantation for children with severe sickle cell disease.
Graft vs Host Disease
A gut feeling about murine syngeneic GVHD.
Graft vs Host Disease
A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis.
Graft vs Host Disease
Achalasia in a Patient Undergoing Hematologic Stem Cell Transplant After Exposure to Tacrolimus.
Graft vs Host Disease
Acute Kidney Injury in the Modern Era of Allogeneic Hematopoietic Stem Cell Transplantation.
Graft vs Host Disease
Advances in immune regulation in transplantation.
Graft vs Host Disease
Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma.
Graft vs Host Disease
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
Graft vs Host Disease
Allogeneic Hematopoietic Cell Transplantation with Full-Intensity Conditioning for Adult Acute Lymphoblastic Leukemia: Results from a Single Center, 1998-2006.
Graft vs Host Disease
Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
Graft vs Host Disease
Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine.
Graft vs Host Disease
Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.
Graft vs Host Disease
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors.
Graft vs Host Disease
Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.
Graft vs Host Disease
Bone loss and avascular necrosis of bone after hematopoietic cell transplantation.
Graft vs Host Disease
Calcineurin and mTOR Inhibitor-Free Post-Transplantation Cyclophosphamide and Bortezomib Combination for Graft-versus-Host Disease Prevention after Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I/II Study.
Graft vs Host Disease
Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Graft vs Host Disease
Calcineurin inhibitor-associated oral inflammatory polyps after transplantation.
Graft vs Host Disease
Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.
Graft vs Host Disease
Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation.
Graft vs Host Disease
Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Graft vs Host Disease
Calcineurin inhibitors suppress acute graft-versus-host disease via NFAT-independent inhibition of T cell receptor signaling.
Graft vs Host Disease
Calcineurin inhibitors target Lck activation in graft-versus-host disease.
Graft vs Host Disease
Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study.
Graft vs Host Disease
Chronic Kidney Disease, Thrombotic Microangiopathy and Hypertension Following T-cell Depleted Hematopoietic Stem Cell Transplantation.
Graft vs Host Disease
Chronic liver graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients during tapering or after stopping calcineurin inhibitors.
Graft vs Host Disease
Clinical Management of Posterior Reversible Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series and Review of the Literature.
Graft vs Host Disease
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Graft vs Host Disease
Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations.
Graft vs Host Disease
Comparative Study of Tacrolimus and Short-Term Methotrexate: 2-Day versus 3-Day Methotrexate as Graft-versus-Host-Disease Prophylaxis after Umbilical Cord Blood Transplantation in Adults.
Graft vs Host Disease
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation.
Graft vs Host Disease
Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation.
Graft vs Host Disease
Correlates and Outcomes of Early Acute Kidney Injury after Hematopoietic Cell Transplantation.
Graft vs Host Disease
Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.
Graft vs Host Disease
DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.
Graft vs Host Disease
Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.
Graft vs Host Disease
Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients.
Graft vs Host Disease
Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease.
Graft vs Host Disease
Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.
Graft vs Host Disease
Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases.
Graft vs Host Disease
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
Graft vs Host Disease
Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
Graft vs Host Disease
Haploidentical Peripheral Stem Cell Transplantation for Young Patients with Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide and Methotrexate.
Graft vs Host Disease
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.
Graft vs Host Disease
Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report.
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation in Children with Inborn Errors of Immunity: a Multi-center Experience in Colombia.
Graft vs Host Disease
Hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome.
Graft vs Host Disease
High incidence of haemophagocytic syndrome following umbilical cord blood transplantation for adults.
Graft vs Host Disease
Human herpesvirus 6 encephalitis in patients administered mycophenolate mofetil as prophylaxis for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Graft vs Host Disease
Human Leukocyte Antigen-Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Analysis.
Graft vs Host Disease
Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis.
Graft vs Host Disease
Impact of Body Mass Index on Outcomes of Hematopoietic Stem Cell Transplantation in Adults.
Graft vs Host Disease
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Graft vs Host Disease
Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation.
Graft vs Host Disease
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Graft vs Host Disease
Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.
Graft vs Host Disease
Inhibition of Calcineurin Abrogates While Inhibition of mTOR Promotes Regulatory T Cell Expansion and Graft-Versus-Host Disease Protection by IL-2 in Allogeneic Bone Marrow Transplantation.
Graft vs Host Disease
Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A.
Graft vs Host Disease
Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation.
Graft vs Host Disease
Midostaurin and cyclosporine drug interaction: A case report.
Graft vs Host Disease
Mini-review of kidney disease following hematopoietic stem cell transplant?.
Graft vs Host Disease
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.
Graft vs Host Disease
Novel Insights Into the Mechanism of GVHD-Induced Tissue Damage.
Graft vs Host Disease
Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized Study.
Graft vs Host Disease
Oral Pyogenic Granuloma After Bone Marrow Transplant in the Pediatric/Adolescent Population: Report of 5 Cases.
Graft vs Host Disease
Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia.
Graft vs Host Disease
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
Graft vs Host Disease
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
Graft vs Host Disease
Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease.
Graft vs Host Disease
Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors.
Graft vs Host Disease
Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation.
Graft vs Host Disease
Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation.
Graft vs Host Disease
Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation.
Graft vs Host Disease
Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies.
Graft vs Host Disease
Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.
Graft vs Host Disease
Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation.
Graft vs Host Disease
Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
Graft vs Host Disease
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
Graft vs Host Disease
Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
Graft vs Host Disease
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.
Graft vs Host Disease
Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?
Graft vs Host Disease
Renal thrombotic microangiopathy associated with chronic humoral graft versus host disease after hematopoietic stem cell transplantation.
Graft vs Host Disease
Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
Graft vs Host Disease
Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Graft vs Host Disease
Safety and interactions of new antifungals in stem cell transplant recipients.
Graft vs Host Disease
Serum IgM levels independently predict immune response to influenza vaccine in long-term survivors vaccinated at >1 year after undergoing allogeneic hematopoietic stem cell transplantation.
Graft vs Host Disease
Significant improvement following combination treatment with mefloquine and mirtazapine in a patient with progressive multifocal leukoencephalopathy after allogeneic peripheral blood stem cell transplantation.
Graft vs Host Disease
Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.
Graft vs Host Disease
Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease.
Graft vs Host Disease
Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.
Graft vs Host Disease
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Graft vs Host Disease
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors.
Graft vs Host Disease
Successful switch to oral tacrolimus in a patient with hypersensitivity reaction to parenteral vitamin K, cyclosporine, and tacrolimus: A case report.
Graft vs Host Disease
Successful treatment of calcineurin inhibitor-induced pain syndrome with acute graft versus host disease by switching calcineurin inhibitors followed by pregabalin.
Graft vs Host Disease
Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors.
Graft vs Host Disease
T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.
Graft vs Host Disease
Tacrolimus induced pseudogout following allogeneic hematopoietic cell transplant.
Graft vs Host Disease
Thrombotic microangiopathy in transplantation and malignancy.
Graft vs Host Disease
Transitioning tacrolimus to sirolimus in allogeneic hematopoietic cell transplantation.
Graft vs Host Disease
Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.
Graft vs Host Disease
Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases.
Graft vs Host Disease
[Retrospective analysis of posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation]
Graft vs Host Disease
[The clinical observation of sirolimus combined with calcineurin inhibitors for steroid-resistant/steroid-dependent extensive cGVHD].
Granuloma
Successful Treatment of Recalcitrant Granuloma Gluteale Infantum with Topical Tacrolimus 0.03% Ointment.
Granuloma Annulare
[Granuloma annulare.]
Hamartoma Syndrome, Multiple
Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
Head and Neck Neoplasms
Interrelationship between protein phosphatase-2A and cytoskeletal architecture during the endothelial cell response to soluble products produced by human head and neck cancer.
Headache Disorders
Calcineurin inhibitor-induced headache: clinical characteristics and possible mechanisms.
Hearing Loss
Deficit of mitogen-activated protein kinase phosphatase 1 (DUSP1) accelerates progressive hearing loss.
Hearing Loss
Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development.
Hearing Loss
SENS-401 Effectively Reduces Severe Acoustic Trauma-Induced Hearing Loss in Male Rats With Twice Daily Administration Delayed up to 96?hours.
Hearing Loss, Noise-Induced
An experimental comparative study of dexamethasone, melatonin and tacrolimus in noise-induced hearing loss.
Hearing Loss, Noise-Induced
Calcineurin activation contributes to noise-induced hearing loss.
Hearing Loss, Noise-Induced
Treatment With Calcineurin Inhibitor FK506 Attenuates Noise-Induced Hearing Loss.
Hearing Loss, Sensorineural
Prostaglandin E1 effects on CD62p and PAC-1 in patients with sudden sensorineural hearing loss.
Heart Arrest
Heart block in mice overexpressing calcineurin but not NF-AT3.
Heart Arrest
Protein phosphatase-2A is activated in pig brain following cardiac arrest and resuscitation.
Heart Block
Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin.
Heart Block
Heart block in mice overexpressing calcineurin but not NF-AT3.
Heart Block
iNOS in cardiac myocytes plays a critical role in death in a murine model of hypertrophy induced by calcineurin.
Heart Defects, Congenital
De novo missense variants in PPP1CB are associated with intellectual disability and congenital heart disease.
Heart Defects, Congenital
SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
Heart Defects, Congenital
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Heart Diseases
A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.
Heart Diseases
C. sinensis ablates allograft vasculopathy when used as an adjuvant therapy with cyclosporin A.
Heart Diseases
Calcineurin and hypertrophic heart disease: novel insights and remaining questions.
Heart Diseases
Calcineurin increases cardiac transient outward K+ currents via transcriptional up-regulation of Kv4.2 channel subunits.
Heart Diseases
Calcineurin-AKAP interactions: therapeutic targeting of a pleiotropic enzyme with a little help from its friends.
Heart Diseases
Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder.
Heart Diseases
Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy.
Heart Diseases
Inhibition of calcineurin and sarcolemmal Ca2+ influx protects cardiac morphology and ventricular function in K(v)4.2N transgenic mice.
Heart Diseases
Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes.
Heart Diseases
Phenylephrine promotes cardiac fibroblast proliferation through calcineurin-NFAT pathway.
Heart Diseases
Prevention of cardiac hypertrophy in mice by calcineurin inhibition.
Heart Diseases
Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice.
Heart Diseases
[Upstream therapy for atrial fibrillation].
Heart Failure
A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.
Heart Failure
A novel mitochondrial matrix serine/threonine protein phosphatase regulates the mitochondria permeability transition pore and is essential for cellular survival and development.
Heart Failure
Acute cellular transplant rejection following laparoscopic adjustable gastric banding in a morbidly obese patient post heart transplantation.
Heart Failure
Age-Dependent Protein Expression of Serine/Threonine Phosphatases and Their Inhibitors in the Human Cardiac Atrium.
Heart Failure
Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways.
Heart Failure
Ca2+-dependent modulation of single human cardiac L-type calcium channels by the calcineurin inhibitor cyclosporine.
Heart Failure
Calcineurin and human heart failure.
Heart Failure
Calcineurin in human heart hypertrophy.
Heart Failure
Calcineurin inhibition as therapy for cardiac hypertrophy and heart failure: requiescat in pace?
Heart Failure
Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats.
Heart Failure
Calcineurin signaling in the heart: The importance of time and place.
Heart Failure
Calcineurin transgenic mice have mitochondrial dysfunction and elevated superoxide production.
Heart Failure
Calcineurin-induced energy wasting in a transgenic mouse model of heart failure.
Heart Failure
Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure.
Heart Failure
Calcium-calcineurin signaling in the regulation of cardiac hypertrophy.
Heart Failure
Carabin: Endogenous calcineurin inhibitor, a potential diagnostic and therapeutic target for cardiac hypertrophy in heart failure.
Heart Failure
Cardiac calcineurin during transition from hypertrophy to heart failure in rats.
Heart Failure
Cardiac CaM Kinase II genes ? and ? contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy.
Heart Failure
Cardiac hypertrophy and thyroid hormone signaling.
Heart Failure
Cardiac resynchronization therapy reduces expression of inflammation-promoting genes related to interleukin-1? in heart failure.
Heart Failure
Changes in metabolic profile and population of skeletal muscle fibers of mice overexpressing calsequestrin: Influence of losartan.
Heart Failure
Chronic ?-adrenergic stimulation reverses depressed Ca handling in mice overexpressing inhibitor-2 of protein phosphatase 1.
Heart Failure
Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A.
Heart Failure
Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats.
Heart Failure
Cyclosporin A regulates sodium-calcium exchanger (NCX1) gene expression in vitro and cardiac hypertrophy in NCX1 transgenic mice.
Heart Failure
Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1.
Heart Failure
End-stage renal disease after orthotopic heart transplantation: a single-institute experience.
Heart Failure
Enhanced activation of p21-activated kinase 1 in heart failure contributes to dephosphorylation of connexin 43.
Heart Failure
Enhanced Ca2+ channel currents in cardiac hypertrophy induced by activation of calcineurin-dependent pathway.
Heart Failure
Enhanced myocyte contractility and Ca2+ handling in a calcineurin transgenic model of heart failure.
Heart Failure
Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia.
Heart Failure
Evidence for calcineurin-mediated regulation of SERCA 2a activity in human myocardium.
Heart Failure
Galactokinase is a novel modifier of calcineurin-induced cardiomyopathy in Drosophila.
Heart Failure
Ginseng Inhibits Cardiomyocyte Hypertrophy and Heart Failure via NHE-1 Inhibition and Attenuation of Calcineurin Activation.
Heart Failure
High throughput phenotyping of left and right ventricular cardiomyopathy in calcineurin transgene mice.
Heart Failure
HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.
Heart Failure
Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function.
Heart Failure
Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure.
Heart Failure
Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure.
Heart Failure
Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality.
Heart Failure
Isoform- and tissue-specific regulation of the Ca2+-sensitive transcription factor NFAT in cardiac myocytes and in heart failure.
Heart Failure
Isoform-specific roles of protein phosphatase 1 catalytic subunits in sarcoplasmic reticulum-mediated Ca2+ cycling.
Heart Failure
Losartan decreases p42/44 MAPK signaling and preserves LZ+ MYPT1 expression.
Heart Failure
Mechanisms underlying pathological Ca2+ handling in diseases of the heart.
Heart Failure
Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart.
Heart Failure
Neutrophil Gelatinase-Associated Lipocalin: Ready for Routine Clinical Use? An International Perspective.
Heart Failure
NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure.
Heart Failure
Overexpression of heart-specific small subunit of myosin light chain phosphatase results in heart failure and conduction disturbance.
Heart Failure
Peroxynitrite Increases Protein Phosphatase Activity and Promotes the Interaction of Phospholamban with Protein Phosphatase 2a in the Myocardium.
Heart Failure
Possible therapeutic targets in cardiac myocyte apoptosis.
Heart Failure
Protective effect of the endothelin antagonist CPU0213 against isoprenaline-induced heart failure by suppressing abnormal expression of leptin, calcineurin and SERCA2a in rats.
Heart Failure
Reply to revisiting calcineurin and human heart failure
Heart Failure
Reversibility of adverse, calcineurin-dependent cardiac remodeling.
Heart Failure
Revisiting calcineurin and human heart failure.
Heart Failure
Serine-threonine protein phosphatase regulation of Cx43 dephosphorylation in arrhythmogenic disorders.
Heart Failure
Skeletal muscle fibres synthesis in heart failure: role of PGC-1alpha, calcineurin and GH.
Heart Failure
The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene Ppm1d Promotes Inflammation and Non-Ischemic Heart Failure in Mice.
Heart Failure
Therapeutic Chemical Screen Identifies Phosphatase Inhibitors to Reconstitute PKB Phosphorylation and Cardiac Contractility in ILK-Deficient Zebrafish.
Heart Failure
Thyroid hormone plus dual-specificity phosphatase-5 siRNA increases the number of cardiac muscle cells and improves left ventricular contractile function in chronic doxorubicin-injured hearts.
Heart Failure
Vascular reactivity in heart failure: role of myosin light chain phosphatase.
Heart Failure
Z-disc protein CHAPb induces cardiomyopathy and contractile dysfunction in the postnatal heart.
Heart Failure
[Cardiac hypertrophy and calcium signaling]
Heart Failure
[Effects of valsartan on sarcoplasmic reticulum calcium adenodine triphosphatase, protein kinase A and protein phosphatase 1 alpha in a rabbit model of heart failure]
Heart Failure
[Expression profile of calcineurin pathway genes in myocardium tissues in relation to ischemic heart remodeling in humans].
Heart Failure
[Role of calcineurin in down-regulation of left ventricular transmural voltage- dependent K(+) currents in mice with heart failure].
Heart Failure
[The mutants of calcineurin transgenic mice]
Heart Septal Defects, Atrial
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Heart Septal Defects, Ventricular
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Heart Valve Diseases
[Calpain-2 and calcineurin protein expression in right atrial appendages from patients underwent valve replacement with or without atrial fibrillation].
Hematologic Neoplasms
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT.
Hematologic Neoplasms
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Hematologic Neoplasms
Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.
Hematologic Neoplasms
Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab.
Hematologic Neoplasms
Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double-Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin.
Hematologic Neoplasms
Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation has Unique Features and an Association with Engrafting Unit-to-Recipient HLA Match.
Hematologic Neoplasms
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
Hematologic Neoplasms
Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.
Hematologic Neoplasms
Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.
Hematologic Neoplasms
The role of exosomes and MYC in therapy resistance of acute myeloid leukemia: Challenges and opportunities.
Hematuria
Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients.
Hemic and Lymphatic Diseases
Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients.
Hemolytic-Uremic Syndrome
Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus.
Hemolytic-Uremic Syndrome
Chronic renal failure and end-stage renal disease are associated with a high rate of mortality after heart transplantation.
Hemolytic-Uremic Syndrome
Conversion to sirolimus in pediatric renal transplantation recipients.
Hemolytic-Uremic Syndrome
Conversion to sirolimus in solid organ transplantation: a single-center experience.
Hemolytic-Uremic Syndrome
Cyclosporine Induces Endothelial Cell Release of Complement-Activating Microparticles.
Hemolytic-Uremic Syndrome
Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome.
Hemolytic-Uremic Syndrome
Electron paramagnetic resonance study of erythrocyte membrane fluidity in renal transplant recipients.
Hemolytic-Uremic Syndrome
Growth failure associated with sirolimus: case report.
Hemolytic-Uremic Syndrome
Postrenal transplant hemolytic uremic syndrome/thrombotic microangiopathy: Ahmedabad experience.
Hemolytic-Uremic Syndrome
Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience.
Hemolytic-Uremic Syndrome
Rescue treatment for cyclosporine-associated hemolytic-uremic syndrome with intravenous immunoglobulin.
Hemophilia A
Acquired haemophilia A. First line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up study.
Hemophilia A
Liver transplantation for patients with human immunodeficiency virus and hepatitis C virus coinfection with special reference to hemophiliac recipients in Japan.
Hepatic Encephalopathy
Hepatic encephalopathy and post-transplant hyponatremia predict early calcineurin inhibitor-induced neurotoxicity after liver transplantation.
Hepatic Encephalopathy
Neurologic complications after liver transplantation.
Hepatic Veno-Occlusive Disease
The fifth epidermal growth factor-like region of thrombomodulin exerts cytoprotective function and prevents SOS in a murine model.
Hepatitis
Accompanying renal injuries did not impact graft survival in patients with transplant glomerulopathy.
Hepatitis
Choice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-GSTT1 antibodies after liver transplantation.
Hepatitis
Development of lymphoproliferative disease after liver transplantation.
Hepatitis
Hepatitis C infection in liver transplantation.
Hepatitis
Hypertension and hepatitis C virus infection are strong risk factors for developing late renal dysfunction after living donor liver transplantation: significance of renal biopsy.
Hepatitis
Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients.
Hepatitis
PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury.
Hepatitis
[A case of idiopathic postinfantile giant cell hepatitis treated with a calcineurin inhibitor].
Hepatitis B
A Genetic Variant of PPP1CB Influences Risk of Hepatitis B Virus-Related Hepatocellular Carcinoma in Han Chinese: A Pathway Based Analysis.
Hepatitis B
Does Induction Type Influence Outcomes in Kidney Transplant Recipients at Different Phases of Hepatitis B Infection?
Hepatitis B
ER stress regulating protein phosphatase 2A-B56?, targeted by hepatitis B virus X protein, induces cell cycle arrest and apoptosis of hepatocytes.
Hepatitis B
Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients.
Hepatitis B
Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.
Hepatitis B
Outcome of second kidney transplant: a single center experience.
Hepatitis B
The interaction of hepatitis B virus X protein and protein phosphatase type 2 Calpha and its effect on IL-6.
Hepatitis B
Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.
Hepatitis C
A single-center experience of the use of interleukin-2 receptor antagonists for various situations in liver transplant recipients.
Hepatitis C
Acute confusional state following liver transplantation for alcoholic liver disease.
Hepatitis C
Acute transplant glomerulopathy is associated with antibody-mediated rejection and poor graft outcome.
Hepatitis C
Approach to recurrent hepatitis C following liver transplantation.
Hepatitis C
Calcineurin A versus NS5A-TP2/HD domain containing 2: a case study of site-directed low-frequency random mutagenesis for dissecting target specificity of peptide aptamers.
Hepatitis C
Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient.
Hepatitis C
Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha.
Hepatitis C
Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant.
Hepatitis C
Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: Effects on virus replication and recurrent hepatitis.
Hepatitis C
Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells.
Hepatitis C
Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.
Hepatitis C
Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
Hepatitis C
Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients.
Hepatitis C
Effects of Sofosbuvir-Based Hepatitis C Treatment Regimens on Calcineurin Inhibitor Dosing in Liver and Kidney Transplant Recipients.
Hepatitis C
Enhancement of Programmed Death Ligand 2 on Hepatitis C Virus Infected Hepatocytes by Calcineurin Inhibitors.
Hepatitis C
Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Hepatitis C
Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors.
Hepatitis C
Fluctuations in the concentration/dose ratio of calcineurin inhibitors after simeprevir administration in patients with recurrent hepatitis C after liver transplantation.
Hepatitis C
Hepatitis C infection in liver transplantation.
Hepatitis C
Hepatitis C virus-induced reduction in miR-181a impairs CD4(+) T-cell responses through overexpression of DUSP6.
Hepatitis C
Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair.
Hepatitis C
Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis.
Hepatitis C
Impact of calcineurin inhibitors on hepatitis C recurrence after liver transplantation.
Hepatitis C
Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation.
Hepatitis C
Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C.
Hepatitis C
Interfering with interferon: re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence.
Hepatitis C
Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients.
Hepatitis C
Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine.
Hepatitis C
Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C.
Hepatitis C
Management of liver transplant recipients with recurrent hepatitis C.
Hepatitis C
MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course.
Hepatitis C
Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
Hepatitis C
Natural history of hepatitis C and outcomes following liver transplantation.
Hepatitis C
New-Onset Diabetes after Kidney Transplantation.
Hepatitis C
New-onset diabetes after renal transplantation.
Hepatitis C
New-onset diabetes after transplantation: risk factors and clinical impact.
Hepatitis C
New-onset diabetes mellitus after kidney transplantation: Current status and future directions.
Hepatitis C
New-onset diabetes mellitus after solid organ transplantation.
Hepatitis C
Of mice and men, calcineurin inhibitors and hepatitis C.
Hepatitis C
Outcome of second kidney transplant: a single center experience.
Hepatitis C
Protection of CD4+ T cells from hepatitis C virus infection-associated senescence via ?Np63-miR-181a-Sirt1 pathway.
Hepatitis C
PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism.
Hepatitis C
Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor.
Hepatitis C
Review article: hepatitis C virus and calcineurin inhibition after renal transplantation.
Hepatitis C
Risk assessment and management of post-transplant diabetes mellitus.
Hepatitis C
Risk factors for development of new-onset diabetes mellitus and progressive impairment of glucose metabolism after living-donor liver transplantation.
Hepatitis C
Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study.
Hepatitis C
Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication.
Hepatitis C
Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.
Hepatitis C
The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice.
Hepatitis C
The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
Hepatitis C
The role of antibody induction in liver transplantation.
Hepatitis C
The year in review--ATC 2002.
Hepatitis C
Therapeutic management of recurrent hepatitis C after liver transplantation.
Hepatitis C
Trends of Immunosuppression and Outcomes Following Liver Transplantation: An Analysis of the United Network for Organ Sharing Registry.
Hepatitis C
Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1.
Hepatitis C
[Treatment of recurrent HCV infection after liver transplantation]
Hepatitis C
[Treatment of recurrent hepatitis C infection after liver transplantation]
Hepatitis C, Chronic
Do anti-CD25 monoclonal antibodies potentiate posttransplant diabetes mellitus?
Hepatitis C, Chronic
Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation.
Hepatitis C, Chronic
Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report.
Hepatitis E
Calcineurin Inhibitors Stimulate and Mycophenolic Acid Inhibits Replication of Hepatitis E Virus.
Hepatitis, Autoimmune
Autoimmune liver disease and rheumatic manifestations.
Hepatitis, Autoimmune
De novo autoimmune hepatitis after liver transplantation.
Hepatitis, Autoimmune
Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis.
Hepatitis, Autoimmune
Immunological aspects and therapeutic significance of an autoantibody against histone H1 in a rat model of concanavalin A-induced hepatitis.
Hepatitis, Autoimmune
Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience.
Hepatoblastoma
Glomerular filtration rate in liver transplant for unresectable hepatoblastoma.
Hepatomegaly
Complementary Indicators for Diagnosis of Hepatic Vein Stenosis After Pediatric Living-donor Liver Transplantation.
Hepatomegaly
Oral intake of genetically engineered high-carotenoid corn ameliorates hepatomegaly and hepatic steatosis in PTEN haploinsufficient mice.
Hepatorenal Syndrome
Role of endothelin and endothelin receptor antagonists in renal disease.
Hepatorenal Syndrome
Simultaneous Liver-Kidney Transplant: Too Many or Just Enough?
Hepatorenal Syndrome
Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation.
Hepatorenal Syndrome
[Simultaneous Hepatorenal Transplantation from a Brain-Dead Donor for Graft Dysfunction and Renal Insufficiency in a Liver Transplant Recipient : A Case Report].
Herpes Simplex
A conserved domain of herpes simplex virus ICP34.5 regulates protein phosphatase complex in mammalian cells.
Herpes Simplex
A host cell protein binds to a highly conserved sequence element (pac-2) within the cytomegalovirus a sequence.
Herpes Simplex
Alkaline phosphodiesterase I and alkaline phosphatase I in plasma membranes of herpes simplex virus type 1 transformed hamster cells.
Herpes Simplex
Calcineurin phosphatase activity regulates Varicella-Zoster Virus induced cell-cell fusion.
Herpes Simplex
Effects of herpes simplex virus vectors encoding poreless TRPV1 or protein phosphatase 1? in a rat cystitis model induced by hydrogen peroxide.
Herpes Simplex
Functions of the sequences at the ends of the inverted repeats of pseudorabies virus.
Herpes Simplex
PPP6C Negatively Regulates STING-Dependent Innate Immune Responses.
Herpes Simplex
Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.
Herpes Simplex
The effect of herpes simplex virus vector-mediated gene therapy of protein phosphatase 1? on bladder overactivity and nociception.
Herpes Simplex
The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase.
Herpes Simplex
The gamma134.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase 1 regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cells.
Herpes Simplex
The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2.
Herpes Zoster
The protein phosphatase with EF-hand domain 1 is a calmodulin-binding protein that interacts with proteins involved in sperm capacitation, binding to the zona pellucida, and motility.
Hirschsprung Disease
Differential expression of FOXA1, DUSP6, and HA117 in colon segments of Hirschsprung's disease.
Histiocytoma, Malignant Fibrous
Enhanced expression of catalytic subunit isoform PP1 gamma 1 of protein phosphatase type 1 in malignant fibrous histiocytoma.
Hodgkin Disease
Potential role of hypoxia in early stages of Hodgkin lymphoma pathogenesis.
Hodgkin Disease
Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma.
Huntington Disease
An immunohistochemical investigation of the human neostriatum in Huntington's disease.
Huntington Disease
Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation.
Huntington Disease
Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease.
Huntington Disease
Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders.
Huntington Disease
Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity.
Huntington Disease
Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: Role in excitotoxicity.
Huntington Disease
Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro.
Huntington Disease
Synaptophysin expression in the striatum in Huntington's disease.
Huntington Disease
Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease.
Huntington Disease
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Hydatidiform Mole
[Expression and significance of LMP2 and PPM1A in gestational trophoblastic disease].
Hydrocephalus
Tacrolimus and cyclosporine A are of no benefit to young rats with kaolin-induced hydrocephalus.
Hyperaldosteronism
Recent insights into sodium and potassium handling by the aldosterone-sensitive distal nephron: implications on pathophysiology and drug discovery.
Hyperalgesia
Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis.
Hyperalgesia
Increases in the phosphorylation of cyclic AMP response element binding protein (CREB) and decreases in the content of calcineurin accompany thermal hyperalgesia following chronic constriction injury in rats.
Hyperalgesia
Melatonin relieves neuropathic allodynia through spinal MT2-enhanced PP2Ac and downstream HDAC4 shuttling-dependent epigenetic modification of hmgb1 transcription.
Hyperalgesia
Potentiation of spinal NMDA-mediated nociception by cocaine- and amphetamine-regulated transcript peptide via PKA and PKC signaling pathways in rats.
Hyperalgesia
Ropivacaine relieves pain and prevents chondrocyte degradation probably through Calcineurin/NFAT1 signaling pathway in osteoarthritis rats.
Hyperalgesia
Upregulation of nuclear factor of activated T-cells by nerve injury contributes to development of neuropathic pain.
Hypercalcemia
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
Hypercholesterolemia
Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis.
Hypercholesterolemia
Impact of Cardiovascular Risk Factors on Long-Term Mortality After Liver Transplantation.
Hypercholesterolemia
Loss of Down Syndrome Critical Region-1 Mediated-Hypercholesterolemia Accelerates Corneal Opacity Via Pathological Neovessel Formation.
Hyperferritinemia
Hemophagocytic Syndrome Complicated with Dermatomyositis Controlled Successfully with Infliximab and Conventional Therapies.
Hyperglycemia
A new cell-permeable peptide allows successful allogeneic islet transplantation in mice.
Hyperglycemia
Activation of the PP2A catalytic subunit by ivabradine attenuates the development of diabetic cardiomyopathy.
Hyperglycemia
Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans.
Hyperglycemia
Cardiovascular risk estimates and risk factors in renal transplant recipients.
Hyperglycemia
Conversion to sirolimus in kidney-pancreas and pancreas transplantation.
Hyperglycemia
Early non-immunological post transplant complications: a single center experience.
Hyperglycemia
Fasting and rapamycin: diabetes versus benevolent glucose intolerance.
Hyperglycemia
Hyperglycemia induced activation of type-1 protein phosphatase activator (kinase FA) in perfused human placenta.
Hyperglycemia
Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy.
Hyperglycemia
mTOR and Cardiovascular Diseases: Diabetes Mellitus.
Hyperglycemia
New-onset post-transplant diabetes mellitus after allogeneic hematopoietic cell transplant is initiated by insulin resistance, not immunosuppressive medications.
Hyperglycemia
Role of ROCK upregulation in endothelial and smooth muscle vascular functions in diabetic rat aorta.
Hyperglycemia
THE RATIONALE FOR USE OF INCRETINS IN THE MANAGEMENT OF NEW ONSET DIABETES AFTER TRANSPLANTATION (NODAT).
Hyperglycemia
Transgenic overexpression of active calcineurin in beta-cells results in decreased beta-cell mass and hyperglycemia.
Hyperglycemia
[Outcome of renal transplantation after tacrolimus switch to cyclosporine].
Hyperkalemia
Aldosterone Resistance Due to Tacrolimus: A Case Report.
Hyperkalemia
Calcineurin dephosphorylates Kelch-like 3, reversing phosphorylation by angiotensin II and regulating renal electrolyte handling.
Hyperkalemia
Changes in magnesium and potassium homeostasis after conversion from a calcineurin inhibitor regimen to an mTOR inhibitor-based regimen.
Hyperkalemia
Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation.
Hyperkalemia
Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia.
Hyperkalemia
Fludrocortisone-a treatment for tubulopathy post-paediatric renal transplantation: A national paediatric nephrology unit experience.
Hyperkalemia
Hyperchloremic metabolic acidosis in the kidney transplant patient.
Hyperkalemia
Hyperkalemia and Hypertension Post Organ Transplantation - A Management Challenge.
Hyperkalemia
Incidence of Co-Trimoxazole-Induced Hyperkalemia in a Tertiary Care Hospital.
Hyperkalemia
Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients.
Hyperkalemia
Severe Hyperkalemia Complicating Voriconazole Treatment in a Kidney Transplant Recipient With Histoplasmosis: A Case Report.
Hyperkalemia
Specific disruption of calcineurin-signaling in the distal convoluted tubule impacts the transcriptome and proteome, and causes hypomagnesemia and metabolic acidosis.
Hyperkalemia
Tacrolimus ameliorates the phenotypes of type 4 Bartter syndrome model mice through activation of sodium-potassium-2 chloride cotransporter and sodium-chloride cotransporter.
Hyperkalemia
[Electrolyte and acid-base balance disorders in advanced chronic kidney disease]
Hyperlipidemias
Ablation of calcineurin A? reveals hyperlipidemia and signaling cross-talks with phosphodiesterases.
Hyperlipidemias
Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Hyperlipidemias
Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
Hyperlipidemias
Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
Hyperlipidemias
Cardiovascular risk estimates and risk factors in renal transplant recipients.
Hyperlipidemias
Chronic allograft nephropathy--immunologic and nonimmunologic factors.
Hyperlipidemias
Chronic allograft nephropathy: pathogenesis and management of an important posttransplant complication.
Hyperlipidemias
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
Hyperlipidemias
Cyclosporin A decreases apolipoprotein E secretion from human macrophages via a protein phosphatase 2B-dependent and ATP-binding cassette transporter A1 (ABCA1)-independent pathway.
Hyperlipidemias
Cyclosporin A inhibits apolipoprotein AI gene expression.
Hyperlipidemias
De Novo Belatacept in a Human Immunodeficiency Virus-Positive Kidney Transplant Recipient.
Hyperlipidemias
Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
Hyperlipidemias
Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity.
Hyperlipidemias
Future directions in immunosuppression.
Hyperlipidemias
Hepatitis C: liver transplantation.
Hyperlipidemias
Obesity, lipid profiles and oxidative stress in children after liver transplantation.
Hyperlipidemias
Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study.
Hyperlipidemias
Renal dysfunction in liver transplantation: The problem and preventive strategies.
Hyperlipidemias
Sirolimus experience at a Swedish transplantation center.
Hyperlipidemias
Strategies to reduce toxicities and improve outcomes in renal transplant recipients.
Hyperlipidemias
The effect of cyclosporine A on the phosphorylation of the AMPK pathway in the rat hippocampus.
Hyperlipidemias
The pathogenesis and treatment of chronic allograft nephropathy.
Hyperlipidemias
The problem of late allograft loss in kidney transplantation.
Hyperoxaluria
Early renal failure after domino hepatic transplantation using the liver from a compound heterozygous patient with primary hyperoxaluria.
Hyperoxaluria
Hypocitraturia as a risk factor for nephrocalcinosis after kidney transplantation.
Hyperparathyroidism
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
Hyperparathyroidism
Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet.
Hyperparathyroidism
Hyperchloremic metabolic acidosis in the kidney transplant patient.
Hyperparathyroidism
[Effects of kidney transplantation on bone: osteoporosis or other?]
Hypersensitivity
Atf1 is a target of the mitogen-activated protein kinase Pmk1 and regulates cell integrity in fission yeast.
Hypersensitivity
Calcineurin and calcium channel CchA coordinate the salt stress response by regulating the cytoplasmic Ca2+ homeostasis in Aspergillus nidulans.
Hypersensitivity
Calcineurin Inhibition Causes ?2?-1-Mediated Tonic Activation of Synaptic NMDA Receptors and Pain Hypersensitivity.
Hypersensitivity
Calcineurin Inhibitor Induces Pain Hypersensitivity by Potentiating Pre- and Postsynaptic NMDA Receptor Activity in Spinal Cords.
Hypersensitivity
Calcineurin is essential for virulence in Candida albicans.
Hypersensitivity
Calcineurin is essential in cyclosporin A- and FK506-sensitive yeast strains.
Hypersensitivity
Calcineurin-dependent growth of an FK506- and CsA-hypersensitive mutant of Saccharomyces cerevisiae.
Hypersensitivity
Calcium- and calcineurin-independent roles for calmodulin in Cryptococcus neoformans morphogenesis and high-temperature growth.
Hypersensitivity
Casein Kinase II Inhibition Reverses Pain Hypersensitivity and Potentiated Spinal N-Methyl-D-aspartate Receptor Activity Caused by Calcineurin Inhibitor.
Hypersensitivity
Comparison of expression profiles induced by dust mite in airway epithelia reveals a common pathway.
Hypersensitivity
Decreased abundance of TRESK two-pore domain potassium channels in sensory neurons underlies the pain associated with bone metastasis.
Hypersensitivity
Ectopic Expression of SjCBL1, Calcineurin B-Like 1 Gene From Sedirea japonica, Rescues the Salt and Osmotic Stress Hypersensitivity in Arabidopsis cbl1 Mutant.
Hypersensitivity
Editorial comments on this issue of the Journal.
Hypersensitivity
Effects of variations in access to care for children with atopic dermatitis.
Hypersensitivity
Genome-wide screening for genes associated with FK506 sensitivity in fission yeast.
Hypersensitivity
Human protein phosphatase PP6 regulatory subunits provide Sit4-dependent and rapamycin-sensitive sap function in Saccharomyces cerevisiae.
Hypersensitivity
Human skin safety test of green tea cell extracts in condition of allergic contact dermatitis.
Hypersensitivity
Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.
Hypersensitivity
Rho2 is a target of the farnesyltransferase Cpp1 and acts upstream of Pmk1 mitogen-activated protein kinase signaling in fission yeast.
Hypersensitivity
Role of HSP90 in salt stress tolerance via stabilization and regulation of calcineurin.
Hypersensitivity
Spatial regulation of the KH domain RNA-binding protein Rnc1 mediated by a Crm1-independent nuclear export system in Schizosaccharomyces pombe.
Hypersensitivity
Spinal nNOS activation mediates sigma-1 receptor-induced mechanical and thermal hypersensitivity in mice: involvement of PKC-dependent NR1 phosphorylation.
Hypersensitivity
Successful switch to oral tacrolimus in a patient with hypersensitivity reaction to parenteral vitamin K, cyclosporine, and tacrolimus: A case report.
Hypersensitivity
Tacrolimus, a calcineurin inhibitor, promotes capsaicin-induced colonic pain in mice.
Hypersensitivity
The effect of herpes simplex virus vector-mediated gene therapy of protein phosphatase 1? on bladder overactivity and nociception.
Hypersensitivity
The protein phosphatase 7 regulates phytochrome signaling in Arabidopsis.
Hypersensitivity
The Pzh1 protein phosphatase and the Spm1 protein kinase are involved in the regulation of the plasma membrane H+-ATPase in fission yeast.
Hypersensitivity
The Vacuolar Ca2+ Exchanger Vcx1 Is Involved in Calcineurin-Dependent Ca2+ Tolerance and Virulence in Cryptococcus neoformans.
Hypersensitivity
Zinc finger protein Prz1 regulates Ca2+ but not Cl- homeostasis in fission yeast. Identification of distinct branches of calcineurin signaling pathway in fission yeast.
Hypersensitivity
[Evidence-based treatment options for allergic diseases in otolaryngology: an update].
Hypersensitivity
[The practice guideline 'Atopic dermatitis' (first revision) from the Dutch College of General Practitioners; a response from the perspective of dermatology]
Hypertension
3A.03: HYPERTENSION IN PATIENTS AFTER LIVER TRANSPLANTATION.
Hypertension
Activation of NFATc3 down-regulates the beta1 subunit of large conductance, calcium-activated K+ channels in arterial smooth muscle and contributes to hypertension.
Hypertension
Age and gender may affect posterior reversible encephalopathy syndrome in renal disease.
Hypertension
An emerging role for calcineurin A{alpha} in the development and function of the kidney.
Hypertension
Anemia in solid organ transplantation.
Hypertension
Angiotensin-(1-7) prevents angiotensin II-induced fibrosis in cremaster microvessels.
Hypertension
Angiotensin-converting enzyme inhibitor-induced isolated visceral angioedema in a liver transplant recipient.
Hypertension
Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Hypertension
Approach and Management of Hypertension After Kidney Transplantation.
Hypertension
Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
Hypertension
Association Between CYP3A5 Polymorphisms and Blood Pressure in Kidney Transplant Recipients Receiving Calcineurin Inhibitors.
Hypertension
AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats.
Hypertension
Axillary Artery Dissection After Ultrasound-Guided Infraclavicular Brachial Plexus Block: A Case Report.
Hypertension
Benefit-risk assessment of sirolimus in renal transplantation.
Hypertension
Blood pressure control according to the prevalence of diabetes in renal transplant recipients.
Hypertension
Blood Pressure in De novo Heart Transplant Recipients Treated with Everolimus Compared with a Cyclosporine-Based Regimen: Results from the Randomized SCHEDULE Trial.
Hypertension
Cadmium-induced hypertension is associated with renal myosin light chain phosphatase inhibition via increased T697 phosphorylation and p44 mitogen-activated protein kinase levels.
Hypertension
Calcineurin dephosphorylates Kelch-like 3, reversing phosphorylation by angiotensin II and regulating renal electrolyte handling.
Hypertension
Calcineurin expression and activity is regulated by the intracellular redox status and under hypertension in human neutrophils.
Hypertension
Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
Hypertension
Calcineurin inhibition normalizes beta-adrenergic responsiveness in the spontaneously hypertensive rat.
Hypertension
Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension.
Hypertension
Calcineurin inhibitor cyclosporine A activates renal Na-K-Cl cotransporters via local and systemic mechanisms.
Hypertension
Calcineurin Inhibitor Toxicity in Solid Organ Transplantation.
Hypertension
Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Hypertension
Calcineurin inhibitor-associated early renal insufficiency in cardiac transplant recipients: risk factors and strategies for prevention and treatment.
Hypertension
Calcineurin inhibitors and hypertension: a role for pharmacogenetics?
Hypertension
Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension.
Hypertension
Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder.
Hypertension
Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
Hypertension
Cardiovascular risk estimates and risk factors in renal transplant recipients.
Hypertension
Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study.
Hypertension
Characteristics and Outcomes of Kidney Transplant Recipients with a Functioning Graft for More than 25 Years.
Hypertension
Chronic allograft nephropathy--immunologic and nonimmunologic factors.
Hypertension
Chronic allograft nephropathy: current concepts and future directions.
Hypertension
Chronic allograft nephropathy: pathogenesis and management of an important posttransplant complication.
Hypertension
Chronic renal allograft injury: early detection, accurate diagnosis and management.
Hypertension
Clinical Utility of Computed Tomography and Magnetic Resonance Imaging for Diagnosis of Posterior Reversible Encephalopathy Syndrome after Stem Cell Transplantation in Children and Adolescents.
Hypertension
Comparative in vitro effects of calcineurin inhibitors on functional vascular relaxations of both rat thoracic and abdominal aorta.
Hypertension
Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial.
Hypertension
Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Hypertension
Comparison of long-term actual renal allograft survival in mycophenolate mofetil and azathioprine-based triple drug immunosuppression protocols.
Hypertension
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Hypertension
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
Hypertension
Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report.
Hypertension
Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report.
Hypertension
Correlation between Serum Calcineurin Activity and Left Ventricular Hypertrophy in Hypertensive Patients and Its Clinical Significance.
Hypertension
Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings.
Hypertension
De Novo Belatacept in a Human Immunodeficiency Virus-Positive Kidney Transplant Recipient.
Hypertension
Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism.
Hypertension
Diltiazem use in tacrolimus-treated renal transplant recipients.
Hypertension
Early non-immunological post transplant complications: a single center experience.
Hypertension
Elucidating the mechanism of posterior reversible encephalopathy syndrome: a case of transient blindness after central venous catheterization.
Hypertension
Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
Hypertension
FK506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension.
Hypertension
Future directions in immunosuppression.
Hypertension
Genomics of chronic allograft injury.
Hypertension
Hepatitis C: liver transplantation.
Hypertension
High Frequency of Arterial Hypertension in Patients After Liver Transplantation.
Hypertension
High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
Hypertension
High-Throughput Proteomic Approaches to the Elucidation of Potential Biomarkers of Chronic Allograft Injury (CAI).
Hypertension
How calcineurin inhibitors cause hypertension.
Hypertension
Hyperkalemia and Hypertension Post Organ Transplantation - A Management Challenge.
Hypertension
Hypertension after kidney transplant.
Hypertension
Hypertension after kidney transplantation: a pathophysiologic approach.
Hypertension
Hypertension after kidney transplantation: calcineurin inhibitors increase salt-sensitivity.
Hypertension
Hypertension after Kidney Transplantation: Clinical Significance and Therapeutical Aspects.
Hypertension
Hypertension after renal transplantation.
Hypertension
Hypertension and hepatitis C virus infection are strong risk factors for developing late renal dysfunction after living donor liver transplantation: significance of renal biopsy.
Hypertension
Hypertension in renal allograft recipients.
Hypertension
Hypertension in renal transplantation: donor and recipient risk factors.
Hypertension
Hypertension, Living Kidney Donors, and Transplantation: Where Are We Today?
Hypertension
Immunology Update: Long-Term Care of Solid Organ Transplant Recipients.
Hypertension
Immunosuppression in liver transplantation.
Hypertension
Impact of Cardiovascular Risk Factors on Long-Term Mortality After Liver Transplantation.
Hypertension
Kidney Function after Treatment for Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study.
Hypertension
KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin.
Hypertension
Knockout of Dual-Specificity Protein Phosphatase 5 Protects Against Hypertension-Induced Renal Injury.
Hypertension
Late kidney allograft loss: what we know about it, and what we can do about it.
Hypertension
Left ventricular remodeling with exercise in hypertension.
Hypertension
Long-term results of liver transplantation.
Hypertension
Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus.
Hypertension
Maintenance of normal blood pressure is dependent on IP3R1-mediated regulation of eNOS.
Hypertension
Management of hypertension in solid-organ transplantation.
Hypertension
Management strategies for posttransplant hypertension.
Hypertension
MicroRNA-31 Regulates Immunosuppression in Ang II (Angiotensin II)-induced Hypertension by Targeting Ppp6C (Protein Phosphatase 6c).
Hypertension
Mitochondrial fission protein, dynamin-related protein 1, contributes to the promotion of hypertensive cardiac hypertrophy and fibrosis in Dahl-salt sensitive rats.
Hypertension
Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
Hypertension
Myeloid-Derived Suppressor Cells Ameliorate Cyclosporine A-Induced Hypertension in Mice.
Hypertension
Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart.
Hypertension
Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation.
Hypertension
New onset diabetes after transplantation (NODAT): an overview.
Hypertension
Nutritional and metabolic issues in solid organ transplantation: targets for future research.
Hypertension
Obesity, hyperlipidemia, and metabolic syndrome.
Hypertension
Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: Prevention and treatment.
Hypertension
Our approach to a renal transplant biopsy.
Hypertension
Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril.
Hypertension
Pathogenesis of calcineurin inhibitor-induced hypertension.
Hypertension
Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension.
Hypertension
Pathophysiology of Post Transplant Hypertension in Kidney Transplant: Focus on Calcineurin Inhibitors Induced Oxidative Stress and Renal Sodium Retention and Implications with RhoA/Rho Kinase Pathway.
Hypertension
Patterns of chronic injury in pediatric renal allografts.
Hypertension
Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study.
Hypertension
Posterior reversible encephalopathy syndrome after kidney transplantation in pediatric recipients: Two cases.
Hypertension
Posterior reversible encephalopathy syndrome in children with kidney disease.
Hypertension
Posterior reversible encephalopathy syndrome in children with kidney diseases.
Hypertension
Posttransplant diastolic hypertension: associations with intragraft transforming growth factor-beta, endothelin, and renin transcription.
Hypertension
Posttransplantation hypertension related to calcineurin inhibitors.
Hypertension
Predictors of decline in renal function after lung transplantation.
Hypertension
Pregnancy in renal transplant recipients: the Royal Free Hospital experience.
Hypertension
PREVALENCE AND TIME OF DEVELOPMENT OF SYSTEMIC ARTERIAL HYPERTENSION IN PATIENTS AFTER LIVER TRANSPLANTATION.
Hypertension
Preventing renal transplant failure.
Hypertension
Proliferation signal inhibitors and cardiac allograft vasculopathy.
Hypertension
Pulse wave analysis to assess vascular compliance changes in stable renal transplant recipients.
Hypertension
Reduced endothelin-1- and nitric oxide-mediated arteriolar tone in hypertensive renal transplant recipients.
Hypertension
Regulation of gene expression by cyclic GMP.
Hypertension
Regulatory T-Cell Augmentation or Interleukin-17 Inhibition Prevents Calcineurin Inhibitor-Induced Hypertension in Mice.
Hypertension
Renal Deletion of 12 kDa FK506-Binding Protein Attenuates Tacrolimus-Induced Hypertension.
Hypertension
Renal dysfunction in liver transplantation: The problem and preventive strategies.
Hypertension
Renal function in pediatric liver transplantation: a long-term follow-up study.
Hypertension
Replacing calcineurin inhibitors with mTOR inhibitors in children.
Hypertension
Reversible leukoencephalopathy syndrome associated to leukopenia in a chronic hemodialysis patient.
Hypertension
Reversible posterior encephalopathy syndrome in children with nephrotic syndrome.
Hypertension
Review of symposium.
Hypertension
Rho GTPases in kidney physiology and diseases.
Hypertension
Risk factors for hypertension 3 years after renal transplantation in children.
Hypertension
Sarpogrelate attenuates pulmonary arterial hypertension via calcium/calcineurin axis.
Hypertension
SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients.
Hypertension
Sirolimus in pediatric renal transplantation.
Hypertension
Sirolimus in renal transplantation.
Hypertension
Sirolimus monotherapy in liver transplantation.
Hypertension
Specific disruption of calcineurin-signaling in the distal convoluted tubule impacts the transcriptome and proteome, and causes hypomagnesemia and metabolic acidosis.
Hypertension
Strategies to reduce toxicities and improve outcomes in renal transplant recipients.
Hypertension
Successful treatment of class V+IV lupus nephritis with multitarget therapy.
Hypertension
Sympathetic neural mechanisms of cyclosporine-induced hypertension.
Hypertension
Sympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander?
Hypertension
The adolescent and liver transplantation.
Hypertension
The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension.
Hypertension
The pathogenesis and treatment of chronic allograft nephropathy.
Hypertension
The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists.
Hypertension
The problem of late allograft loss in kidney transplantation.
Hypertension
The role and value of sirolimus administration in kidney and liver transplantation.
Hypertension
The role of immunosuppressive medications in the pathogenesis of hypertension and efficacy and safety of antihypertensive agents in kidney transplant recipients.
Hypertension
Three novel sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 3 isoforms. Expression, regulation, and function of the membranes of the SERCA3 family.
Hypertension
Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
Hypertension
Use of calcium channel blockers and angiotensin-converting enzyme inhibitors after cardiac transplantation.
Hypertension
[Arterial hypertension in renal transplant recipients]
Hypertension
[Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension]
Hypertension
[Chronic renal failure after heart, lung, liver, or intestine transplantation]
Hypertension
[Effect of immunosuppressive treatment on diurnal profile of blood pressure]
Hypertension
[Mycophenolate mofetil (MMF) as the first choice immunosuppressive drug in treatment of steroid-dependent nephrotic syndrome in children].
Hypertension, Malignant
Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus.
Hypertension, Malignant
Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?
Hypertension, Portal
Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.
Hypertension, Pulmonary
Cyclosporin A Inhibits Hypoxia-induced Pulmonary Hypertension and Right Ventricle Hypertrophy.
Hypertension, Pulmonary
DUSP5-mediated inhibition of smooth muscle cell proliferation suppresses pulmonary hypertension and right ventricular hypertrophy.
Hypertension, Pulmonary
Myosin light chain phosphatase and kinase abnormalities in fetal sheep pulmonary hypertension.
Hypertension, Pulmonary
Regulation of myosin light chain phosphatase and pulmonary arterial relaxation.
Hypertension, Renovascular
Angiotensin-converting enzyme inhibitor suppresses activation of calcineurin in renovascular hypertensive rats.
Hypertension, Renovascular
Blockade of calcineurin reverses cardiac hypertrophy and induces the down-regulation of JNK mRNA expression in renovascular hypertensive rats.
Hypertension, Renovascular
Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension.
Hypertensive Encephalopathy
Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin.
Hyperthyroidism
Cardiac microRNA-133 is down-regulated in thyroid hormone-mediated cardiac hypertrophy partially via Type 1 Angiotensin II receptor.
Hyperthyroidism
Cissampelos pareira Linn. ameliorates thyroxin-induced cardiac hypertrophy in rats.
Hyperthyroidism
Repression of T-cell function by thionamides is mediated by inhibition of the activator protein-1/nuclear factor of activated T-cells pathway and is associated with a common structure.
Hypertriglyceridemia
New Onset Diabetes and Non-Alcoholic Fatty Liver Disease after Liver Transplantation.
Hypertriglyceridemia
[Mycosis fungoides in a heart transplant recipient].
Hypertrophy, Left Ventricular
Calcineurin and matrix protein expression in cardiac hypertrophy : Evidence for calcineurin B to control excessive hypertrophic signaling.
Hypertrophy, Left Ventricular
Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats.
Hypertrophy, Left Ventricular
Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training.
Hypertrophy, Left Ventricular
Cardiac calcineurin during transition from hypertrophy to heart failure in rats.
Hypertrophy, Left Ventricular
Caveolin-3 is Up-Regulated in the Physiological Left Ventricular Hypertrophy Induced by Voluntary Exercise Training in Rats.
Hypertrophy, Left Ventricular
Correlation between Serum Calcineurin Activity and Left Ventricular Hypertrophy in Hypertensive Patients and Its Clinical Significance.
Hypertrophy, Left Ventricular
Early and transient sodium-hydrogen exchanger isoform 1 inhibition attenuates subsequent cardiac hypertrophy and heart failure following coronary artery ligation.
Hypertrophy, Left Ventricular
Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial.
Hypertrophy, Left Ventricular
Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats.
Hypertrophy, Left Ventricular
Ginsenoside Rg(1) inhibits rat left ventricular hypertrophy induced by abdominal aorta coarctation: involvement of calcineurin and mitogen-activated protein kinase signalings.
Hypertrophy, Left Ventricular
Ginsenoside Rg(1) inhibits rat left ventricular hypertrophy induced by abdominal aorta coarctation: Involvement of calcineurin and mitogen-activated protein kinase signalings.
Hypertrophy, Left Ventricular
Identification of a novel 5-base pair deletion in calcineurin B (PPP3R1) promoter region and its association with left ventricular hypertrophy.
Hypertrophy, Left Ventricular
KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin.
Hypertrophy, Left Ventricular
Positive correlations between serum calcineurin activity and left ventricular hypertrophy.
Hypertrophy, Left Ventricular
Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin.
Hypertrophy, Left Ventricular
Proteomic analysis of left ventricular diastolic dysfunction hearts in renovascular hypertensive rats.
Hypertrophy, Left Ventricular
[The influence of calcineurin gene polymorphism on morphofunctional characteristics of cardiovascular system of athletes]
Hypertrophy, Right Ventricular
Inhibitory effect of ginsenoside Rb1 on cardiac hypertrophy induced by monocrotaline in rat.
Hypertrophy, Right Ventricular
L-type calcium channel blocker suppresses calcineurin signal pathway and development of right ventricular hypertrophy.
Hypertrophy, Right Ventricular
[Total ginsenosides fought against right ventricular hypertrophy through inhibiting calcineurin signal pathway].
Hypoalbuminemia
Predictors of Proctocolectomy in Children with Ulcerative Colitis.
Hypoglycemia
Estrogen regulates energy metabolic pathway and upstream adenosine 5'-monophosphate-activated protein kinase and phosphatase enzyme expression in dorsal vagal complex metabolosensory neurons during glucostasis and hypoglycemia.
Hypoglycemia
Impact of severe hypoglycemia on the heat shock and related protein response.
Hypogonadism
Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism.
Hypogonadism
Prevalence and associated phenotypes of DUSP6, IL17RD and SPRY4 variants in a large Chinese cohort with isolated hypogonadotropic hypogonadism.
Hyponatremia
Aldosterone Resistance Due to Tacrolimus: A Case Report.
Hyponatremia
Fludrocortisone-a treatment for tubulopathy post-paediatric renal transplantation: A national paediatric nephrology unit experience.
Hyponatremia
Hepatic encephalopathy and post-transplant hyponatremia predict early calcineurin inhibitor-induced neurotoxicity after liver transplantation.
Hypopigmentation
Combination of non-ablative fractional photothermolysis and 0.1% tacrolimus ointment is efficacious for treating idiopathic guttate hypomelanosis.
Hypopigmentation
Comparative efficacy of topical application of tacrolimus and clotrimazole in the treatment of pityriasis versicolor: A single blind, randomised clinical trial.
Hypopigmentation
PP2A and DUSP6 are involved in sphingosylphosphorylcholine-induced hypopigmentation.
Hypotension
Acute kidney injury epidemiology, risk factors, and outcomes in critically ill patients 16-25 years of age treated in an adult intensive care unit.
Hypotension
Modifiable risk factors of acute kidney injury after liver transplantation: a systematic review and meta-analysis.
Hypothyroidism
Developmental Iodine Deficiency and Hypothyroidism Impair Spatial Memory in Adolescent Rat Hippocampus: Involvement of CaMKII, Calmodulin and Calcineurin.
Hypothyroidism
Developmental Iodine Deficiency and Hypothyroidism Reduce Phosphorylation of Calcium/Calmodulin-Dependent Kinase II in the Rat Entorhinal Cortex.
Hypothyroidism
Expression of ZAKI-4 messenger ribonucleic acid in the brain during rat development and the effect of hypothyroidism.
Hypothyroidism
Hypothyroidism following developmental iodine deficiency reduces hippocampal neurogranin, CaMK II and calmodulin and elevates calcineurin in lactational rats.
Hypothyroidism
Identification of novel loci for pediatric cholestatic liver disease defined by KIF12, PPM1F, USP53, LSR, and WDR83OS pathogenic variants.
Hypothyroidism
Mitochondrial and energetic cardiac phenotype in hypothyroid rat. Relevance to heart failure.
Hypothyroidism
Molecular studies on the protective effect of nicotine in adult-onset hypothyroidism-induced impairment of long-term potentiation.
Hypothyroidism
Role of phosphorylated CaMKII and calcineurin in the differential effect of hypothyroidism on LTP of CA1 and dentate gyrus.
Hypothyroidism
Thyroid hormone is required for the phenotype transitions induced by the pharmacological inhibition of calcineurin in adult soleus muscle of rats.
Hypoxia-Ischemia, Brain
Single-nucleotide polymorphism screening and RNA sequencing of key messenger RNAs associated with neonatal hypoxic-ischemia brain damage.
Ichthyosis
Dermatology Part 2: Ichthyoses and Psoriasis.
Ichthyosis, Lamellar
Harlequin ichthyosis. Variability in expression and hypothesis for disease mechanism.
Ichthyosis, Lamellar
Protein phosphatase activity in human keratinocytes cultured from normal epidermis and epidermis from patients with harlequin ichthyosis.
Immune System Diseases
Calcineurin inhibitors and nephrotoxicity in children.
Immune System Diseases
Calcineurin/NFAT signaling and innate host defence: a role for NOD1-mediated phagocytic functions.
Immune System Diseases
Hyperchloremic metabolic acidosis in the kidney transplant patient.
Immune System Diseases
Massive Analysis of cDNA Ends (MACE) and miRNA expression profiling identifies proatherogenic pathways in chronic kidney disease MACE and miRNA profiling in CKD.
Immune System Diseases
Selective inhibitors of nuclear factor of activated T cells: potential therapeutic drugs for the treatment of immunological and inflammatory diseases.
Immune System Diseases
Tacrolimus inhibits oral carcinogenesis through cell cycle control.
Infarction, Middle Cerebral Artery
A novel PGAM5 inhibitor LFHP-1c protects blood-brain barrier integrity in ischemic stroke.
Infections
A case of recurrent anemia due to chronic parvovirus B19 infection in a kidney transplant recipient. Can everolimus make a difference?
Infections
A Magnaporthe grisea cyclophilin acts as a virulence determinant during plant infection.
Infections
A multi-centre, parallel group superiority trial of silk therapeutic clothing compared to standard care for the management of eczema in children (CLOTHES Trial): study protocol for a randomised controlled trial.
Infections
A serine/threonine-protein phosphatase PP2A catalytic subunit is essential for asexual development and plant infection in Magnaporthe oryzae.
Infections
Activation of protein phosphatase-2A1 by HIV-1 Vpr cell death causing peptide in intact CD(4+) T cells and in vitro.
Infections
Addressing treatment challenges in atopic dermatitis with novel topical therapies.
Infections
Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.
Infections
Altering of host larval (Spodoptera exigua) calcineurin activity in response to ascovirus infection.
Infections
Anemia in solid organ transplantation.
Infections
Angiotensin II induces myocyte enhancer factor 2- and calcineurin/nuclear factor of activated T cell-dependent transcriptional activation in vascular myocytes.
Infections
Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation.
Infections
Arabidopsis Protein Phosphatase DBP1 Nucleates a Protein Network with a Role in Regulating Plant Defense.
Infections
Atopic dermatitis.
Infections
Atopic Dermatitis: Early Treatment in Children.
Infections
Atopic dermatitis: skin care and topical therapies.
Infections
Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with antineutrophil cytoplasmic antibody-associated vasculitis and nephrosis.
Infections
Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with chronic renal failure on hemodialysis treatment.
Infections
Basiliximab: a review of its use as induction therapy in renal transplantation.
Infections
Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes.
Infections
Ca2+-Calcineurin Axis-Controlled NFAT Nuclear Translocation Is Crucial for Optimal T Cell Immunity in an Early Vertebrate.
Infections
Calcineurin A Is Essential in the Regulation of Asexual Development, Stress Responses and Pathogenesis in Talaromyces marneffei.
Infections
Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence.
Infections
Calcineurin as a Multifunctional Regulator: Unraveling Novel Functions in Fungal Stress Responses, Hyphal Growth, Drug Resistance, and Pathogenesis.
Infections
Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis.
Infections
Calcineurin controls hyphal growth, virulence, and drug tolerance of Candida tropicalis.
Infections
Calcineurin inhibitor Tacrolimus impairs host immune response against urinary tract infection.
Infections
Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Infections
Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus.
Infections
Calcineurin Inhibitors and Variation in the Performance of Interferon-? Release Assays Used to Detect Tuberculosis Infection.
Infections
Calcineurin is essential for Candida albicans survival in serum and virulence.
Infections
Calcineurin is required for Candida albicans to survive calcium stress in serum.
Infections
Calcineurin Is Required for Pseudohyphal Growth, Virulence, and Drug Resistance in Candida lusitaniae.
Infections
Calcineurin Orchestrates Lateral Transfer of Aspergillus fumigatus During Macrophage Cell Death.
Infections
Calcineurin phosphatase activity regulates Varicella-Zoster Virus induced cell-cell fusion.
Infections
Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy.
Infections
Calcineurin Regulates Conidiation, Chlamydospore Formation and Virulence in Fusarium oxysporum f. sp. lycopersici.
Infections
Calcineurin signaling: lessons from Candida species.
Infections
Calcineurin transgenic mice have mitochondrial dysfunction and elevated superoxide production.
Infections
Calcineurin-mediated regulation of hyphal growth, septation, and virulence in Aspergillus fumigatus.
Infections
Calcineurin-NFAT signalling in myeloid leucocytes: new prospects and pitfalls in immunosuppressive therapy.
Infections
Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection.
Infections
Cellular serine/threonine phosphatase activity during human cytomegalovirus infection.
Infections
Central nervous system involvement in cryptococcal infection in individuals after solid organ transplantation or with AIDS.
Infections
Chronic allograft nephropathy in paediatric renal transplantation.
Infections
Chronic allograft nephropathy.
Infections
Clinical and pathological features of thrombotic microangiopathy influencing long-term kidney transplant outcomes.
Infections
Clinical aspects of tacrolimus use in paediatric renal transplant recipients.
Infections
Cognitive Changes in Chronic Kidney Disease and After Transplantation.
Infections
Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
Infections
Convergent Evolution of Calcineurin Pathway Roles in Thermotolerance and Virulence in Candida glabrata.
Infections
Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation.
Infections
COVID-19 pneumonia in lung transplant recipients: Report of 2 cases.
Infections
Coxsackievirus B3 targets TFEB to disrupt lysosomal function.
Infections
Critical involvement of IL-12 in IFN-gamma induction by calcineurin antagonists in activated human lymphocytes.
Infections
Cryptococcal meningitis following umbilical cord blood transplantation, association between the occurrence of cryptococcal infection and tacrolimus discontinuation among allogeneic hematopoietic stem cell recipients.
Infections
Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme.
Infections
Cyclophilin A and calcineurin functions investigated by gene inactivation, cyclosporin A inhibition and cDNA arrays approaches in the phytopathogenic fungus Botrytis cinerea.
Infections
Cyclosporine a directly affects human and mouse b cell migration in vitro by disrupting a hIF-1 ?dependent, o2 sensing, molecular switch.
Infections
Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection.
Infections
Cytosolic CARP promotes angiotensin II- or pressure overload-induced cardiomyocyte hypertrophy through calcineurin accumulation.
Infections
De Novo Thrombotic Microangiopathy in Renal Transplant Patients.
Infections
Discovery of a protein phosphatase activity encoded in the genome of bacteriophage lambda. Probable identity with open reading frame 221.
Infections
Do anti-CD25 monoclonal antibodies potentiate posttransplant diabetes mellitus?
Infections
DUSP1 regulates apoptosis and cell migration, but not the JIP1-protected cytokine response, during Respiratory Syncytial Virus and Sendai Virus infection.
Infections
DUSP10 Negatively Regulates the Inflammatory Response to Rhinovirus through Interleukin-1? Signaling.
Infections
DUSP5 (dual-specificity protein phosphatase 5) suppresses BCG-induced autophagy via ERK 1/2 signaling pathway.
Infections
Early conversion to prednisolone/everolimus as an alternative weaning regimen associates with beneficial renal transplant histology and function: the randomized-controlled MECANO trial.
Infections
Early non-immunological post transplant complications: a single center experience.
Infections
Early Outcomes of Living-Donor Kidney Transplantation With Immunosuppression Therapy Induction With Tacrolimus Extended-Release: A Comparison With Cyclosporine.
Infections
Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients.
Infections
Effects of light and the regulatory B-subunit composition of protein phosphatase 2A on the susceptibility of Arabidopsis thaliana to aphid (Myzus persicae) infestation.
Infections
Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation.
Infections
Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients.
Infections
Enhancement of lipopolysaccharide-stimulated JNK activity in rat aortic smooth muscle cells by pharmacological and adenovirus-mediated inhibition of inhibitory kappa B kinase signalling.
Infections
Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience.
Infections
ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection.
Infections
Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Infections
Evaluation of host immune responses to pulmonary cryptococcosis using a temperature-sensitive C. neoformans calcineurin A mutant strain.
Infections
Everolimus in lung transplantation in Chile.
Infections
Expression analysis of a plum pathogenesis related 10 (PR10) protein during brown rot infection.
Infections
Five years' experience with thymoglobulin induction in a pediatric renal transplant population.
Infections
Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double-Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin.
Infections
Functional characterization of calcineurin homologs PsCNA1/PsCNB1 in Puccinia striiformis f. sp. tritici using a host-induced RNAi system.
Infections
Good fungi gone bad: the corruption of calcineurin.
Infections
Guidelines for the Management of Atopic Dermatitis in Singapore.
Infections
Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair.
Infections
High-Throughput Proteomic Approaches to the Elucidation of Potential Biomarkers of Chronic Allograft Injury (CAI).
Infections
Human Herpesvirus-6 Infection and Calcineurin Inhibitor Pain Syndrome Interaction after Umbilical Cord Blood Transplant.
Infections
Hypothalamic digoxin deficiency in obsessive compulsive disorder and la Tourette's syndrome.
Infections
Identification of a PP2A gene in Bombyx mori with antiviral function against B. mori nucleopolyhedrovirus.
Infections
Identification of replication-competent HSV-1 Cgal+ strain signaling targets in human hepatoma cells by functional organelle proteomics.
Infections
Identification of the putative protein phosphatase gene PTC1 as a virulence-related gene using a silkworm model of Candida albicans infection.
Infections
ILKAP Binding to and Dephosphorylating HIF-1? is Essential for Apoptosis Induced by Severe Hypoxia.
Infections
Immunosuppressive agents for treating IgA nephropathy.
Infections
Immunosuppressive Therapy for Elderly Kidney Transplant Recipients.
Infections
Immunosuppressive treatment for proliferative lupus nephritis.
Infections
Impact of acute kidney injury on renal allograft survival.
Infections
Impaired calcineurin signaling in myeloid cells results in downregulation of pentraxin-3 and increased susceptibility to aspergillosis.
Infections
Incidence and risk factors of incisional hernia formation following abdominal organ transplantation.
Infections
Increased eIF2alpha phosphorylation attenuates replication of herpes simplex virus 2 vhs mutants in mouse embryonic fibroblasts and correlates with reduced accumulation of the PKR antagonist ICP34.5.
Infections
Increased inflammation and impaired resistance to Chlamydophila pneumoniae infection in Dusp1(-/-) mice: critical role of IL-6.
Infections
Induction therapy for membranous lupus nephritis: a systematic review and network meta-analysis.
Infections
Influence of glutathione S-transferase M1 and T1 polymorphisms with acute rejection in Iranian liver transplant recipients.
Infections
Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection.
Infections
Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?
Infections
Is there such a thing as protocol immunosuppression in liver transplantation?
Infections
Kaposi's sarcoma-associated herpesvirus suppression of DUSP1 facilitates cellular pathogenesis following de novo infection.
Infections
Kidney Fibrosis: Origins and Interventions.
Infections
Kinome-Wide RNA Interference Screening Identifies Mitogen-Activated Protein Kinases and Phosphatidylinositol Metabolism as Key Factors for Rabies Virus Infection.
Infections
Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients.
Infections
Lipopolysaccharide activates calcineurin in ventricular myocytes.
Infections
Loss of chloroplast localized protein phosphatase 2Cs in Arabidopsis thaliana leads to enhancement of the plant immunity and resistance to Xanthomonas campestris pv. campestris infection.
Infections
Lysosomes Integrate Metabolic-Inflammatory Cross-talk in Primary Macrophage Inflammasome Activation.
Infections
Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
Infections
Mammalian target of rapamycin signal inhibitors could play a role in the treatment of BK polyomavirus nephritis in renal allograft recipients.
Infections
Massive Analysis of cDNA Ends (MACE) and miRNA expression profiling identifies proatherogenic pathways in chronic kidney disease MACE and miRNA profiling in CKD.
Infections
Measles Virus Infection Inactivates Cellular Protein Phosphatase 5 with Consequent Suppression of Sp1 and c-Myc Activities.
Infections
Metastatic lung adenocarcinoma- associated thrombotic microangiopathy in a renal transplant recipient.
Infections
Milk fermentation products of L. helveticus R389 activate calcineurin as a signal to promote gut mucosal immunity.
Infections
Modifiable risk factors of acute kidney injury after liver transplantation: a systematic review and meta-analysis.
Infections
Molecular cloning of the MARCH family in grass carp (Ctenopharyngodon idellus) and their response to grass carp reovirus challenge.
Infections
Mycophenolate Monotherapy in HLA-Matched Kidney Transplant Recipients: A Case Series of 20 Patients.
Infections
Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation.
Infections
Neutrophil gelatinase-associated lipocalin in kidney transplantation: A review.
Infections
New-onset diabetes after renal transplantation.
Infections
New-onset diabetes after transplantation: risk factors and clinical impact.
Infections
New-onset diabetes mellitus after solid organ transplantation.
Infections
NFAT AND CREB REGULATE KAPOSI'S SARCOMA ASSOCIATED HERPES VIRUS (KSHV) INDUCED CYCLOOXYGENASE-2 (COX-2).
Infections
Nocardiosis in transplant recipients.
Infections
Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation.
Infections
Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors.
Infections
Pathophysiology and Management of Hyperammonemia in Organ Transplant Patients.
Infections
PGAM5-MAVS interaction regulates TBK1/ IRF3 dependent antiviral responses.
Infections
Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus.
Infections
Phosphorylation-mediated Regulatory Networks in Mycelia of Pyricularia oryzae Revealed by Phosphoproteomic Analyses.
Infections
Plasma phosphoproteome and differential plasma phosphoproteins with opisthorchis viverrini-related cholangiocarcinoma.
Infections
Porcine HMGCR Inhibits Porcine Circovirus Type 2 Infection by Directly Interacting with the Viral Proteins.
Infections
Posttransplantation chronic renal damage in nonrenal transplant recipients.
Infections
PP2Ac Modulates AMPK-Mediated Induction of Autophagy in Mycobacterium bovis-Infected Macrophages.
Infections
Preventing renal transplant failure.
Infections
Prevention of allogeneic cardiac graft rejection by transfer of ex vivo expanded antigen-specific regulatory T-cells.
Infections
Profiling Subcellular Protein Phosphatase Responses to Coxsackievirus B3 Infection of Cardiomyocytes.
Infections
Protection of CD4+ T cells from hepatitis C virus infection-associated senescence via ?Np63-miR-181a-Sirt1 pathway.
Infections
Protein Kinase B/Akt Is Present in Activated Form throughout the Entire Replicative Cycle of {Delta}US3 Mutant Virus but Only at Early Times after Infection with Wild-Type Herpes Simplex Virus 1.
Infections
Protein Phosphatase PP1 Negatively Regulates IRF3 in Response to GCRV Infection in Grass Carp (Ctenopharyngodon idella).
Infections
Protein Phosphatase, Mg2+/Mn2+-dependent 1A controls the innate antiviral and antibacterial response of macrophages during HIV-1 and Mycobacterium tuberculosis infection.
Infections
Recent advances in new-onset diabetes mellitus after kidney transplantation.
Infections
Recurrent hepatitis C after liver transplantation.
Infections
Reduction of I(to) causes hypertrophy in neonatal rat ventricular myocytes.
Infections
Reductions in the Cardiac Transient Outward K+ Current Ito Caused by Chronic ?-Adrenergic Receptor Stimulation Are Partly Rescued by Inhibition of Nuclear Factor ?B.
Infections
Regulator of calcineurin 1 differentially regulates TLR-dependent MyD88 and TRIF signaling pathways.
Infections
Regulator of calcineurin 1 suppresses inflammation during respiratory tract infections.
Infections
Renal transplantation with expanded criteria donors: Which is the optimal immunosuppression?
Infections
Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
Infections
RIPK1 and PGAM5 Control Leishmania Replication through Distinct Mechanisms.
Infections
Risk factors for development of new-onset diabetes mellitus and progressive impairment of glucose metabolism after living-donor liver transplantation.
Infections
Risk factors for Pneumocystis pneumonia after the first 6 months following renal transplantation.
Infections
Risk factors of recipient receiving living donor liver transplantation in the comprehensive era of indication and perioperative managements.
Infections
Role of calcineurin in stress resistance, morphogenesis, and virulence of a Candida albicans wild-type strain.
Infections
Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy.
Infections
Serine/threonine phosphatase (SP-STP), secreted from Streptococcus pyogenes, is a proapoptotic protein.
Infections
Serological and molecular detection of chicken anaemia virus in Iranian poultry flocks.
Infections
Single-center experience with tacrolimus-based immunosuppressive regimens in renal transplantation.
Infections
Skin-protective effects of a zinc oxide-functionalized textile and its relevance for atopic dermatitis.
Infections
Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Infections
Specific calcineurin isoforms are involved in Drosophila toll immune signaling.
Infections
Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors.
Infections
Suppressed calcineurin-dependent gene expression identifies lung allograft recipients at increased risk of infection.
Infections
Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication.
Infections
Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin.
Infections
Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.
Infections
T11TS immunotherapy potentiates the repressed Calcineurin-NFAT signaling pathway of T cells in Cryptococcus neoformans infected rats: A cue towards T cell activation for antifungal immunity.
Infections
Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients.
Infections
Tacrolimus impairs Kupffer cell capacity to control bacteremia: why transplant recipients are susceptible to infection.
Infections
Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials.
Infections
Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus.
Infections
Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model.
Infections
Temporal and spatial assessment of defence responses in resistant and susceptible hop cultivars during infection with Verticillium nonalfalfae.
Infections
The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms.
Infections
The CRH family coding for cell wall glycosylphosphatidylinositol proteins with a predicted transglycosidase domain affects cell wall organization and virulence of Candida albicans.
Infections
The expression of IFN-? is suppressed by the viral 3D polymerase via its impact on PGAM5 expression during enterovirus D68 infection.
Infections
The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein.
Infections
The impact of calcineurin inhibitors with and without interferon on HCV titers in a chimeric mouse model of HCV infection.
Infections
The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the 'silo hypothesis'.
Infections
The role of three calcineurin subunits and a related transcription factor (Crz1) in conidiation, multistress tolerance and virulence in Beauveria bassiana.
Infections
The Wound Healing Peptide, AES16-2M, Ameliorates Atopic Dermatitis In Vivo.
Infections
Thrombotic microangiopathy in transplantation and malignancy.
Infections
Tinea incognito in Korea and its risk factors: nine-year multicenter survey.
Infections
Topical calcineurin inhibitors in cutaneous lupus erythematosus.
Infections
Topical tacrolimus for atopic dermatitis.
Infections
Topical Therapy in Atopic Dermatitis in Children.
Infections
Translation elongation factor EF-Tu is a target for Stp, a serine-threonine phosphatase involved in virulence of Listeria monocytogenes.
Infections
Transplantation for liver failure in patients with sickle cell disease: Challenging but feasible.
Infections
Treatment strategies for atopic dermatitis: optimizing the available therapeutic options.
Infections
Trends of Immunosuppression and Outcomes Following Liver Transplantation: An Analysis of the United Network for Organ Sharing Registry.
Infections
Upregulation of DUSP6 impairs infectious bronchitis virus replication by negatively regulating ERK pathway and promoting apoptosis.
Infections
Urinary Chemokines CXCL9 and CXCL10 Are Noninvasive Markers of Renal Allograft Rejection and BK Viral Infection.
Infections
Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post-Kidney Transplant: A Case Report.
Infections
[Construction of rAAV2-GPIIb/IIIa vector and test of its expression and function in vitro]
Infections
[Effect of Epstein-Barr virus reactivation on gene expression profile of nasopharyngeal carcinoma]
Infections
[Management of transplant-associated thrombotic microangiopathy].
Infections
[Practice experience with topical calcineurin inhibitors]
Infections
[Treatment of diabetes mellitus in patients after renal transplantation]
Infertility
Alterations in sperm protein phosphorylation in male infertility.
Infertility
Endometrial ILKAP expression among patients with endometriosis and its association with clinical characteristics.
Infertility
Expression of Transgenic PPP1CC2 in the Testis of Ppp1cc-Null Mice Rescues Spermatid Viability and Spermiation but Does Not Restore Normal Sperm Tail Ultrastructure, Sperm Motility, or Fertility.
Infertility
Integrative Proteomic and Phosphoproteomic Profiling of Testis from Wip1 Phosphatase-Knockout Mice: Insights into Mechanisms of Reduced Fertility.
Infertility
Oligoasthenoteratospermia and sperm tail bending in PPP4C-deficient mice.
Infertility
Selective Ablation of Ppp1cc Gene in Testicular Germ Cells Causes Oligo-Teratozoospermia and Infertility in Mice.
Infertility, Male
Alterations in sperm protein phosphorylation in male infertility.
Infertility, Male
Analysis of Ppp1cc-null mice suggests a role for PP1gamma2 in sperm morphogenesis.
Infertility, Male
DCW11, down-regulated gene 11 in CW-type cytoplasmic male sterile rice, encoding mitochondrial protein phosphatase 2c is related to cytoplasmic male sterility.
Infertility, Male
Loss of Protein Phosphatase 1c{gamma}(PPP1CC) Leads to Impaired Spermatogenesis Associated with Defects in Chromatin Condensation and Acrosome Development: An Ultrastructural Analysis.
Infertility, Male
New candidate targets of protein phosphatase-1c-gamma-2 in mouse testis revealed by a differential phosphoproteome analysis.
Infertility, Male
Protein phosphatase PP1 gamma 2 in sperm morphogenesis and epididymal initiation of sperm motility.
Infertility, Male
Selective Ablation of Ppp1cc Gene in Testicular Germ Cells Causes Oligo-Teratozoospermia and Infertility in Mice.
Infertility, Male
Significant expression levels of transgenic PPP1CC2 in testis and sperm are required to overcome the male infertility phenotype of Ppp1cc null mice.
Inflammatory Bowel Diseases
Amelioration of murine experimental colitis using biocompatible cyclosporine A lipid carriers.
Inflammatory Bowel Diseases
Drug monitoring in inflammatory bowel disease: helpful or dispensable?
Inflammatory Bowel Diseases
Dual-specificity phosphatase 6 regulates CD4+ T-cell functions and restrains spontaneous colitis in IL-10-deficient mice.
Inflammatory Bowel Diseases
Effective use of switching biologics for ulcerative colitis complicated with pyoderma gangrenosum and primary sclerosing cholangitis.
Inflammatory Bowel Diseases
Immunomodulator and calcineurin inhibitors on inflammatory bowel disease.
Inflammatory Bowel Diseases
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
Inflammatory Bowel Diseases
Role in Calcineurin Inhibitors for Inflammatory Bowel Disease in the Biologics Era: When and How to Use.
Inflammatory Bowel Diseases
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study.
Inflammatory Bowel Diseases
The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease.
Influenza, Human
A role for protein phosphatase 2A in regulating p38 mitogen activated protein kinase activation and tumor necrosis factor-alpha expression during influenza virus infection.
Influenza, Human
Interactome analysis of the influenza A virus transcription/replication machinery identifies protein phosphatase 6 as a cellular factor required for efficient virus replication.
Influenza, Human
NH2-terminal modification of the phosphatase 2A catalytic subunit allows functional expression in mammalian cells.
Influenza, Human
The effect of sirolimus therapy on vaccine responses in transplant recipients.
Insulin Resistance
Ablation of calcineurin A? reveals hyperlipidemia and signaling cross-talks with phosphodiesterases.
Insulin Resistance
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
Insulin Resistance
BCAA Catabolic Defect Alters Glucose Metabolism in Lean Mice.
Insulin Resistance
Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy.
Insulin Resistance
Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers.
Insulin Resistance
Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus.
Insulin Resistance
Ceramide-activated protein phosphatase involvement in insulin resistance via Akt, serine/arginine-rich protein 40, and ribonucleic acid splicing in L6 skeletal muscle cells.
Insulin Resistance
Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells.
Insulin Resistance
Deciphering Tacrolimus-Induced Toxicity in Pancreatic ? Cells.
Insulin Resistance
Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes.
Insulin Resistance
Dysglycemia after renal transplantation: Definition, pathogenesis, outcomes and implications for management.
Insulin Resistance
Effect of an Asp905Tyr mutation of the glycogen-associated regulatory subunit of protein phosphatase-1 on the regulation of glycogen synthesis by insulin and cyclic adenosine 3',5'-monophosphate agonists.
Insulin Resistance
Effect of insulin on protein phosphatase 2A expression in muscle in type 2 diabetes.
Insulin Resistance
Effects of calcineurin activation on insulin-, AICAR- and contraction-induced glucose transport in skeletal muscle.
Insulin Resistance
Egr-1 transcriptionally activates protein phosphatase PTP1B to facilitate hyperinsulinemia-induced insulin resistance in the liver in type 2 diabetes.
Insulin Resistance
Genetic disruption of protein phosphatase 5 in mice prevents high-fat diet feeding-induced weight gain.
Insulin Resistance
Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus.
Insulin Resistance
Hypomagnesemia after heart transplantation or left ventricular assist device implant for end-stage heart failure.
Insulin Resistance
Immunology of pancreatic islet transplantation.
Insulin Resistance
Immunosuppressive agents and metabolic factors of cardiovascular risk in renal transplant recipients.
Insulin Resistance
In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides.
Insulin Resistance
Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistance.
Insulin Resistance
Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance.
Insulin Resistance
Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle.
Insulin Resistance
Inositol-1,4,5-trisphosphate receptor regulates hepatic gluconeogenesis in fasting and diabetes.
Insulin Resistance
Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors.
Insulin Resistance
Insulin resistance induced by a high-fat diet is associated with the induction of genes related to leukocyte activation in rat peripheral leukocytes.
Insulin Resistance
Lack of Improvement in Insulin Sensitivity After Pancreas Transplantation in Recipients With a High Level of Calcineurin Inhibitors.
Insulin Resistance
Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity.
Insulin Resistance
Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.
Insulin Resistance
Liver-specific deletion of Ppp2c? enhances glucose metabolism and insulin sensitivity.
Insulin Resistance
Magnesemia in renal transplant recipients: relation with immunosuppression and posttransplant diabetes.
Insulin Resistance
Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation.
Insulin Resistance
MicroRNA-181b Improves Glucose Homeostasis and Insulin Sensitivity by Regulating Endothelial Function in White Adipose Tissue.
Insulin Resistance
miR-140-5p Aggravates Insulin Resistance via Directly Targeting GYS1 and PPP1CC in Insulin-Resistant HepG2 Cells.
Insulin Resistance
Molecular and linkage analysis of type-1 protein phosphatase catalytic beta-subunit gene: lack of evidence for its major role in insulin resistance in Pima Indians.
Insulin Resistance
New-onset diabetes after renal transplantation.
Insulin Resistance
New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management.
Insulin Resistance
Phosphatase activity in rat adipocytes: effects of insulin and insulin resistance.
Insulin Resistance
Post-transplant diabetic ketoacidosis--a possible consequence of immunosuppression with calcineurin inhibiting agents: a case series.
Insulin Resistance
Protein phosphatase 1 regulatory subunit 12A and catalytic subunit ?, new members in the phosphatidylinositide 3 kinase insulin-signaling pathway.
Insulin Resistance
Protein phosphatase 4 (PP4) functions as a critical regulator in tumor necrosis factor (TNF)-?-induced hepatic insulin resistance.
Insulin Resistance
Protein Phosphatase 4 Promotes Hepatocyte Lipoapoptosis by Regulating RAC1/MLK3/JNK Pathway.
Insulin Resistance
Protein phosphatase-2C alpha as a positive regulator of insulin sensitivity through direct activation of phosphatidylinositol 3-kinase in 3T3-L1 adipocytes.
Insulin Resistance
Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo.
Insulin Resistance
SCR-1693 inhibits tau phosphorylation and improves insulin resistance associated cognitive deficits.
Insulin Resistance
Selective hepatic insulin resistance in mice heterozygous for a mitochondrial trifunctional protein defect.
Insulin Resistance
The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats.
Insulin Resistance
The impact of calcineurin inhibitors on insulin sensitivity and insulin secretion: a randomized crossover trial in uraemic patients.
Insulinoma
Calcineurin activity as an indicator of oxidative stress in normal islet cells and insulinoma cells.
Insulinoma
CRTC2 is required for ?-cell function and proliferation.
Insulinoma
Cyclosporin A stimulation of glucose-induced insulin secretion in MIN6 cells.
Insulinoma
Role of calcium in pancreatic islet cell death by IFN-gamma/TNF-alpha.
Intellectual Disability
B56?-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.
Intellectual Disability
Confirmed rare copy number variants implicate novel genes in schizophrenia.
Intellectual Disability
De novo missense variants in PPP1CB are associated with intellectual disability and congenital heart disease.
Intellectual Disability
De Novo Mutations Affecting the Catalytic C? Subunit of PP2A, PPP2CA, Cause Syndromic Intellectual Disability Resembling Other PP2A-Related Neurodevelopmental Disorders.
Intellectual Disability
De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome.
Intellectual Disability
Novel truncating PPM1D mutation in a patient with intellectual disability.
Intellectual Disability
PPP2R5D-Related Intellectual Disability and Neurodevelopmental Delay: A Review of the Current Understanding of the Genetics and Biochemical Basis of the Disorder.
Intellectual Disability
Presence of potential G-quadruplex RNA forming motifs at the 5'-UTR of PP2Ac? mRNA repress translation.
Intellectual Disability
Protein expression profiles that underpin the preventive and therapeutic potential of Moringa oleifera Lam against azoxymethane and dextran sodium sulfate-induced mouse colon carcinogenesis.
Intellectual Disability
Protein Phosphatase 2A (PP2A) mutations in brain function, development, and neurologic disease.
Intellectual Disability
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Intellectual Disability
Two unrelated girls with intellectual disability associated with a truncating mutation in the PPM1D penultimate exon.
Intervertebral Disc Degeneration
FK506 Induces the TGF-?1/Smad 3 Pathway Independently of Calcineurin Inhibition to Prevent Intervertebral Disk Degeneration.
Intervertebral Disc Degeneration
Mitophagy in degenerative joint diseases.
Intestinal Pseudo-Obstruction
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Invasive Fungal Infections
Calcineurin regulates innate antifungal immunity in neutrophils.
Invasive Fungal Infections
Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections.
Invasive Fungal Infections
Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus.
Invasive Fungal Infections
Spectrum of cytomegalovirus-induced renal pathology in renal allograft recipients.
Invasive Pulmonary Aspergillosis
Impaired calcineurin signaling in myeloid cells results in downregulation of pentraxin-3 and increased susceptibility to aspergillosis.
Iron Overload
Iron overload-induced calcium signals modulate mitochondrial fragmentation in HT-22 hippocampal neuron cells.
Ischemic Attack, Transient
Neuroprotective efficacy of FR901459, a novel derivative of cyclosporin A, in in vitro mitochondrial damage and in vivo transient cerebral ischemia models.
Ischemic Stroke
A novel PGAM5 inhibitor LFHP-1c protects blood-brain barrier integrity in ischemic stroke.
Ischemic Stroke
Cilostazol Reduces PAC-1 Expression on Platelets in Ischemic Stroke.
Ischemic Stroke
Gene polymorphism of platelet glycoprotein I balpha in Chinese patients with large- and small-artery subtypes of ischemic stroke.
Ischemic Stroke
Intra-arterial Stem Cell Therapy Diminishes Inflammasome Activation After Ischemic Stroke: a Possible Role of Acid Sensing Ion Channel 1a.
Ischemic Stroke
Intra-arterial stem cell therapy modulates neuronal calcineurin and confers neuroprotection after ischemic stroke.
Keloid
Innovative therapies in the treatment of keloids and hypertrophic scars.
Keratitis
Polyhexamethylene Biguanide and Calcineurin Inhibitors as Novel Antifungal Treatments for Aspergillus Keratitis.
Keratoconjunctivitis
Management of ocular allergy.
Keratoconjunctivitis
Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis.
Keratoconjunctivitis
Topical Calcineurin Inhibitors in the Treatment of Steroid-Dependent Atopic Keratoconjunctivitis.
Keratoconjunctivitis Sicca
A topical aqueous calcineurin inhibitor for the treatment of naturally occurring keratoconjunctivitis sicca in dogs.
Ketosis
Post-transplant diabetic ketoacidosis--a possible consequence of immunosuppression with calcineurin inhibiting agents: a case series.
Kidney Diseases
"Smartphone Medication Adherence Saves Kidneys" for Kidney Transplantation Recipients: Protocol for a Randomized Controlled Trial.
Kidney Diseases
Abdominal tuberculosis in renal transplant recipient. Presentation of a case and literature review
Kidney Diseases
Clinical and genetic risk factors for new-onset diabetes mellitus after transplantation (NODAT) in major transplant centres in Malaysia.
Kidney Diseases
Cyclosporine A protects podocytes by regulating WAVE1 phosphorylation.
Kidney Diseases
Efficacy and safety of tacrolimus and low-dose prednisone in Chinese children with steroid-resistant nephrotic syndrome.
Kidney Diseases
Glucocorticoids use in kidney transplant setting.
Kidney Diseases
Impact of acute kidney injury on renal allograft survival.
Kidney Diseases
Non-immunologic actions of calcineurin inhibitors in proteinuric kidney diseases.
Kidney Diseases
Steroid-free immunosuppression after renal transplantation-long-term experience from a single centre.
Kidney Diseases
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.
Kidney Diseases
The long-term effect of simultaneous heart and kidney transplantation on native renal function.
Kidney Diseases
Therapeutic Effects of FK506 on IgA Nephropathy Rat.
Kidney Diseases, Cystic
Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Kidney Failure, Chronic
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Kidney Failure, Chronic
A putative role for calcineurin in lymphopenia associated with chronic renal failure.
Kidney Failure, Chronic
ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients.
Kidney Failure, Chronic
Acute kidney injury in solid organ transplant recipients.
Kidney Failure, Chronic
Aortic valve replacement performed twice through ministernotomy 15 years after lung transplantation.
Kidney Failure, Chronic
Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with chronic renal failure on hemodialysis treatment.
Kidney Failure, Chronic
Calcineurin inhibitor withdrawal and conversion to mycophenolate mofetil and steroids in cardiac transplant recipients with chronic renal failure: a word of caution.
Kidney Failure, Chronic
Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients - assessment of renal and allograft function, cardiovascular risk factors and immune monitoring.
Kidney Failure, Chronic
Combined heart and liver transplantation: a single-center experience.
Kidney Failure, Chronic
Comparative study of the cellular pharmacodynamics of calcineurin inhibitors between patients with chronic renal failure awaiting renal transplantation and cirrhosis patients awaiting liver transplantation.
Kidney Failure, Chronic
Comparative Study of the Cellular Pharmacodynamics of Calcineurin Inhibitors between Patients with Chronic Renal Failure Awaiting Renal Transplantation and Cirrhosis Patients Awaiting Liver Transplantation.
Kidney Failure, Chronic
Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults.
Kidney Failure, Chronic
Cyclosporine triggers endoplasmic reticulum stress in endothelial cells: a role for endothelial phenotypic changes and death.
Kidney Failure, Chronic
Decline in 51Cr-labelled EDTA measured glomerular filtration rate following lung transplantation.
Kidney Failure, Chronic
Dual kidney transplantation after liver transplantation: a good option to rescue a patient from dialysis.
Kidney Failure, Chronic
Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Kidney Failure, Chronic
Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
Kidney Failure, Chronic
Evolution of lung and kidney allograft function in patients receiving kidney after lung transplantation.
Kidney Failure, Chronic
Glomerular Neovascularization in Nondiabetic Renal Allograft Is Associated with Calcineurin Inhibitor Toxicity.
Kidney Failure, Chronic
Hot-topic debate on kidney function: renal-sparing approaches are ineffective.
Kidney Failure, Chronic
Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.
Kidney Failure, Chronic
Immunosuppressive treatment for proliferative lupus nephritis.
Kidney Failure, Chronic
Immunosuppressive treatment of idiopathic membranous nephropathy: the dilemma continues.
Kidney Failure, Chronic
Improvement in chronic renal failure after mycophenolate mofetil introduction and cyclosporine dose reduction: four-year results from a cohort of heart transplant recipients.
Kidney Failure, Chronic
Incisional Hernia After Peritoneal Dialysis Catheter Placement in a Patient on Sirolimus.
Kidney Failure, Chronic
Kidney after nonrenal transplantation-the impact of alemtuzumab induction.
Kidney Failure, Chronic
Kidney transplantation after liver transplantation.
Kidney Failure, Chronic
Kidney transplantation as a therapeutic option for end-stage renal disease developing after heart transplantation.
Kidney Failure, Chronic
Management of steroid-resistant nephrotic syndrome in children and adolescents.
Kidney Failure, Chronic
Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Kidney Failure, Chronic
Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure.
Kidney Failure, Chronic
Outcomes after liver transplantation: Chronic kidney disease.
Kidney Failure, Chronic
Peritoneal dialysis after nonrenal solid organ transplantation: clinical outcomes and practical considerations.
Kidney Failure, Chronic
Peritoneal Dialysis in Orthotopic Liver Transplantation Recipients.
Kidney Failure, Chronic
Peritoneal-mediastinal communication complication in peritoneal dialysis.
Kidney Failure, Chronic
pERK-dependent defective TCR-mediated activation of CD4(+) T cells in end-stage renal disease patients.
Kidney Failure, Chronic
Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference.
Kidney Failure, Chronic
Remission of proteinuria in multidrug resistant idiopathic nephrotic syndrome following immunoglobulin immunoadsorption.
Kidney Failure, Chronic
Renal protective strategies in heart transplant patients.
Kidney Failure, Chronic
Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity.
Kidney Failure, Chronic
Simultaneous Liver-Kidney Transplant: Too Many or Just Enough?
Kidney Failure, Chronic
Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure.
Kidney Failure, Chronic
Supplementation with omega-3 polyunsaturated fatty acids and experimental tacrolimus-induced nephrotoxicity.
Kidney Failure, Chronic
Thrombosis in end-stage renal disease.
Kidney Failure, Chronic
Time to Conversion to an Everolimus-Based Regimen: Renal Outcomes in Liver Transplant Recipients From the EVEROLIVER Registry.
Kidney Failure, Chronic
Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.
Kidney Failure, Chronic
Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients.
Kidney Failure, Chronic
[Mycosis fungoides in a heart transplant recipient].
Kidney Failure, Chronic
[Renal complications after hematopoietic stem cell transplantation].
Kidney Failure, Chronic
[The effect of the different immunosuppression therapy on CD4(+)Foxp3(+) Treg cells in kidney recipients.]
Kidney Neoplasms
Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.
Kidney Neoplasms
Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells.
Kidney Neoplasms
Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression.
Kidney Neoplasms
Cordycepin promotes apoptosis by modulating the ERK-JNK signaling pathway via DUSP5 in renal cancer cells.
Kidney Neoplasms
Critical role of mTOR in calcineurin inhibitor-induced renal cancer progression.
Kidney Neoplasms
Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression.
Kidney Neoplasms
Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.
Kidney Neoplasms
Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells.
Kidney Neoplasms
Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer.
Kidney Neoplasms
Re: effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression.
Lafora Disease
4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease.
Lafora Disease
A bioassay for Lafora disease and laforin glucan phosphatase activity.
Lafora Disease
A novel compound heterozygous EPM2A mutation in a Chinese boy with Lafora disease.
Lafora Disease
A novel EPM2A mutation in a patient with Lafora disease presenting with early parkinsonism symptoms in childhood.
Lafora Disease
A novel EPM2A mutation yields a slow progression form of Lafora disease.
Lafora Disease
A PTG variant contributes to a milder phenotype in Lafora disease.
Lafora Disease
A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.
Lafora Disease
Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.
Lafora Disease
Abnormal metabolism of glycogen phosphate as a cause for Lafora disease.
Lafora Disease
Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion.
Lafora Disease
Advances in lafora progressive myoclonus epilepsy.
Lafora Disease
Advances in the genetics of progressive myoclonus epilepsy.
Lafora Disease
Are there errors in glycogen biosynthesis and is laforin a repair enzyme?
Lafora Disease
Assessing the Biological Activity of the Glucan Phosphatase Laforin.
Lafora Disease
Astrocytes and neurons produce distinct types of polyglucosan bodies in Lafora disease.
Lafora Disease
Biophysical characterization of laforin-carbohydrate interaction.
Lafora Disease
Bioptically demonstrated Lafora disease without EPM2A mutation: a clinical and neurophysiological study of two sisters.
Lafora Disease
Brain glycogen in health and disease.
Lafora Disease
Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.
Lafora Disease
Conservation of the glucan phosphatase laforin is linked to rates of molecular evolution and the glucan metabolism of the organism.
Lafora Disease
Correction to: Interdependence of laforin and malin proteins for their stability and functions could underlie the molecular basis of locus heterogeneity in Lafora disease.
Lafora Disease
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
Lafora Disease
Degradation of altered mitochondria by autophagy is impaired in Lafora disease.
Lafora Disease
Dimeric quaternary structure of human laforin.
Lafora Disease
Dimerization of the glucan phosphatase laforin requires the participation of cysteine 329.
Lafora Disease
Early-onset Lafora body disease.
Lafora Disease
Endocytosis of the glutamate transporter 1 is regulated by laforin and malin: Implications in Lafora disease.
Lafora Disease
Enhanced sensitivity of laforin- and malin-deficient mice to the convulsant agent pentylenetetrazole.
Lafora Disease
EPM2A in-frame deletion slows neurological decline in Lafora Disease.
Lafora Disease
Escherichia coli expression, refolding and characterization of human laforin.
Lafora Disease
Expression, purification and characterization of soluble red rooster laforin as a fusion protein in Escherichia coli.
Lafora Disease
FDG-PET assessment and metabolic patterns in Lafora disease.
Lafora Disease
Founder effect with variable age at onset in Arab families with Lafora disease and EPM2A mutation.
Lafora Disease
Four novel and two recurrent NHLRC1 (EPM2B) and EPM2A gene mutations leading to Lafora disease in six Turkish families.
Lafora Disease
FoxO3a-mediated autophagy is down-regulated in the laforin deficient mice, an animal model for Lafora progressive myoclonus epilepsy.
Lafora Disease
Generation and characterization of a laforin nanobody inhibitor.
Lafora Disease
Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
Lafora Disease
Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22.
Lafora Disease
Genetics of Lafora progressive myoclonic epilepsy: current perspectives.
Lafora Disease
Genotypes and phenotypes of patients with Lafora disease living in Germany.
Lafora Disease
Glycogen and related polysaccharides inhibit the laforin dual-specificity protein phosphatase.
Lafora Disease
Glycogen hyperphosphorylation underlies lafora body formation.
Lafora Disease
Glycogen metabolism in tissues from a mouse model of Lafora disease.
Lafora Disease
Glycogen phosphorylation and Lafora disease.
Lafora Disease
Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is modulated by the laforin-malin complex.
Lafora Disease
Hepatic disease as the first manifestation of progressive myoclonus epilepsy of Lafora.
Lafora Disease
Hyperphosphorylation of glucosyl C6 carbons and altered structure of glycogen in the neurodegenerative epilepsy Lafora disease.
Lafora Disease
Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy.
Lafora Disease
Identification of new and common mutations in the EPM2A gene in Lafora disease.
Lafora Disease
Incorporation of phosphate into glycogen by glycogen synthase.
Lafora Disease
Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin.
Lafora Disease
Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.
Lafora Disease
Increased Oxidative Stress and Impaired Antioxidant Response in Lafora Disease.
Lafora Disease
Increased oxidative stress and impaired antioxidant response in Lafora disease.
Lafora Disease
Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models.
Lafora Disease
Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.
Lafora Disease
Interdependence of laforin and malin proteins for their stability and functions could underlie the molecular basis of locus heterogeneity in Lafora disease.
Lafora Disease
Isolation and characterization of mouse homologue for the human epilepsy gene, EPM2A.
Lafora Disease
Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy.
Lafora Disease
Lafora disease - from pathogenesis to treatment strategies.
Lafora Disease
Lafora disease due to EPM2B mutations: a clinical and genetic study.
Lafora Disease
Lafora disease in a Malaysian with a rare mutation in the EPM2A gene.
Lafora Disease
Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin.
Lafora Disease
Lafora disease proteins laforin and malin negatively regulate the HIPK2-p53 cell death pathway.
Lafora Disease
Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment.
Lafora Disease
Lafora disease ubiquitin ligase malin promotes proteasomal degradation of neuronatin and regulates glycogen synthesis.
Lafora Disease
Lafora disease.
Lafora Disease
Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EMP2B) genes.
Lafora Disease
Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes.
Lafora Disease
Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.
Lafora Disease
Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration.
Lafora Disease
Laforin and malin deletions in mice produce similar neurologic impairments.
Lafora Disease
Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity.
Lafora Disease
Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo.
Lafora Disease
Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
Lafora Disease
Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.
Lafora Disease
Laforin, a dual specificity phosphatase involved in Lafora disease, is present mainly as monomeric form with full phosphatase activity.
Lafora Disease
Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.
Lafora Disease
Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates.
Lafora Disease
Laforin, a dual specificity protein phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase.
Lafora Disease
Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.
Lafora Disease
Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.
Lafora Disease
Laforin, the most common protein mutated in Lafora disease, regulates autophagy.
Lafora Disease
Laforin-Malin Complex Degrades Polyglucosan Bodies in Concert with Glycogen Debranching Enzyme and Brain Isoform Glycogen Phosphorylase.
Lafora Disease
Late onset Lafora disease and novel EPM2A mutations: breaking paradigms.
Lafora Disease
Late-onset Lafora disease with prominent parkinsonism due to a rare mutation in EPM2A.
Lafora Disease
Loss of function of the cytoplasmic isoform of the protein laforin (EPM2A) causes Lafora progressive myoclonus epilepsy.
Lafora Disease
Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease.
Lafora Disease
Loss of laforin or malin results in increased Drp1 level and concomitant mitochondrial fragmentation in Lafora disease mouse models.
Lafora Disease
Malin and laforin are essential components of a protein complex that protects cells from thermal stress.
Lafora Disease
Malin knockout mice support a primary role of autophagy in the pathogenesis of Lafora disease.
Lafora Disease
Managing Lafora body disease with vagal nerve stimulation.
Lafora Disease
Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy.
Lafora Disease
Mechanistic Insights into Glucan Phosphatase Activity against Polyglucan Substrates.
Lafora Disease
Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy.
Lafora Disease
Molecular characterization of laforin, a dual-specificity protein phosphatase implicated in Lafora disease.
Lafora Disease
Molecular dynamics simulations and principal component analysis on human laforin mutation W32G and W32G/K87A.
Lafora Disease
MRI volumetry and proton MR spectroscopy of the brain in Lafora disease.
Lafora Disease
Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice.
Lafora Disease
Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.
Lafora Disease
Mutations in NHLRC1 cause progressive myoclonus epilepsy.
Lafora Disease
Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease.
Lafora Disease
Neuronatin-mediated Aberrant Calcium Signaling and Endoplasmic Reticulum Stress Underlie Neuropathology in Lafora Disease.
Lafora Disease
NHLRC1 homozygous dodecamer expansion in a Newfoundland dog with Lafora disease.
Lafora Disease
Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy.
Lafora Disease
Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy.
Lafora Disease
Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease.
Lafora Disease
Oxidative stress, a new hallmark in the pathophysiology of Lafora progressive myoclonus epilepsy.
Lafora Disease
Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease.
Lafora Disease
Phosphate incorporation during glycogen synthesis and Lafora disease.
Lafora Disease
Polyglucosan body structure in Lafora disease.
Lafora Disease
Progressive Myoclonus Epilepsy in Congenital Generalized Lipodystrophy type 2: Report of 3 cases and literature review.
Lafora Disease
Protein Degradation and Quality Control in Cells from Laforin and Malin Knockout Mice.
Lafora Disease
Relationship between glycogen accumulation and the laforin dual specificity phosphatase.
Lafora Disease
Sensitive quantification of ?-glucans in mouse tissues, cell cultures, and human cerebrospinal fluid.
Lafora Disease
Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease.
Lafora Disease
Structural and Functional Brain Abnormalities in Mouse Models of Lafora Disease.
Lafora Disease
Structural insights into glucan phosphatase dynamics using amide hydrogen-deuterium exchange mass spectrometry.
Lafora Disease
Structural mechanism of laforin function in glycogen dephosphorylation and lafora disease.
Lafora Disease
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
Lafora Disease
Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.
Lafora Disease
The 6th International Lafora Epilepsy Workshop: Advances in the search for a cure.
Lafora Disease
The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain.
Lafora Disease
The laforin-malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase beta subunits.
Lafora Disease
The laforin/malin E3-ubiquitin ligase complex ubiquitinates pyruvate kinase M1/M2.
Lafora Disease
The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease.
Lafora Disease
Three Patients With Lafora Disease: Different Clinical Presentations and a Novel Mutation.
Lafora Disease
Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the malin-laforin E3-ubiquitin ligase complex.
Lafora Disease
Whole exome sequencing identified a novel missense mutation in EPM2A underlying Lafora disease in a Pakistani family.
Lafora Disease
[Lafora disease: a review of the literature].
Learning Disabilities
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Leishmaniasis, Cutaneous
Phlebotomus papatasi saliva inhibits protein phosphatase activity and nitric oxide production by murine macrophages.
Leishmaniasis, Visceral
Lymph node cells from BALB/c mice with chronic visceral leishmaniasis exhibiting cellular anergy and apoptosis: involvement of Ser/Thr phosphatase.
Lentigo
Induced lentiginosis with use of topical calcineurin inhibitors.
Lentivirus Infections
[PPP3CA silence regulates MET process, cell apoptosis, proliferation and migration in metanephric mesenchyme cells].
Leprosy
Alterations in T cell signal transduction by M. leprae antigens is associated with downregulation of second messengers PKC, calcium, calcineurin, MAPK and various transcription factors in leprosy patients.
Leukemia
Activation of MAP kinase family members triggered by TPA or ionomycin occurs via the protein phosphatase 4 pathway in Jurkat leukemia T cells.
Leukemia
Age-related mutations associated with clonal hematopoietic expansion and malignancies.
Leukemia
Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2.
Leukemia
Antitumor antibiotic fostriecin covalently binds to cysteine-269 residue of protein phosphatase 2A catalytic subunit in mammalian cells.
Leukemia
Apoptosis induced by protein phosphatase 2A (PP2A) inhibition in T leukemia cells is negatively regulated by PP2A-associated p38 mitogen-activated protein kinase.
Leukemia
Arsenic sulfide promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
Leukemia
Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study.
Leukemia
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.
Leukemia
Calyculin A modulates activation of the NADPH-oxidase in Me2SO-differentiated HL-60 cells.
Leukemia
Characterization of a variant of PAC-1 in large granular lymphocyte leukemia.
Leukemia
CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
Leukemia
Clinical significance of serum calcineurin in acute leukemia.
Leukemia
Cluster analysis and phylogenetic relationship in biomarker identification of type 2 diabetes and nephropathy.
Leukemia
Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Leukemia
Comparative effects of protein phosphatase inhibitors (okadaic acid and calyculin A) on human leukemia HL60, HL60/ADR and K562 cells.
Leukemia
Decreased calcineurin immunoreactivity in the postmortem brain of a patient with schizophrenia who had been prescribed the calcineurin inhibitor, tacrolimus, for leukemia.
Leukemia
Direct evidence that FK506 inhibition of FcepsilonRI-mediated exocytosis from RBL mast cells involves calcineurin.
Leukemia
Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants.
Leukemia
Ex Vivo CD34(+)-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.
Leukemia
Haploidentical HSCT: a 15-year experience at San Raffaele.
Leukemia
IL12 Abrogates Calcineurin-Dependent Immune Evasion during Leukemia Progression.
Leukemia
Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.
Leukemia
Inhibition by calyculin A and okadaic acid of the Ca(2+) release-activated Ca(2+) entry pathway in rat basophilic leukemia cells: evidence for regulation by type 1/2A serine/threonine phosphatase activity.
Leukemia
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.
Leukemia
Inhibition of Ser/Thr phosphatase PPM1D induces neutrophil differentiation in HL-60 cells.
Leukemia
Knockdown of protein phosphatase 5 (PPP5C) suppresses the growth of leukemic cell line U937.
Leukemia
Mitotic arrest and enhanced nuclear protein phosphorylation in human leukemia K562 cells by okadaic acid, a potent protein phosphatase inhibitor and tumor promoter.
Leukemia
Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line.
Leukemia
Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2A inhibition.
Leukemia
Okadaic acid-induced apoptosis of HL60 leukemia cells is preceded by destabilization of bcl-2 mRNA and downregulation of bcl-2 protein.
Leukemia
Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia.
Leukemia
Protein phosphatase inhibitors induce the release of serotonin from rat basophilic leukemia cells (RBL-2H3).
Leukemia
RCAN1 is an important mediator of glucocorticoid-induced apoptosis in human leukemic cells.
Leukemia
Regulation of dual-specificity phosphatases M3/6 and hVH5 by phorbol esters. Analysis of a delta-like domain.
Leukemia
Role of protein phosphatases in the cancer microenvironment.
Leukemia
Sanguinarine as a potent and specific inhibitor of protein phosphatase 2C in vitro and induces apoptosis via phosphorylation of p38 in HL60 cells.
Leukemia
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Leukemia
Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia.
Leukemia
Tetra-arsenic tetra-sulfide (As4S 4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
Leukemia
The effect of okadaic acid on histamine release, cell morphology and phosphorylation in rat basophilic leukemia (RBL-2H3) cells, human basophils and rat peritoneal mast cells.
Leukemia
Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling.
Leukemia
[Influence of calcineurin on apoptosis of pre-B lymphocytes and the leukemia cells derived from pre-B lymphocytes].
Leukemia
[Study on platelet activated state and platelet activated function in adults with acute leukemia]
Leukemia, B-Cell
Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia.
Leukemia, B-Cell
Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment.
Leukemia, Erythroblastic, Acute
Ca2+/calmodulin-dependent and -independent down-regulation of c-myb mRNA levels in erythropoietin-responsive murine erythroleukemia cells. The role of calcineurin.
Leukemia, Large Granular Lymphocytic
Characterization of a variant of PAC-1 in large granular lymphocyte leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Expressions of four major protein Ser/Thr phosphatases in human primary leukemic cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia.
Leukemia, Lymphoid
Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Calcium ionophore activation of chronic myelogenous leukemia progenitor cells into dendritic cells is mediated by calcineurin phosphatase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Leukemia, Myeloid
Down-regulation of c-Myc and Max genes is associated to inhibition of protein phosphatase 2A in K562 human leukemia cells.
Leukemia, Myeloid
Effects of tautomycin, a protein phosphatase inhibitor, on recycling of mammalian cell surface molecules.
Leukemia, Myeloid
Morphological changes and reorganization of actinfilaments in human myeloid leukemia cells induced by a novel protein phosphatase inhibitor, tautomycin.
Leukemia, Myeloid
Relationship between phosphatase activity and cytotoxic effect of two protein phosphatase inhibitors, okadaic acid and pervanadate, on human myeloid leukemia cell line.
Leukemia, Myeloid
The interaction between taxoids and serine/threonine protein phosphatase activities during taxan-induced apoptosis of HL 60 leukemic cells.
Leukemia, Myeloid, Acute
Clinical significance of serum calcineurin in acute leukemia.
Leukemia, Myeloid, Acute
Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT.
Leukemia, Myeloid, Acute
Deregulation of protein phosphatase expression in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.
Leukemia, Myeloid, Acute
Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression.
Leukemia, Myeloid, Acute
Expressions of four major protein Ser/Thr phosphatases in human primary leukemic cells.
Leukemia, Myeloid, Acute
High expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) is associated with poor prognosis in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Potentiality of Protein phosphatase Mg2+ /Mn2+ dependent 1D as a biomarker for predicting prognosis in acute myeloid leukemia patients.
Leukemia, Myeloid, Acute
PPM1D Knockdown Suppresses Cell Proliferation, Promotes Cell Apoptosis, and Activates p38 MAPK/p53 Signaling Pathway in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.
Leukemia, Myelomonocytic, Juvenile
Role of protein phosphatases in the cancer microenvironment.
Leukemia, T-Cell
Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia.
Leukocytosis
Pleocytosis after hemopoietic stem cell transplantation.
Leukoencephalopathies
Cerebellar ataxia in a patient receiving calcineurin inhibitors after living donor liver transplantation: a case report.
Leukoencephalopathies
Neurologic complications after solid organ transplantation.
Leukoencephalopathies
Neurologic complications of transplantation.
Leukoencephalopathies
Neurologic Complications of Transplantation.
Leukoencephalopathies
Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors.
Leukoencephalopathies
Reversible leukoencephalopathy syndrome associated to leukopenia in a chronic hemodialysis patient.
Leukoencephalopathies
Reversible posterior leukoencephalopathy syndrome (RPLS) in a heart transplant recipient treated by substitution of cyclosporine A with tacrolimus.
Leukoencephalopathies
Reversible posterior leukoencephalopathy syndrome: diagnosis and management in the setting of lung transplantation.
Leukoencephalopathies
Successful retransplantation using rapamycin in a patient with previous calcineurin inhibitor-induced posterior leukoencephalopathy syndrome.
Leukoencephalopathies
Transplantation for liver failure in patients with sickle cell disease: Challenging but feasible.
Leukoencephalopathies
Two cases of calcineurin inhibitor-associated reversible posterior leukoencephalopathy syndrome in renal transplant recipients.
Leukoencephalopathy, Progressive Multifocal
Neurologic Complications of Transplantation.
Lichen Planus
Anti-inflammatory treatment.
Lichen Planus
Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial.
Lichen Planus
Efficacy of topical calcineurin inhibitors in lichen planus.
Lichen Planus
Potential new indications of topical calcineurin inhibitors.
Lichen Planus, Oral
Calcineurin inhibitors in oral medicine.
Lichen Planus, Oral
Challenges in using topical calcineurin inhibitors as a treatment for recalcitrant oral lichen planus.
Lichen Planus, Oral
Clinical and serological efficacy of topical calcineurin inhibitors in oral lichen planus: a prospective randomized controlled trial.
Lichen Planus, Oral
Efficacy of Topical Calcineurin Inhibitors in Oral Lichen Planus.
Lichen Planus, Oral
Interventions for oral lichen planus: A systematic review and network meta-analysis of randomized clinical trials.
Lichen Planus, Oral
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Lichen Planus, Oral
The use of topical calcineurin inhibitors in the management of oral lichen planus.
Lichen Planus, Oral
Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis.
Lichen Sclerosus et Atrophicus
A retrospective analysis of pediatric patients with lichen sclerosus treated with a standard protocol of class I topical corticosteroid and topical calcineurin inhibitor.
Lichen Sclerosus et Atrophicus
Anti-inflammatory treatment.
Lichen Sclerosus et Atrophicus
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Lichen Sclerosus et Atrophicus
Safety of calcineurin inhibitors in the management of lichen sclerosis.
Lichen Sclerosus et Atrophicus
The role of calcineurin inhibitors in the management of lichen sclerosus.
Lichen Sclerosus et Atrophicus
[Lichen sclerosus--a neglected disease].
Lichen Sclerosus et Atrophicus
[Lichen sclerosus. New aspects of pathogenesis and treatment]
Limbic Encephalitis
Risk Factor and Long-Term Outcome Analyses for Acute Limbic Encephalitis and Calcineurin Inhibitor-Induced Encephalopathy in Adults following Allogeneic Hematopoietic Cell Transplantation.
Lipid Metabolism Disorders
Comparison of Kidney Transplant Function, Lipid Metabolism Disorders, and Glucose and Hemoglobin Concentration in Transplant Patients Treated With Proliferation Signal Inhibitor (Everolimus) or Calcineurin Inhibitor (Tacrolimus).
Lipoma
Enhanced expression of catalytic subunits of protein phosphatase type 1 and high S-phase fraction in liposarcoma.
Liposarcoma
Enhanced expression of catalytic subunits of protein phosphatase type 1 and high S-phase fraction in liposarcoma.
Liver Cirrhosis
Activation of protein serine/threonine phosphatase PP2C? efficiently prevents liver fibrosis.
Liver Cirrhosis
Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: Effects on virus replication and recurrent hepatitis.
Liver Cirrhosis
Endoplasmic Reticulum Stress Increases DUSP5 Expression via PERK-CHOP Pathway, Leading to Hepatocyte Death.
Liver Cirrhosis
Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation.
Liver Cirrhosis
Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.
Liver Cirrhosis
Progression of liver fibrosis in HCV-positive liver transplant recipients randomized to everolimus with reduced calcineurin inhibitor (CNI) therapy or a standard CNI regimen.
Liver Cirrhosis
Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.
Liver Cirrhosis, Alcoholic
Deficiency in calcineurin activity in liver transplantation candidates with alcoholic cirrhosis or hepatocellular carcinoma.
Liver Cirrhosis, Alcoholic
Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience.
Liver Cirrhosis, Biliary
Calcineurin Inhibitors and the IL12A Locus Influence Risk of Recurrent Primary Biliary Cirrhosis After Liver Transplantation.
Liver Diseases
A comprehensive review of immunosuppression used for liver transplantation.
Liver Diseases
Chemical and biological evidence links microcystins to salmon 'netpen liver disease'.
Liver Diseases
Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation.
Liver Diseases
De novo autoimmune hepatitis after liver transplantation.
Liver Diseases
Endoplasmic Reticulum Stress Increases DUSP5 Expression via PERK-CHOP Pathway, Leading to Hepatocyte Death.
Liver Diseases
Identification of novel loci for pediatric cholestatic liver disease defined by KIF12, PPM1F, USP53, LSR, and WDR83OS pathogenic variants.
Liver Diseases
Impact of recipient age and preoperative fasting blood glucose level as the risk factors of living donor liver transplantation in cirrhotic patients in the recent comprehensive era with knowledge of indications: Recent status in a Japanese single center.
Liver Diseases
Pediatric post-transplant metabolic syndrome: New clouds on the horizon.
Liver Diseases
Renal function in pediatric liver transplantation: a long-term follow-up study.
Liver Diseases
Risk factors of recipient receiving living donor liver transplantation in the comprehensive era of indication and perioperative managements.
Liver Diseases
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients.
Liver Failure
Diagnosis and management of autoimmune hepatitis.
Liver Failure
Metabolic Bone Disease in the Post-transplant Population: Preventative and Therapeutic Measures.
Liver Failure
Rescue therapy with sirolimus in a renal transplant recipient with tacrolimus-induced hepatotoxicity.
Liver Neoplasms
Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies.
Liver Neoplasms
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Liver Neoplasms
Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3.
Liver Neoplasms
Protein phosphatase 2 regulatory subunit B''Alpha silencing inhibits tumor cell proliferation in liver cancer.
Liver Neoplasms
Transcriptional toxicity of the Yangtze River source water on mouse (Mus musculus) detected by cDNA microarray.
Liver Neoplasms
[Studies on protein phosphatase 1/2A in liver cancer tissues: preliminary report]
Liver Neoplasms, Experimental
Nucleolar phosphoprotein phosphatase from Novikoff hepatoma and rat liver: characterization and partial purification.
Liver Neoplasms, Experimental
Phosphoprotein phosphatase activity of Novikoff hepatoma nucleoli.
Locked-In Syndrome
Recovery of locked-in syndrome following liver transplantation with calcineurin inhibitor cessation and supportive treatment.
Loeys-Dietz Syndrome
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Lung Diseases
Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: A case series.
Lung Diseases
Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease.
Lung Diseases, Interstitial
Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease.
Lung Diseases, Interstitial
Effective Use of Calcineurin Inhibitor in Combination Therapy for Interstitial Lung Disease in Patients With Dermatomyositis and Polymyositis.
Lung Diseases, Interstitial
Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.
Lung Diseases, Interstitial
Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
Lung Diseases, Interstitial
The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis.
Lung Diseases, Interstitial
Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation.
Lung Injury
Dual specificity phosphatase DUSP6 promotes endothelial inflammation through inducible expression of ICAM-1.
Lung Injury
Hypaphorine exerts anti-inflammatory effects in sepsis induced acute lung injury via modulating DUSP1/p38/JNK pathway.
Lung Injury
Inhibition of calcineurin/NFATc4 signaling attenuates ventilator?induced lung injury.
Lung Injury
Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition.
Lung Neoplasms
Altered expression of phosphatase of regenerating liver gene family in non-small cell lung cancer.
Lung Neoplasms
An okadaic acid fragment analogue prevents nicotine-induced resistance to cisplatin by recovering PP2A activity in non-small cell lung cancer cells.
Lung Neoplasms
APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP.
Lung Neoplasms
Association of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese.
Lung Neoplasms
Calcineurin homologous protein isoform 2 supports tumor survival via the sodium hydrogen exchanger isoform 1 in non-small cell lung cancer.
Lung Neoplasms
Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer.
Lung Neoplasms
Corrigendum to "APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP" [EBioMedicine (2019)].
Lung Neoplasms
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].
Lung Neoplasms
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
Lung Neoplasms
Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling.
Lung Neoplasms
Direct regulation of transforming growth factor ?-induced epithelial-mesenchymal transition by the protein phosphatase activity of unphosphorylated PTEN in lung cancer cells.
Lung Neoplasms
Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.
Lung Neoplasms
Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy.
Lung Neoplasms
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Lung Neoplasms
Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese.
Lung Neoplasms
DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
Lung Neoplasms
DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer.
Lung Neoplasms
Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.
Lung Neoplasms
Functional genetic polymorphisms in PP2A subunit genes confer increased risks of lung cancer in southern and eastern Chinese.
Lung Neoplasms
High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.
Lung Neoplasms
Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.
Lung Neoplasms
Involvement of CHP2 in the Development of Non-Small Cell Lung Cancer and Patients' Poor Prognosis.
Lung Neoplasms
Key genes in lung cancer translational research: a meta-analysis.
Lung Neoplasms
MicroRNA-365b-3p represses the proliferation and promotes the apoptosis of non-small cell lung cancer cells by targeting PPP5C.
Lung Neoplasms
miR-1297 Promotes Cell Proliferation of Non-Small Cell Lung Cancer Cells: Involving in PTEN/Akt/Skp2 Signaling Pathway.
Lung Neoplasms
miR129-1 regulates protein phosphatase 1D protein expression under hypoxic conditions in non-small cell lung cancer cells harboring a TP53 mutation.
Lung Neoplasms
Overexpression of Protein Phosphatase 4 Correlates with Poor Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma.
Lung Neoplasms
PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).
Lung Neoplasms
PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
Lung Neoplasms
PPM1D silencing by RNA interference inhibits the proliferation of lung cancer cells.
Lung Neoplasms
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.
Lung Neoplasms
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
Lung Neoplasms
Proto-oncogene Wip1, a member of a new family of proliferative genes in NSCLC and its clinical significance.
Lung Neoplasms
Repressive role of stabilized hypoxia inducible factor 1? expression on transforming growth factor ?-induced extracellular matrix production in lung cancer cells.
Lung Neoplasms
Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer.
Lung Neoplasms
Sirolimus in heart transplantation: a single center initial experience.
Lung Neoplasms
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
Lung Neoplasms
Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299.
Lung Neoplasms
The effect of down regulation of calcineurin A? by lentiviral vector-mediated RNAi on the biological behavior of small-cell lung cancer and its bone metastasis.
Lung Neoplasms
The ISG15-specific protease USP18 regulates stability of PTEN.
Lung Neoplasms
Tripartite motif protein 11 (TRIM11), an oncogene for human lung cancer via the DUSP6-mediated ERK1/2 signaling pathway.
Lung Neoplasms
Truncating and missense PPM1D mutations in early-onset and/or familial/hereditary prostate cancer patients.
Lung Neoplasms
Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Lung Neoplasms
[Expression and clinical significance of CIP2A in small cell lung cancer patients].
Lupus Erythematosus, Cutaneous
Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus.
Lupus Erythematosus, Cutaneous
Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial.
Lupus Erythematosus, Cutaneous
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Lupus Erythematosus, Cutaneous
Therapeutic effectiveness of calcineurin inhibitors in canine vesicular cutaneous lupus erythematosus.
Lupus Erythematosus, Cutaneous
Topical calcineurin inhibitors in cutaneous lupus erythematosus.
Lupus Erythematosus, Cutaneous
Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus.
Lupus Erythematosus, Discoid
Comparison of effectiveness of topical tacrolimus 0.1% vs topical halobetasol propionate 0.05% as an add-on to oral hydroxychloroquine in discoid lupus erythematosus.
Lupus Erythematosus, Systemic
Association between PPP2CA polymorphisms and clinical features in southwest Chinese systemic lupus erythematosus patients.
Lupus Erythematosus, Systemic
Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis.
Lupus Erythematosus, Systemic
Calcineurin inhibitors in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
CD40L overexpression on T cells and monocytes from patients with systemic lupus erythematosus is resistant to calcineurin inhibition.
Lupus Erythematosus, Systemic
Estradiol upregulates calcineurin expression via overexpression of estrogen receptor alpha gene in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Gender differences in autoimmune diseases: estrogen increases calcineurin expression in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Increased estrogen-dependent expression of calcineurin in female SLE T cells is regulated by multiple mechanisms.
Lupus Erythematosus, Systemic
Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor.
Lupus Erythematosus, Systemic
Molecular mechanisms involved in the estrogen-dependent regulation of calcineurin in systemic lupus erythematosus T cells.
Lupus Erythematosus, Systemic
Multiple variants in 5q31.1 are associated with systemic lupus erythematosus susceptibility and sub-phenotypes in the Han Chinese population.
Lupus Erythematosus, Systemic
Nifedipine suppresses Th1/Th2 cytokine production and increased apoptosis of anti-CD3 + anti-CD28-activated mononuclear cells from patients with systemic lupus erythematosus via calcineurin pathway.
Lupus Erythematosus, Systemic
Standard chronic immunosuppression after kidney transplantation for systemic lupus erythematosus eliminates recurrence of disease.
Lupus Erythematosus, Systemic
The Role of Calcium-Calcineurin-NFAT Signaling Pathway in Health and Autoimmune Diseases.
Lupus Erythematosus, Systemic
Topical calcineurin inhibitors in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus.
Lupus Nephritis
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
Lupus Nephritis
An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus.
Lupus Nephritis
Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.
Lupus Nephritis
Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis.
Lupus Nephritis
Calcineurin inhibitors in lupus nephritis.
Lupus Nephritis
Calcineurin Inhibitors in the Treatment of Lupus Nephritis: A Hare Versus Turtle Story?
Lupus Nephritis
Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis.
Lupus Nephritis
Cellular aspects of the pathogenesis of lupus nephritis.
Lupus Nephritis
Changing paradigms in the treatment of systemic lupus erythematosus.
Lupus Nephritis
Con: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Lupus Nephritis
CYP3A and P-glycoprotein Drug-Drug Interactions with Voclosporin.
Lupus Nephritis
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lupus Nephritis
How cyclosporin reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not.
Lupus Nephritis
Journal Club: Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Phase 3 Trial.
Lupus Nephritis
Kidney transplantation after liver transplantation.
Lupus Nephritis
Moderator's view: the use of calcineurin inhibitors in the treatment of lupus nephritis.
Lupus Nephritis
Pharmacokinetics of voclosporin in renal impairment and hepatic impairment.
Lupus Nephritis
Posterior Reversible Encephalopathy Syndrome in Henoch-Schonlein Purpura and Hemolytic Uremic Syndrome.
Lupus Nephritis
Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Lupus Nephritis
Recurrence of disease following organ transplantation in autoimmune liver disease and systemic lupus erythematosus.
Lupus Nephritis
Renal Biopsy in Children-Effect on Treatment Decisions: A Single-Center Experience.
Lupus Nephritis
The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis.
Lupus Nephritis
The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis.
Lupus Nephritis
The pathology of T cells in systemic lupus erythematosus.
Lupus Nephritis
Therapeutic options for resistant lupus nephritis.
Lupus Nephritis
Towards new avenues in the management of lupus glomerulonephritis.
Lupus Nephritis
Treatment of severe lupus nephritis: the new horizon.
Lupus Nephritis
Treatment of young patients with lupus nephritis using calcineurin inhibitors.
Lupus Nephritis
Treatment with cyclosporine A improves SLE disease activity of Japanese patients with diffuse proliferative lupus nephritis.
Lupus Nephritis
Understanding lupus nephritis: diagnosis, management, and treatment options.
Lupus Nephritis
Update on clinical trials in systemic lupus erythematosus.
Lupus Nephritis
Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamic studies in healthy human subjects.
Lupus Nephritis
Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis.
Lupus Nephritis
[Meta-analysis of calcineurin inhibitor in the treatment of lupus nephritis].
Lupus Nephritis
[Significance of calcineurin activation and CD40L expression in patients with active lupus nephritis].
Lymphatic Metastasis
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Lymphatic Metastasis
Dephosphorylation of Girdin by PP2A inhibits breast cancer metastasis.
Lymphatic Metastasis
Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.
Lymphatic Metastasis
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Lymphatic Metastasis
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Lymphatic Metastasis
PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Lymphatic Metastasis
PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
Lymphedema
Spontaneous Chylous Ascites After Liver Transplantation Secondary to Everolimus: A Case Report.
Lymphocele
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Lymphocele
Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials.
Lymphocele
Intraoperative placing of drains decreases the incidence of lymphocele and deep vein thrombosis after renal transplantation.
Lymphocytic Choriomeningitis
Calcineurin Aalpha plays an exclusive role in TCR signaling in mature but not in immature T cells.
Lymphocytic Choriomeningitis
Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation.
Lymphocytosis
Omenn syndrome: therapeutic effects of cyclosporin.
Lymphoma
A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis.
Lymphoma
Association Between Malignancy and Topical Use of Pimecrolimus.
Lymphoma
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.
Lymphoma
Characterization of a mutant calcineurin A alpha gene expressed by EL4 lymphoma cells.
Lymphoma
Conversion to sirolimus in posttransplant renal neoplasms.
Lymphoma
Current approaches to the use of sirolimus in renal transplantation.
Lymphoma
Cutaneous T cell lymphoma complicating severe atopic dermatitis. Is making a diagnosis the main challenge?
Lymphoma
Dephosphorylation of catalytic subunit of cAMP-dependent protein kinase at Thr-197 by a cellular protein phosphatase and by purified protein phosphatase-2A.
Lymphoma
Differential effects of procaspase-3 activating compounds in the induction of cancer cell death.
Lymphoma
Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity.
Lymphoma
Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling.
Lymphoma
Evaluation of Cancer Risk Related to Atopic Dermatitis and Use of Topical Calcineurin Inhibitors.
Lymphoma
FK506 (tacrolimus) inhibits extravasation of lymphoid cells by abrogating VLA-4/VCAM-1 mediated transendothelial migration.
Lymphoma
Identification of downstream genes up-regulated by the tumor necrosis factor family member TALL-1.
Lymphoma
Laforin confers cancer resistance to energy deprivation-induced apoptosis.
Lymphoma
Long-term use of everolimus in lung transplant patients.
Lymphoma
Loss of calcineurin homologous protein-1 in chicken B lymphoma DT40 cells destabilizes Na+/H+ exchanger isoform-1 protein.
Lymphoma
Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom.
Lymphoma
Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.
Lymphoma
Modulation of CD40L antigen expression in Jurkat cells: involvement of protein kinase C activity.
Lymphoma
Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation.
Lymphoma
Overexpression of the mTOR alpha4 phosphoprotein activates protein phosphatase 2A and increases Stat1alpha binding to PIAS1.
Lymphoma
Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1).
Lymphoma
Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs.
Lymphoma
Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis.
Lymphoma
Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.
Lymphoma
Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56? stabilizes its antiapoptotic activity.
Lymphoma
Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics.
Lymphoma
Study of "de novo" malignancies among greek renal transplant recipients.
Lymphoma
Subthalamic nucleus deep brain stimulation protects neurons by activating autophagy via PP2A inactivation in a rat model of Parkinson's disease.
Lymphoma
Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits.
Lymphoma
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma.
Lymphoma
The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo.
Lymphoma
The natural tumorcide Manumycin-A targets protein phosphatase 1? and reduces hydrogen peroxide to induce lymphoma apoptosis.
Lymphoma
The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma.
Lymphoma
The regulator of calcineurin 1 (RCAN1) inhibits nuclear factor kappaB signaling pathway and suppresses human malignant glioma cells growth.
Lymphoma
Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.
Lymphoma
Topical calcineurin inhibitors and risk of lymphoma: a systematic review and meta-analysis.
Lymphoma
Topical Treatments with Pimecrolimus, Tacrolimus and Medium- to High-Potency Corticosteroids, and Risk of Lymphoma.
Lymphoma
Truncated PPM1D Prevents Apoptosis in the Murine Thymus and Promotes Ionizing Radiation-Induced Lymphoma.
Lymphoma
[Influence of dipyridamole on expression of PAC-1 and CD62p in patients with malignant lymphoma].
Lymphoma
[Topical pimecrolimus and tacrolimus and the risk of cancer]
Lymphoma, B-Cell
Identification of collaborative activities with oxidative phosphorylation in bipolar disorder.
Lymphoma, B-Cell
Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs.
Lymphoma, B-Cell
Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Subthalamic nucleus deep brain stimulation protects neurons by activating autophagy via PP2A inactivation in a rat model of Parkinson's disease.
Lymphoma, B-Cell
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma.
Lymphoma, Follicular
Differential expression of Ca(2+)-binding proteins on follicular dendritic cells in non-neoplastic and neoplastic lymphoid follicles.
Lymphoma, Large B-Cell, Diffuse
Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants.
Lymphoma, Large B-Cell, Diffuse
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma.
Lymphoma, Mantle-Cell
The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma.
Lymphoma, T-Cell
Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia.
Lymphoma, T-Cell, Cutaneous
Cutaneous T cell lymphoma complicating severe atopic dermatitis. Is making a diagnosis the main challenge?
Lymphoma, T-Cell, Cutaneous
Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk.
Lymphopenia
A putative role for calcineurin in lymphopenia associated with chronic renal failure.
Lymphopenia
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.
Lymphoproliferative Disorders
Advances in pediatric heart transplantation.
Lymphoproliferative Disorders
Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Lymphoproliferative Disorders
Biomarkers of immune tolerance in kidney transplantation: an overview.
Lymphoproliferative Disorders
Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: A retrospective analysis based on the prospective, international, multicenter PTLD-1 trials.
Lymphoproliferative Disorders
Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival.
Magnesium Deficiency
Hypomagnesemia is associated with new-onset diabetes mellitus following heart transplantation.
Magnesium Deficiency
Interaction of cyclosporine and FK506 with diuretics in transplant patients.
Malaria
A unique protein phosphatase with kelch-like domains (PPKL) in Plasmodium modulates ookinete differentiation, motility and invasion.
Malaria
Characterization of a novel serine/threonine protein phosphatase (PfPPJ) from the malaria parasite, Plasmodium falciparum.
Malaria
Characterization of protein Ser/Thr phosphatases of the malaria parasite, Plasmodium falciparum: inhibition of the parasitic calcineurin by cyclophilin-cyclosporin complex.
Malaria
Identification and characterization of an unusual double serine/threonine protein phosphatase 2C in the malaria parasite Plasmodium falciparum.
Malaria
Parasite Calcineurin Regulates Host Cell Recognition and Attachment by Apicomplexans.
Malaria
Plasmodium berghei serine/threonine protein phosphatase PP5 plays a critical role in male gamete fertility.
Malaria
Plasmodium protein phosphatase 2C dephosphorylates translation elongation factor 1beta and inhibits its PKC-mediated nucleotide exchange activity in vitro.
Malaria
Protein phosphatase beta, a putative type-2A protein phosphatase from the human malaria parasite Plasmodium falciparum.
Malaria
Regulation of protein phosphatase type 1 and cell cycle progression by PfLRR1, a novel leucine-rich repeat protein of the human malaria parasite Plasmodium falciparum.
Malnutrition
Calcineurin B1 Deficiency in Glial Cells Induces Mucosal Degeneration and Inflammation in Mouse Small Intestine.
Malocclusion
A Missense Mutation in DUSP6 is Associated with Class III Malocclusion.
Malocclusion
Corrigendum.
Mania
Deletion of GSK3? in D2R-expressing neurons reveals distinct roles for ?-arrestin signaling in antipsychotic and lithium action.
Maple Syrup Urine Disease
A novel regulatory defect in the branched-chain ?-keto acid dehydrogenase complex due to a mutation in the PPM1K gene causes a mild variant phenotype of maple syrup urine disease.
Maple Syrup Urine Disease
Catabolism of branched-chain amino acids in heart failure: insights from genetic models.
Marfan Syndrome
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Mastocytosis
Mast cells as targets of pimecrolimus.
Mastocytosis, Cutaneous
Mast cells as targets of pimecrolimus.
Measles
Measles Virus Infection Inactivates Cellular Protein Phosphatase 5 with Consequent Suppression of Sp1 and c-Myc Activities.
Medulloblastoma
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma.
Medulloblastoma
HDM2 promotes WIP1-mediated medulloblastoma growth.
Medulloblastoma
p53 Function is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
Medulloblastoma
PPM1D/WIP1 in medulloblastoma.
Medulloblastoma
WIP1 modulates responsiveness to Sonic Hedgehog signaling in neuronal precursor cells and medulloblastoma.
Megacolon, Toxic
Medical Therapy of Active Ulcerative Colitis.
Melanoma
A landscape of driver mutations in melanoma.
Melanoma
A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.
Melanoma
A mutation in protein phosphatase type 2A as a cause of melanoma progression.
Melanoma
Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA.
Melanoma
Active ?-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A.
Melanoma
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.
Melanoma
ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma.
Melanoma
Characterization of human melanoma cell lines and melanocytes by proteome analysis.
Melanoma
Circ_0002770, acting as a competitive endogenous RNA, promotes proliferation and invasion by targeting miR-331-3p in melanoma.
Melanoma
Combination of ?-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study.
Melanoma
Detection of driver mutations in FFPE samples from patients with verified malignant melanoma.
Melanoma
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Melanoma
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
Melanoma
Ectopic alphaIIbbeta3 integrin signaling involves 12-lipoxygenase- and PKC-mediated serine phosphorylation events in melanoma cells.
Melanoma
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Melanoma
Glucose-6-phosphate dehydrogenase and NADPH oxidase 4 control STAT3 activity in melanoma cells through a pathway involving reactive oxygen species, c-SRC and SHP2.
Melanoma
Identification by differential display of a protein phosphatase-2A regulatory subunit preferentially expressed in malignant melanoma cells.
Melanoma
Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a molecularly distinct melanoma subtype.
Melanoma
Inhibition of calcineurin by cyclosporine A exerts multiple effects on human melanoma cell lines HT168 and WM35.
Melanoma
Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses.
Melanoma
Involvement of ANXA5 and ILKAP in susceptibility to malignant melanoma.
Melanoma
Ligand-Mimetic Anti-alphaIIbbeta3 Antibody PAC-1 Inhibits Tyrosine Signaling, Proliferation and Lung Colonization of Melanoma Cells.
Melanoma
Melanoma-associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage owing to dysregulated Aurora-A.
Melanoma
MicroRNA-211 modulates the DUSP6-ERK5 signaling axis to promote BRAFV600E-driven melanoma growth in vivo and BRAF/MEK inhibitor resistance.
Melanoma
NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma.
Melanoma
Oncogenic suppression of PHLPP1 in human melanoma.
Melanoma
Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo.
Melanoma
PP6C Hotspot Mutations in Melanoma Display Sensitivity to Aurora Kinase Inhibition.
Melanoma
Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis.
Melanoma
PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK.
Melanoma
Redox modulation of protein kinase/phosphatase balance in melanoma cells: the role of endogenous and gamma-glutamyltransferase-dependent H2O2 production.
Melanoma
Resolution of sirolimus-induced pneumonitis after conversion to everolimus.
Melanoma
Statistical Detection of Intrinsically Multivariate Predictive Genes.
Melanoma
Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma.
Melanoma
Tacrolimus and ascomycin inhibit melanoma cell growth, migration and invasion via targeting nuclear factor of activated T-cell 3.
Melanoma
The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.
Melanoma
The high affinity alphaIIb beta3 integrin is involved in invasion of human melanoma cells.
Melanoma
The protein phosphatase 2A subunit Bgamma gene is identified to be differentially expressed in malignant melanomas by subtractive suppression hybridization.
Melanoma
The protein phosphatase 6 catalytic subunit (Ppp6c) is indispensable for proper post-implantation embryogenesis.
Melanoma
Tumor suppressor and growth regulatory genes are overexpressed in severe early-onset preeclampsia--an array study on case-specific human preeclamptic placental tissue.
Melanoma
Weighted correlation network and differential expression analyses identify candidate genes associated with BRAF gene in melanoma.
Melanoma
[Ultraviolet A-induced DNA damage: role in skin cancer].
Melanoma, Experimental
Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells.
Memory Disorders
Bidirectional Regulation of Amyloid Precursor Protein-Induced Memory Defects by Nebula/DSCR1: A Protein Upregulated in Alzheimer's Disease and Down Syndrome.
Memory Disorders
Calcineurin inhibitors improve memory loss and neuropathological changes in mouse model of dementia.
Memory Disorders
Crocin-protected malathion-induced spatial memory deficits by inhibiting TAU protein hyperphosphorylation and antiapoptotic effects.
Memory Disorders
Enhanced sensitivity of laforin- and malin-deficient mice to the convulsant agent pentylenetetrazole.
Memory Disorders
Immature dentate gyrus: an endophenotype of neuropsychiatric disorders.
Memory Disorders
Inhibition of protein phosphatases induces transport deficits and axonopathy.
Memory Disorders
Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition.
Memory Disorders
Laforin and malin deletions in mice produce similar neurologic impairments.
Memory Disorders
Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment.
Memory Disorders
Methionine-Mediated Protein Phosphatase 2A Catalytic Subunit (PP2Ac) Methylation Ameliorates the Tauopathy Induced by Manganese in Cell and Animal Models.
Memory Disorders
Selective induction of calcineurin activity and signaling by oligomeric amyloid beta.
Memory Disorders
Transthyretin: a key gene involved in the maintenance of memory capacities during aging.
Meniere Disease
Association of a functional polymorphism of PTPN22 encoding a lymphoid protein phosphatase in bilateral Meniere's disease.
Meningioma
Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
Meningioma
Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression?
Meningioma
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.
Meningioma
p38MAPK activation and DUSP10 expression in meningiomas.
Meningioma
The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies.
Meningitis, Cryptococcal
Calcineurin is required for virulence of Cryptococcus neoformans.
Meningitis, Cryptococcal
Favorable Evolution of Cryptococcal Meningitis in the Context of Flucytosine Resistance.
Meningitis, Cryptococcal
The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein.
Meningitis, Fungal
A Mechanosensitive Channel Governs Lipid Flippase-Mediated Echinocandin Resistance in Cryptococcus neoformans.
Meningitis, Fungal
Calcium Binding Protein Ncs1 Is Calcineurin Regulated in Cryptococcus neoformans and Essential for Cell Division and Virulence.
MERRF Syndrome
Advances in the genetics of progressive myoclonus epilepsy.
Metabolic Diseases
Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study.
Metabolic Diseases
miR-140-5p Aggravates Insulin Resistance via Directly Targeting GYS1 and PPP1CC in Insulin-Resistant HepG2 Cells.
Metabolic Diseases
Variations in DNA elucidate molecular networks that cause disease.
Metabolic Syndrome
DUSP1 Gene Polymorphisms Are Associated with Obesity-Related Metabolic Complications among Severely Obese Patients and Impact on Gene Methylation and Expression.
Metabolic Syndrome
Is a flavonoid-rich diet with steamer cooking safe during calcineurin inhibitors therapy?
Metabolic Syndrome
Management of posttransplant hepatitis C infection.
Metabolic Syndrome
Metabolic syndrome in transplant patients: an academic or a health burden?
Metabolic Syndrome
New-onset diabetes mellitus after kidney transplantation: Current status and future directions.
Metabolic Syndrome
Nutritional and metabolic issues in solid organ transplantation: targets for future research.
Metabolic Syndrome
Pathophysiologic and Treatment Strategies for Cardiovascular Disease in End Stage Renal Disease and Kidney Transplantation.
methylenetetrahydrofolate dehydrogenase (nad+) deficiency
Altered protein phosphatase 2A methylation and Tau phosphorylation in the young and aged brain of methylenetetrahydrofolate reductase (MTHFR) deficient mice.
Migraine Disorders
Calcineurin inhibitor-induced headache: clinical characteristics and possible mechanisms.
Mitochondrial Diseases
mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases.
Mitochondrial Diseases
Preparation and characterization of a polyclonal antibody against PTEN-Long.
Mouth Neoplasms
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Mouth Neoplasms
Saliva as a tool for oral cancer diagnosis and prognosis.
Movement Disorders
Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder.
Mucocutaneous Lymph Node Syndrome
Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant kawasaki disease.
Mucocutaneous Lymph Node Syndrome
Calcineurin inhibitors exacerbate coronary arteritis via the MyD88 signalling pathway in a murine model of Kawasaki disease.
Mucocutaneous Lymph Node Syndrome
The elevated serum levels of calcineurin and nuclear factor of activated T-cells 1 in children with Kawasaki disease.
Mucormycosis
A Novel Resistance Pathway for Calcineurin Inhibitors in the Human-Pathogenic Mucorales Mucor circinelloides.
Mucormycosis
Heterotrimeric G-alpha subunits Gpa11 and Gpa12 define a transduction pathway that control spore size and virulence in Mucor circinelloides.
Mucormycosis
Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors.
Mucormycosis
Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.
Mucormycosis
Tornadic Shear Stress Induces a Transient, Calcineurin-Dependent Hypervirulent Phenotype in Mucorales Molds.
Multiple Myeloma
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
Multiple Myeloma
Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin.
Multiple Sclerosis
Dual-specific Phosphatase-6 (Dusp6) and ERK Mediate AMPA Receptor-induced Oligodendrocyte Death.
Multiple Sclerosis
Inhibition of Calcineurin Abrogates While Inhibition of mTOR Promotes Regulatory T Cell Expansion and Graft-Versus-Host Disease Protection by IL-2 in Allogeneic Bone Marrow Transplantation.
Multiple System Atrophy
Cell type-specific neuronal loss in the putamen of patients with multiple system atrophy.
Muscle Cramp
Treatment of Myasthenia Gravis With High-Dose Cholinesterase Inhibitors and Calcineurin Inhibitors Caused Spontaneous Muscle Cramps in Patients.
Muscle Spasticity
Recent insights into the mechanisms, predisposing factors, and racial differences of coronary vasospasm.
Muscular Atrophy
Anabolic steroids activate calcineurin-NFAT signaling and thereby increase myotube size and reduce denervation atrophy.
Muscular Atrophy
Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins.
Muscular Atrophy
Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex.
Muscular Atrophy
Calcineurin signaling and PGC-1alpha expression are suppressed during muscle atrophy due to diabetes.
Muscular Atrophy
Maintenance of muscle mass is not dependent on the calcineurin-NFAT pathway.
Muscular Atrophy
miR-23a is decreased during muscle atrophy by a mechanism that includes calcineurin signaling and exosome-mediated export.
Muscular Atrophy
Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy.
Muscular Atrophy
Risk of Myopathy in Patients in Therapy with Statins: Identification of Biological Markers in a Pilot Study.
Muscular Atrophy
Tiny transporters: how exosomes and calcineurin signaling regulate miR-23a levels during muscle atrophy. Focus on "miR-23a is decreased during muscle atrophy by a mechanism that includes calcineurin signaling and exosome-mediated export".
Muscular Atrophy
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Muscular Atrophy, Spinal
CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.
Muscular Diseases
Prevention of Recurrent Episodes of Rhabdomyolysis With Tacrolimus in a Transplant Recipient With Myopathy.
Muscular Disorders, Atrophic
Signaling mechanisms involved in disuse muscle atrophy.
Muscular Dystrophies
Dusp6 is a genetic modifier of growth through enhanced ERK activity.
Muscular Dystrophies, Limb-Girdle
Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy.
Muscular Dystrophy, Duchenne
Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles.
Muscular Dystrophy, Duchenne
Decreased calcineurin activity in circulation of Duchenne muscular dystrophy.
Mutism
Liver Transplant Can Resolve Severe Neuropsychiatric Manifestations of Wilson Disease: A Case Report.
Mutism
Mutism and Persistent Dysarthria Due to Tacrolimus-Based Immunosuppression Following Allogeneic Liver Transplantation.
Mutism
Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation.
Myasthenia Gravis
Clinical implications of the type 1/ type 2 balance of helper T cells and P-glycoprotein function in peripheral T lymphocytes of myasthenia gravis patients.
Myasthenia Gravis
Factors associated with response to calcineurin inhibitors in myasthenia gravis.
Myasthenia Gravis
Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis.
Myasthenia Gravis
Suppressive potencies of calcineurin inhibitors against the mitogen-induced blastogenesis of peripheral-blood mononuclear cells of myasthenia gravis patients.
Myasthenia Gravis
Treatment of Myasthenia Gravis With High-Dose Cholinesterase Inhibitors and Calcineurin Inhibitors Caused Spontaneous Muscle Cramps in Patients.
Myasthenia Gravis
[Calcineurin inhibitors and IVIg in the treatment of myasthenia gravis].
Myasthenia Gravis
[Directions for use of corticosteroids and calcineurin inhibitors against generalized myasthenia gravis: therapeutic strategies that can lead to early improvements and veer away from high-dose oral corticosteroids].
Mycoses
15N, 13C and 1H resonance assignments of FKBP12 proteins from the pathogenic fungi Mucor circinelloides and Aspergillus fumigatus.
Mycoses
Calcineurin inhibitors reduce NFAT-dependent expression of antifungal pentraxin-3 by human monocytes.
Mycoses
Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus.
Mycoses
Epithelial cells treated with genistein inhibit adhesion and endocytosis of Paracoccidioides brasiliensis.
Mycoses
Fungal infections in renal transplant patients.
Mycoses
Psoriasis-like tinea incognita: a case report and literature review.
Mycosis Fungoides
Follicular Eruption With Folliculotropic Lymphocytic Infiltrates Associated With Iatrogenic Immunosuppression: Report and Study of 3 Cases, and Review of the Literature.
Myelitis
Human Herpes Virus-6-Associated Encephalitis/Myelitis Mimicking Calcineurin Inhibitor-Induced Pain Syndrome in Allogeneic Stem Cell Transplantation Recipients.
Myelodysplastic Syndromes
Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants.
Myelodysplastic Syndromes
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.
Myelodysplastic Syndromes
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.
Myelodysplastic Syndromes
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes.
Myocardial Infarction
Association of platelet-derived microparticles with C-C chemokines on vascular complication in patients with acute myocardial infarction.
Myocardial Infarction
Calcineurin splicing variant calcineurin A?1 improves cardiac function after myocardial infarction without inducing hypertrophy.
Myocardial Infarction
Effects of the calcineurin dependent signaling pathway inhibition by cyclosporin A on early and late cardiac remodeling following myocardial infarction.
Myocardial Infarction
Hydrogen sulfide protects cardiomyocytes from myocardial ischemia-reperfusion injury by enhancing phosphorylation of apoptosis repressor with caspase recruitment domain.
Myocardial Infarction
Induction of the calcineurin variant CnA?1 after myocardial infarction reduces post-infarction ventricular remodelling by promoting infarct vascularization.
Myocardial Infarction
Mitochondrial phosphatase PGAM5 regulates Keap1-mediated Bcl-xL degradation and controls cardiomyocyte apoptosis driven by myocardial ischemia/reperfusion injury.
Myocardial Infarction
Mitochondrial Protein PGAM5 Regulates Mitophagic Protection against Cell Necroptosis.
Myocardial Infarction
PP2Cm overexpression alleviates MI/R injury mediated by a BCAA catabolism defect and oxidative stress in diabetic mice.
Myocardial Infarction
Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice.
Myocardial Infarction
Total Saponins of Aralia Elata (Miq) Seem Alleviate Calcium Homeostasis Imbalance and Endoplasmic Reticulum Stress-Related Apoptosis Induced by Myocardial Ischemia/Reperfusion Injury.
Myocardial Ischemia
AMP-activated protein kinase protects against necroptosis via regulation of Keap1-PGAM5 complex.
Myocardial Ischemia
Immunology Update: Long-Term Care of Solid Organ Transplant Recipients.
Myocardial Ischemia
Negative Cardiovascular Consequences of Small Molecule Immunosuppressants.
Myocardial Ischemia
Serine-threonine protein phosphatase regulation of Cx43 dephosphorylation in arrhythmogenic disorders.
Myocardial Ischemia
[The Role of Laboratory Medicine in Hematopoietic Stem Cell Transplantation "Echocardiogram"].
Myocarditis
Three types of striational antibodies in myasthenia gravis.
Myoclonic Epilepsies, Progressive
4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease.
Myoclonic Epilepsies, Progressive
A novel compound heterozygous EPM2A mutation in a Chinese boy with Lafora disease.
Myoclonic Epilepsies, Progressive
A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.
Myoclonic Epilepsies, Progressive
Alternative splicing modulates subcellular localization of laforin.
Myoclonic Epilepsies, Progressive
Dimeric quaternary structure of human laforin.
Myoclonic Epilepsies, Progressive
Early-onset Lafora body disease.
Myoclonic Epilepsies, Progressive
Enhanced sensitivity of laforin- and malin-deficient mice to the convulsant agent pentylenetetrazole.
Myoclonic Epilepsies, Progressive
Escherichia coli expression, refolding and characterization of human laforin.
Myoclonic Epilepsies, Progressive
FDG-PET assessment and metabolic patterns in Lafora disease.
Myoclonic Epilepsies, Progressive
Four novel and two recurrent NHLRC1 (EPM2B) and EPM2A gene mutations leading to Lafora disease in six Turkish families.
Myoclonic Epilepsies, Progressive
Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
Myoclonic Epilepsies, Progressive
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Myoclonic Epilepsies, Progressive
Glycogen and related polysaccharides inhibit the laforin dual-specificity protein phosphatase.
Myoclonic Epilepsies, Progressive
Glycogen metabolism in tissues from a mouse model of Lafora disease.
Myoclonic Epilepsies, Progressive
Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is modulated by the laforin-malin complex.
Myoclonic Epilepsies, Progressive
Hepatic disease as the first manifestation of progressive myoclonus epilepsy of Lafora.
Myoclonic Epilepsies, Progressive
Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product.
Myoclonic Epilepsies, Progressive
Identification of new and common mutations in the EPM2A gene in Lafora disease.
Myoclonic Epilepsies, Progressive
Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.
Myoclonic Epilepsies, Progressive
Isolation and characterization of mouse homologue for the human epilepsy gene, EPM2A.
Myoclonic Epilepsies, Progressive
Lafora disease ubiquitin ligase malin promotes proteasomal degradation of neuronatin and regulates glycogen synthesis.
Myoclonic Epilepsies, Progressive
Lafora disease.
Myoclonic Epilepsies, Progressive
Laforin and malin deletions in mice produce similar neurologic impairments.
Myoclonic Epilepsies, Progressive
Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity.
Myoclonic Epilepsies, Progressive
Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy.
Myoclonic Epilepsies, Progressive
Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.
Myoclonic Epilepsies, Progressive
Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.
Myoclonic Epilepsies, Progressive
Late-onset Lafora disease with prominent parkinsonism due to a rare mutation in EPM2A.
Myoclonic Epilepsies, Progressive
Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease.
Myoclonic Epilepsies, Progressive
Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy.
Myoclonic Epilepsies, Progressive
Mutation screening for Japanese Lafora's disease patients: identification of novel sequence variants in the coding and upstream regulatory regions of EPM2A gene.
Myoclonic Epilepsies, Progressive
Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy.
Myoclonic Epilepsies, Progressive
Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.
Myoclonic Epilepsies, Progressive
Neuronatin-mediated Aberrant Calcium Signaling and Endoplasmic Reticulum Stress Underlie Neuropathology in Lafora Disease.
Myoclonic Epilepsies, Progressive
Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy.
Myoclonic Epilepsies, Progressive
Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease.
Myoclonic Epilepsies, Progressive
Phosphate incorporation during glycogen synthesis and Lafora disease.
Myoclonic Epilepsies, Progressive
Progressive myoclonus epilepsies: EPM1, EPM2A, EPM2B.
Myoclonic Epilepsies, Progressive
Protein Degradation and Quality Control in Cells from Laforin and Malin Knockout Mice.
Myoclonic Epilepsies, Progressive
Regional and developmental expression of Epm2a gene and its evolutionary conservation.
Myoclonic Epilepsies, Progressive
Relationship between glycogen accumulation and the laforin dual specificity phosphatase.
Myoclonic Epilepsies, Progressive
Structural and Functional Brain Abnormalities in Mouse Models of Lafora Disease.
Myoclonic Epilepsies, Progressive
The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain.
Myoclonic Epilepsies, Progressive
Transcriptional profiling of a mouse model for Lafora disease reveals dysregulation of genes involved in the expression and modification of proteins.
Myoclonic Epilepsies, Progressive
Two novel mutations in the EPM2A gene in a Korean patient with Lafora's progressive myoclonus epilepsy.
Myoclonic Epilepsies, Progressive
[Lafora disease: a review of the literature].
Myoclonus
Corrigendum to "FoxO3a-mediated autophagy is down-regulated in the laforin deficient mice, an animal model for Lafora progressive myoclonus epilepsy" [Biochem. Biophys. Res. Commun. 474 (2) (2016) 321-327].
Myoclonus
Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling.
Myoclonus
Laforin and malin deletions in mice produce similar neurologic impairments.
Myoclonus
Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy.
Myositis
Advances in the therapy of idiopathic inflammatory myopathies.
Myositis
Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy.
Myxoma
Myxoma virus and Shope fibroma virus encode dual-specificity tyrosine/serine phosphatases which are essential for virus viability.
Nasopharyngeal Carcinoma
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Nasopharyngeal Carcinoma
Overexpression of Wild-Type p53-Induced Phosphatase 1 Confers Poor Prognosis of Patients with Nasopharyngeal Carcinoma.
Necrobiosis Lipoidica
Treatment of ulcerative necrobiosis lipoidica with topical calcineurin inhibitor: case report and literature review.
Neoplasm Metastasis
Analysis of methylation profiling data of hyperplasia and primary and metastatic endometrial cancers.
Neoplasm Metastasis
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Neoplasm Metastasis
Antibody Array Revealed PRL-3 Affects Protein Phosphorylation and Cytokine Secretion.
Neoplasm Metastasis
Arsenic Trioxide Inhibits the Metastasis of Small Cell Lung Cancer by Blocking Calcineurin-Nuclear Factor of Activated T Cells (NFAT) Signaling.
Neoplasm Metastasis
Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer.
Neoplasm Metastasis
CircSEC24A promotes tumor progression through sequestering miR-455-3p in hepatocellular carcinoma.
Neoplasm Metastasis
CircSLC3A2 functions as an oncogenic factor in hepatocellular carcinoma by sponging miR-490-3p and regulating PPM1F expression.
Neoplasm Metastasis
Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
Neoplasm Metastasis
Dephosphorylation of Girdin by PP2A inhibits breast cancer metastasis.
Neoplasm Metastasis
Detection of driver mutations in FFPE samples from patients with verified malignant melanoma.
Neoplasm Metastasis
Down-regulation of dual-specificity phosphatase 5 predicts poor prognosis of patients with prostate cancer.
Neoplasm Metastasis
Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.
Neoplasm Metastasis
Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.
Neoplasm Metastasis
Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
Neoplasm Metastasis
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
Neoplasm Metastasis
DUSP1 inhibits cell proliferation, metastasis and invasion and angiogenesis in gallbladder cancer.
Neoplasm Metastasis
DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer.
Neoplasm Metastasis
Endothelial Calcineurin Signaling Restrains Metastatic Outgrowth by Regulating Bmp2.
Neoplasm Metastasis
Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays.
Neoplasm Metastasis
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
Neoplasm Metastasis
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Neoplasm Metastasis
FK506 binding proteins as targets in anticancer therapy.
Neoplasm Metastasis
Gene expression profile analysis of ENO1 knockdown in gastric cancer cell line MGC-803.
Neoplasm Metastasis
Gene heterogeneity in metastasis of colorectal cancer to the lung.
Neoplasm Metastasis
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
Neoplasm Metastasis
Identification of proteins suppressing the functions of oncogenic phosphatase of regenerating liver 1 and 3.
Neoplasm Metastasis
In vivo Dynamics and Distinct Functions of Hypoxia in Primary Tumor Growth and Organotropic Metastasis of Breast Cancer.
Neoplasm Metastasis
Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-?B pathway dependent repression of PP2Ac.
Neoplasm Metastasis
Integrated analysis identifies DUSP5 as a novel prognostic indicator for thyroid follicular carcinoma.
Neoplasm Metastasis
KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity.
Neoplasm Metastasis
Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Neoplasm Metastasis
Localizing PRL-2 expression and determining the effects of dietary Mg(2+) on expression levels.
Neoplasm Metastasis
Loss of PPM1F expression predicts tumour recurrence and is negatively regulated by miR-590-3p in gastric cancer.
Neoplasm Metastasis
MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets.
Neoplasm Metastasis
MicroRNA-222 Promotes Invasion and Metastasis of Papillary Thyroid Cancer Through Targeting Protein Phosphatase 2 Regulatory Subunit B Alpha Expression.
Neoplasm Metastasis
MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase.
Neoplasm Metastasis
Migration of renal tumor cells depends on dephosphorylation of Shc by PTEN.
Neoplasm Metastasis
Minimizing the risk of posttransplant malignancy.
Neoplasm Metastasis
miR-149 represses metastasis of hepatocellular carcinoma by targeting actin-regulatory proteins PPM1F.
Neoplasm Metastasis
MiR-96 induced non-small-cell lung cancer progression through competing endogenous RNA network and affecting EGFR signaling pathway.
Neoplasm Metastasis
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Neoplasm Metastasis
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Neoplasm Metastasis
Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance.
Neoplasm Metastasis
Phosphatase activity, trimerization, and the C-terminal polybasic region are all required for PRL1-mediated cell growth and migration.
Neoplasm Metastasis
Phosphatase of Regenerating Liver 3 (PRL3) provokes a tyrosine phosphoproteome to drive pro-metastatic signal transduction.
Neoplasm Metastasis
Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.
Neoplasm Metastasis
Phosphatase POPX2 Exhibits Dual Regulatory Functions in Cancer Metastasis.
Neoplasm Metastasis
Phosphorylation of nucleophosmin at threonine 234/237 is associated with HCC metastasis.
Neoplasm Metastasis
Poor prognosis of phosphatase of regenerating liver 3 expression in gastric cancer: a meta-analysis.
Neoplasm Metastasis
Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy.
Neoplasm Metastasis
PPM1D accelerates proliferation and metastasis of osteosarcoma by activating PKP2.
Neoplasm Metastasis
PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms.
Neoplasm Metastasis
PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Neoplasm Metastasis
PPM1D is a prognostic marker and therapeutic target in colorectal cancer.
Neoplasm Metastasis
PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
Neoplasm Metastasis
PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3.
Neoplasm Metastasis
PRL-3 activates NF-?B signaling pathway by interacting with RAP1.
Neoplasm Metastasis
PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation.
Neoplasm Metastasis
Prognostic value of PPM1D in 800 gastric cancer patients.
Neoplasm Metastasis
Prognostic value of PRL-3 overexpression in early stages of colonic cancer.
Neoplasm Metastasis
Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation.
Neoplasm Metastasis
Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Neoplasm Metastasis
Regulator of calcineurin 1 modulates cancer cell migration in vitro.
Neoplasm Metastasis
Regulatory mechanisms of phosphatase of regenerating liver (PRL)-3.
Neoplasm Metastasis
Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.
Neoplasm Metastasis
Siglec-15 Promotes Tumor Progression in Osteosarcoma via DUSP1/MAPK Pathway.
Neoplasm Metastasis
Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.
Neoplasm Metastasis
Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells.
Neoplasm Metastasis
Synaptopodin-2 promotes hepatocellular carcinoma metastasis via calcineurin-induced nuclear-cytoplasmic translocation.
Neoplasm Metastasis
Targeting PTPs with small molecule inhibitors in cancer treatment.
Neoplasm Metastasis
The Calcineurin-NFAT-Angiopoietin-2 Signaling Axis in Lung Endothelium Is Critical for the Establishment of Lung Metastases.
Neoplasm Metastasis
The Clinical Significance of PPEF1 as a Promising Biomarker and Its Potential Mechanism in Breast Cancer.
Neoplasm Metastasis
The effect of down regulation of calcineurin A? by lentiviral vector-mediated RNAi on the biological behavior of small-cell lung cancer and its bone metastasis.
Neoplasm Metastasis
Tissue-specific gene therapy directed to tumor angiogenesis.
Neoplasm Metastasis
TP53INP1 Downregulation Activates a p73-Dependent DUSP10/ERK Signaling Pathway to Promote Metastasis of Hepatocellular Carcinoma.
Neoplasm Metastasis
Translational Control of C-terminal Src Kinase (Csk) Expression by PRL3 Phosphatase.
Neoplasm Metastasis
Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype.
Neoplasm Metastasis
Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner.
Neoplasm Metastasis
Tumor-associated macrophages promote the metastasis and growth of non-small-cell lung cancer cells through NF-?B/PP2Ac-positive feedback loop.
Neoplasm Metastasis
Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.
Neoplasm Metastasis
USP11 promotes growth and metastasis of colorectal cancer via PPP1CA-mediated activation of ERK/MAPK signaling pathway.
Neoplasm Metastasis
[Cancer and immunosuppression: pro- and antitumoral effects of immunosuppressive drugs]
Neoplasm Metastasis
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
Neoplasm Metastasis
[Minimizing the risk of cancer in transplant patients.]
Neoplasms
1alpha,25-dihydroxyvitamin D3 activates T cells of tumor bearers through protein phosphatase 2A.
Neoplasms
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.
Neoplasms
A comparative characterization of the circulating miRNome in whole blood and serum of HCC patients.
Neoplasms
A comprehensive review and update on ulcerative colitis
Neoplasms
A FRET-based screening method to detect potential inhibitors of the binding of CNNM3 to PRL2.
Neoplasms
A Genetic Variant of PPP1CB Influences Risk of Hepatitis B Virus-Related Hepatocellular Carcinoma in Han Chinese: A Pathway Based Analysis.
Neoplasms
A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.
Neoplasms
A new concept of tumor promotion by tumor necrosis factor-alpha, and cancer preventive agents (-)-epigallocatechin gallate and green tea--a review.
Neoplasms
A Nonsynonymous/Synonymous Substitution Analysis of the B56 Gene Family Aids in Understanding B56 Isoform Diversity.
Neoplasms
A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.
Neoplasms
A novel small-molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts.
Neoplasms
A potential role of the unfolded protein response in post-transplant cancer.
Neoplasms
A proteomics analysis of cell signaling alterations in colorectal cancer.
Neoplasms
A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.
Neoplasms
A Review of DUSP26: Structure, Regulation and Relevance in Human Disease.
Neoplasms
A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis.
Neoplasms
A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.
Neoplasms
A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment.
Neoplasms
A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis.
Neoplasms
A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
Neoplasms
A stable association with PME-1 may be dispensable for PP2A demethylation - implications for the detection of PP2A methylation and immunoprecipitation.
Neoplasms
A suppressive role of ionizing radiation-responsive miR-29c in the development of liver carcinoma via targeting WIP1.
Neoplasms
A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins.
Neoplasms
Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
Neoplasms
Activation of protein phosphatase causes alternative splicing of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): potential effect on immune surveillance.
Neoplasms
Activation of tumor suppressor protein PTEN and induction of apoptosis are involved in cAMP-mediated inhibition of cell number in B92 glial cells.
Neoplasms
Addressing treatment challenges in atopic dermatitis with novel topical therapies.
Neoplasms
Adenomatous polyposis coli heterozygous knockout mice display hypoactivity and age-dependent working memory deficits.
Neoplasms
Adjunctive therapies for Kawasaki disease.
Neoplasms
ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells.
Neoplasms
Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.
Neoplasms
Advances in the therapy of idiopathic inflammatory myopathies.
Neoplasms
Age-related remodelling of oesophageal epithelia by mutated cancer drivers.
Neoplasms
AGEs exacerbates coronary microvascular dysfunction in NoCAD by activating endoplasmic reticulum stress-mediated PERK signaling pathway.
Neoplasms
AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway.
Neoplasms
Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Neoplasms
Allelic loss of the PTEN gene and mutation of the TP53 gene in choriocarcinoma arising from gastric adenocarcinoma: analysis of loss of heterozygosity in two male patients with extragonadal choriocarcinoma.
Neoplasms
Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.
Neoplasms
Alterations of the PPP1R3 gene in human cancer.
Neoplasms
Alterations of the PPP2R1B gene in human lung and colon cancer.
Neoplasms
Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development.
Neoplasms
Alternative splicing of the human PTEN/MMAC1/TEP1 gene.
Neoplasms
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Neoplasms
An Algorithm for Generating Small RNAs Capable of Epigenetically Modulating Transcriptional Gene Silencing and Activation in Human Cells.
Neoplasms
An immunocytochemical demonstration of calcineurin in human nerve cell tumors. A comparison with neuron-specific enolase and glial fibrillary acidic protein.
Neoplasms
An okadaic acid fragment analogue prevents nicotine-induced resistance to cisplatin by recovering PP2A activity in non-small cell lung cancer cells.
Neoplasms
An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome).
Neoplasms
Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy.
Neoplasms
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Neoplasms
Analysis on heat stress-induced hyperphosphorylation of stathmin at serine 37 in Jurkat cells by means of two-dimensional gel electrophoresis and tandem mass spectrometry.
Neoplasms
Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation.
Neoplasms
Anti-tumor effects of perphenazine on canine lymphoma.
Neoplasms
Antibody Array Revealed PRL-3 Affects Protein Phosphorylation and Cytokine Secretion.
Neoplasms
Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Neoplasms
Anticancer potential of curcumin: preclinical and clinical studies.
Neoplasms
Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
Neoplasms
Apigenin Inhibits the Growth of Hepatocellular Carcinoma Cells by Affecting the Expression of microRNA Transcriptome.
Neoplasms
APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP.
Neoplasms
Arsenic Trioxide Inhibits the Metastasis of Small Cell Lung Cancer by Blocking Calcineurin-Nuclear Factor of Activated T Cells (NFAT) Signaling.
Neoplasms
Association between exposure to topical tacrolimus or pimecrolimus and cancers.
Neoplasms
Association Between Malignancy and Topical Use of Pimecrolimus.
Neoplasms
Association between PPP2CA expression and colorectal cancer prognosis Tumour Marker Prognostic Study.
Neoplasms
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.
Neoplasms
Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.
Neoplasms
Association of the tensin N-terminal protein-tyrosine phosphatase domain with the alpha isoform of protein phosphatase-1 in focal adhesions.
Neoplasms
Association of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese.
Neoplasms
Atopic dermatitis: a review of topical nonsteroid therapy.
Neoplasms
Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
Neoplasms
Aurovertin B exerts potent antitumor activity against triple-negative breast cancer in vivo and in vitro via regulating ATP synthase activity and DUSP1 expression.
Neoplasms
Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy.
Neoplasms
Autophagy regulates levels of tumor suppressor enzyme protein phosphatase 6.
Neoplasms
Autophagy-mediated Mir6981 degradation exhibits CDKN1B promotion of PHLPP1 protein translation.
Neoplasms
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
Neoplasms
B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.
Neoplasms
Basiliximab: a review of its use as induction therapy in renal transplantation.
Neoplasms
Berberine induced modulation of PHLPP2-Akt-MST1 kinase signaling is coupled with mitochondrial impairment and hepatoma cell death.
Neoplasms
Biochemical characterization of the phosphatase domain of the tumor suppressor PH domain leucine-rich repeat protein phosphatase.
Neoplasms
Biological evaluation of newly synthesized quinoline-5,8-quinones as Cdc25B inhibitors.
Neoplasms
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.
Neoplasms
Calcineurin a-binding protein, a novel modulator of the calcineurin-nuclear factor of activated T-cell signaling pathway, is overexpressed in wilms' tumors and promotes cell migration.
Neoplasms
Calcineurin as a neuronal marker of human brain tumors.
Neoplasms
Calcineurin deficiency decreases inflammatory lesions in transforming growth factor beta1-deficient mice.
Neoplasms
Calcineurin homologous protein isoform 2 supports tumor survival via the sodium hydrogen exchanger isoform 1 in non-small cell lung cancer.
Neoplasms
Calcineurin in reactive astrocytes plays a key role in the interplay between proinflammatory and anti-inflammatory signals.
Neoplasms
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
Neoplasms
Calcineurin mediates human tumor necrosis factor alpha gene induction in stimulated T and B cells.
Neoplasms
Calcineurin potentiates the activation of procaspase-3 by accelerating its proteolytic maturation.
Neoplasms
Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer.
Neoplasms
Calcineurin Regulates Homologous Desensitization of Natriuretic Peptide Receptor-A and Inhibits ANP-Induced Testosterone Production in MA-10 Cells.
Neoplasms
Calcineurin regulates nuclear factor I dephosphorylation and activity in malignant glioma cell lines.
Neoplasms
Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription.
Neoplasms
Calcineurin signaling as a negative determinant of keratinocyte cancer stem cell potential and carcinogenesis.
Neoplasms
Calcineurin subunit B activates dendritic cells and acts as a cancer vaccine adjuvant.
Neoplasms
Calcineurin, a calcium/calmodulin-regulated protein phosphatase, in mammalian neuroendocrine cells and neoplasms.
Neoplasms
Calprotectin and the Initiation and Progression of Head and Neck Cancer.
Neoplasms
Calyculin A causes sensitization to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by ROS-mediated down-regulation of cellular FLICE-inhibiting protein (c-FLIP) and by enhancing death receptor 4 mRNA stabilization.
Neoplasms
Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
Neoplasms
Can static electric fields increase the activity of nitric oxide synthase and induce oxidative stress and damage of spleen?
Neoplasms
Cancer cell-derived immunoglobulin G activates platelets by binding to platelet Fc?RIIa.
Neoplasms
Cancer predisposition: where's the phosphate?
Neoplasms
Cancer therapy shapes the fitness landscape of clonal hematopoiesis.
Neoplasms
Cancers after renal transplantation.
Neoplasms
Cantharidic acid induces apoptosis in human nasopharyngeal carcinoma cells through p38-mediated upregulation of caspase activation.
Neoplasms
Cardamonin Suppresses TGF-?1-Induced Epithelial Mesenchymal Transition via Restoring Protein Phosphatase 2A Expression.
Neoplasms
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.
Neoplasms
CDKN2B antisense RNA 1 suppresses tumor growth in human colorectal cancer by targeting MAPK inactivator dual specificity phosphatase 1.
Neoplasms
Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity.
Neoplasms
Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle.
Neoplasms
Cellular transformation by Simian Virus 40 and Murine Polyoma Virus T antigens.
Neoplasms
Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor.
Neoplasms
Characterization of a membrane tyrosine phosphatase in AR42J cells: regulation by somatostatin.
Neoplasms
Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D.
Neoplasms
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Neoplasms
Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
Neoplasms
Chronic microcystin exposure induces hepatocyte proliferation with increased expression of mitotic and cyclin-associated genes in P53-deficient mice.
Neoplasms
CIP2A cooperates with H-Ras to promote epithelial-mesenchymal transition in cervical-cancer progression.
Neoplasms
CircSEC24A promotes tumor progression through sequestering miR-455-3p in hepatocellular carcinoma.
Neoplasms
CircSLC3A2 functions as an oncogenic factor in hepatocellular carcinoma by sponging miR-490-3p and regulating PPM1F expression.
Neoplasms
Circulating TGF-?1 and VEGF and risk of cancer among liver transplant recipients.
Neoplasms
Circumventing Cellular Control of PP2A by Methylation Promotes Transformation in an Akt-Dependent Manner.
Neoplasms
Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway.
Neoplasms
Clinical aspects of tacrolimus use in paediatric renal transplant recipients.
Neoplasms
Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes.
Neoplasms
Clinical insights for cancer outcomes in renal transplant patients.
Neoplasms
Clinical-pathological correlations in post-transplant thrombotic microangiopathy.
Neoplasms
Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.
Neoplasms
Clonal hematopoiesis: Pre-cancer PLUS.
Neoplasms
Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease.
Neoplasms
Cloning, tissue distribution, subcellular localization and overexpression of murine histidine-rich Ca2+ binding protein.
Neoplasms
Co-Delivery of Oxaliplatin and Demethylcantharidin via a Polymer-Drug Conjugate.
Neoplasms
Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Neoplasms
Comparison of Kidney Transplant Function, Lipid Metabolism Disorders, and Glucose and Hemoglobin Concentration in Transplant Patients Treated With Proliferation Signal Inhibitor (Everolimus) or Calcineurin Inhibitor (Tacrolimus).
Neoplasms
Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-? Transgenic Mice.
Neoplasms
Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia.
Neoplasms
Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair.
Neoplasms
Constitutive over expression of serine/threonine protein phosphatase 5 (PP5) augments estrogen-dependent tumor growth in mice.
Neoplasms
Constitutively active protein phosphatase 1alpha causes Rb-dependent G1 arrest in human cancer cells.
Neoplasms
Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
Neoplasms
Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
Neoplasms
Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
Neoplasms
Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation.
Neoplasms
Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Neoplasms
Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers.
Neoplasms
Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?
Neoplasms
Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
Neoplasms
Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports.
Neoplasms
Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Neoplasms
Conversion to sirolimus in pediatric renal transplantation recipients.
Neoplasms
Conversion to sirolimus in posttransplant renal neoplasms.
Neoplasms
Conversion to sirolimus in renal transplant patients with tumors.
Neoplasms
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.
Neoplasms
Correction: Liu, Y.-S.; et al. Inhibition of Protein Phosphatase 1 Stimulates Noncanonical ER Stress eIF2? Activation to Enhance Fisetin-Induced Chemosensitivity in HDAC Inhibitor-Resistant Hepatocellular Carcinoma Cells. Cancers 2019, 11, 918.
Neoplasms
Correction: RIF1 promotes tumor growth and cancer stem cell-like traits in NSCLC by protein phosphatase 1-mediated activation of Wnt/?-catenin signaling.
Neoplasms
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].
Neoplasms
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
Neoplasms
Costimulatory Blockade and Use of Mammalian Target of Rapamycin Inhibitors: Avoiding Injury Part 1.
Neoplasms
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.
Neoplasms
Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
Neoplasms
Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme.
Neoplasms
CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site.
Neoplasms
Curcumin inhibits TNFalpha-induced lectin-like oxidised LDL receptor-1 (LOX-1) expression and suppresses the inflammatory response in human umbilical vein endothelial cells (HUVECs) by an antioxidant mechanism.
Neoplasms
Current approaches to the use of sirolimus in renal transplantation.
Neoplasms
Current treatment of ulcerative colitis.
Neoplasms
Cyclin-dependent kinase-associated protein phosphatase is overexpressed in alcohol-related hepatocellular carcinoma and influences xenograft tumor growth.
Neoplasms
Cyclosporin A promotes translational silencing of autocrine interleukin-3 via ribosome-associated deadenylation.
Neoplasms
Cyclosporin A Promotes Tumor Angiogenesis in a Calcineurin-Independent Manner by Increasing Mitochondrial Reactive Oxygen Species.
Neoplasms
Cyclosporine A Inhibits the T-bet-Dependent Antitumor Response of CD8(+) T Cells.
Neoplasms
Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: Role of TGF? signaling pathway.
Neoplasms
Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver transplantation.
Neoplasms
Daunting but worthy goal : reducing the de novo cancer incidence after transplantation.
Neoplasms
Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After Transplantation.
Neoplasms
De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor.
Neoplasms
De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation-8-year results.
Neoplasms
Deactivation of sphingosine kinase 1 by protein phosphatase 2A.
Neoplasms
Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer.
Neoplasms
Deficiency of AMPK in CD8+ T cells suppresses their anti-tumor function by inducing protein phosphatase-mediated cell death.
Neoplasms
Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells.
Neoplasms
Dephosphorylation of Girdin by PP2A inhibits breast cancer metastasis.
Neoplasms
Dephosphorylation of Rb (Thr-821) in response to cell stress.
Neoplasms
Dephosphorylation of the small heat shock protein hsp25 by calcium/calmodulin-dependent (type 2B) protein phosphatase.
Neoplasms
Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities.
Neoplasms
Descriptive Analysis of Everolimus Conversion in Liver Transplant Recipients With Malignant Neoplastic Disease.
Neoplasms
Design, synthesis and anticancer activity of constrained sphingolipid-phenoxazine/phenothiazine hybrid constructs targeting protein phosphatase 2A.
Neoplasms
Design, Synthesis and Antiproliferative Activity of Novel Benzothiazole Derivatives Conjugated with Semicarbazone Scaffold.
Neoplasms
Detection of driver mutations in FFPE samples from patients with verified malignant melanoma.
Neoplasms
Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1.
Neoplasms
Developmental and light regulation of tumor suppressor protein PP2A in the retina.
Neoplasms
Dexamethasone induced expression of phosphatase inhibits generation of reactive oxygen species in Ehrlich ascites tumor cells.
Neoplasms
Differences in association of the serine/threonine protein phosphatase PP-2A with microtubules of metastatic and nonmetastatic tumor cells.
Neoplasms
Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor.
Neoplasms
Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies.
Neoplasms
Differential contribution of protein phosphatase 1? to cell transformation of different cell types.
Neoplasms
Differential Effects of Nitrostyrene Derivatives on Myelopoiesis Involve Regulation of C/EBP? and p38MAPK Activity.
Neoplasms
Differential effects of procaspase-3 activating compounds in the induction of cancer cell death.
Neoplasms
Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma.
Neoplasms
Differential micro ribonucleic acid expression profiling in ovarian endometrioma with leuprolide acetate treatment.
Neoplasms
Differential protein expressions induced by adenovirus-mediated p16 gene transfer into Balb/c nude mouse.
Neoplasms
Differential Requirement for Pten Lipid and Protein Phosphatase Activity during Zebrafish Embryonic Development.
Neoplasms
Digital RNA Sequencing of Human Epidermal Keratinocytes Carrying Human Papillomavirus Type 16 E7.
Neoplasms
Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling.
Neoplasms
Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound.
Neoplasms
Discovery of protein phosphatase 2C inhibitors by virtual screening.
Neoplasms
Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Neoplasms
Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110?/PIK3CA but not by HER2 or mutant AKT1.
Neoplasms
Disruption of serine/threonine protein phosphatase 5 inhibits tumorigenesis of urinary bladder cancer cells.
Neoplasms
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.
Neoplasms
Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
Neoplasms
Docosahexaenoic acid induces apoptosis in Jurkat cells by a protein phosphatase-mediated process.
Neoplasms
Does structural commonality of metal complex formation by PAC-1 (anticancer), DHBNH (anti-HIV), AHL (autoinducer), and UCS1025A (anticancer) denote mechanistic similarity? Signal transduction and medical aspects.
Neoplasms
Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?
Neoplasms
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.
Neoplasms
Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis.
Neoplasms
Down-regulation of dual-specificity phosphatase 5 predicts poor prognosis of patients with prostate cancer.
Neoplasms
Down-regulation of dual-specificity phosphatase 6, a negative regulator of oncogenic ERK signaling, by ACA-28 induces apoptosis in NIH/3T3 cells overexpressing HER2/ErbB2.
Neoplasms
Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.
Neoplasms
Down-regulation of wild-type p53-induced phosphatase 1 (Wip1) plays a critical role in regulating several p53-dependent functions in premature senescent tumor cells.
Neoplasms
Downregulation of calcineurin activity in cervical carcinoma.
Neoplasms
Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.
Neoplasms
Downregulation of PPP2R5E expression by miR-23a suppresses apoptosis to facilitate the growth of gastric cancer cells.
Neoplasms
Downregulation of Snail by DUSP1 Impairs Cell Migration and Invasion through the Inactivation of JNK and ERK and Is Useful as a Predictive Factor in the Prognosis of Prostate Cancer.
Neoplasms
Drosophila PRL-1 is a growth inhibitor that counteracts the function of the Src oncogene.
Neoplasms
Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway.
Neoplasms
Dual Allosteric Inhibition of SHP2 Phosphatase.
Neoplasms
Dual neuroprotective signaling mediated by downregulating two distinct phosphatase activities of PTEN.
Neoplasms
Dual roles for the phosphatase PPM1D in regulating progesterone receptor function.
Neoplasms
Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity.
Neoplasms
Dual specificity phosphatase 1 expression inversely correlates with NF-?B activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
Neoplasms
Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.
Neoplasms
Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.
Neoplasms
Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy.
Neoplasms
Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
Neoplasms
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
Neoplasms
Dual-Modal Split-Type Immunosensor for Sensitive Detection of Microcystin-LR: Enzyme-Induced Photoelectrochemistry and Colorimetry.
Neoplasms
Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer.
Neoplasms
Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma.
Neoplasms
Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma.
Neoplasms
Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53.
Neoplasms
Dual-specificity phosphatase 5 acts as an anti-inflammatory regulator by inhibiting the ERK and NF-?B signaling pathways.
Neoplasms
Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression.
Neoplasms
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Neoplasms
Dual-specificity phosphatase 6 deletion protects the colonic epithelium against inflammation and promotes both proliferation and tumorigenesis.
Neoplasms
Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas.
Neoplasms
Dual-specificity phosphatases regulate mitogen-activated protein kinase signaling in adipocytes in response to inflammatory stress.
Neoplasms
DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer.
Neoplasms
DUSP1 inhibits cell proliferation, metastasis and invasion and angiogenesis in gallbladder cancer.
Neoplasms
DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Neoplasms
DUSP1 is involved in the progression of small cell carcinoma of the prostate.
Neoplasms
DUSP1 phosphatase regulates the proinflammatory milieu in head and neck squamous cell carcinoma.
Neoplasms
DUSP1 promoter methylation in peripheral blood leukocyte is associated with triple-negative breast cancer risk.
Neoplasms
DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer.
Neoplasms
DUSP10 Is a Regulator of YAP1 Activity Promoting Cell Proliferation and Colorectal Cancer Progression.
Neoplasms
DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis.
Neoplasms
DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs.
Neoplasms
DUSP5 expression associates with poor prognosis in human neuroblastoma.
Neoplasms
DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
Neoplasms
Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway.
Neoplasms
DUSP6 protects murine podocytes from high glucose?induced inflammation and apoptosis.
Neoplasms
DUSP6 regulates drug sensitivity by modulating DNA damage response.
Neoplasms
DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma.
Neoplasms
DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5.
Neoplasms
Early conversion to prednisolone/everolimus as an alternative weaning regimen associates with beneficial renal transplant histology and function: the randomized-controlled MECANO trial.
Neoplasms
Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Neoplasms
Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression.
Neoplasms
Effects of arsenite and UVA-1 radiation on calcineurin signaling.
Neoplasms
Effects of protein phosphatase inhibition by okadaic acid on the differentiation of F9 embryonal carcinoma cells.
Neoplasms
Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination with Vedolizumab in Patients With Refractory Ulcerative Colitis.
Neoplasms
Elevated expression of the cdc25A protein phosphatase in colon cancer.
Neoplasms
Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth.
Neoplasms
Endometrial ILKAP expression among patients with endometriosis and its association with clinical characteristics.
Neoplasms
Endothelial Calcineurin Signaling Restrains Metastatic Outgrowth by Regulating Bmp2.
Neoplasms
Endotoxin conditioning induces VCP/p97-mediated and inducible nitric-oxide synthase-dependent Tyr284 nitration in protein phosphatase 2A.
Neoplasms
Enhanced apoptosis and tumor growth suppression elicited by combination of MEK and mTOR kinase inhibitors.
Neoplasms
Enhanced expression of catalytic subunit isoform PP1 gamma 1 of protein phosphatase type 1 associated with malignancy of osteogenic tumor.
Neoplasms
Enhanced expression of catalytic subunits of protein phosphatase type 1 and high S-phase fraction in liposarcoma.
Neoplasms
Enhanced expression of PP1gamma1, a catalytic subunit isoform of protein phosphatase type1 and expression of telomerase activity in Ewing's sarcoma cells.
Neoplasms
Enhancement of fibroblast collagenase-1 (MMP-1) gene expression by tumor promoter okadaic acid is mediated by stress-activated protein kinases Jun N-terminal kinase and p38.
Neoplasms
Epidemiology and molecular pathology at crossroads to establish causation: molecular mechanisms of malignant transformation.
Neoplasms
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
Neoplasms
Epithelial calcineurin controls microbiota-dependent intestinal tumor development.
Neoplasms
Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling.
Neoplasms
ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.
Neoplasms
ERO1?-dependent endoplasmic reticulum-mitochondrial calcium flux contributes to ER stress and mitochondrial permeabilization by procaspase-activating compound-1 (PAC-1).
Neoplasms
Erratum to: Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.
Neoplasms
Estradiol suppresses phosphorylation of ER? serine 167 through upregulation of PP2A in breast cancer cells.
Neoplasms
Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Neoplasms
Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
Neoplasms
Evaluation of Cancer Risk Related to Atopic Dermatitis and Use of Topical Calcineurin Inhibitors.
Neoplasms
Everolimus and sirolimus in transplantation-related but different.
Neoplasms
Everolimus in Heart Transplantation: An Update.
Neoplasms
Everolimus in lung transplantation in Chile.
Neoplasms
Everolimus monotherapy or combined therapy in liver transplantation: indications and results.
Neoplasms
Evidence that Fas-induced apoptosis leads to S phase arrest.
Neoplasms
Evolution of glomerular filtration rate, renal injury markers, anemia, and Angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Neoplasms
Evolutionary Analysis of the B56 Gene Family of PP2A Regulatory Subunits.
Neoplasms
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Neoplasms
Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6-pentakisphosphate 3-phosphatase activity.
Neoplasms
Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery.
Neoplasms
Exploring the role of active site Mn2+ ions in the binding of protein phosphatase 5 with its substrate using molecular dynamics simulations.
Neoplasms
Expression and function of protein phosphatase PP2A in malignant testicular germ cell tumours.
Neoplasms
Expression and function of the high affinity alphaIIbbeta3 integrin in murine melanoma cells.
Neoplasms
Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression?
Neoplasms
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
Neoplasms
Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.
Neoplasms
Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line.
Neoplasms
Expression of calcineurin activity after lung transplantation: a 2-year follow-up.
Neoplasms
Expression of Dual-Specificity Phosphatase 2 (DUSP2) in Patients with Serous Ovarian Carcinoma and in SKOV3 and OVCAR3 Cells In Vitro.
Neoplasms
Expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) in tumor cells.
Neoplasms
Expression of FXYD-3 Is an Independent Prognostic Factor in Rectal Cancer Patients with Preoperative Radiotherapy.
Neoplasms
Expression of PHLPP2 correlates with clinicopathologic characteristics and prognosis in colorectal cancer.
Neoplasms
Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.
Neoplasms
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Neoplasms
Expression Pattern and Prognostic Utility of PME-1 in Patients with Hepatocellular Carcinoma.
Neoplasms
Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors.
Neoplasms
Expression Profiling of the MAP Kinase Phosphatase Family Reveals a Role for DUSP1 in the Glioblastoma Stem Cell Niche.
Neoplasms
Extracellular signal-regulated kinase 1/2-mediated phosphorylation of JunD and FosB is required for okadaic acid-induced activator protein 1 activation.
Neoplasms
Fibroblast-derived CXCL12 regulates PTEN expression and is associated with the proliferation and invasion of colon cancer cells via PI3k/Akt signaling.
Neoplasms
Fine deletion mapping of chromosome 2q21-37 shows three preferentially deleted regions in oral cancer.
Neoplasms
Fine-Tuning of Pten Localization and Phosphatase Activity Is Essential for Zebrafish Angiogenesis.
Neoplasms
FK506 binding proteins as targets in anticancer therapy.
Neoplasms
FK506 reduces calpain-regulated calcineurin activity in both the cytoplasm and the nucleus.
Neoplasms
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.
Neoplasms
Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma.
Neoplasms
From Favorable Histology to Relapse: The Clonal Evolution of a Wilms Tumor.
Neoplasms
FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells.
Neoplasms
Functional Analysis of the Protein Phosphatase Activity of PTEN.
Neoplasms
Functional genetic polymorphisms in PP2A subunit genes confer increased risks of lung cancer in southern and eastern Chinese.
Neoplasms
Functions and Regulation of the PTEN Gene in Colorectal Cancer.
Neoplasms
Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
Neoplasms
Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Neoplasms
Gene expression profile analysis of ENO1 knockdown in gastric cancer cell line MGC-803.
Neoplasms
Gene networks involved in apoptosis induced by hyperthermia in human lymphoma U937 cells.
Neoplasms
Genes are differentially expressed in the epididymal fat of rats rendered obese by a high-fat diet.
Neoplasms
Genetic alterations and oncogenic pathways associated with breast cancer subtypes.
Neoplasms
Genetic association of interleukin-2, interleukin-4, interleukin-6, transforming growth factor-?, tumour necrosis factor-? and blood concentrations of calcineurin inhibitors in Turkish renal transplant patients.
Neoplasms
Genetic network and gene set enrichment analysis to identify biomarkers related to cigarette smoking and lung cancer.
Neoplasms
Genetic variants and mutations of PPM1D control the response to DNA damage.
Neoplasms
Genetic variants in PPP2CA are associated with gastric cancer risk in a Chinese population.
Neoplasms
Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells.
Neoplasms
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma.
Neoplasms
Geraniol ameliorates diabetic nephropathy via interference with miRNA-21/PTEN/Akt/mTORC1 pathway in rats.
Neoplasms
Global gene expression analysis of knockdown Triosephosphate isomerase (TPI) gene in human gastric cancer cell line MGC-803.
Neoplasms
Glomerular diseases and cancer: evaluation of underlying malignancy.
Neoplasms
Glucocorticoids use in kidney transplant setting.
Neoplasms
GP78 Cooperates with Dual-Specificity Phosphatase 1 To Stimulate Epidermal Growth Factor Receptor-Mediated Extracellular Signal-Regulated Kinase Signaling.
Neoplasms
Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway.
Neoplasms
Hepatitis C virus NS3 protein enhances hepatocellular carcinoma cell invasion by promoting PPM1A ubiquitination and degradation.
Neoplasms
Hepatitis C: liver transplantation.
Neoplasms
Herpes viruses and tumours in kidney transplant recipients. The role of immunosuppression.
Neoplasms
HIF-1? suppressing small molecule, LW6, inhibits cancer cell growth by binding to calcineurin b homologous protein 1.
Neoplasms
High Bcl-2/Bax ratio in Walker tumor cells protects mitochondria but does not prevent H2O2-induced apoptosis via calcineurin pathways.
Neoplasms
High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation.
Neoplasms
High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.
Neoplasms
High PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patients.
Neoplasms
High-resolution crystal structure of the catalytic domain of human dual-specificity phosphatase 26.
Neoplasms
Higher intratumor than peritumor expression of DUSP6/MKP-3 is associated with recurrence after curative resection of hepatocellular carcinoma.
Neoplasms
Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium.
Neoplasms
HPV-16 impairs the subcellular distribution and levels of expression of protein phosphatase 1? in cervical malignancy.
Neoplasms
Human T cells depend on functional calcineurin, tumour necrosis factor-? and CD80/CD86 for expansion and activation in mice.
Neoplasms
Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.
Neoplasms
Hypoxia promotes pancreatic cancer cell migration, invasion, and epithelial-mesenchymal transition via modulating the FOXO3a/DUSP6/ERK axis.
Neoplasms
iASPP is important for bladder cancer cell proliferation.
Neoplasms
Ibuprofen-induced Walker 256 tumor cell death: cytochrome c release from functional mitochondria and enhancement by calcineurin inhibition.
Neoplasms
Identification and characterization of a radiation-inducible glycosylated human early-response gene.
Neoplasms
Identification by differential display of a protein phosphatase-2A regulatory subunit preferentially expressed in malignant melanoma cells.
Neoplasms
Identification of an AP1-ZFP36 Regulatory Network Associated with Breast Cancer Prognosis.
Neoplasms
Identification of collaborative activities with oxidative phosphorylation in bipolar disorder.
Neoplasms
Identification of differentially expressed genes after PPM1D silencing in breast cancer.
Neoplasms
Identification of key processes underlying cancer phenotypes using biologic pathway analysis.
Neoplasms
Identification of proteins suppressing the functions of oncogenic phosphatase of regenerating liver 1 and 3.
Neoplasms
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.
Neoplasms
Immunohistochemical expression of dual-specificity protein phosphatase 4 in patients with colorectal adenocarcinoma.
Neoplasms
Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
Neoplasms
Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Neoplasms
Immunostaining for calcineurin, a Ca2+/calmodulin-regulated protein phosphatase, in the diagnostic tumor pathology.
Neoplasms
Immunosuppressive agents for treating IgA nephropathy.
Neoplasms
Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.
Neoplasms
Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis.
Neoplasms
Inactivation of a redox-sensitive protein phosphatase during the early events of tumor necrosis factor/interleukin-1 signal transduction.
Neoplasms
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
Neoplasms
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.
Neoplasms
Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation.
Neoplasms
Incidence of non-skin de novo post-transplant malignancy in kidney transplant recipients maintained on calcineurin inhibitor (cin)/sirolimus (srl) is lower compared to cin/mycophenolate mofetil (mmf) therapy.
Neoplasms
Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factors.
Neoplasms
Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis.
Neoplasms
Increased Calcineurin A Expression Is Associated with a Lower Relapse-Free Survival Rate after Colorectal Cancer Surgery.
Neoplasms
Increased expression of calcineurin in human colorectal adenocarcinomas.
Neoplasms
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Neoplasms
Increased phosphorylation of nuclear phosphoproteins in human lung-cancer cells resistant to cis-diamminedichloroplatinum (II).
Neoplasms
Indications and effectiveness of the mammalian target of rapamycin in liver transplantation.
Neoplasms
Indications and management of everolimus after liver transplantation.
Neoplasms
Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage.
Neoplasms
Induction of differentiation and c-jun expression in human leukemic cells by okadaic acid, an inhibitor of protein phosphatases.
Neoplasms
Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites.
Neoplasms
Induction of Suicidal Erythrocyte Death by Cantharidin.
Neoplasms
Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-?B pathway dependent repression of PP2Ac.
Neoplasms
Influence of dual-specificity protein phosphatase 5 on mechanical properties of rat cerebral and renal arterioles.
Neoplasms
Infrequent methylation of the DUSP6 phosphatase in endometrial cancer.
Neoplasms
Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
Neoplasms
Inhibition of calcineurin by cyclosporine A exerts multiple effects on human melanoma cell lines HT168 and WM35.
Neoplasms
Inhibition of dual-specificity phosphatase 26 by ethyl-3,4-dephostatin: Ethyl-3,4-dephostatin as a multiphosphatase inhibitor.
Neoplasms
Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Neoplasms
Inhibition of protein phosphatase PPM1D enhances retinoic acid-induced differentiation in human embryonic carcinoma cell line.
Neoplasms
Inhibition of protein phosphatases by microcystins and nodularin associated with hepatotoxicity.
Neoplasms
Inhibition of Ser/Thr phosphatase PPM1D induces neutrophil differentiation in HL-60 cells.
Neoplasms
Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms.
Neoplasms
Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses.
Neoplasms
Inhibition of Wild-type p53-induced phosphatase 1 promotes liver regeneration in mice by direct activation of mTOR.
Neoplasms
Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
Neoplasms
Inhibitory role for calcineurin in stimulus-secretion coupling revealed by FK506 and cyclosporin A in pituitary corticotrope tumor cells.
Neoplasms
INPP4B: the new kid on the PI3K block.
Neoplasms
Inside out: targeting NHE1 as an intracellular and extracellular regulator of cancer progression.
Neoplasms
Insulin resistance induced by a high-fat diet is associated with the induction of genes related to leukocyte activation in rat peripheral leukocytes.
Neoplasms
Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitors.
Neoplasms
Investigation of POPX2 phosphatase functions by comparative phosphoproteomic analysis.
Neoplasms
Investigation of two Wnt signalling pathway single nucleotide polymorphisms in a breast cancer-affected Australian population.
Neoplasms
Involvement of Akt1/protein kinase Balpha in tumor conditioned medium-induced endothelial cell migration and survival in vitro.
Neoplasms
Involvement of SET in the Wnt signaling pathway and the development of human colorectal cancer.
Neoplasms
Is protein phosphatase inhibition responsible for the toxic effects of okadaic Acid in animals?
Neoplasms
Is there such a thing as protocol immunosuppression in liver transplantation?
Neoplasms
Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
Neoplasms
KEGG-expressed genes and pathways in triple negative breast cancer: Protocol for a systematic review and data mining.
Neoplasms
Keratinocyte growth factor induces gene expression signature associated with suppression of malignant phenotype of cutaneous squamous carcinoma cells.
Neoplasms
KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity.
Neoplasms
Knockdown of PPP5C inhibits growth of hepatocellular carcinoma cells in vitro.
Neoplasms
Knockdown of Protein Phosphatase Magnesium-dependent 1 (PPM1D) through Lentivirus-mediated RNA Silencing Inhibits Colorectal Carcinoma Cell Proliferation.
Neoplasms
Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells in vitro.
Neoplasms
KRAS mutation leads to decreased expression of regulator of calcineurin 2, resulting in tumor proliferation in colorectal cancer.
Neoplasms
Laforin confers cancer resistance to energy deprivation-induced apoptosis.
Neoplasms
Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3beta-dependent mechanisms.
Neoplasms
Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia.
Neoplasms
Liquid chromatography-linked protein phosphatase bioassay; a highly sensitive marine bioscreen for okadaic acid and related diarrhetic shellfish toxins.
Neoplasms
Liver transplantation and liver cell transplantation.
Neoplasms
Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
Neoplasms
Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis.
Neoplasms
Liver tumor promotion by the cyanobacterial cyclic peptide toxin microcystin-LR.
Neoplasms
Localized Rho GTPase activation regulates RNA dynamics and compartmentalization in tumor cell protrusions.
Neoplasms
Localizing PRL-2 expression and determining the effects of dietary Mg(2+) on expression levels.
Neoplasms
Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1.
Neoplasms
Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Neoplasms
Long-term maintenance of calcineurin inhibitor monotherapy reduces the risk for squamous cell carcinomas after kidney transplantation compared with bi- or tritherapy.
Neoplasms
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
Neoplasms
Long-term safety of tacrolimus ointment in atopic dermatitis.
Neoplasms
Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells invasiveness.
Neoplasms
Loss of phosphatase activity in PTEN (phosphatase and tensin homolog deleted on chromosome ten) results in endometrial carcinoma in humans: An in-silico study.
Neoplasms
Loss of PPM1F expression predicts tumour recurrence and is negatively regulated by miR-590-3p in gastric cancer.
Neoplasms
Loss of protein phosphatase 6 in mouse keratinocytes enhances K-rasG12D -driven tumor promotion.
Neoplasms
Loss of protein phosphatase 6 in mouse keratinocytes increases susceptibility to ultraviolet-B-induced carcinogenesis.
Neoplasms
Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and meta-analysis.
Neoplasms
Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors.
Neoplasms
Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms.
Neoplasms
Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial.
Neoplasms
Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
Neoplasms
Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
Neoplasms
Malignancies in 2,753 kidney recipients transplanted during a 39-year experience.
Neoplasms
Malignancy after transplantation.
Neoplasms
Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.
Neoplasms
Malignancy in kidney transplant recipients.
Neoplasms
Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers.
Neoplasms
Mechanisms of action of okadaic acid class tumor promoters on mouse skin.
Neoplasms
Melanoma-associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage owing to dysregulated Aurora-A.
Neoplasms
Membrane protein CNNM4-dependent Mg2+ efflux suppresses tumor progression.
Neoplasms
Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion.
Neoplasms
Metastatic Phosphatase PRL-3 Induces Ovarian Cancer Stem Cell Sub-population through Phosphatase-Independent Deacetylation Modulations.
Neoplasms
Methylation of the protein phosphatase 2A catalytic subunit is essential for association of Balpha regulatory subunit but not SG2NA, striatin, or polyomavirus middle tumor antigen.
Neoplasms
MicroRNA-145 inhibits human papillary cancer TPC1 cell proliferation by targeting DUSP6.
Neoplasms
MicroRNA-16 sensitizes drug-resistant breast cancer cells to Adriamycin by targeting Wip1 and Bcl-2.
Neoplasms
MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F.
Neoplasms
MicroRNA-205-5p is upregulated in myelodysplastic syndromes and induces cell proliferation via PTEN suppression.
Neoplasms
MicroRNA-21 Orchestrates High Glucose-induced Signals to TOR Complex 1, Resulting in Renal Cell Pathology in Diabetes.
Neoplasms
MicroRNA-222 Promotes Invasion and Metastasis of Papillary Thyroid Cancer Through Targeting Protein Phosphatase 2 Regulatory Subunit B Alpha Expression.
Neoplasms
microRNA-95 knockdown inhibits epithelial-mesenchymal transition and cancer stem cell phenotype in gastric cancer cells through MAPK pathway by upregulating DUSP5.
Neoplasms
Minimizing the risk of posttransplant malignancy.
Neoplasms
mir-182-5p Regulates Cell Growth of Liver Cancer via Targeting RCAN1.
Neoplasms
MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1.
Neoplasms
miR-938 promotes colorectal cancer cell proliferation via targeting tumor suppressor PHLPP2.
Neoplasms
miR129-1 regulates protein phosphatase 1D protein expression under hypoxic conditions in non-small cell lung cancer cells harboring a TP53 mutation.
Neoplasms
miR?338?3p mediates gluconeogenesis via targeting of PP4R1 in hepatocytes.
Neoplasms
Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL.
Neoplasms
Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells.
Neoplasms
Mitogen-activated protein kinase signal transduction in solid tumors.
Neoplasms
Mitophagy in degenerative joint diseases.
Neoplasms
Mitotic arrest and enhanced nuclear protein phosphorylation in human leukemia K562 cells by okadaic acid, a potent protein phosphatase inhibitor and tumor promoter.
Neoplasms
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Neoplasms
Modulation of protein phosphatase 2A (PP2A) activity alters androgen-independent growth of prostate cancer cells: therapeutic implications.
Neoplasms
Modulation of ROS/MAPK signaling pathways by okadaic acid leads to cell death via, mitochondrial mediated caspase-dependent mechanism.
Neoplasms
Modulation of serine/threonine-protein phosphatase 1 (PP1) complexes: A promising approach in cancer treatment.
Neoplasms
Modulation of VEGF receptor 2 signaling by protein phosphatases.
Neoplasms
Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells.
Neoplasms
Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy.
Neoplasms
Molecular cloning of cDNA for the catalytic subunit of rat liver type 2A protein phosphatase, and detection of high levels of expression of the gene in normal and cancer cells.
Neoplasms
Molecular cloning of rat phosphoprotein phosphatase 2A beta cDNA and increased expressions of phosphatase 2A alpha and 2A beta in rat liver tumors.
Neoplasms
Molecular mechanisms of pancreatic carcinogenesis.
Neoplasms
Mouse 4T1 Breast Cancer Cell-Derived Exosomes Induce Proinflammatory Cytokine Production in Macrophages via miR-183.
Neoplasms
mTOR Inhibition and Kidney Diseases.
Neoplasms
mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.
Neoplasms
mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
Neoplasms
mTOR inhibitors for hepatocellular cancer: a forward-moving target.
Neoplasms
mTOR inhibitors in pediatric liver transplant recipients.
Neoplasms
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model.
Neoplasms
Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
Neoplasms
Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Neoplasms
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Neoplasms
Mutational Analysis of a Conserved Glutamate Reveals Unique Mechanistic and Structural Features of the Phosphatase PRL-3.
Neoplasms
Mutations of the KIT gene and loss of heterozygosity of the PTEN region in a primary malignant melanoma arising from a mature cystic teratoma of the ovary.
Neoplasms
Mycophenolate Monotherapy in HLA-Matched Kidney Transplant Recipients: A Case Series of 20 Patients.
Neoplasms
N'-[(E)-Arylidene]-2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)-acetohydrazides: Synthesis and Evaluation of Caspase Activation Activity and Cytotoxicity.
Neoplasms
NDR family of AGC kinases--essential regulators of the cell cycle and morphogenesis.
Neoplasms
Neuroimaging and neurologic complications after organ transplantation.
Neoplasms
Neurologic Toxicities Associated with Tumor Necrosis Factor Inhibitors and Calcineurin Inhibitors.
Neoplasms
Neurotensin Signaling Activates MicroRNAs -21 and -155 and Akt, Promotes Tumor Growth in Mice, and is Increased in Human Colon Tumors.
Neoplasms
New Acetohydrazides Incorporating 2-Oxoindoline and 4-Oxoquinazoline: Synthesis and Evaluation of Cytotoxicity and Caspase Activation Activity.
Neoplasms
New concepts and best practices for management of pre- and post-transplantation cancer.
Neoplasms
NF-kappa B activation in tumor necrosis factor alpha-stimulated neutrophils is mediated by protein kinase Cdelta. Correlation to nuclear Ikappa Balpha.
Neoplasms
Niacin deficiency modulates genes involved in cancer: Are smokers at higher risk?
Neoplasms
Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation.
Neoplasms
Non-canonical function of nuclear PTEN and its implication on tumorigenesis.
Neoplasms
Novel Anticancer Agents Based on Targeting the Trimer Interface of the PRL Phosphatase.
Neoplasms
Novel approaches for chemosensitization of breast cancer cells: the E1A story.
Neoplasms
Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases.
Neoplasms
Novel evidence for a PIWI-interacting RNA (piRNA) as an oncogenic mediator of disease progression, and a potential prognostic biomarker in colorectal cancer.
Neoplasms
Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
Neoplasms
Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation.
Neoplasms
Nuclear accumulation of Calcineurin B Homologous Protein 2 (CHP2) results in enhanced proliferation of tumor cells.
Neoplasms
Nuclear factor-kappaB (NF-kappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase.
Neoplasms
Nuclear localization of the adenovirus E4orf4 protein is mediated through an arginine-rich motif and correlates with cell death.
Neoplasms
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Neoplasms
Obg-like ATPase 1 regulates global protein serine/threonine phosphorylation in cancer cells by suppressing the GSK3?-inhibitor 2-PP1 positive feedback loop.
Neoplasms
Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs).
Neoplasms
Okadaic acid biologically mimics the role of calcium/phospholipid dependent kinase inhibitors in the process of HL-60 cell differentiation.
Neoplasms
Okadaic acid identifies a phosphorylation/dephosphorylation cycle controlling the inhibitory guanine-nucleotide-binding regulatory protein Gi2.
Neoplasms
Okadaic acid inhibits PDGF-induced proliferation and decreases PDGF receptor number in C3H/10T1/2 mouse fibroblasts.
Neoplasms
Okadaic acid mediates p53 hyperphosphorylation and growth arrest in cells with wild-type p53 but increases aberrant mitoses in cells with non-functional p53.
Neoplasms
Okadaic acid stimulated TRE binding activity in a papilloma producing mouse keratinocyte cell line involves increased AP-1 expression.
Neoplasms
Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway.
Neoplasms
Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1).
Neoplasms
Optimizing the clinical utility of sirolimus-based immunosuppression for kidney transplantation.
Neoplasms
Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting.
Neoplasms
Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway.
Neoplasms
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer.
Neoplasms
Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up.
Neoplasms
Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer.
Neoplasms
Overexpression of wip1 is associated with biologic behavior in human clear cell renal cell carcinoma.
Neoplasms
p21 expression is induced by activation of nuclear nerve growth factor-induced Balpha (Nur77) in pancreatic cancer cells.
Neoplasms
p53 protein-mediated up-regulation of MAP kinase phosphatase 3 (MKP-3) contributes to the establishment of the cellular senescent phenotype through dephosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2).
Neoplasms
p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors.
Neoplasms
P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
Neoplasms
PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition.
Neoplasms
PAC-1 and its derivative WF-210 Inhibit Angiogenesis by inhibiting VEGF/VEGFR pathway.
Neoplasms
Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control.
Neoplasms
Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1).
Neoplasms
Partners in crime: POPX2 phosphatase and its interacting proteins in cancer.
Neoplasms
PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase.
Neoplasms
Pentosan polysulfate, a potent anti HIV and anti tumor agent, inhibits protein serine/threonine and tyrosine kinases.
Neoplasms
PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).
Neoplasms
PHLPP regulates hexokinase 2-dependent glucose metabolism in colon cancer cells.
Neoplasms
PHLPP Sensitizes Multiple Myeloma Cells to Bortezomib Through Regulating LAMP2.
Neoplasms
PHLPP2 as a novel metastatic and prognostic biomarker in non-small cell lung cancer patients.
Neoplasms
PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein.
Neoplasms
PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.
Neoplasms
PHLPPing the balance: restoration of protein kinase C in cancer.
Neoplasms
Phosphatase and Tensin Homolog in Non-neoplastic Digestive Disease: More Than Just Tumor Suppressor.
Neoplasms
Phosphatase assay for multi-phosphorylated substrates using phosphatase specific-motif antibody.
Neoplasms
Phosphatase of regenerating liver maintains cellular magnesium homeostasis.
Neoplasms
Phosphatase of regenerating liver sensitizes MET to functional activation by hepatocyte growth factor.
Neoplasms
Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells.
Neoplasms
Phosphatase of regenerating liver: a novel target for cancer therapy.
Neoplasms
Phosphatase POPX2 Exhibits Dual Regulatory Functions in Cancer Metastasis.
Neoplasms
Phosphatase POPX2 interferes with cell cycle by interacting with Chk1.
Neoplasms
Phosphatase Wip1 Masters IL-17-producing Neutrophil-mediated Colitis in Mice.
Neoplasms
Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.
Neoplasms
Phosphoproteome and drug response effects mediated by the three Protein Phosphatase 2A inhibitor proteins CIP2A, SET and PME-1.
Neoplasms
Photoaffinity labeling of protein phosphatase 2A, the receptor for a tumor promoter okadaic acid, by [27-3H]methyl 7-O-(4-azidobenzoyl)okadaate.
Neoplasms
Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.
Neoplasms
Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.
Neoplasms
POPX2 phosphatase regulates apoptosis through the TAK1-IKK-NF-?B pathway.
Neoplasms
Possible involvement of protein phosphatase type 2A in tumor necrosis factor alpha-induced tissue factor expression in endothelial cells.
Neoplasms
Post-transcriptional modulation of protein phosphatase PPP2CA and tumor suppressor PTEN by endogenous siRNA cleaved from hairpin within PTEN mRNA 3'UTR in human liver cells.
Neoplasms
Post-transcriptional regulation of the DUSP6/MKP-3 phosphatase by MEK/ERK signaling and hypoxia.
Neoplasms
Post-transplant de novo malignancies in renal transplant recipients: the past and present.
Neoplasms
Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy.
Neoplasms
Post-Traumatic Brain Injury: Genetic Susceptibility to Outcome.
Neoplasms
Posttransplant Kaposi's sarcoma: report from a single center.
Neoplasms
Potential biomarkers of HCC based on gene expression and DNA methylation profiles.
Neoplasms
Potential small-molecule activators of caspase-7 identified using yeast-based caspase-3 and -7 screening assays.
Neoplasms
Potential targets identified in adenoid cystic carcinoma point out new directions for further research.
Neoplasms
Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer.
Neoplasms
PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKK? and sustained activation of the NF-?B pathway.
Neoplasms
PP2A-B55? Antagonizes Cyclin E1 Proteolysis and Promotes Its Dysregulation in Cancer.
Neoplasms
PP2A-dependent disruption of centrosome replication and cytoskeleton organization in Drosophila by SV40 small tumor antigen.
Neoplasms
PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer.
Neoplasms
PP2A: unveiling a reluctant tumor suppressor.
Neoplasms
PP2AC? of Alveolar Macrophages Is a Novel Protective Factor for LPS-Induced Acute Respiratory Distress Syndrome.
Neoplasms
PP2C? inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response in breast cancer.
Neoplasms
PP4C facilitates lung cancer proliferation and inhibits apoptosis via activating MAPK/ERK pathway.
Neoplasms
PP4R1 interacts with HMGA2 to promote non-small-cell lung cancer migration and metastasis via activating MAPK/ERK-induced epithelial-mesenchymal transition.
Neoplasms
PP4R4/KIAA1622 Forms a Novel Stable Cytosolic Complex with Phosphoprotein Phosphatase 4.
Neoplasms
PP6 Disruption Synergizes with Oncogenic Ras to Promote JNK-Dependent Tumor Growth and Invasion.
Neoplasms
PPM1A is a RelA phosphatase with tumor suppressor-like activity.
Neoplasms
PPM1D accelerates proliferation and metastasis of osteosarcoma by activating PKP2.
Neoplasms
PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Neoplasms
PPM1D controls nucleolar formation by up-regulating phosphorylation of nucleophosmin.
Neoplasms
PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.
Neoplasms
PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms.
Neoplasms
PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Neoplasms
PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study.
Neoplasms
PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma.
Neoplasms
PPM1D is a potential target for 17q gain in neuroblastoma.
Neoplasms
PPM1D is a prognostic marker and therapeutic target in colorectal cancer.
Neoplasms
PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.
Neoplasms
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Neoplasms
PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
Neoplasms
PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
Neoplasms
PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
Neoplasms
PPM1D silencing by RNA interference inhibits the proliferation of lung cancer cells.
Neoplasms
PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.
Neoplasms
PPM1H is a p27 phosphatase implicated in trastuzumab resistance.
Neoplasms
PPM1H is an independent prognostic biomarker of non-small cell lung cancer.
Neoplasms
PPP1CA contributes to the senescence program induced by oncogenic Ras.
Neoplasms
PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Neoplasms
PPP2R2C loss promotes castration-resistant prostate cancer growth and is associated with increased prostate cancer-specific mortality.
Neoplasms
PPP2R5A: A multirole protein phosphatase subunit in regulating cancer development.
Neoplasms
PPP3CB contributes to poor prognosis through activating nuclear factor of activated T-cells signaling in neuroblastoma.
Neoplasms
Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis.
Neoplasms
Premature chromosome condensation revisited: a novel chemical approach permits efficient cytogenetic analysis of cancers.
Neoplasms
PRL phosphatases as potential molecular targets in cancer.
Neoplasms
PRL-3 activates NF-?B signaling pathway by interacting with RAP1.
Neoplasms
PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.
Neoplasms
PRL-3 induces a positive signaling circuit between glycolysis and activation of STAT1/2.
Neoplasms
PRL-3 Mediates the Protein Maturation of ULBP2 by Regulating the Tyrosine Phosphorylation of HSP60.
Neoplasms
PRL-3 phosphatase and cancer metastasis.
Neoplasms
PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation.
Neoplasms
Pro-necrotic molecules impact local immunosurveillance in human breast cancer.
Neoplasms
Pro?apoptotic effects of pycnogenol on HT1080 human fibrosarcoma cells.
Neoplasms
Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3.
Neoplasms
Procaspase-activating compound 1 induces a caspase-3-dependent cell death in cerebellar granule neurons.
Neoplasms
Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro.
Neoplasms
Production of DUSP1 protein using the baculovirus insect cell expression system and its in vitro effects on cancer cells.
Neoplasms
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Neoplasms
Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma.
Neoplasms
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.
Neoplasms
Prognostic value of PPM1D in 800 gastric cancer patients.
Neoplasms
Prognostic value of PRL-3 overexpression in early stages of colonic cancer.
Neoplasms
Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation.
Neoplasms
Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions.
Neoplasms
Proliferation signal inhibitors in cardiac transplantation.
Neoplasms
Proliferation signal inhibitors in heart transplantation: a 5-year experience.
Neoplasms
Protein expression profiles in hematopoietic stem/progenitor cells after exposure of mice to silicon (28Si) ions.
Neoplasms
Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis.
Neoplasms
Protein phosphatase 1alpha activity prevents oncogenic transformation.
Neoplasms
Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers.
Neoplasms
Protein phosphatase 2 regulatory subunit B''Alpha silencing inhibits tumor cell proliferation in liver cancer.
Neoplasms
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
Neoplasms
Protein Phosphatase 2A as a Potential Target for Anticancer Therapy.
Neoplasms
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
Neoplasms
Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53.
Neoplasms
Protein phosphatase 2A promotes the transition to G0 during terminal differentiation in Drosophila.
Neoplasms
Protein phosphatase 4 (PP4) functions as a critical regulator in tumor necrosis factor (TNF)-?-induced hepatic insulin resistance.
Neoplasms
Protein phosphatase 4 catalytic subunit is overexpressed in glioma and promotes glioma cell proliferation and invasion.
Neoplasms
Protein phosphatase 4 catalytic subunit regulates Cdk1 activity and microtubule organization via NDEL1 dephosphorylation.
Neoplasms
Protein phosphatase 4 interacts with and down-regulates insulin receptor substrate 4 following tumor necrosis factor-alpha stimulation.
Neoplasms
Protein phosphatase 4 is involved in tumor necrosis factor-alpha-induced activation of c-Jun N-terminal kinase.
Neoplasms
Protein phosphatase 5 and the tumor suppressor P53 down-regulate each other's activities in mice.
Neoplasms
Protein phosphatase 6 subunit with conserved Sit4-associated protein domain targets IkappaBepsilon.
Neoplasms
Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer.
Neoplasms
Protein Phosphatase Magnesium-Dependent 1? (PPM1D) Expression as a Prognostic Marker in Adult Supratentorial Diffuse Astrocytic and Oligodendroglial Tumors.
Neoplasms
Protein phosphatase magnesium-dependent 1? (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma.
Neoplasms
Protein phosphatase magnesium-dependent 1? is a novel tumor marker and target in hepatocellular carcinoma.
Neoplasms
Protein phosphatase methylesterase-1 (PME-1) expression predicts a favorable clinical outcome in colorectal cancer.
Neoplasms
Protein phosphatase Mg2+/Mn2+ dependent 1F promotes smoking-induced breast cancer by inactivating phosphorylated-p53-induced signals.
Neoplasms
Protein phosphatase PP4 is overexpressed in human breast and lung tumors.
Neoplasms
Protein phosphatase PP6 is required for homology-directed repair of DNA double-strand breaks.
Neoplasms
Protein phosphatase PP6 N terminal domain restricts G1 to S phase progression in human cancer cells.
Neoplasms
Protein phosphatase type 1-dependent dephosphorylation of the retinoblastoma tumor suppressor protein in ultraviolet-irradiated human skin and keratinocytes.
Neoplasms
Protein phosphatase, Mg2+/Mn2+-dependent 1D (PPM1D) mutations in haematological cancer.
Neoplasms
Protein phosphatase-2A association with microtubules and its role in restricting the invasiveness of human head and neck squamous cell carcinoma cells.
Neoplasms
Protein phosphatase-2A modulates the serine and tyrosine phosphorylation of paxillin in Lewis lung carcinoma tumor variants.
Neoplasms
Protein phosphatase-2A regulates endothelial cell motility and both the phosphorylation and the stability of focal adhesion complexes.
Neoplasms
Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants.
Neoplasms
Protein phosphatase-2A restricts migration of Lewis lung carcinoma cells by modulating the phosphorylation of focal adhesion proteins.
Neoplasms
Protein phosphatases and DNA tumor viruses: transformation through the back door?
Neoplasms
Protein serine/threonine phosphatases: life, death, and sleeping.
Neoplasms
Proteome profile changes that are differentially regulated by lipid and protein phosphatase activities of tumor suppressor PTEN in PTEN-expressing U-87 MG human glioblastoma cells.
Neoplasms
Proteomics analysis of in vitro protein methylation during Src-induced transformation.
Neoplasms
Proteomics Identified Overexpression of SET Oncogene Product and Possible Therapeutic Utility of Protein Phosphatase 2A in Alveolar Soft Part Sarcoma.
Neoplasms
PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway.
Neoplasms
PTEN Inhibition in Human Disease Therapy.
Neoplasms
PTEN lipid phosphatase inactivation links the hippo and PI3K/Akt pathways to induce gastric tumorigenesis.
Neoplasms
PTEN Mouse Models of Cancer Initiation and Progression.
Neoplasms
PTEN Protein Phosphatase Activity Correlates with Control of Gene Expression and Invasion, a Tumor-Suppressing Phenotype, But Not with AKT Activity.
Neoplasms
PTEN regulates RANKL- and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility.
Neoplasms
PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma.
Neoplasms
PTPN3 suppresses the proliferation and correlates with favorable prognosis of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation.
Neoplasms
Purification and characterization of butyrate-induced protein phosphatase involved in apoptosis of Ehrlich ascites tumor cells.
Neoplasms
Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters.
Neoplasms
Quantitative and dynamic analysis of PTEN phosphorylation by NMR.
Neoplasms
Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma.
Neoplasms
Quercetin inhibits angiogenesis by targeting calcineurin in the xenograft model of human breast cancer.
Neoplasms
RCAN1 in the inverse association between Alzheimer's disease and cancer.
Neoplasms
RCAN1-4 is a thyroid cancer growth and metastasis suppressor.
Neoplasms
RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma.
Neoplasms
Recent Patents and Advances in Genomic Biomarker Discovery for Colorectal Cancers.
Neoplasms
Reciprocal REG?-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma.
Neoplasms
Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference.
Neoplasms
Redox modulation of protein kinase/phosphatase balance in melanoma cells: the role of endogenous and gamma-glutamyltransferase-dependent H2O2 production.
Neoplasms
Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells.
Neoplasms
Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling.
Neoplasms
Reduction-Sensitive Fluorinated-Pt(IV) Universal Transfection Nanoplatform Facilitating CT45-Targeted CRISPR/dCas9 Activation for Synergistic and Individualized Treatment of Ovarian Cancer.
Neoplasms
Regulation of mammalian ribonucleotide reductase by the tumor promoters and protein phosphatase inhibitors okadaic acid and calyculin A.
Neoplasms
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling.
Neoplasms
Regulation of PTEN expression in intestinal epithelial cells by c-Jun NH2-terminal kinase activation and nuclear factor-kappaB inhibition.
Neoplasms
Regulation of the phosphatase calcineurin by insulin-like growth factor I unveils a key role of astrocytes in Alzheimer's pathology.
Neoplasms
Regulation of tumor necrosis factor cytotoxicity by calcineurin.
Neoplasms
Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells.
Neoplasms
Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Neoplasms
Regulator of Calcineurin 1 Gene Transcription is Regulated by Nuclear Factor-kappaB.
Neoplasms
Regulator of calcineurin 1 modulates cancer cell migration in vitro.
Neoplasms
Regulatory mechanisms of phosphatase of regenerating liver (PRL)-3.
Neoplasms
Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics.
Neoplasms
Renal cancer in kidney transplanted patients.
Neoplasms
Renal transplantation with expanded criteria donors: Which is the optimal immunosuppression?
Neoplasms
Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway.
Neoplasms
Resolution of sirolimus-induced pneumonitis after conversion to everolimus.
Neoplasms
Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.
Neoplasms
Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D.
Neoplasms
Reverse dipper pattern of blood pressure at 3 months is associated with inflammation and outcome after renal transplantation.
Neoplasms
RIF1 promotes tumor growth and cancer stem cell-like traits in NSCLC by protein phosphatase 1-mediated activation of Wnt/?-catenin signaling.
Neoplasms
RNA expression profiling of normal and tumor cells following photodynamic therapy with 5-aminolevulinic acid-induced protoporphyrin IX in vitro.
Neoplasms
Role of AKT and ERK pathways in controlling sensitivity to ionizing radiation and adaptive response induced by low-dose radiation in human immune cells.
Neoplasms
Role of cantharidin in the activation of IKK?/I?B?/NF??B pathway by inhibiting PP2A activity in cholangiocarcinoma cell lines.
Neoplasms
Role of DUSP1/MKP1 in tumorigenesis, tumor progression and therapy.
Neoplasms
Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer.
Neoplasms
Role of Gadd45a in Wip1-dependent regulation of intestinal tumorigenesis.
Neoplasms
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients.
Neoplasms
Role of PHLPP1 in inflammation response: Its loss contributes to gliomas development and progression.
Neoplasms
Role of PP2C-alpha in cell growth, in radio- and chemosensitivity, and in tumorigenicity.
Neoplasms
Role of protein phosphatase in malignant osteogenic and soft tissue tumors.
Neoplasms
Role of protein phosphatases in genitourinary cancers.
Neoplasms
Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants.
Neoplasms
Role of serine/threonine protein phosphatase 2A in cancer.
Neoplasms
Role of type 2C protein phosphatases in growth regulation and in cellular stress signaling.
Neoplasms
Role of wild-type p53-induced phosphatase 1 in cancer.
Neoplasms
Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence.
Neoplasms
Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Neoplasms
Saliva as a tool for oral cancer diagnosis and prognosis.
Neoplasms
Screening for differentially expressed genes between left- and right-sided colon carcinoma by microarray analysis.
Neoplasms
Scribble-mediated membrane targeting of PHLPP1 is required for its negative regulation of Akt.
Neoplasms
Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis.
Neoplasms
Selective increase in expression of isoform PP1 gamma 1 of type-1 protein phosphatase in chondrosarcoma cells.
Neoplasms
Serendipitous discovery of light-induced (In Situ) formation of an Azo-bridged dimeric sulfonated naphthol as a potent PTP1B inhibitor.
Neoplasms
Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A.
Neoplasms
Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma.
Neoplasms
Serine/Threonine Protein Phosphatase-5 Accelerates Cell Growth and Migration in Human Glioma.
Neoplasms
SET levels contribute to cohesion fatigue.
Neoplasms
Severe everolimus-associated pneumonitis in a renal transplant recipient.
Neoplasms
SEVERE HYPERTRIGLYCERIDEMIA ASSOCIATED WITH EVEROLIMUS TREATMENT AFTER HEART TRANSPLANTATION.
Neoplasms
Sevoflurane inhibits the proliferation and invasion of hepatocellular carcinoma cells through regulating the PTEN/Akt/GSK?3?/??catenin signaling pathway by downregulating miR?25?3p.
Neoplasms
Signal transducer and activator of transcription 3 (STAT3) degradation by proteasome controls a developmental switch in neurotrophin dependence.
Neoplasms
SIGNIFICANTLY LOWER MALIGNANCY RATES IN RENAL TRANSPLANT RECIPIENTS CONVERTED FROM CALCINEURIN INHIBITORS (CNIs) TO SIROLIMUS (SRL) COMPARED WITH THOSE WHO CONTINUED CNI THERAPY.
Neoplasms
Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma.
Neoplasms
Simian virus 40 small t antigen cooperates with mitogen-activated kinases to stimulate AP-1 activity.
Neoplasms
Simian virus 40 small tumor antigen induces deregulation of the actin cytoskeleton and tight junctions in kidney epithelial cells.
Neoplasms
Sirolimus (rapamycin): from the soil of Easter Island to a bright future.
Neoplasms
Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
Neoplasms
Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma.
Neoplasms
Sirolimus Therapy after Early Cyclosporine Withdrawal Reduces the Risk for Cancer in Adult Renal Transplantation.
Neoplasms
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
Neoplasms
Sirolimus therapy in liver transplant patients: an initial experience at a single center.
Neoplasms
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
Neoplasms
Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.
Neoplasms
Skeletal muscle cell hypertrophy induced by inhibitors of metalloproteases; myostatin as a potential mediator.
Neoplasms
Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair.
Neoplasms
Skin conditions: new drugs for managing skin disorders.
Neoplasms
SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice.
Neoplasms
SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis.
Neoplasms
Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy.
Neoplasms
Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics.
Neoplasms
Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
Neoplasms
Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.
Neoplasms
STAT3-iNOS Signaling Mediates EGFRvIII-Induced Glial Proliferation and Transformation.
Neoplasms
Steroids versus other immune modulators in the management of allergic dermatoses.
Neoplasms
Stimulation of Suicidal Erythrocyte Death by Phosphatase Inhibitor Calyculin A.
Neoplasms
Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.
Neoplasms
STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells.
Neoplasms
Structure and function of the co-chaperone protein phosphatase 5 in cancer.
Neoplasms
Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins.
Neoplasms
Structure-activity relationship within a series of okadaic acid derivatives.
Neoplasms
Structure-dependent activation of endoplasmic reticulum stress-mediated apoptosis in pancreatic cancer by 1,1-bis(3'-indoly)-1-(p-substituted phenyl)methanes.
Neoplasms
Structure-function relationships of microcystins, liver tumor promoters, in interaction with protein phosphatase.
Neoplasms
Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.
Neoplasms
Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience.
Neoplasms
Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.
Neoplasms
Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299.
Neoplasms
Synthesis and Biological Evaluation of Novel 4-(2-Fluorophenoxy)-2-(1H-tetrazol-1-yl)pyridines Bearing Semicarbazone Moieties as Potent Antitumor Agents.
Neoplasms
Synthesis of Dual Target CPT-Ala-Nor Conjugates and Their Biological Activity Evaluation.
Neoplasms
Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.
Neoplasms
Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors.
Neoplasms
Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma.
Neoplasms
Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship.
Neoplasms
Tacrolimus ointment: a new therapy for atopic dermatitis--review of the literature.
Neoplasms
Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials.
Neoplasms
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth.
Neoplasms
Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
Neoplasms
Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late.
Neoplasms
Targeting Angiogenesis in Prostate Cancer.
Neoplasms
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Neoplasms
Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia.
Neoplasms
Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Neoplasms
Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell apoptosis.
Neoplasms
Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents.
Neoplasms
Targeting PTPs with small molecule inhibitors in cancer treatment.
Neoplasms
Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines.
Neoplasms
Tescalcin/c-Src/IGF1R?-mediated STAT3 activation enhances cancer stemness and radioresistant properties through ALDH1.
Neoplasms
The "black box" warning and allergy drugs.
Neoplasms
The 17q23 amplicon and breast cancer.
Neoplasms
The 1p36 Tumor Suppressor KIF 1B? Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis.
Neoplasms
The 3D structure of protein phosphatase 2A: new insights into a ubiquitous regulator of cell signaling.
Neoplasms
The ARE-binding protein Tristetraprolin (TTP) is a novel target and mediator of calcineurin tumor suppressing function in the skin.
Neoplasms
The calcineurin B subunit induces TNF-related apoptosis-inducing ligand (TRAIL) expression via CD11b-NF-?B pathway in RAW264.7 macrophages.
Neoplasms
The Calcineurin-NFAT-Angiopoietin-2 Signaling Axis in Lung Endothelium Is Critical for the Establishment of Lung Metastases.
Neoplasms
The calcineurin/NFAT signaling pathway: a novel therapeutic target in leukemia and solid tumors.
Neoplasms
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Neoplasms
The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene Ppm1d Promotes Inflammation and Non-Ischemic Heart Failure in Mice.
Neoplasms
The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report.
Neoplasms
The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
Neoplasms
The Clinical Significance of PPEF1 as a Promising Biomarker and Its Potential Mechanism in Breast Cancer.
Neoplasms
The critical role of calcineurin/NFAT (C/N) pathways and effective antitumor prospect for colorectal cancers.
Neoplasms
The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer.
Neoplasms
The Dual-Specificity Phosphatase 10 (DUSP10): Its Role in Cancer, Inflammation, and Immunity.
Neoplasms
The DUSP26 phosphatase activator adenylate kinase 2 regulates FADD phosphorylation and cell growth.
Neoplasms
The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma.
Neoplasms
The Effect of Conversion from a Calcineurin Inhibitor to Sirolimus on Skin Cancer Reduction in Post-renal Transplantation Patients.
Neoplasms
The effect of decitabine on the expression and methylation of the PPP1CA, BTG2, and PTEN in association with changes in miR-125b, miR-17, and miR-181b in NALM6 cell line.
Neoplasms
The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
Neoplasms
The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection.
Neoplasms
The effect of RCAN1 on the biological behaviors of small cell lung cancer.
Neoplasms
The expression and clinical prognostic value of protein phosphatase 1 catalytic subunit beta in pancreatic cancer.
Neoplasms
The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Neoplasms
The functions of tumor suppressor PTEN in innate and adaptive immunity.
Neoplasms
The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function.
Neoplasms
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.
Neoplasms
The high affinity alphaIIb beta3 integrin is involved in invasion of human melanoma cells.
Neoplasms
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes.
Neoplasms
The immunosuppressed traveler.
Neoplasms
The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors.
Neoplasms
The Interplay between PP2A and microRNAs in Leukemia.
Neoplasms
The intrinsically disordered tails of PTEN and PTEN-L have distinct roles in regulating substrate specificity and membrane activity.
Neoplasms
The ISG15-specific protease USP18 regulates stability of PTEN.
Neoplasms
The mechanism of action of the tumour suppressor gene PTEN.
Neoplasms
The membrane immunoglobulin receptor utilizes a Shc/Grb2/hSOS complex for activation of the mitogen-activated protein kinase cascade in a B-cell line.
Neoplasms
The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies.
Neoplasms
The Metastasis-Promoting Phosphatase PRL-3 Shows Activity toward Phosphoinositides.
Neoplasms
The multiple functions of protein phosphatase 6.
Neoplasms
The natural anticancer agent cantharidin alters GPI-anchored protein sorting by targeting Cdc1-mediated remodeling in endoplasmic reticulum.
Neoplasms
The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways.
Neoplasms
The Oncogenic PRL Protein Causes Acid Addiction of Cells by Stimulating Lysosomal Exocytosis.
Neoplasms
The ordering of expression among a few genes can provide simple cancer biomarkers and signal BRCA1 mutations.
Neoplasms
The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair.
Neoplasms
The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression.
Neoplasms
The pleiotropic effects of mTor inhibitors.
Neoplasms
The POPX2 phosphatase regulates cancer cell motility and invasiveness.
Neoplasms
The PP4R1 sub-unit of protein phosphatase PP4 is essential for inhibition of NF-?B by merkel polyomavirus small tumour antigen.
Neoplasms
The ratio of thioredoxin/Keap1 protein level is a predictor of distant metastasis in colorectal cancer.
Neoplasms
The Regulation of Trophoblastic p53 Homeostasis by the p38-Wip1 Feedback Loop is Disturbed in Placentas from Pregnancies Complicated by Preeclampsia.
Neoplasms
The retinoid anticancer signal: mechanisms of target gene regulation.
Neoplasms
The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
Neoplasms
The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells.
Neoplasms
The role of basiliximab in the evolving renal transplantation immunosuppression protocol.
Neoplasms
The role of PPM1D in cancer and advances in studies of its inhibitors.
Neoplasms
The role of proliferation signal inhibitors in post-transplant malignancies.
Neoplasms
The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer.
Neoplasms
The role of SET/I2PP2A in canine mammary tumors.
Neoplasms
The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
Neoplasms
The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer.
Neoplasms
The synergistic interaction between the calcineurin B subunit and IFN-? enhances macrophage antitumor activity.
Neoplasms
The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
Neoplasms
The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.
Neoplasms
The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review).
Neoplasms
The unintended effects of a boxed warning.
Neoplasms
Tiling path genomic profiling of grade 3 invasive ductal breast cancers.
Neoplasms
Tissue-specific gene therapy directed to tumor angiogenesis.
Neoplasms
Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis.
Neoplasms
Topical calcineurin inhibitors in eczema and cancer association: A cohort study.
Neoplasms
Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues.
Neoplasms
Topical Calcineurin Inhibitors, Topical Glucocorticoids and Cancer in Children: A Nationwide Study.
Neoplasms
Toxicity and uptake mechanism of cylindrospermopsin and lophyrotomin in primary rat hepatocytes.
Neoplasms
Transcription factor C/EBP-? induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells.
Neoplasms
Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells.
Neoplasms
Translational Control of C-terminal Src Kinase (Csk) Expression by PRL3 Phosphatase.
Neoplasms
Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis.
Neoplasms
Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options.
Neoplasms
Treatment of young patients with lupus nephritis using calcineurin inhibitors.
Neoplasms
Trends of Immunosuppression and Outcomes Following Liver Transplantation: An Analysis of the United Network for Organ Sharing Registry.
Neoplasms
TRPV6 calcium channel regulation, downstream pathways, and therapeutic targeting in cancer.
Neoplasms
Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
Neoplasms
Truncated PPM1D Prevents Apoptosis in the Murine Thymus and Promotes Ionizing Radiation-Induced Lymphoma.
Neoplasms
Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS mutant cancers.
Neoplasms
Tumor necrosis factor-alpha activation of nuclear transcription factor-kappaB in marrow macrophages is mediated by c-Src tyrosine phosphorylation of Ikappa Balpha.
Neoplasms
Tumor necrosis factor-alpha, a new tumor promoter, engendered by biochemical studies of okadaic acid.
Neoplasms
Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype.
Neoplasms
Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis.
Neoplasms
Tumor Tolerance-Promoting Function of Regulatory T Cells Is Optimized by CD28, but Strictly Dependent on Calcineurin.
Neoplasms
Tumor-specific mutation and down-regulation of ING5 detected in oral squamous cell carcinoma.
Neoplasms
Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma.
Neoplasms
Turning off AKT: PHLPP as a drug target.
Neoplasms
Two cases of colon LST in transplanted liver patients.
Neoplasms
Type-2A protein phosphatase activity is required to maintain death receptor responsiveness.
Neoplasms
Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression.
Neoplasms
Understanding PTEN regulation: PIP2, polarity and protein stability.
Neoplasms
Unique features of the okadaic acid activity class of tumor promoters.
Neoplasms
Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.
Neoplasms
Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases.
Neoplasms
Use of Everolimus in Liver Transplantation: Recommendations From a Working Group.
Neoplasms
Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Neoplasms
USP11 promotes growth and metastasis of colorectal cancer via PPP1CA-mediated activation of ERK/MAPK signaling pathway.
Neoplasms
Validation of Reference Genes for Oral Cancer Detection Panels in a Prospective Blinded Cohort.
Neoplasms
VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C.
Neoplasms
Violacein cytotoxicity on human blood lymphocytes and effect on phosphatases.
Neoplasms
Vitamin D3 and ceramide reduce the invasion of tumor cells through extracellular matrix components by elevating protein phosphatase-2A.
Neoplasms
Weighted correlation network and differential expression analyses identify candidate genes associated with BRAF gene in melanoma.
Neoplasms
Wild-type p53-induced phosphatase 1 (WIP1) regulates the proliferation of swine Sertoli cells through P53.
Neoplasms
Wild-type p53-induced Phosphatase 1 Deficiency Exacerbates Myocardial Infarction-induced Ischemic Injury.
Neoplasms
Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma.
Neoplasms
Wip1 cooperates with KPNA2 to modulate the cell proliferation and migration of colorectal cancer via a p53-dependent manner.
Neoplasms
Wip1 deficiency impairs haematopoietic stem cell function via p53 and mTORC1 pathways.
Neoplasms
Wip1 directly dephosphorylates gamma-H2AX and attenuates the DNA damage response.
Neoplasms
WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma.
Neoplasms
WIP1 phosphatase at the crossroads of cancer and aging.
Neoplasms
Wip1 phosphatase in breast cancer.
Neoplasms
Wip1 phosphatase modulates ATM-dependent signaling pathways.
Neoplasms
WIP1 regulates the proliferation and invasion of nasopharyngeal carcinoma in vitro.
Neoplasms
Wip1: A candidate phosphatase for cancer diagnosis and treatment.
Neoplasms
X-linked inhibitor of apoptosis protein (XIAP) regulation of cyclin D1 protein expression and cancer cell anchorage-independent growth via its E3 ligase-mediated protein phosphatase 2A/c-Jun axis.
Neoplasms
[Calcineurin contributed to tumor necrosis factor alpha-induced cardiomyocyte hypertrophy in rats].
Neoplasms
[Cancer and immunosuppression: pro- and antitumoral effects of immunosuppressive drugs]
Neoplasms
[Central neurocytomas of the lateral ventricle. A series of 35 cases with review of the literature].
Neoplasms
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
Neoplasms
[Function of Proto-oncogene Product PPM1D and Development of PPM1D Inhibitors for Cancer Chemotherapy].
Neoplasms
[Influence of calcineurin on apoptosis of pre-B lymphocytes and the leukemia cells derived from pre-B lymphocytes].
Neoplasms
[Minimizing the risk of cancer in transplant patients.]
Neoplasms
[Research progress of suppressor gene PTEN].
Neoplasms
[The mechanism and current strategies for preventing the recurrence of hepatocellular carcinoma after liver transplantation].
Neoplasms, Germ Cell and Embryonal
A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment.
Neoplasms, Germ Cell and Embryonal
Expression and function of protein phosphatase PP2A in malignant testicular germ cell tumours.
Neoplasms, Germ Cell and Embryonal
MKP-8, a novel MAPK phosphatase that inhibits p38 kinase.
Neoplastic Cells, Circulating
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Nephritis
Con: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Nephritis
mRNAs in urinary nano-extracellular vesicles as potential biomarkers for non-invasive kidney biopsy.
Nephritis
Polyomavirus in kidney and kidney-pancreas transplant recipients.
Nephritis, Interstitial
Investigating the threshold for early renal allograft biopsy: A South African single-centre perspective.
Nephrocalcinosis
A rare case of nephrocalcinosis in the distal tubules caused by hereditary renal hypouricemia three months after kidney transplantation.
Nephrocalcinosis
Direct evidence for calcineurin binding to the exon-7 loop of the sodium-bicarbonate cotransporter NBCn1.
Nephrolithiasis
Direct evidence for calcineurin binding to the exon-7 loop of the sodium-bicarbonate cotransporter NBCn1.
Nephrolithiasis
Synthesis, Maturation, and Trafficking of Human Na+-Dicarboxylate Cotransporter NaDC1 Requires the Chaperone Activity of Cyclophilin B.
Nephrosclerosis
Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient.
Nephrosclerosis
[Deceased Donor Kidney Transplantation from a Liver Transplantation Recipient].
Nephrosis
Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with antineutrophil cytoplasmic antibody-associated vasculitis and nephrosis.
Nephrosis
Collecting duct (Na+/K+)-ATPase activity is correlated with urinary sodium excretion in rat nephrotic syndromes.
Nephrosis, Lipoid
Different targets for treating focal segmental glomerular sclerosis.
Nephrosis, Lipoid
miR-499 Ameliorates Podocyte Injury by Targeting Calcineurin in Minimal Change Disease.
Nephrosis, Lipoid
Persistent CD-19 Depletion by Rituximab is Cost-effective in Maintaining Remission in Calcineurin-inhibitor Dependent Podocytopathy.
Nephrosis, Lipoid
Renal Complications of Hematopoietic Stem Cell Transplantation: Report of a Case and Review of the Literature.
Nephrotic Syndrome
A case report of immunoglobulin M nephropathy manifesting as crescentic glomerulonephritis and nephrotic syndrome in an adult.
Nephrotic Syndrome
A comparative study on renal biopsy before and after long-term calcineurin inhibitors therapy: an insight for pathogenesis of its toxicity.
Nephrotic Syndrome
A new 'tac' for childhood nephrotic syndrome.
Nephrotic Syndrome
Annexin V in children with idiopathic nephrotic syndrome treated with cyclosporine A.
Nephrotic Syndrome
Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
Nephrotic Syndrome
Antifibrotic actions of mycophenolic acid.
Nephrotic Syndrome
Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome.
Nephrotic Syndrome
Calcineurin inhibitors and nephrotoxicity in children.
Nephrotic Syndrome
Calcineurin inhibitors and renal biopsy in children with idiopathic nephrotic syndrome.
Nephrotic Syndrome
Calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene mutations: a systematic review.
Nephrotic Syndrome
CD44-Positive Glomerular Parietal Epithelial Cells in a Mouse Model of Calcineurin Inhibitors-Induced Nephrotoxicity.
Nephrotic Syndrome
Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant.
Nephrotic Syndrome
Collecting duct (Na+/K+)-ATPase activity is correlated with urinary sodium excretion in rat nephrotic syndromes.
Nephrotic Syndrome
Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome.
Nephrotic Syndrome
Cyclosporine in the treatment of childhood idiopathic steroid resistant nephrotic syndrome: a single centre experience in Nigeria.
Nephrotic Syndrome
Different targets for treating focal segmental glomerular sclerosis.
Nephrotic Syndrome
Early Use of Rituximab in Calcineurin Inhibitor-Refractory and Steroid-Resistant Nephrotic Syndrome.
Nephrotic Syndrome
Efficacy and Safety of Cyclosporine versus Tacrolimus in Steroid and Cyclophosphamide Resistant Nephrotic Syndrome: A Prospective Study.
Nephrotic Syndrome
Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
Nephrotic Syndrome
Efficacy and safety of tacrolimus and low-dose prednisone in Chinese children with steroid-resistant nephrotic syndrome.
Nephrotic Syndrome
Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial.
Nephrotic Syndrome
Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
Nephrotic Syndrome
Familial forms of nephrotic syndrome.
Nephrotic Syndrome
Glucose metabolism disorders in children with refractory nephrotic syndrome.
Nephrotic Syndrome
Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
Nephrotic Syndrome
Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.
Nephrotic Syndrome
Infrequent tacrolimus-induced nephrotoxicity in French patients with steroid-dependent nephrotic syndrome.
Nephrotic Syndrome
Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Nephrotic Syndrome
Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children.
Nephrotic Syndrome
Long-Term Outcomes in Children with Steroid-Resistant Nephrotic Syndrome Treated with Calcineurin Inhibitors.
Nephrotic Syndrome
Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy.
Nephrotic Syndrome
Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
Nephrotic Syndrome
Nephrotic syndrome.
Nephrotic Syndrome
New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome.
Nephrotic Syndrome
Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis.
Nephrotic Syndrome
Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome.
Nephrotic Syndrome
Posterior Reversible Encephalopathy Syndrome in Henoch-Schonlein Purpura and Hemolytic Uremic Syndrome.
Nephrotic Syndrome
Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
Nephrotic Syndrome
Remission of proteinuria in multidrug resistant idiopathic nephrotic syndrome following immunoglobulin immunoadsorption.
Nephrotic Syndrome
Renal Biopsy in Children-Effect on Treatment Decisions: A Single-Center Experience.
Nephrotic Syndrome
Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.
Nephrotic Syndrome
Rituximab efficiency in children with steroid-dependent nephrotic syndrome.
Nephrotic Syndrome
Rituximab in children with resistant idiopathic nephrotic syndrome.
Nephrotic Syndrome
Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
Nephrotic Syndrome
Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome.
Nephrotic Syndrome
Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?
Nephrotic Syndrome
Second-line options for refractory steroid-sensitive and -resistant nephrotic syndrome.
Nephrotic Syndrome
Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.
Nephrotic Syndrome
Steroid-resistant nephrotic syndrome associated with steroid sulfatase deficiency-x-linked recessive ichthyosis: a case report and review of literature.
Nephrotic Syndrome
Successful treatment of recurrent focal segmental glomerulosclerosis combined with calcineurin inhibitor nephrotoxicity four yr after kidney transplantation.
Nephrotic Syndrome
The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective.
Nephrotic Syndrome
The prevalence and clinicopathological profile of IgM nephropathy in children with steroid-resistant nephrotic syndrome at a single centre in Pakistan.
Nephrotic Syndrome
Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistance to corticosteroids and calcineurin inhibitors.
Nephrotic Syndrome
Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.
Nephrotic Syndrome
Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome.
Nephrotic Syndrome
Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing.
Nephrotic Syndrome
[Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
Nervous System Diseases
A Friend or Foe: Calcineurin across the Gamut of Neurological Disorders.
Nervous System Diseases
Cognitive Evaluation in Liver Transplant Patients Under Calcineurin Inhibitor Maintenance Therapy.
Nervous System Diseases
Fecal corticosterone levels in RCAN1 mutant mice.
Nervous System Diseases
Regulation of Synaptic Transmission and Plasticity by Protein Phosphatase 1.
Nervous System Diseases
[Expression of protein phosphatase 2AC in the brain of mice and Alzheimer's patients].
Neuralgia
Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation.
Neuralgia
Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states.
Neuralgia
Changes in calcineurin message, enzyme activity and protein content in the spinal dorsal horn are associated with chronic constriction injury of the rat sciatic nerve.
Neuralgia
DUSP1 Promotes Microglial Polarization toward M2 Phenotype in the Medial Prefrontal Cortex of Neuropathic Pain Rats via Inhibition of MAPK Pathway.
Neuralgia
Identification of Key Pathways and Genes in L4 Dorsal Root Ganglion (DRG) After Sciatic Nerve Injury via Microarray Analysis.
Neuralgia
Loss of calcineurin in the spinal dorsal horn contributes to neuropathic pain, and intrathecal administration of the phosphatase provides prolonged analgesia.
Neuralgia
miR-32-5p-mediated Dusp5 downregulation contributes to neuropathic pain.
Neuralgia
Nerve Injury Increases GluA2-lacking AMPA Receptor Prevalence in Spinal Cords: Functional Significance and Signaling Mechanisms.
Neuralgia
Protein kinase C gamma-mediated phosphorylation of GluA1 in the postsynaptic density of spinal dorsal horn neurons accompanies neuropathic pain, and dephosphorylation by calcineurin is associated with prolonged analgesia.
Neuralgia
Ulinastatin attenuates neuropathic pain induced by L5-VRT via the calcineurin/IL-10 pathway.
Neurilemmoma
Modulation of cell rounding and apoptosis in trigeminal neurinoma cells by protein phosphatase inhibitors.
Neuroblastoma
?-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases.
Neuroblastoma
A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration.
Neuroblastoma
A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes.
Neuroblastoma
A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
Neuroblastoma
Calcineurin dephosphorylates glycogen synthase kinase-3 beta at serine-9 in neuroblast-derived cells.
Neuroblastoma
Calcineurin involvement in the regulation of high-threshold Ca2+ channels in NG108-15 (rodent neuroblastoma x glioma hybrid) cells.
Neuroblastoma
Calpastatin overexpression reduces oxidative stress-induced mitochondrial impairment and cell death in human neuroblastoma SH-SY5Y cells by decreasing calpain and calcineurin activation, induction of mitochondrial fission and destruction of mitochondrial fusion.
Neuroblastoma
Caspase-mediated proteolytic activation of calcineurin in thapsigargin-mediated apoptosis in SH-SY5Y neuroblastoma cells.
Neuroblastoma
Cyclic AMP induces activity increase of kinase FA (a transmembrane signal of insulin) during NG108-15 hybrid cell differentiation.
Neuroblastoma
Differential susceptibilities of serine/threonine phosphatases to oxidative and nitrosative stress.
Neuroblastoma
Dimethyl Fumarate Exerts Neuroprotection by Modulating Calcineurin/NFAT1 and NF?B Dependent BACE1 Activity in a Neuronal Model of Alzheimer's Disease.
Neuroblastoma
Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT 1) signaling.
Neuroblastoma
Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma.
Neuroblastoma
DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs.
Neuroblastoma
DUSP5 expression associates with poor prognosis in human neuroblastoma.
Neuroblastoma
Effect of let-7c on the PI3K/Akt/FoxO signaling pathway in hepatocellular carcinoma.
Neuroblastoma
Evidence of okadaic acid production in a cultured strain of the marine dinoflagellate Prorocentrum rhathymum from Malaysia.
Neuroblastoma
Expression of calmodulin-dependent phosphodiesterase, calmodulin-dependent protein phosphatase, and other calmodulin-binding proteins in human SMS-KCNR neuroblastoma cells.
Neuroblastoma
Heterocyclic thioureylenes protect from calcium-dependent neuronal cell death.
Neuroblastoma
Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species.
Neuroblastoma
Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells.
Neuroblastoma
Increased production of paired helical filament epitopes in a cell culture system reduces the turnover of tau.
Neuroblastoma
Inhibition of protein phosphatases induces transport deficits and axonopathy.
Neuroblastoma
Inhibition of Ser/Thr phosphatase PPM1D induces neutrophil differentiation in HL-60 cells.
Neuroblastoma
Involvement of a ceramide activated protein phosphatase in the differentiation of neuroblastoma Neuro2a cells.
Neuroblastoma
Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.
Neuroblastoma
Melatonin ameliorated okadaic-acid induced Alzheimer-like lesions.
Neuroblastoma
Melatonin protects SH-SY5Y neuroblastoma cells from calyculin A-induced neurofilament impairment and neurotoxicity.
Neuroblastoma
Melatonin reduces the impairment of axonal transport and axonopathy induced by calyculin A.
Neuroblastoma
Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Neuroblastoma
Methamphetamine toxicity-induced calcineurin activation, nuclear translocation of nuclear factor of activated T-cells and elevation of cyclooxygenase 2 levels are averted by calpastatin overexpression in neuroblastoma SH-SY5Y cells.
Neuroblastoma
Modulation by calcineurin of 5-HT3 receptor function in NG108-15 neuroblastoma x glioma cells.
Neuroblastoma
Neuroblastoma PTPome analysis unveils association of DUSP5 and PTPN1 expression with poor prognosis.
Neuroblastoma
Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
Neuroblastoma
NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
Neuroblastoma
Oxidative inactivation of calcineurin by Cu,Zn superoxide dismutase G93A, a mutant typical of familial amyotrophic lateral sclerosis.
Neuroblastoma
Oxidative modulation of nuclear factor-kappaB in human cells expressing mutant fALS-typical superoxide dismutases.
Neuroblastoma
PPM1D is a potential target for 17q gain in neuroblastoma.
Neuroblastoma
Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation.
Neuroblastoma
Protein phosphatase in neuroblastoma cells: [3H]cantharidin binding site in relation to cytotoxicity.
Neuroblastoma
Screening of tau protein kinase inhibitors in a tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization.
Neuroblastoma
Structural Insight into the Critical Role of the N-Terminal Region in the Catalytic Activity of Dual-Specificity Phosphatase 26.
Neuroblastoma
The 1p36 Tumor Suppressor KIF 1B? Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis.
Neuroblastoma
The phosphatase inhibitor okadaic acid induces a phosphorylated paired helical filament tau epitope in human LA-N-5 neuroblastoma cells.
Neuroblastoma
The retinoid anticancer signal: mechanisms of target gene regulation.
Neuroblastoma
Transcriptional response to muscarinic acetylcholine receptor stimulation: regulation of Egr-1 biosynthesis by ERK, Elk-1, MKP-1, and calcineurin in carbachol-stimulated human neuroblastoma cells.
Neuroblastoma
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Neuroblastoma
WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma.
Neuroblastoma
[Alzheimer-like protein phosphatase deficiency leads to abnormal phosphorylation and accumulation of neurofilaments]
Neurocytoma
Immunocytochemical detection of calcineurin and microtubule-associated protein 2 in central neurocytoma.
Neurodegenerative Diseases
A central role for calcineurin in protein misfolding neurodegenerative diseases.
Neurodegenerative Diseases
A stable association with PME-1 may be dispensable for PP2A demethylation - implications for the detection of PP2A methylation and immunoprecipitation.
Neurodegenerative Diseases
A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.
Neurodegenerative Diseases
Alterations of STEP46 and STEP61 Expression in the Rat Retina with Age and AMD-Like Retinopathy Development.
Neurodegenerative Diseases
Calcineurin proteolysis in astrocytes: Implications for impaired synaptic function.
Neurodegenerative Diseases
Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.
Neurodegenerative Diseases
Degradation of altered mitochondria by autophagy is impaired in Lafora disease.
Neurodegenerative Diseases
Detailed in vitro pharmacological analysis of FK506-induced neuroprotection.
Neurodegenerative Diseases
FK506 attenuates intracerebroventricular streptozotocin-induced neurotoxicity in rats.
Neurodegenerative Diseases
Genetics of Lafora progressive myoclonic epilepsy: current perspectives.
Neurodegenerative Diseases
Genotypes and phenotypes of patients with Lafora disease living in Germany.
Neurodegenerative Diseases
Glycogen metabolism in tissues from a mouse model of Lafora disease.
Neurodegenerative Diseases
High level calcineurin activity predisposes neuronal cells to apoptosis.
Neurodegenerative Diseases
Human prion protein-mediated calcineurin activation induces neuron cell death via AMPK and autophagy pathway.
Neurodegenerative Diseases
Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy.
Neurodegenerative Diseases
Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin.
Neurodegenerative Diseases
Increased Oxidative Stress and Impaired Antioxidant Response in Lafora Disease.
Neurodegenerative Diseases
Increased oxidative stress and impaired antioxidant response in Lafora disease.
Neurodegenerative Diseases
Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models.
Neurodegenerative Diseases
Inhibition of Calcineurin A by FK506 Suppresses Seizures and Reduces the Expression of GluN2B in Membrane Fraction.
Neurodegenerative Diseases
Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy.
Neurodegenerative Diseases
Lafora Disease: A Review of Molecular Mechanisms and Pathology.
Neurodegenerative Diseases
Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates.
Neurodegenerative Diseases
Laforin, a dual specificity protein phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase.
Neurodegenerative Diseases
Loss of malin, but not laforin, results in compromised autophagic flux and proteasomal dysfunction in cells exposed to heat shock.
Neurodegenerative Diseases
Malin and laforin are essential components of a protein complex that protects cells from thermal stress.
Neurodegenerative Diseases
Malin knockout mice support a primary role of autophagy in the pathogenesis of Lafora disease.
Neurodegenerative Diseases
Mechanistic Insights into Glucan Phosphatase Activity against Polyglucan Substrates.
Neurodegenerative Diseases
Methionine-Mediated Protein Phosphatase 2A Catalytic Subunit (PP2Ac) Methylation Ameliorates the Tauopathy Induced by Manganese in Cell and Animal Models.
Neurodegenerative Diseases
Molecular dynamics simulations and principal component analysis on human laforin mutation W32G and W32G/K87A.
Neurodegenerative Diseases
Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice.
Neurodegenerative Diseases
Neuroprotective effect of dual specificity phosphatase 6 against glutamate-induced cytotoxicity in mouse hippocampal neurons.
Neurodegenerative Diseases
Oxidative stress, a new hallmark in the pathophysiology of Lafora progressive myoclonus epilepsy.
Neurodegenerative Diseases
Partial Inhibition of Calcineurin Activity by Rcn2 as a Potential Remedy for Vps13 Deficiency.
Neurodegenerative Diseases
Persistent accumulation of unrepaired DNA damage in rat cortical neurons: nuclear organization and ChIP-seq analysis of damaged DNA.
Neurodegenerative Diseases
PP2AC? of Alveolar Macrophages Is a Novel Protective Factor for LPS-Induced Acute Respiratory Distress Syndrome.
Neurodegenerative Diseases
Proteasome inhibition stabilizes tau inclusions in oligodendroglial cells that occur after treatment with okadaic acid.
Neurodegenerative Diseases
Protein Phosphatase 2a (Pp2a) Regulates Innate Immune and Proteolytic Responses to Cigarette Smoke Exposure in the Lung.
Neurodegenerative Diseases
Proteomic analysis of rat cerebral cortex following subchronic acrolein toxicity.
Neurodegenerative Diseases
Relationship between glycogen accumulation and the laforin dual specificity phosphatase.
Neurodegenerative Diseases
Role of calcineurin in neurodegeneration produced by misfolded proteins and endoplasmic reticulum stress.
Neurodegenerative Diseases
Structural insights into glucan phosphatase dynamics using amide hydrogen-deuterium exchange mass spectrometry.
Neurodegenerative Diseases
Substituent effect of N-benzylated gramine derivatives that prevent the PP2A inhibition and dissipate the neuronal Ca2+ overload, as a multitarget strategy for the treatment of Alzheimer's disease.
Neurodegenerative Diseases
The Emerging Roles of the Calcineurin-Nuclear Factor of Activated T-Lymphocytes Pathway in Nervous System Functions and Diseases.
Neurodegenerative Diseases
The laforin-malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase beta subunits.
Neurodegenerative Diseases
The laforin/malin E3-ubiquitin ligase complex ubiquitinates pyruvate kinase M1/M2.
Neurodegenerative Diseases
The Molecular Mechanism of Alpha-Synuclein Dependent Regulation of Protein Phosphatase 2A Activity.
Neurodegenerative Diseases
Translating protein phosphatase research into treatments for neurodegenerative diseases.
Neurodegenerative Diseases
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Neurodermatitis
[Selective calcineurin inhibitor. Neurodermatitis patients need fewer corticoids]
Neuroendocrine Tumors
Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy.
Neurofibrosarcoma
Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
Neuroinflammatory Diseases
Calcineurin and glial signaling: neuroinflammation and beyond.
Neuroinflammatory Diseases
Calcineurin signaling as a target for the treatment of alcohol abuse and neuroinflammatory disorders.
Neuroinflammatory Diseases
Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models.
Neuroinflammatory Diseases
Calcineurin, Calcium-Dependent Serine-Threonine Phosphatase Activation by Prion Peptide 106-126 Enhances Nuclear Factor-?B-Linked Proinflammatory Response through Autophagy Pathway.
Neuroinflammatory Diseases
Calcineurin/nuclear factor-?B signaling mediates isoflurane-induced hippocampal neuroinflammation and subsequent cognitive impairment in aged rats.
Neuroinflammatory Diseases
Deletion of calcineurin from GFAP-expressing astrocytes impairs excitability of cerebellar and hippocampal neurons through astroglial Na+ /K+ ATPase.
Neuroinflammatory Diseases
Early Minocycline and Late FK506 Treatment Improves Survival and Alleviates Neuroinflammation, Neurodegeneration, and Behavioral Deficits in Prion-Infected Hamsters.
Neuroinflammatory Diseases
Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity.
Neuroinflammatory Diseases
miR-32-5p-mediated Dusp5 downregulation contributes to neuropathic pain.
Neuroinflammatory Diseases
Phosphoglycerate Mutase 5 Knockdown Alleviates Neuronal Injury After Traumatic Brain Injury Through Drp1-Mediated Mitochondrial Dysfunction.
Neuroinflammatory Diseases
Tacrolimus Protects against Age-Associated Microstructural Changes in the Beagle Brain.
Neurologic Manifestations
A case of central nervous system graft-versus-host disease following allogeneic stem cell transplantation.
Neurologic Manifestations
Neurologic complications of transplantation.
Neurologic Manifestations
Pathophysiology and Management of Hyperammonemia in Organ Transplant Patients.
Neuronal Ceroid-Lipofuscinoses
Advances in the genetics of progressive myoclonus epilepsy.
Neutropenia
Calcineurin Inhibitors and Neutropenia: Is Cyclosporine Superior to Tacrolimus?
Neutropenia
Impaired interferon-gamma responses, increased interleukin-17 expression, and a tumor necrosis factor-alpha transcriptional program in invasive aspergillosis.
Nocardia Infections
Nocardia Infection in Solid Organ Transplant Recipients: A Multicenter European Case-control Study.
Nocardia Infections
Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study.
Non-alcoholic Fatty Liver Disease
Dual-specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice through TAK1 Suppression.
Non-alcoholic Fatty Liver Disease
New Onset Diabetes and Non-Alcoholic Fatty Liver Disease after Liver Transplantation.
Non-alcoholic Fatty Liver Disease
Oral intake of genetically engineered high-carotenoid corn ameliorates hepatomegaly and hepatic steatosis in PTEN haploinsufficient mice.
Non-alcoholic Fatty Liver Disease
Pediatric post-transplant metabolic syndrome: New clouds on the horizon.
Noonan Syndrome
A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles Noonan syndrome with loose anagen hair.
Noonan Syndrome
Further evidence that variants in PPP1CB cause a rasopathy similar to Noonan syndrome with loose anagen hair.
Noonan Syndrome
Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations.
Noonan Syndrome
Noonan syndrome with loose anagen hair with variants in the PPP1CB gene: First familial case reported.
Noonan Syndrome
SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis.
Noonan Syndrome
SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
Obesity
Ceramide-Initiated Protein Phosphatase 2A Activation Contributes to Arterial Dysfunction In Vivo.
Obesity
Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant.
Obesity
Dual specificity phosphatase 6 deficiency is associated with impaired systemic glucose tolerance and reversible weight retardation in mice.
Obesity
Dual-specificity phosphatase 6 deficiency regulates gut microbiome and transcriptome response against diet-induced obesity in mice.
Obesity
DUSP1 Is a Potential Marker of Chronic Inflammation in Arabs with Cardiovascular Diseases.
Obesity
DUSP5 functions as a feedback regulator of TNF?-induced ERK1/2 dephosphorylation and inflammatory gene expression in adipocytes.
Obesity
Frequency and risks associated with Clostridium difficile-associated diarrhea after pediatric solid organ transplantation: a single-center retrospective review.
Obesity
Genetic disruption of protein phosphatase 5 in mice prevents high-fat diet feeding-induced weight gain.
Obesity
Incidence of development of obesity after heart transplantation according to the calcineurin inhibitor.
Obesity
Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance.
Obesity
m6A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells.
Obesity
MAP kinase phosphatase DUSP1 is overexpressed in obese humans and modulated by physical exercise.
Obesity
New Onset Diabetes and Non-Alcoholic Fatty Liver Disease after Liver Transplantation.
Obesity
New-onset diabetes mellitus after kidney transplantation: Current status and future directions.
Obesity
Patterns of chronic injury in pediatric renal allografts.
Obesity
Phosphoprotein phosphatase 1CB (PPP1CB), a novel adipogenic activator, promotes 3T3-L1 adipogenesis.
Obesity
PPM1l encodes an inositol requiring-protein 1 (IRE1) specific phosphatase that regulates the functional outcome of the ER stress response.
Obesity
Risk assessment and management of post-transplant diabetes mellitus.
Obesity
Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management.
Obesity
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Obesity
TRPV4 deficiency increases skeletal muscle metabolic capacity and resistance against diet-induced obesity.
Obesity
Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases.
Obesity
Variations in DNA elucidate molecular networks that cause disease.
Ocular Hypertension
Calcineurin activation causes retinal ganglion cell degeneration.
Oligospermia
Oligoasthenoteratospermia and sperm tail bending in PPP4C-deficient mice.
Oliguria
Adenosine receptor antagonism in acute tacrolimus toxicity.
Opportunistic Infections
Biomarkers of immune tolerance in kidney transplantation: an overview.
Opportunistic Infections
Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation.
Opportunistic Infections
Electromagnetic fields may act via calcineurin inhibition to suppress immunity, thereby increasing risk for opportunistic infection: Conceivable mechanisms of action.
Opportunistic Infections
Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.
Opportunistic Infections
Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.
Opportunistic Infections
Inpatient Neurologic Consultation in Solid Organ Transplant Patients.
Opportunistic Infections
Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary.
Opportunistic Infections
Neuroimaging and neurologic complications after organ transplantation.
Opportunistic Infections
Neurologic Complications of Transplantation.
Opportunistic Infections
NFATc1 releases BCL6-dependent repression of CCR2 agonist expression in peritoneal macrophages from Saccharomyces cerevisiae infected mice.
Opportunistic Infections
Nocardiosis in transplant recipients.
Opportunistic Infections
Pulmonary abnormalities in inflammatory bowel disease.
Opportunistic Infections
The role of basiliximab in the evolving renal transplantation immunosuppression protocol.
Opportunistic Infections
[Chronic renal failure after hematopoietic stem cell transplantation]
Optic Atrophy
[Down-regulation of Protein Phosphatase 2A Catalytic Subunit Involved in Mitochondria Fission/fusion Dynamics Imbalance and Functional Impairment Induced by Human tau].
Optic Atrophy, Autosomal Dominant
PGAM5 regulates PINK1/Parkin-mediated mitophagy via DRP1 in CCCP-induced mitochondrial dysfunction.
Optic Nerve Diseases
Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals.
Oral Manifestations
Gingival overgrowth in renal transplant recipients: a study concerning prevalence, severity, periodontal, and predisposing factors.
Orbital Cellulitis
Bilateral cavernous sinus thrombosis in a patient with tacrolimus-associated posttransplant thrombotic microangiopathy.
Osteoarthritis
Calcineurin is expressed and plays a critical role in inflammatory arthritis.
Osteoarthritis
Calcineurin modulates the catabolic and anabolic activity of chondrocytes and participates in the progression of experimental osteoarthritis.
Osteoarthritis
DUSP5 suppresses interleukin-1?-induced chondrocyte inflammation and ameliorates osteoarthritis in rats.
Osteoarthritis
Mitophagy in degenerative joint diseases.
Osteoarthritis
Protein phosphatase magnesium-dependent 1A induces inflammation in rheumatoid arthritis.
Osteochondroma
Selective increase in expression of isoform PP1 gamma 1 of type-1 protein phosphatase in chondrosarcoma cells.
Osteolysis
Inhibition of protein phosphatase 2A attenuates titanium-particle induced suppression of bone formation.
Osteolysis
Protein phosphatase 2A as a new target for downregulating osteoclastogenesis and alleviating titanium particle-induced bone resorption.
Osteonecrosis
Bone loss and avascular necrosis of bone after hematopoietic cell transplantation.
Osteonecrosis
From marrow oedema to osteonecrosis: common paths in the development of post-transplant bone pain.
Osteonecrosis
Pain syndrome with stress fractures in transplanted patients treated with calcineurin inhibitors.
Osteoporosis
Bone loss and avascular necrosis of bone after hematopoietic cell transplantation.
Osteoporosis
Calcineurin regulates bone formation by the osteoblast.
Osteoporosis
Cellular and molecular consequences of calcineurin A alpha gene deletion.
Osteoporosis
Drug-induced bone loss: a major safety concern in Europe.
Osteoporosis
DUSP5 promotes osteogenic differentiation through SCP1/2-dependent phosphorylation of SMAD1.
Osteoporosis
DUSP6 expression is associated with osteoporosis through the regulation of osteoclast differentiation via ERK2/Smad2 signaling.
Osteoporosis
Integrative genomics analysis of eQTL and GWAS summary data identifies PPP1CB as a novel bone mineral density risk genes.
Osteoporosis
Liver and gastrointestinal transplantation at the University of Miami.
Osteoporosis
Pain syndrome with stress fractures in transplanted patients treated with calcineurin inhibitors.
Osteoporosis
Peptide 11R-VIVIT stimulates osteoblastogenesis through regulating the expression of nuclear factor of activated T cells cytoplasmic 1.
Osteoporosis
The Calcineurin-NFAT Pathway and Bone: Intriguing New Findings.
Osteosarcoma
Elevated expression of serine/threonine phosphatase type 5 correlates with malignant proliferation in human osteosarcoma.
Osteosarcoma
Enhanced expression of PP1gamma1, a catalytic subunit isoform of protein phosphatase type1 and expression of telomerase activity in Ewing's sarcoma cells.
Osteosarcoma
Inhibitors of protein synthesis and RNA synthesis protect against okadaic acid-induced apoptosis in human osteosarcoma cell line MG63 cells but not in Saos-2 cells.
Osteosarcoma
MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets.
Osteosarcoma
MicroRNA-34a promotes cell cycle arrest and apoptosis and suppresses cell adhesion by targeting DUSP1 in osteosarcoma.
Osteosarcoma
MicroRNA-499a-5p inhibits osteosarcoma cell proliferation and differentiation by targeting protein phosphatase 1D through protein kinase B/glycogen synthase kinase 3? signaling.
Osteosarcoma
Okadaic acid activates the PKR pathway and induces apoptosis through PKR stimulation in MG63 osteoblast-like cells.
Osteosarcoma
Okadaic acid induces apoptosis through double-stranded RNA-dependent protein kinase/eukaryotic initiation factor-2alpha pathway in human osteoblastic MG63 cells.
Osteosarcoma
Okadaic acid induces tyrosine phosphorylation of IkappaBalpha that mediated by PKR pathway in human osteoblastic MG63 cells.
Osteosarcoma
P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
Osteosarcoma
PPM1D accelerates proliferation and metastasis of osteosarcoma by activating PKP2.
Osteosarcoma
RCAN1.4 suppresses the osteosarcoma growth and metastasis via interfering with the calcineurin/NFAT signaling pathway.
Osteosarcoma
Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics.
Osteosarcoma
Tripartite Motif Containing 11 Interacts with DUSP6 to Promote the Growth of Human Osteosarcoma Cells through Regulating ERK1/2 Pathway.
Ovarian Cysts
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Ovarian Neoplasms
Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.
Ovarian Neoplasms
Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells.
Ovarian Neoplasms
Dual-specificity phosphatase 5 suppresses ovarian cancer progression by inhibiting IL-33 signaling.
Ovarian Neoplasms
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Ovarian Neoplasms
DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells.
Ovarian Neoplasms
DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs.
Ovarian Neoplasms
Gi protein-mediated translocation of serine/threonine phosphatase to the plasma membrane and apoptosis of ovarian cancer cell in response to gonadotropin-releasing hormone antagonist cetrorelix.
Ovarian Neoplasms
Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview.
Ovarian Neoplasms
Gonadotropin-releasing hormone retards doxorubicin-induced apoptosis and serine/threonine phosphatase inhibition in ovarian cancer cells.
Ovarian Neoplasms
Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer.
Ovarian Neoplasms
Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6.
Ovarian Neoplasms
Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes.
Ovarian Neoplasms
Knockdown of protein phosphatase 5 inhibits ovarian cancer growth in vitro.
Ovarian Neoplasms
KRAS K104 modification affects the KRASG12D-GEF interaction and mediates cell growth and motility.
Ovarian Neoplasms
Mosaic mutations in blood DNA sequence are associated with solid tumor cancers.
Ovarian Neoplasms
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
Ovarian Neoplasms
Overexpression of CHP2 enhances tumor cell growth, invasion and metastasis in ovarian cancer.
Ovarian Neoplasms
Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway.
Ovarian Neoplasms
PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.
Ovarian Neoplasms
PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.
Ovarian Neoplasms
Protein phosphatase magnesium-dependent 1? (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma.
Ovarian Neoplasms
Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid.
Ovarian Neoplasms
RE: PPM1D Mutations in Circulating White Blood Cells and the Risk for Ovarian Cancer.
Ovarian Neoplasms
Regulation of LC3-Dependent Protective Autophagy in Ovarian Cancer Cells by Protein Phosphatase 2A.
Ovarian Neoplasms
Role for DUSP1 (dual-specificity protein phosphatase 1) in the regulation of autophagy.
Ovarian Neoplasms
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
Ovarian Neoplasms
Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
Ovarian Neoplasms
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.
Ovarian Neoplasms
The integrin-linked kinase-associated phosphatase (ILKAP) is a regulatory hub of ovarian cancer cell susceptibility to platinum drugs.
Ovarian Neoplasms
Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Ovarian Neoplasms
WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma.
Overweight
Modifiable risk factors of acute kidney injury after liver transplantation: a systematic review and meta-analysis.
Pancreatic Neoplasms
Abrogation of DUSP6 by hypermethylation in human pancreatic cancer.
Pancreatic Neoplasms
An Algorithm for Generating Small RNAs Capable of Epigenetically Modulating Transcriptional Gene Silencing and Activation in Human Cells.
Pancreatic Neoplasms
AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer.
Pancreatic Neoplasms
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Pancreatic Neoplasms
DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Pancreatic Neoplasms
Effect of PPM1H on malignant phenotype of human pancreatic cancer cells.
Pancreatic Neoplasms
Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression.
Pancreatic Neoplasms
Expression of Concern: DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine.
Pancreatic Neoplasms
Expression of TMEFF2 in Human Pancreatic Cancer Tissue and the Effects of TMEFF2 Knockdown on Cell, Proliferation, and Apoptosis in Human Pancreatic Cell Lines.
Pancreatic Neoplasms
Feedback regulation of DUSP6 transcription responding to MAPK1 via ETS2 in human cells.
Pancreatic Neoplasms
Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer.
Pancreatic Neoplasms
Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-?B pathway dependent repression of PP2Ac.
Pancreatic Neoplasms
Infrequent methylation of the DUSP6 phosphatase in endometrial cancer.
Pancreatic Neoplasms
Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells in vitro.
Pancreatic Neoplasms
Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924.
Pancreatic Neoplasms
Molecular mechanisms of pancreatic carcinogenesis.
Pancreatic Neoplasms
Molecular pathology of pancreatic cancer: implications for molecular targeting therapy.
Pancreatic Neoplasms
p21 expression is induced by activation of nuclear nerve growth factor-induced Balpha (Nur77) in pancreatic cancer cells.
Pancreatic Neoplasms
pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.
Pancreatic Neoplasms
PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms.
Pancreatic Neoplasms
SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer.
Pancreatic Neoplasms
The growth inhibitory effect of gambogic acid on pancreatic cancer cells.
Pancreatic Neoplasms
The role of phosphoprotein phosphatases catalytic subunit genes in pancreatic cancer.
Pancreatic Neoplasms
Trisomy of the Dscr1 gene suppresses early progression of pancreatic intraepithelial neoplasia driven by oncogenic Kras.
Pancreatitis
A case report of tigecycline induced acute pancreatitis in a renal transplant patient and review of the literature: Should we avoid tigecycline in patients on calcineurin inhibitors?
Pancreatitis
Bile acids induce pancreatic acinar cell injury and pancreatitis by activating calcineurin.
Pancreatitis
Disulfide stress: a novel type of oxidative stress in acute pancreatitis.
Pancreatitis
Effect of calcineurin inhibitor on post-endoscopic retrograde cholangiopancreatography pancreatitis in patients with liver transplantation: a propensity-matched cohort study.
Pancreatitis
Effects of silencing the DUSP1 gene using lentiviral vector-mediated siRNA on the release of proinflammatory cytokines through regulation of the MAPK signaling pathway in mice with acute pancreatitis.
Pancreatitis
Exposure to Radiocontrast Agents Induces Pancreatic Inflammation by Activation of Nuclear Factor-?B, Calcium Signaling, and Calcineurin.
Pancreatitis
PENTOXIFYLLINE PREVENTS LOSS OF PP2A PHOSPHATASE ACTIVITY AND RECRUITMENT OF HISTONE ACETYLTRANSFERASES TO PRO-INFLAMMATORY GENES IN ACUTE PANCREATITIS.
Pancreatitis
Pharmacologic and genetic inhibition of calcineurin protects against carbachol-induced pathologic zymogen activation and acinar cell injury.
Pancreatitis
Protease activation during in vivo pancreatitis is dependent on calcineurin activation.
Pancreatitis
Protease Activation during in vivo Pancreatitis is Dependent upon Calcineurin Activation.
Pancreatitis
RCAN1 is a marker of oxidative stress, induced in acute pancreatitis.
Pancreatitis
SOCE induced calcium overload regulates autophagy in acute pancreatitis via calcineurin activation.
Pancreatitis
Targeted inhibition of pancreatic acinar cell calcineurin is a novel strategy to prevent post-ERCP pancreatitis.
Pancreatitis
The Protective Effects of Calcineurin on Pancreatitis in Mice Depend on the Cellular Source.
Pancreatitis
Transient High Pressure in Pancreatic Ducts Promotes Inflammation and Alters Tight Junctions via Calcineurin Signaling in Mice.
Pancreatitis, Chronic
Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-?B pathway dependent repression of PP2Ac.
Pancytopenia
Acute Graft-vs-Host Disease After Liver Transplantation: Experience at a High-volume Liver Transplantation Center in Korea.
Pancytopenia
Sirolimus in heart transplantation: a single center initial experience.
Papilloma
Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA.
Papilloma
Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression.
Papilloma
Egyptian clinical practice guideline for kidney transplantation.
Papilloma
Loss of protein phosphatase 6 in mouse keratinocytes increases susceptibility to ultraviolet-B-induced carcinogenesis.
Papilloma
Okadaic acid stimulated TRE binding activity in a papilloma producing mouse keratinocyte cell line involves increased AP-1 expression.
Papillomavirus Infections
Downregulation of calcineurin activity in cervical carcinoma.
Paracoccidioidomycosis
Evidence for the role of calcineurin in morphogenesis and calcium homeostasis during mycelium-to-yeast dimorphism of Paracoccidioides brasiliensis.
Paraganglioma
Calcineurin, a calcium/calmodulin-regulated protein phosphatase, in mammalian neuroendocrine cells and neoplasms.
Paraganglioma
Genomic organization and precise physical location of protein phosphatase 2A regulatory subunit A beta isoform gene on chromosome band 11q23.
Paralysis
Isolated diplopia associated with calcineurin inhibitor therapy in a patient with idiopathic membranous nephropathy: a case report.
Paralysis
Mitochondrial health and muscle plasticity after spinal cord injury.
Paralysis
Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci.
Paralysis
Screening and identification of proteins interacting with nucleostemin.
Paraplegia
Neurologic complications in renal transplantation.
Paresthesia
Completeness of reporting of adverse events in trials of maintenance immunosuppression in kidney transplantation: a systematic review.
Paresthesia
Neurologic complications after solid organ transplantation.
Parkinson Disease
Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes.
Parkinson Disease
Calcineurin as a possible new target for treatment of Parkinson's disease.
Parkinson Disease
Calcineurin immunoreactivity in striatonigral degeneration.
Parkinson Disease
Calcineurin in human brain and its relation to extrapyramidal system. Immunohistochemical study on postmortem human brains.
Parkinson Disease
Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder.
Parkinson Disease
Mitophagy in degenerative joint diseases.
Parkinson Disease
Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity.
Parkinson Disease
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Parkinson Disease
PARL Protease: A Glimpse at Intramembrane Proteolysis in the Inner Mitochondrial Membrane.
Parkinson Disease
Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration.
Parkinson Disease
The Molecular Mechanism of Alpha-Synuclein Dependent Regulation of Protein Phosphatase 2A Activity.
Parkinson Disease
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Parkinsonian Disorders
A novel EPM2A mutation in a patient with Lafora disease presenting with early parkinsonism symptoms in childhood.
Parkinsonian Disorders
Cell type-specific neuronal loss in the putamen of patients with multiple system atrophy.
Parkinsonian Disorders
Late-onset Lafora disease with prominent parkinsonism due to a rare mutation in EPM2A.
Pemphigoid, Bullous
Anti-inflammatory treatment.
Pemphigus
Anti-inflammatory treatment.
Pemphigus, Benign Familial
A Case of Hailey-Hailey Disease Managed With Oral Magnesium Citrate and High-Dose Vitamin D3.
Pemphigus, Benign Familial
Safety of Topical Calcineurin Inhibitors for Hailey-Hailey Disease.
Periodontal Diseases
Regulator of Calcineurin 1 in Periodontal Disease.
Periodontitis
Elevated platelet and leukocyte response to oral bacteria in periodontitis.
Periodontitis
Periodontitis is associated with platelet activation.
Periodontitis
Protective effects of Tacrolimus, a calcineurin inhibitor, in experimental periodontitis in rats.
Peripheral Nerve Injuries
Deletion of Calcineurin in Schwann Cells Does Not Affect Developmental Myelination, But Reduces Autophagy and Delays Myelin Clearance after Peripheral Nerve Injury.
Peripheral Nervous System Diseases
Inpatient Neurologic Consultation in Solid Organ Transplant Patients.
Peripheral Vascular Diseases
Recent advances in new-onset diabetes mellitus after kidney transplantation.
Peritonitis
Time Is Not Always the Matter: An Instance of Encapsulating Peritoneal Sclerosis Developing in a Patient on Peritoneal Dialysis for a Short Term.
Persistent Infection
Our approach to a renal transplant biopsy.
Persistent Infection
Protein phosphatase 2A impairs IFN?-induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation.
Pheochromocytoma
Calmodulin-dependent phosphatases of PC12, GH3, and C6 cells: physical, kinetic, and immunochemical properties.
Pheochromocytoma
Effects of protein kinase inhibitors and protein phosphatase inhibitors on cyclic AMP-dependent down-regulation of vesicular monoamine transport in pheochromocytoma PC12 cells.
Pheochromocytoma
Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia.
Pheochromocytoma
Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy.
Pheochromocytoma
The regulator of calcineurin (RCAN1) an important factor involved in atherosclerosis and cardiovascular diseases development.
Photosensitivity Disorders
UVA1 radiation inhibits calcineurin through oxidative damage mediated by photosensitization.
Pinealoma
Calcineurin, a calcium/calmodulin-regulated protein phosphatase, in mammalian neuroendocrine cells and neoplasms.
Pituitary Neoplasms
Calcineurin feedback inhibition of agonist-evoked cAMP formation.
Pituitary Neoplasms
Calmodulin-dependent phosphatases of PC12, GH3, and C6 cells: physical, kinetic, and immunochemical properties.
Pituitary Neoplasms
Mechanism of Ca(2+)-dependent inactivation of L-type Ca2+ channels in GH3 cells: direct evidence against dephosphorylation by calcineurin.
Pituitary Neoplasms
The effects of calyculin A upon calcium-, guanine nucleotides- and phorbol 12-myristate 13-acetate-stimulated ACTH secretion from AtT-20 cells.
Pituitary Neoplasms
Thyroid hormone antagonizes tumor necrosis factor-alpha signaling in pituitary cells through the induction of dual specificity phosphatase 1.
Pityriasis
An exploratory study to evaluate the efficacy of pimecrolimus cream 1% for the treatment of pityriasis alba.
Pneumococcal Infections
Calcineurin subunit B is an immunostimulatory protein and acts as a vaccine adjuvant inducing protective cellular and humoral responses against pneumococcal infection.
Pneumonia
Ab initio calcineurin inhibitor-based monotherapy immunosuppression after liver transplantation reduces the risk for Pneumocystis jirovecii pneumonia.
Pneumonia
Early-Onset Pneumonia After Liver Transplant: Microbial Causes, Risk Factors, and Outcomes, Mansoura University, Egypt, Experience.
Pneumonia
In Vivo Platelet Activation in Critically-Ill Patients with Primary H1N1 Influenza.
Pneumonia
The Protective Effects of Calcineurin on Pancreatitis in Mice Depend on the Cellular Source.
Pneumonia, Bacterial
Regulator of calcineurin 1 suppresses inflammation during respiratory tract infections.
Pneumonia, Pneumocystis
Ab initio calcineurin inhibitor-based monotherapy immunosuppression after liver transplantation reduces the risk for Pneumocystis jirovecii pneumonia.
Pneumonia, Pneumocystis
High-dose calcineurin inhibitor-free everolimus as a maintenance regimen for heart transplantation may be a risk factor for Pneumocystis pneumonia.
Pneumonia, Pneumocystis
Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients.
Pneumonia, Pneumocystis
Significant improvement following combination treatment with mefloquine and mirtazapine in a patient with progressive multifocal leukoencephalopathy after allogeneic peripheral blood stem cell transplantation.
Polycystic Kidney, Autosomal Dominant
Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Polycythemia
Hypertension after renal transplantation.
Polycythemia
Recent advances in new-onset diabetes mellitus after kidney transplantation.
Polycythemia Vera
Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.
Polymyositis
Effective Use of Calcineurin Inhibitor in Combination Therapy for Interstitial Lung Disease in Patients With Dermatomyositis and Polymyositis.
Polyomavirus Infections
Late kidney allograft loss: what we know about it, and what we can do about it.
Porphyria, Acute Intermittent
Pretransplant evaluation of a patient with acute intermittent porphyria.
Porphyria, Acute Intermittent
The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria.
Porphyrias
Pretransplant evaluation of a patient with acute intermittent porphyria.
Porphyrias
The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria.
Posterior Leukoencephalopathy Syndrome
Alternative tacrolimus and sirolimus regimen associated with rapid resolution of posterior reversible encephalopathy syndrome after lung transplantation.
Posterior Leukoencephalopathy Syndrome
Basiliximab for posterior reversible encephalopathy syndrome after lung transplantation.
Posterior Leukoencephalopathy Syndrome
Brain MR imaging abnormalities in kidney transplant recipients.
Posterior Leukoencephalopathy Syndrome
Calcineurin inhibitor-free strategies for prophylaxis and treatment of GVHD in children with posterior reversible encephalopathy syndrome after stem cell transplantation.
Posterior Leukoencephalopathy Syndrome
Calcineurin Inhibitors Associated Posterior Reversible Encephalopathy Syndrome in Solid Organ Transplantation: Report of 2 Cases and Literature Review.
Posterior Leukoencephalopathy Syndrome
Neurologic complications in renal transplantation.
Posterior Leukoencephalopathy Syndrome
Neurologic Complications of Transplantation.
Posterior Leukoencephalopathy Syndrome
Neurotoxicity including posterior reversible encephalopathy syndrome after initiation of calcineurin inhibitors in transplanted methylmalonic acidemia patients: Two case reports and review of the literature.
Posterior Leukoencephalopathy Syndrome
Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies.
Posterior Leukoencephalopathy Syndrome
Posterior reversible encephalopathy syndrome after liver transplantation in children: a rare complication related to calcineurin inhibitor effects.
Posterior Leukoencephalopathy Syndrome
Posterior Reversible Encephalopathy Syndrome After Orthotopic Heart Transplantation: A Case Report.
Posterior Leukoencephalopathy Syndrome
Posterior reversible encephalopathy syndrome due to immunosuppressant after living-donor lobar lung transplantation: report of a case.
Posterior Leukoencephalopathy Syndrome
Posterior reversible encephalopathy syndrome in children with kidney disease.
Posterior Leukoencephalopathy Syndrome
Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors.
Posterior Leukoencephalopathy Syndrome
Reversible posterior leukoencephalopathy syndrome (RPLS) in a heart transplant recipient treated by substitution of cyclosporine A with tacrolimus.
Posterior Leukoencephalopathy Syndrome
Reversible posterior leukoencephalopathy syndrome: diagnosis and management in the setting of lung transplantation.
Posterior Leukoencephalopathy Syndrome
Seizure treatment in transplant patients.
Posterior Leukoencephalopathy Syndrome
Successful retransplantation using rapamycin in a patient with previous calcineurin inhibitor-induced posterior leukoencephalopathy syndrome.
Posterior Leukoencephalopathy Syndrome
Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.
Posterior Leukoencephalopathy Syndrome
Tacrolimus-Induced Vision Loss in a Renal Transplant Patient: Posterior Reversible Encephalopathy Syndrome.
Posterior Leukoencephalopathy Syndrome
Two cases of calcineurin inhibitor-associated reversible posterior leukoencephalopathy syndrome in renal transplant recipients.
Posterior Leukoencephalopathy Syndrome
[Retrospective analysis of posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation]
Pouchitis
Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery.
Poxviridae Infections
Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection.
Pre-Eclampsia
miR-141-5p regulate ATF2 via effecting MAPK1/ERK2 signaling to promote preeclampsia.
Pre-Eclampsia
Posterior Reversible Encephalopathy Syndrome Associated with Hemorrhage.
Pre-Eclampsia
Silencing of AFAP1-AS1 lncRNA impairs cell proliferation and migration by epigenetically promoting DUSP5 expression in pre-eclampsia.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Calcineurin and GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor of apoptosis protein degradation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with Calcineurin inhibition to promote T-ALL cell death.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical significance of serum calcineurin in acute leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expressions of four major protein Ser/Thr phosphatases in human primary leukemic cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Molecular cloning of a novel PPEF-1 gene variant from a T-cell lymphoblastic lymphoma cell line.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with Calcineurin inhibition to promote T-ALL cell death.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
NFAT transcription factors are essential and redundant actors for leukemia initiating potential in T-cell acute lymphoblastic leukemia.
Prediabetic State
Prediabetes in Pediatric Recipients of Liver Transplant: Mechanism and Risk Factors.
Prion Diseases
Analysis of the cerebellar proteome in a transgenic mouse model of inherited prion disease reveals preclinical alteration of calcineurin activity.
Prion Diseases
Calcineurin Activation by Prion Protein Induces Neurotoxicity via Mitochondrial Reactive Oxygen Species.
Prion Diseases
Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival.
Prion Diseases
Calcineurin, Calcium-Dependent Serine-Threonine Phosphatase Activation by Prion Peptide 106-126 Enhances Nuclear Factor-?B-Linked Proinflammatory Response through Autophagy Pathway.
Prion Diseases
Early Minocycline and Late FK506 Treatment Improves Survival and Alleviates Neuroinflammation, Neurodegeneration, and Behavioral Deficits in Prion-Infected Hamsters.
Prion Diseases
Human prion protein-mediated calcineurin activation induces neuron cell death via AMPK and autophagy pathway.
Prion Diseases
Inhibition of the FKBP family of peptidyl prolyl isomerases induces abortive translocation and degradation of the cellular prion protein.
Prostatic Hyperplasia
Dual specificity phosphatase 1 expression inversely correlates with NF-?B activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
Prostatic Hyperplasia
PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Prostatic Intraepithelial Neoplasia
Dual specificity phosphatase 1 expression inversely correlates with NF-?B activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
Prostatic Neoplasms
Active ?-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A.
Prostatic Neoplasms
Androgen attenuates the inactivating phospho-Ser-127 modification of yes-associated protein 1 (YAP1) and promotes YAP1 nuclear abundance and activity.
Prostatic Neoplasms
Caveolin-1 interacts with protein phosphatase 5 and modulates its activity in prostate cancer cells.
Prostatic Neoplasms
Ceramide produces apoptosis through induction of p27(kip1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells.
Prostatic Neoplasms
Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.
Prostatic Neoplasms
Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer.
Prostatic Neoplasms
Down-regulation of dual-specificity phosphatase 5 predicts poor prognosis of patients with prostate cancer.
Prostatic Neoplasms
Downregulation of Snail by DUSP1 Impairs Cell Migration and Invasion through the Inactivation of JNK and ERK and Is Useful as a Predictive Factor in the Prognosis of Prostate Cancer.
Prostatic Neoplasms
Dual specificity phosphatase 1 expression inversely correlates with NF-?B activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
Prostatic Neoplasms
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
Prostatic Neoplasms
Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer.
Prostatic Neoplasms
DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
Prostatic Neoplasms
Effects of a fluorescent Myosin light chain phosphatase inhibitor on prostate cancer cells.
Prostatic Neoplasms
Exploitation of the Ability of ?-Tocopherol to Facilitate Membrane Co-localization of Akt and PHLPP1 to Develop PHLPP1-Targeted Akt Inhibitors.
Prostatic Neoplasms
Expression of microRNA-99a-3p in Prostate Cancer Based on Bioinformatics Data and Meta-Analysis of a Literature Review of 965 Cases.
Prostatic Neoplasms
Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.
Prostatic Neoplasms
Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells.
Prostatic Neoplasms
Identification of androgen-regulated genes in human prostate.
Prostatic Neoplasms
Induction of p27(kip1) by 2,4,3',5'- tetramethoxystilbene is regulated by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells.
Prostatic Neoplasms
KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells.
Prostatic Neoplasms
Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Prostatic Neoplasms
Modulation of protein phosphatase 2A (PP2A) activity alters androgen-independent growth of prostate cancer cells: therapeutic implications.
Prostatic Neoplasms
New Acetohydrazides Incorporating 2-Oxoindoline and 4-Oxoquinazoline: Synthesis and Evaluation of Cytotoxicity and Caspase Activation Activity.
Prostatic Neoplasms
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Prostatic Neoplasms
Positive feedback loop mediated by protein phosphatase 1? mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer.
Prostatic Neoplasms
PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Prostatic Neoplasms
PPP2R2C loss promotes castration-resistant prostate cancer growth and is associated with increased prostate cancer-specific mortality.
Prostatic Neoplasms
PPP5C promotes cell proliferation and survival in human prostate cancer by regulating of the JNK and ERK1/2 phosphorylation.
Prostatic Neoplasms
Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer.
Prostatic Neoplasms
PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer.
Prostatic Neoplasms
Resveratrol promotes apoptosis through the induction of dual specificity phosphatase 1 and sensitizes prostate cancer cells to cisplatin.
Prostatic Neoplasms
Simvastatin inducing PC3 prostate cancer cell necrosis mediated by calcineurin and mitochondrial dysfunction.
Prostatic Neoplasms
Truncating and missense PPM1D mutations in early-onset and/or familial/hereditary prostate cancer patients.
Prostatic Neoplasms
Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1.
Prostatic Neoplasms
Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
protein-serine/threonine phosphatase deficiency
Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA.
protein-serine/threonine phosphatase deficiency
Calcineurin Antagonizes AMPK to Regulate Lipolysis in Caenorhabditis elegans.
protein-serine/threonine phosphatase deficiency
Calcineurin deficiency decreases inflammatory lesions in transforming growth factor beta1-deficient mice.
protein-serine/threonine phosphatase deficiency
Clinical and Genetic Study on a Chinese Patient with Infantile Onset Epileptic Encephalopathy carrying a PPP3CA Null Variant: a case report.
protein-serine/threonine phosphatase deficiency
Dual Specificity Phosphatase 1 null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis.
protein-serine/threonine phosphatase deficiency
Dual specificity phosphatase 6 deficiency is associated with impaired systemic glucose tolerance and reversible weight retardation in mice.
protein-serine/threonine phosphatase deficiency
Dual-specificity Phosphatase 1 Deficiency Induces Endometrioid Adenocarcinoma Progression via Activation of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Pathway.
protein-serine/threonine phosphatase deficiency
Dual-specificity phosphatase 6 deficiency regulates gut microbiome and transcriptome response against diet-induced obesity in mice.
protein-serine/threonine phosphatase deficiency
DUSP26 regulates podocyte oxidative stress and fibrosis in a mouse model with diabetic nephropathy through the mediation of ROS.
protein-serine/threonine phosphatase deficiency
FoxO3a-mediated autophagy is down-regulated in the laforin deficient mice, an animal model for Lafora progressive myoclonus epilepsy.
protein-serine/threonine phosphatase deficiency
Functional characterization of a mitochondrial Ser/Thr protein phosphatase in cell death regulation.
protein-serine/threonine phosphatase deficiency
Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle fiber type switching but not hypertrophy.
protein-serine/threonine phosphatase deficiency
Loss of protein phosphatase 6 in mouse keratinocytes enhances K-rasG12D -driven tumor promotion.
protein-serine/threonine phosphatase deficiency
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
protein-serine/threonine phosphatase deficiency
PGAM5 is a key driver of mitochondrial dysfunction in experimental lung fibrosis.
protein-serine/threonine phosphatase deficiency
Phosphoglycerate mutase 5 exacerbates cardiac ischemia-reperfusion injury through disrupting mitochondrial quality control.
protein-serine/threonine phosphatase deficiency
Phosphoglycerate Mutase 5 Knockdown Alleviates Neuronal Injury After Traumatic Brain Injury Through Drp1-Mediated Mitochondrial Dysfunction.
protein-serine/threonine phosphatase deficiency
pmp1+, a suppressor of calcineurin deficiency, encodes a novel MAP kinase phosphatase in fission yeast.
protein-serine/threonine phosphatase deficiency
Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1.
protein-serine/threonine phosphatase deficiency
PP2A regulates kinetochore-microtubule attachment during meiosis I in oocyte.
protein-serine/threonine phosphatase deficiency
Ppp6c deficiency accelerates K-rasG12D -induced tongue carcinogenesis.
protein-serine/threonine phosphatase deficiency
The Ablation of Mitochondrial Protein Phosphatase Pgam5 Confers Resistance Against Metabolic Stress.
protein-serine/threonine phosphatase deficiency
The mitochondrial protein PGAM5 suppresses energy consumption in brown adipocytes by repressing expression of uncoupling protein 1.
protein-serine/threonine phosphatase deficiency
The POPX2 phosphatase regulates cancer cell motility and invasiveness.
protein-serine/threonine phosphatase deficiency
Two classes of plant cDNA clones differentially complement yeast calcineurin mutants and increase salt tolerance of wild-type yeast.
protein-serine/threonine phosphatase deficiency
[Alzheimer-like protein phosphatase deficiency leads to abnormal phosphorylation and accumulation of neurofilaments]
protein-serine/threonine phosphatase deficiency
[PPP3CA silence regulates MET process, cell apoptosis, proliferation and migration in metanephric mesenchyme cells].
Proteinuria
An overview of immunosuppressive therapy in idiopathic membranous nephropathy.
Proteinuria
Angiotensin II Contributes to Podocyte Injury by Increasing TRPC6 Expression via an NFAT-Mediated Positive Feedback Signaling Pathway.
Proteinuria
Antifibrotic actions of mycophenolic acid.
Proteinuria
Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis.
Proteinuria
Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Proteinuria
Calcineurin inhibitors ameliorate PAN-induced podocyte injury through the NFAT-Angptl4 pathway.
Proteinuria
Calcineurin inhibitors and proximal renal tubular injury in renal transplant patients with proteinuria and chronic allograft nephropathy.
Proteinuria
Calpain-Mediated Cleavage of Calcineurin in Puromycin Aminonucleoside-Induced Podocyte Injury.
Proteinuria
Cellular effects of everolimus and sirolimus on podocytes.
Proteinuria
Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
Proteinuria
Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients.
Proteinuria
CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
Proteinuria
Collecting duct (Na+/K+)-ATPase activity is correlated with urinary sodium excretion in rat nephrotic syndromes.
Proteinuria
Comparative Proteomic Analysis of Rapamycin Versus Cyclosporine Combination Treatment in Mouse Podocytes.
Proteinuria
Consensus Guidelines on Management of Steroid-Resistant Nephrotic Syndrome.
Proteinuria
Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
Proteinuria
Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria.
Proteinuria
Conversion to everolimus in kidney transplant recipients with decreased renal function.
Proteinuria
Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria.
Proteinuria
Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults.
Proteinuria
Cyclosporine A protects podocytes via stabilization of cofilin-1 expression in the unphosphorylated state.
Proteinuria
Cyclosporine versus everolimus: effects on the glomerulus.
Proteinuria
Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients.
Proteinuria
Determinants of proteinuria after conversion from calcineurin inhibitor- to sirolimus-based immunosuppression: results from the multicenter convert trial.
Proteinuria
Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
Proteinuria
Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria.
Proteinuria
Effect of Clinical Variables and Immunosuppression on Serum Cystatin C and Beta-Trace Protein in Kidney Transplant Recipients.
Proteinuria
Effectiveness and safety of sofosbuvir-based therapy against chronic hepatitis C infection after successful kidney transplantation.
Proteinuria
Endoplasmic Reticulum Stress Predicts Clinical Response to Cyclosporine Treatment in Primary Membranous Nephropathy.
Proteinuria
Evolution of glomerular filtration rate, renal injury markers, anemia, and Angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Proteinuria
Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study.
Proteinuria
Experience with belatacept rescue therapy in kidney transplant recipients.
Proteinuria
Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules.
Proteinuria
FK506 alleviates proteinuria in rats with adriamycin-induced nephropathy by down-regulating TRPC6 and CaN expression.
Proteinuria
FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats.
Proteinuria
High sirolimus levels may induce focal segmental glomerulosclerosis de novo.
Proteinuria
Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
Proteinuria
Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols.
Proteinuria
Is sirolimus responsible for proteinuria?
Proteinuria
Knockout of Dual-Specificity Protein Phosphatase 5 Protects Against Hypertension-Induced Renal Injury.
Proteinuria
Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children.
Proteinuria
Long-term outcome of third kidney transplants.
Proteinuria
Lupus Nephritis in Asia: Clinical Features and Management.
Proteinuria
Lupus nephritis: An update on treatments and pathogenesis.
Proteinuria
Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
Proteinuria
Membranous Nephropathy: Approaches to Treatment.
Proteinuria
mTOR inhibitor-associated proteinuria in kidney transplant recipients.
Proteinuria
mTOR inhibitors and renal allograft: Yin and Yang.
Proteinuria
mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
Proteinuria
Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies.
Proteinuria
Proteinuria following a switch from calcineurin inhibitors to sirolimus.
Proteinuria
Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients.
Proteinuria
Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?
Proteinuria
Rapamycin promotes podocyte migration through the up-regulation of urokinase receptor.
Proteinuria
Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study.
Proteinuria
Renal Biopsy in Children-Effect on Treatment Decisions: A Single-Center Experience.
Proteinuria
Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
Proteinuria
Reversible posterior encephalopathy syndrome in children with nephrotic syndrome.
Proteinuria
Role of calcineurin (CN) in kidney glomerular podocyte: CN inhibitor ameliorated proteinuria by inhibiting the redistribution of CN at the slit diaphragm.
Proteinuria
Sirolimus and Proteinuria in Renal Transplant Patients: Evidence for a Dose-Dependent Effect on Slit Diaphragm-Associated Proteins.
Proteinuria
Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
Proteinuria
Sirolimus-associated proteinuria and renal dysfunction.
Proteinuria
Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients.
Proteinuria
The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4.
Proteinuria
The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury.
Proteinuria
The Calcium-Dependent Protease Calpain-1 Links TRPC6 Activity to Podocyte Injury.
Proteinuria
The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis.
Proteinuria
The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
Proteinuria
Treatment of membranous nephropathy: time for a paradigm shift.
Proteinuria
[Changes in renal function in renal transplantation. Predictive factors for functional deterioration]
Proteinuria
[Clinical and pathological features and mutational types of WT1 mutation-associated nephropathy].
Proteinuria
[Clinical results of immunosuppressive triple therapies in living-related renal transplantation--a single center experience]
Proteinuria
[Renal Involvement in Connective Tissue Diseases].
Prurigo
Actinic prurigo in a dermatological reference center in Colombia: 108 cases
Prurigo
Prurigo Nodularis and Its Management.
Pruritus
An approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature.
Pruritus
Atopic dermatitis.
Pruritus
Atopic Dermatitis: Managing the Itch.
Pruritus
Chronic pruritus: targets, mechanisms and future therapies.
Pruritus
Clinical Efficacy of Oligofructans from Ophiopogon japonicus in Reducing Atopic Dermatitis Flare-ups in Caucasian Patients.
Pruritus
Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
Pruritus
Diagnosis and Management of Chronic Pruritus: An Expert Consensus Review.
Pruritus
Lack of efficacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients.
Pruritus
MECHANISMS OF SENSORY EFFECTS OF TACROLIMUS ON THE SKIN.
Pruritus
Practical algorithm to inform clinical decision-making in the topical treatment of atopic dermatitis.
Pruritus
Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
Pruritus
Short-term efficacy of tacrolimus ointment and impact on quality of life.
Pruritus
Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience.
Pruritus
Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use.
Pruritus
Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin.
Pruritus
Topical therapy of atopic dermatitis with a focus on pimecrolimus.
Pruritus
Topical treatment of perianal eczema with tacrolimus 0.1%
Pruritus
Treatment strategies for atopic dermatitis: optimizing the available therapeutic options.
Pruritus
[Antipruritic effects of pimecrolimus and tacrolimus]
Pruritus
[Lichen nitidus and lichen striatus].
Pruritus
[Pruritus and dryness of the skin in chronic kidney insufficiency and dialysis patients - a review]
Pruritus
[The treatment of atopic dermatitis in adults with topical calcineurin inhibitors]
Pseudomonas Infections
Regulator of calcineurin 1 differentially regulates TLR-dependent MyD88 and TRIF signaling pathways.
Psoriasis
A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis.
Psoriasis
Changes in the expression pattern of DUSP1-7 and miRNA regulating their expression in the keratinocytes treated with LPS and adalimumab.
Psoriasis
Dermatology Part 2: Ichthyoses and Psoriasis.
Psoriasis
Determination of the effect of calcineurin inhibitors on the rat's immune system after KLH immunisation.
Psoriasis
DUSP1/MKP-1 regulates proliferation and apoptosis in keratinocytes through the ERK/Elk-1/Egr-1 signaling pathway.
Psoriasis
Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review.
Psoriasis
Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study.
Psoriasis
Efficacy of topical calcineurin inhibitors in psoriasis.
Psoriasis
Excimer laser therapy for hairline psoriasis: a useful addition to the scalp psoriasis treatment algorithm.
Psoriasis
Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management.
Psoriasis
Inhibition of calcineurin by cyclosporine A exerts multiple effects on human melanoma cell lines HT168 and WM35.
Psoriasis
Inverse Psoriasis: From Diagnosis to Current Treatment Options.
Psoriasis
ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
Psoriasis
LITAF, HHEX, and DUSP1 expression in mesenchymal stem cells from patients with psoriasis.
Psoriasis
Mechanisms of action of topical therapies and the rationale for combination therapy.
Psoriasis
Nanostructured lipid carrier co-delivering tacrolimus and TNF-? siRNA as an innovate approach to psoriasis.
Psoriasis
NF-?B-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis.
Psoriasis
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Psoriasis
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
Psoriasis
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
Psoriasis
Pharmacogenetics of topical and systemic treatment of psoriasis.
Psoriasis
Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies.
Psoriasis
Pimecrolimus for psoriasis.
Psoriasis
Potential new indications of topical calcineurin inhibitors.
Psoriasis
Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis.
Psoriasis
Psoriasis clinical implications and treatment: a review.
Psoriasis
Psoriasis of the face and flexures.
Psoriasis
Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas.
Psoriasis
The expression of dual specificity phosphatase 1 mRNA is downregulated in lesional psoriatic skin.
Psoriasis
Therapeutic options in the treatment of psoriasis and atopic dermatitis.
Psoriasis
Tumor necrosis factor antagonist-induced psoriasis in a 3-year-old boy with Kawasaki disease.
Psoriasis
Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review.
Psoriasis
Voclosporin as a treatment for noninfectious uveitis.
Psoriasis
[Calcineurin inhibitors for topical therapy in psoriasis.]
Psoriasis
[Systemic voclosporin for uveitis treatment]
Psoriasis
[Update of the topical treatment of psoriasis]
Puberty, Precocious
Study of lipid metabolism-related genes as candidate genes of sexual precocity in Nellore cattle.
Pulmonary Arterial Hypertension
Sarpogrelate attenuates pulmonary arterial hypertension via calcium/calcineurin axis.
Pulmonary Aspergillosis
A new and clinically relevant murine model of solid-organ transplant aspergillosis.
Pulmonary Atelectasis
Early-Onset Pneumonia After Liver Transplant: Microbial Causes, Risk Factors, and Outcomes, Mansoura University, Egypt, Experience.
Pulmonary Disease, Chronic Obstructive
?1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses.
Pulmonary Disease, Chronic Obstructive
Chronic Cigarette Smoke Exposure Subdues PP2A Activity by Enhancing Expression of the Oncogene CIP2A.
Pulmonary Disease, Chronic Obstructive
Enhancing tristetraprolin activity reduces the severity of cigarette smoke-induced experimental chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Pulmonary Disease, Chronic Obstructive
Pathways associated with reduced quadriceps oxidative fibres and endurance in COPD.
Pulmonary Disease, Chronic Obstructive
PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).
Pulmonary Disease, Chronic Obstructive
The GPx1-PTP1B-PP2A Axis: A Key Determinant of Airway Inflammation and Alveolar Destruction.
Pulmonary Disease, Chronic Obstructive
[Qibaipingfei Capsule down-regulate the levels of calcineurin and nuclear factor of activated T-cells isoform c3 (NFATc3) in chronic obstructive pulmonary disease].
Pulmonary Embolism
Comparison of denovo sirolimus vs. Calcineurin inhibitor immunosuppression regarding incidence of deep venous thrombosis and pulmonary embolism following renal transplantation.
Pulmonary Eosinophilia
Regulator of calcineurin 1 (rcan1) is required for the development of pulmonary eosinophilia in allergic inflammation in mice.
Pulmonary Fibrosis
Long-term use of everolimus in lung transplant patients.
Pulmonary Fibrosis
PGAM5 is a key driver of mitochondrial dysfunction in experimental lung fibrosis.
Purpura
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to Henoch-Schönlein purpura.
Purpura, Thrombocytopenic
Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus.
Purpura, Thrombocytopenic, Idiopathic
Flow cytometric evaluation of platelet activation in chronic autoimmune thrombocytopenia.
Pyelonephritis
Clinical Significance of Renal Allograft Protocol Biopsies: A Single Tertiary Center Experience in Malaysia.
Pyelonephritis
Comparison between doppler ultrasound resistive index, serum creatinine, and histopathologic changes in patients with kidney transplant dysfunction in early posttransplantation period: A single center study with review of literature.
Pyelonephritis
Our approach to a renal transplant biopsy.
Pyoderma Gangrenosum
Effective use of switching biologics for ulcerative colitis complicated with pyoderma gangrenosum and primary sclerosing cholangitis.
Pyoderma Gangrenosum
Efficacy of topical calcineurin inhibitors in pyoderma gangrenosum.
pyruvate dehydrogenase system deficiency
Diagnosis of partial deficiency of the pyruvate dehydrogenase complex in biopsied muscle.
Rectal Neoplasms
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Rectal Neoplasms
MAP kinase genes and colon and rectal cancer.
Red-Cell Aplasia, Pure
Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report.
Reflex Sympathetic Dystrophy
Calcineurin Inhibitor-Induced Pain Syndrome in ABO-Incompatible Living Kidney Transplantation: A Case Report.
Reflex Sympathetic Dystrophy
Sympathetic dystrophy associated with sirolimus therapy.
Reflex, Abnormal
Unusual cerebral white matter change in a Chinese family with Spinocerebellar ataxia type 12.
Refsum Disease
Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation.
Renal Artery Obstruction
Egyptian clinical practice guideline for kidney transplantation.
Renal Artery Obstruction
European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.2.1 Differential diagnosis of chronic graft dysfunction.
Renal Artery Obstruction
Risk factors for hypertension 3 years after renal transplantation in children.
Renal Artery Obstruction
[Arterial hypertension in renal transplant recipients]
Renal Insufficiency
A case of polyomavirus-associated nephropathy presenting late after transplantation.
Renal Insufficiency
A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation.
Renal Insufficiency
An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
Renal Insufficiency
Atypical calcineurin inhibitor-induced haemolytic uremic syndrome after liver transplantation.
Renal Insufficiency
Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
Renal Insufficiency
Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency.
Renal Insufficiency
Calcineurin Inhibitor Sparing With Mycophenolate Mofetil in Liver Transplantion: A Systematic Review of Randomized Controlled Trials.
Renal Insufficiency
Calcineurin inhibitor-associated early renal insufficiency in cardiac transplant recipients: risk factors and strategies for prevention and treatment.
Renal Insufficiency
Challenging immunosuppression treatment in lung transplant recipients with kidney failure.
Renal Insufficiency
Chronic renal insufficiency in heart transplant recipients: risk factors and management options.
Renal Insufficiency
Combined Heart-Kidney Transplant versus Sequential Kidney Transplant in Heart Transplant Recipients.
Renal Insufficiency
Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation.
Renal Insufficiency
Controversies about induction therapy.
Renal Insufficiency
Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
Renal Insufficiency
Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction.
Renal Insufficiency
Discontinuation of calcineurin inhibitors in heart transplant patients with end stage renal insufficiency as an alternative model of immunosuppression.
Renal Insufficiency
Early renal failure after domino hepatic transplantation using the liver from a compound heterozygous patient with primary hyperoxaluria.
Renal Insufficiency
Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
Renal Insufficiency
Evaluation of Longitudinal Exposure to Tacrolimus as a Risk Factor of Chronic Kidney Disease Occurrence Within the First Year Post-Liver Transplantation.
Renal Insufficiency
Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency.
Renal Insufficiency
Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated.
Renal Insufficiency
Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus.
Renal Insufficiency
Incidence of cardiovascular and cerebrovascular events associated with sirolimus use after liver transplantation.
Renal Insufficiency
Kidney transplantation in previous heart or lung recipients.
Renal Insufficiency
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis.
Renal Insufficiency
Liver transplantation and liver cell transplantation.
Renal Insufficiency
Long-term effects on renal function of dose-reduced calcineurin inhibitor and sirolimus in cardiac transplant patients.
Renal Insufficiency
Multi organ transplantation: a review of the Irish experience.
Renal Insufficiency
Nephrotoxicity of intravenous immmunoglobulin in the setting of liver transplantation or HBV-related cirrhosis: an undervalued topic.
Renal Insufficiency
Nonnephrotoxic immunosuppression in patients after liver transplantation.
Renal Insufficiency
Pharmacokinetics of sirolimus in heart transplant recipients with chronic renal impairment.
Renal Insufficiency
Phase iii prospective, randomised study to compare conversion from calcineurin inhibitors to sirolimus versus standard therapy for twelve months in established renal allograft recipients with mild to moderate renal insufficiency.
Renal Insufficiency
Randomized Controlled Trial of Sirolimus Conversion in Cardiac Transplant Recipients With Renal Insufficiency.
Renal Insufficiency
Recommendations of everolimus use in liver transplant.
Renal Insufficiency
Relationship between renal resistance index and renal function in liver transplant recipients after cessation of calcineurin inhibitor.
Renal Insufficiency
Renal dysfunction following bone marrow transplantation.
Renal Insufficiency
Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal.
Renal Insufficiency
Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity.
Renal Insufficiency
Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Renal Insufficiency
Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
Renal Insufficiency
Repeated Daclizumab Administration to Delay the Introduction of Calcineurin Inhibitors in Heart Transplant Patients With Postoperative Renal Dysfunction.
Renal Insufficiency
Repeated daclizumab administration to delay the introduction of calcineurin inhibitors in heart transplant patients with postoperative renal dysfunction.
Renal Insufficiency
Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
Renal Insufficiency
Risk Factors for Chronic Renal Insufficiency Following Cardiac Transplantation.
Renal Insufficiency
Risk factors for hypertension 3 years after renal transplantation in children.
Renal Insufficiency
Role of endothelin and endothelin receptor antagonists in renal disease.
Renal Insufficiency
Severe sirolimus-related inflammatory state anemia in an HIV+ liver transplant patient with calcineurin inhibitor renal insufficiency: a case report.
Renal Insufficiency
Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.
Renal Insufficiency
Sirolimus conversion after heart transplant: risk factors for acute rejection and predictors of renal function response.
Renal Insufficiency
Sirolimus conversion efficacy for graft function improvement and histopathology in renal recipients with mild to moderate renal insufficiency.
Renal Insufficiency
Sirolimus experience in heart transplantation.
Renal Insufficiency
Sirolimus in heart transplantation: a single center initial experience.
Renal Insufficiency
Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients.
Renal Insufficiency
Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency.
Renal Insufficiency
The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial.
Renal Insufficiency
The effects of rapamycin in murine peripheral nerve isografts and allografts.
Renal Insufficiency
The Functional Implications of Common Genetic Variation in CYP3A5 and ABCB1 in Human Proximal Tubule Cells.
Renal Insufficiency
The long-term effect of simultaneous heart and kidney transplantation on native renal function.
Renal Insufficiency
Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
Renal Insufficiency
Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study.
Renal Insufficiency
Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis.
Renal Insufficiency
Usefulness of Rabbit Anti-thymocyte Globulin in Patients With Giant Cell Myocarditis.
Renal Insufficiency
Vitamin D and systemic lupus erythematosus: an update.
Renal Insufficiency
[A case of gout secondary to primary myelofibrosis].
Renal Insufficiency
[Kidney and statins]
Renal Insufficiency
[Living donor liver transplantation for a patient with renal failure]
Renal Insufficiency
[Renal failure following liver transplantation]
Renal Insufficiency, Chronic
Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Renal Insufficiency, Chronic
Calcineurin inhibitor-associated new-onset diabetes mellitus in chronic kidney disease treatment: a 4-year single-center cross-sectional study in China.
Renal Insufficiency, Chronic
Chronic kidney disease after heart transplantation.
Renal Insufficiency, Chronic
Chronic kidney disease after nonrenal solid organ transplantation: a histological assessment and utility of chronic allograft damage index scoring.
Renal Insufficiency, Chronic
Chronic kidney disease after orthotopic liver transplantation in recipients receiving tacrolimus.
Renal Insufficiency, Chronic
Chronic renal insufficiency in heart transplant recipients: risk factors and management options.
Renal Insufficiency, Chronic
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
Renal Insufficiency, Chronic
Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
Renal Insufficiency, Chronic
Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction.
Renal Insufficiency, Chronic
Effectiveness and cost of replacing a calcineurin inhibitor with sirolimus to slow the course of chronic kidney disease in renal allografts.
Renal Insufficiency, Chronic
Egyptian clinical practice guideline for kidney transplantation.
Renal Insufficiency, Chronic
End-stage renal disease after high-dose carboplatinum in preparation of autologous stem cell transplantation.
Renal Insufficiency, Chronic
Hyperkalemia and blood pressure regulation.
Renal Insufficiency, Chronic
Immunosuppressive therapy in older cardiac transplant patients.
Renal Insufficiency, Chronic
Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
Renal Insufficiency, Chronic
Impact of immunosuppressive therapy on arterial stiffness in kidney transplantation: are all treatments the same?
Renal Insufficiency, Chronic
Influence of Blood Pressure and Calcineurin Inhibitors on Kidney Function After Heart or Liver Transplantation.
Renal Insufficiency, Chronic
Initial single-center experience with sirolimus after lung transplantation.
Renal Insufficiency, Chronic
Kidney dysfunction in the recipients of liver transplants.
Renal Insufficiency, Chronic
Kidney injury molecule-1 correlates with kidney function in heart allograft recipients.
Renal Insufficiency, Chronic
Kidney Transplantation in Patients With Chronic Kidney Disease After a Previous Lung Transplantation.
Renal Insufficiency, Chronic
Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices.
Renal Insufficiency, Chronic
Loss of expression of protein phosphatase magnesium-dependent 1A during kidney injury promotes fibrotic maladaptive repair.
Renal Insufficiency, Chronic
Outcomes after liver transplantation: Chronic kidney disease.
Renal Insufficiency, Chronic
Peri-operative kidney injury and long-term chronic kidney disease following orthotopic heart transplantation in children.
Renal Insufficiency, Chronic
Prediction of chronic kidney disease progression used by calcineurin inhibitor concentration and estimated glomerular filtration rate early after liver transplantation.
Renal Insufficiency, Chronic
Prevalence and risk factors of long-term proton pump inhibitors-associated hypomagnesemia: a cross-sectional study in hospitalized patients.
Renal Insufficiency, Chronic
Prophylaxis of chronic kidney disease after liver transplantation - experience from west China.
Renal Insufficiency, Chronic
Renal Complications of Hematopoietic Stem Cell Transplantation: Report of a Case and Review of the Literature.
Renal Insufficiency, Chronic
Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
Renal Insufficiency, Chronic
Renal histological lesions and outcome in liver transplant recipients.
Renal Insufficiency, Chronic
Risk factors associated with moderate-to-severe renal dysfunction among heart transplant patients: results from the CAPRI study.
Renal Insufficiency, Chronic
Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.
Renal Insufficiency, Chronic
Safety of mTOR inhibitors in adult solid organ transplantation.
Renal Insufficiency, Chronic
Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
Renal Insufficiency, Chronic
Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant Recipients.
Renal Insufficiency, Chronic
Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency.
Renal Insufficiency, Chronic
TT genotype of transforming growth factor beta1 +869C/T is associated with the development of chronic kidney disease after liver transplantation.
Renal Insufficiency, Chronic
Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients.
Renal Insufficiency, Chronic
[Infective endocarditis caused by Chlamydia pneumoniae after liver transplantation. Case report].
Reperfusion Injury
A Sarcoplasmic Reticulum Localized Protein Phosphatase Regulates Phospholamban Phosphorylation and Promotes Ischemia Reperfusion Injury in the Heart.
Reperfusion Injury
Antioxidant supplementation may improve renal transplant function: a preliminary report.
Reperfusion Injury
Apoptosis in Ca2 + reperfusion injury of cultured astrocytes: roles of reactive oxygen species and NF-kappaB activation.
Reperfusion Injury
Calcineurin Abeta gene targeting predisposes the myocardium to acute ischemia-induced apoptosis and dysfunction.
Reperfusion Injury
Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury.
Reperfusion Injury
Chronic allograft nephropathy in paediatric renal transplantation.
Reperfusion Injury
Chronic allograft nephropathy--immunologic and nonimmunologic factors.
Reperfusion Injury
Chronic allograft nephropathy: current concepts and future directions.
Reperfusion Injury
Chronic renal allograft dysfunction.
Reperfusion Injury
Construction of rat calcineurin A alpha cDNA recombinant adenovirus vector and its identification.
Reperfusion Injury
Decreased lung ischemia-reperfusion injury in rats after preoperative administration of cyclosporine and tacrolimus.
Reperfusion Injury
DUSP1 alleviates cerebral ischaemia reperfusion injury via inactivating JNK-Mff pathways and repressing mitochondrial fission.
Reperfusion Injury
Effect of perioperative administration of a drug regimen on the primary function of human renal allografts.
Reperfusion Injury
Endotracheal calcineurin inhibition ameliorates injury in an experimental model of lung ischemia-reperfusion.
Reperfusion Injury
FK506 reduces calpain-regulated calcineurin activity in both the cytoplasm and the nucleus.
Reperfusion Injury
Genomics of chronic allograft injury.
Reperfusion Injury
Hydrogen sulphide as a novel therapy to ameliorate cyclosporine nephrotoxicity.
Reperfusion Injury
Influence of glutathione S-transferase M1 and T1 polymorphisms with acute rejection in Iranian liver transplant recipients.
Reperfusion Injury
Methylxanthines and the kidney.
Reperfusion Injury
MicroRNA-760-mediated low expression of DUSP1 impedes the protective effect of NaHS on myocardial ischemia-reperfusion injury.
Reperfusion Injury
MiRNAs in kidney transplantation: potential role as new biomarkers.
Reperfusion Injury
Mitochondrial Protein PGAM5 Regulates Mitophagic Protection against Cell Necroptosis.
Reperfusion Injury
Okadaic acid, an inhibitor of protein phosphatase, exerts a protective effect on ischemia-reperfusion injury in rat kidneys.
Reperfusion Injury
Phosphoglycerate mutase 5 exacerbates cardiac ischemia-reperfusion injury through disrupting mitochondrial quality control.
Reperfusion Injury
Preconditioning: from experimental findings to novel therapies in acute kidney injury.
Reperfusion Injury
Sirolimus: a current perspective.
Reperfusion Injury
Sirolimus: a ten-year perspective.
Reperfusion Injury
Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition.
Reperfusion Injury
Transient Receptor Potential Vanilloid 1 Regulates Mitochondrial Membrane Potential and Myocardial Reperfusion Injury.
Reperfusion Injury
Trends in donation after cardiac death.
Reperfusion Injury
Use of Anti-Thymocyte Globulin for Induction Therapy in Cardiac Transplantation: A Review.
Reperfusion Injury
[Use of new non-nephrotoxic immunosuppressive drugs in kidney transplantation, especially after ischemia-reperfusion injury].
Respiratory Distress Syndrome
Fulminant Acute Respiratory Distress Syndrome after Calcineurin Inhibitor-belatacept Conversion in a Lung Transplant Recipient.
Respiratory Tract Infections
Regulator of calcineurin 1 suppresses inflammation during respiratory tract infections.
Retinal Degeneration
A novel human serine-threonine phosphatase related to the Drosophila retinal degeneration C (rdgC) gene is selectively expressed in sensory neurons of neural crest origin.
Retinal Degeneration
Accumulation of calcium in degenerating photoreceptors of several Drosophila mutants.
Retinal Degeneration
Functional characterization of the three Drosophila retinal degeneration C (RDGC) protein phosphatase isoforms.
Retinal Degeneration
Identification and characterization of a conserved family of protein serine/threonine phosphatases homologous to Drosophila retinal degeneration C.
Retinal Degeneration
PP7 is a positive regulator of blue light signaling in Arabidopsis.
Retinoblastoma
Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as candidate.
Retinoblastoma
Cyclosporin a inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells.
Retinoblastoma
Dephosphorylation of Rb (Thr-821) in response to cell stress.
Retinoblastoma
DUSP1 promotes senescence of retinoblastoma cell line SO-Rb5 cells by activating AKT signaling pathway.
Retinoblastoma
Evidence that Fas-induced apoptosis leads to S phase arrest.
Retinoblastoma
Functions of ceramide in coordinating cellular responses to stress.
Retinoblastoma
G1/S transcriptional networks modulated by the HOX11/TLX1 oncogene of T-cell acute lymphoblastic leukemia.
Retinoblastoma
High molecular weight protein phosphatase type 1 dephosphorylates the retinoblastoma protein.
Retinoblastoma
Inducible expression of catalytically active type 1 serine/threonine protein phosphatase in a human carcinoma cell line.
Retinoblastoma
Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid.
Retinoblastoma
Inhibitory phosphorylation of PP1alpha catalytic subunit during the G(1)/S transition.
Retinoblastoma
Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors.
Retinoblastoma
Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Retinoblastoma
Protein Phosphatase 1 binds strongly to the retinoblastoma protein but not to p107 or p130 in vitro and in vivo.
Retinoblastoma
Protein phosphatase 1alpha-mediated stimulation of apoptosis is associated with dephosphorylation of the retinoblastoma protein.
Retinoblastoma
Protein phosphatase type 1, the product of the retinoblastoma susceptibility gene, and cell cycle control.
Retinoblastoma
Protein phosphatase type 1-dependent dephosphorylation of the retinoblastoma tumor suppressor protein in ultraviolet-irradiated human skin and keratinocytes.
Retinoblastoma
Regulation of E2Fs and senescence by PML nuclear bodies.
Retinoblastoma
Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment.
Retinoblastoma
Site-specific and temporally-regulated retinoblastoma protein dephosphorylation by protein phosphatase type 1.
Retinoblastoma
The carboxyl-terminal region of the retinoblastoma protein binds non-competitively to protein phosphatase type 1alpha and inhibits catalytic activity.
Retinoblastoma
The involvement of protein phosphatases in the activation of ICE/CED-3 protease, intracellular acidification, DNA digestion, and apoptosis.
Retinoblastoma
The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit.
Retinoblastoma
The tumor suppressor Pml regulates cell fate in the developing neocortex.
Retinoschisis
Characterization of two unusual RS1 gene deletions segregating in Danish retinoschisis families.
Rett Syndrome
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
Rhabdomyolysis
Mild rhabdomyolysis after renal transplantation.
Rhabdomyolysis
Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia.
Rheumatic Diseases
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.
Rhinitis, Allergic, Seasonal
Identification of novel targets for seasonal allergic rhinitis during and outside the pollen season by microarray analysis.
Rift Valley Fever
Protein Phosphatase 1? Interacts with Venezuelan Equine Encephalitis Virus Capsid Protein and Regulates Viral Replication through Modulation of Capsid Phosphorylation.
Rosacea
Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial.
Rosacea
Pimecrolimus for treatment of acne rosacea.
Rosacea
Rosacea-like eruption due to topical pimecrolimus.
Rosacea
Topical calcineurin inhibitors as a double-edged sword in rosacea: A systematic review.
Rosacea
Topical therapies for rosacea.
Salmonella Infections
Posttransplant Kaposi's sarcoma: report from a single center.
Sarcoidosis
Hypothalamic digoxin, hemispheric chemical dominance and sarcoidosis.
Sarcoma
Current approaches to the use of sirolimus in renal transplantation.
Sarcoma
Synergistic cytotoxic effect between serine-threonine phosphatase inhibitors and 5-fluorouracil: a novel concept for modulation of cytotoxic effect.
Sarcoma
The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells.
Sarcoma
[Experimental study of hematopoietic cell gene expression profile induced by panax notoginosides in vitro]
Sarcoma, Avian
Activation of protein serine/threonine kinases p42, p63, and p87 in Rous sarcoma virus-transformed cells: signal transduction/transformation-dependent MBP kinases.
Sarcoma, Avian
Protein kinase and its regulatory effect on reverse transcriptase activity of Rous sarcoma virus.
Sarcoma, Ewing
Enhanced expression of PP1gamma1, a catalytic subunit isoform of protein phosphatase type1 and expression of telomerase activity in Ewing's sarcoma cells.
Sarcoma, Ewing
Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma.
Sarcoma, Kaposi
Early non-immunological post transplant complications: a single center experience.
Sarcoma, Kaposi
First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation.
Sarcoma, Kaposi
No recurrence of Kaposi's sarcoma in a case of renal retransplantation under a calcineurin inhibitor free immunosuppressive regimen: first report.
Sarcoma, Kaposi
Sirolimus (rapamycin): from the soil of Easter Island to a bright future.
Sarcoma, Kaposi
Sirolimus conversion for patients with posttransplant Kaposi's sarcoma.
Sarcoma, Kaposi
Sirolimus monotherapy in liver transplantation.
Sarcoma, Synovial
Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.
Sarcopenia
Posttransplant Sarcopenia: An Underrecognized Early Consequence of Liver Transplantation.
Scleroderma, Diffuse
Fibrosis caused by loss of PTEN expression by fibroblasts is crucially dependent on CCN2.
Scleroderma, Localized
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Scleroderma, Systemic
Fibrosis caused by loss of PTEN expression by fibroblasts is crucially dependent on CCN2.
Scoliosis
Mutation analysis of MESP2, HES7 and DUSP6 gene exons in patients with congenital scoliosis.
Seizures
A Wide Spectrum of Genetic Disorders Causing Severe Childhood Epilepsy in Taiwan: A Case Series of Ultrarare Genetic Cause and Novel Mutation Analysis in a Pilot Study.
Seizures
AMPA Receptor Antagonists Facilitate NEDD4-2-Mediated GRIA1 Ubiquitination by Regulating PP2B-ERK1/2-SGK1 Pathway in Chronic Epilepsy Rats.
Seizures
AMPA/kainate receptor-mediated downregulation of GABAergic synaptic transmission by calcineurin after seizures in the developing rat brain.
Seizures
Anticonvulsant effect of the calcineurin inhibitor ascomycin on seizures induced by picrotoxin microperfusion in the rat hippocampus.
Seizures
Bioinformatics Analysis of Microarray Profiling Identifies That the miR-203-3p Target Ppp2ca Aggravates Seizure Activity in Mice.
Seizures
De Novo Mutations in PPP3CA Cause Severe Neurodevelopmental Disease with Seizures.
Seizures
Decreased expression of calmodulin kinase II and calcineurin messenger RNAs in the mouse hippocampus after kainic acid-induced seizures.
Seizures
Drug-induced alterations in Mg2+ homoeostasis.
Seizures
Early-onset infant epileptic encephalopathy associated with a de novo PPP3CA gene mutation.
Seizures
Effects of MK-801, dantrolene, and FK506 on convulsive seizures and brain nitric oxide production in seizure-susceptible EL mice.
Seizures
Epileptic spasms in PPP1CB-associated Noonan-like syndrome: a case report with clinical and therapeutic implications.
Seizures
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Seizures
Hypomagnesaemia in cystic fibrosis patients referred for lung transplant assessment.
Seizures
Hypoxia enhances high-voltage-activated calcium currents in rat primary cortical neurons via calcineurin.
Seizures
Inhibition of Calcineurin A by FK506 Suppresses Seizures and Reduces the Expression of GluN2B in Membrane Fraction.
Seizures
Kainate seizures cause acute dendritic injury and actin depolymerization in vivo.
Seizures
Laforin and malin deletions in mice produce similar neurologic impairments.
Seizures
Malin and laforin are essential components of a protein complex that protects cells from thermal stress.
Seizures
Managing Lafora body disease with vagal nerve stimulation.
Seizures
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children: Analysis of Prognostic Factors.
Seizures
Neurologic complications of transplantation.
Seizures
Pathophysiology and Management of Hyperammonemia in Organ Transplant Patients.
Seizures
Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies.
Seizures
Posterior reversible encephalopathy syndrome in children with kidney disease.
Seizures
Rapamycin: brain excitability studied in vitro.
Seizures
Seeing the forest and the trees: dendritic injury after status epilepticus.
Seizures
Seizure treatment in transplant patients.
Seizures
Single audiogenic seizures induce increases in calcineurin and Ca²+-calmodulin-dependent protein kinase II in the rat brain.
Seizures
Suppression of leptin signaling reduces polyglucosan inclusions and seizure susceptibility in a mouse model for Lafora disease.
Seizures
Tacrolimus-Associated Psychotic Disorder: A Report of 2 Cases.
Seizures
The Ca2+/calmodulin signaling system in the neural response to excitability. Involvement of neuronal and glial cells.
Seizures
The Impact of Electrographic Seizures on Developing Hippocampal Dendrites Is Calcineurin Dependent.
Seizures
Transplantation for liver failure in patients with sickle cell disease: Challenging but feasible.
Seizures
Traumatic Brain Injury Causes a Tacrolimus-Sensitive Increase in Non-Convulsive Seizures in a Rat Model of Post-Traumatic Epilepsy.
Seizures
[Single audiogenic seizure promote the increased levels of calcineurin and Ca(2+)-calmodulin-dependent protein kinase II in the rat's brain]
Sepsis
Clinical-pathological correlations in post-transplant thrombotic microangiopathy.
Sepsis
Cyclosporine A attenuates cardiac dysfunction induced by sepsis via inhibiting calcineurin and activating AMPK signaling.
Sepsis
Determination of protein phosphatase type 2A in monocytes from multiple trauma patients: a potential biomarker for sepsis.
Sepsis
Dual specificity phosphatase DUSP6 promotes endothelial inflammation through inducible expression of ICAM-1.
Sepsis
Fever in a transplant recipient: think beyond infection.
Sepsis
Neutrophil Gelatinase-Associated Lipocalin: Ready for Routine Clinical Use? An International Perspective.
Sepsis
Postoperative Acute Kidney Injury in Young Adults with Congenital Heart Disease.
Sepsis
Renal dysfunction following bone marrow transplantation.
Sepsis
Role of platelet TLR4 expression in pathogensis of septic thrombocytopenia.
Sepsis
Sepsis, calcineurin, and cardiac dysfunction: the saga of life and death.
Sepsis
Sofosbuvir Monotherapy for Asymptomatic and Noncirrhotic Hepatitis C Infection in a Renal Retransplantation Recipient: A Case Report.
Sepsis
Wip1 Deficiency Promotes Neutrophil Recruitment to the Infection Site and Improves Sepsis Outcome.
Sepsis
[The Role of Laboratory Medicine in Hematopoietic Stem Cell Transplantation "Echocardiogram"].
Serum Sickness
Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation.
Severe Acute Respiratory Syndrome
The Course of SARS-CoV-2 in a Patient After a Recent Kidney Transplant: A Literature Review on COVID-19 Therapy.
Shock, Septic
Attenuated platelet aggregation in patients with septic shock is independent from the activity state of myosin light chain phosphorylation or a reduction in Rho kinase-dependent inhibition of myosin light chain phosphatase.
Shock, Septic
Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock.
Sick Sinus Syndrome
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Skin Diseases
A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030.
Skin Diseases
Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test.
Skin Diseases
Calcineurin antagonists differentially affect mediator secretion, p38 mitogen-activated protein kinase and extracellular signal-regulated kinases from immunologically activated human basophils.
Skin Diseases
Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology.
Skin Diseases
Calcineurin inhibitors for the treatment of skin disease: how do they work?
Skin Diseases
Calcineurin inhibitors: a novel approach to canine atopic dermatitis.
Skin Diseases
Can we teach old drugs new tricks?-Repurposing of neuropharmacological drugs for inflammatory skin diseases.
Skin Diseases
Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
Skin Diseases
Editorial comments on this issue of the Journal.
Skin Diseases
Effect of pimecrolimus vs. corticosteroids on murine bone marrow-derived dendritic cell differentiation, maturation and function.
Skin Diseases
Effect of topical calcineurin inhibitors as monotherapy or combined with phototherapy for vitiligo treatment: a meta-analysis.
Skin Diseases
Erosive Pustular Dermatosis of the Scalp. A Chronic Recalcitrant Dermatosis Developed upon CO(2) Laser Treatment.
Skin Diseases
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
Skin Diseases
Management of atopic dermatitis: nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema.
Skin Diseases
Multiple labial melanotic macules occurring after topical application of calcineurin inhibitors.
Skin Diseases
Pimecrolimus -- an anti-inflammatory drug targeting the skin.
Skin Diseases
Pimecrolimus in dermatology: atopic dermatitis and beyond.
Skin Diseases
Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro.
Skin Diseases
Potential new indications of topical calcineurin inhibitors.
Skin Diseases
Steroid-sparing properties of emollients in dermatology.
Skin Diseases
Successful treatment of nodular actinic reticuloid with tacrolimus ointment.
Skin Diseases
Systemic ciclosporin and tacrolimus in dermatology.
Skin Diseases
The Itch that
freckles? Development of lentigines in areas of resolved chronic atopic dermatitis.
Skin Diseases
The role of calcineurin inhibitors in the management of lichen sclerosus.
Skin Diseases
The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis.
Skin Diseases
The stable cyclic adenosine monophosphate analogue, dibutyryl cyclo-adenosine monophosphate (bucladesine), is active in a model of acute skin inflammation.
Skin Diseases
Topical calcineurin inhibitors for the treatment of vulvar dermatoses.
Skin Diseases
Topical treatment of perianal eczema with tacrolimus 0.1%
Skin Diseases
Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Skin Diseases
[Antipruritic effects of pimecrolimus and tacrolimus]
Skin Diseases
[Topical treatment of bullous pemphigoid with tacrolimus. Case report with brief literature review]
Skin Diseases
[Topical treatment of vulvar lichen sclerosus with calcineurin inhibitors].
Skin Neoplasms
Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis.
Skin Neoplasms
Calcineurin inhibitor (CNI)-associated skin cancers: New insights on exploring mechanisms by which CNIs downregulate DNA repair machinery.
Skin Neoplasms
Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation.
Skin Neoplasms
Comparison of two strategies based on mammalian target of rapamycin inhibitors in secondary prevention of non-melanoma skin cancer after kidney transplantation, a pilot study.
Skin Neoplasms
Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression.
Skin Neoplasms
Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression.
Skin Neoplasms
Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients.
Skin Neoplasms
Interventions to Prevent Nonmelanoma Skin Cancers in Recipients of a Solid Organ Transplant: Systematic Review of Randomized Controlled Trials.
Skin Neoplasms
Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults.
Skin Neoplasms
Long-Term Immunosuppression Management: Opportunities and Uncertainties.
Skin Neoplasms
Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.
Skin Neoplasms
Opposing roles for calcineurin and ATF3 in squamous skin cancer.
Skin Neoplasms
Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer.
Skin Neoplasms
Ras and TGF-? signaling enhance cancer progression by promoting the ?Np63 transcriptional program.
Skin Neoplasms
Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient.
Skin Neoplasms
Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
Skin Neoplasms
Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant Recipients.
Skin Neoplasms
Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair.
Skin Neoplasms
Skin cancer in organ transplant recipients: More than the immune system.
Skin Neoplasms
Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits.
Skin Neoplasms
The Effect of Conversion from a Calcineurin Inhibitor to Sirolimus on Skin Cancer Reduction in Post-renal Transplantation Patients.
Skin Neoplasms
The effect of switching from calcineurin inhibitor to sirolimus on the incidence of skin cancers in kidney transplant recipients.
Skin Neoplasms
The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
Skin Neoplasms
The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo.
Skin Neoplasms
The protein phosphatase 6 catalytic subunit (Ppp6c) is indispensable for proper post-implantation embryogenesis.
Skin Neoplasms
The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
Skin Neoplasms
The role of drugs and selected dietary factors in cutaneous squamous cell carcinogenesis.
Skin Neoplasms
[Topical pimecrolimus and tacrolimus and the risk of cancer]
Sleep Apnea, Obstructive
Obstructive sleep apnea and intermittent hypoxia increase expression of dual specificity phosphatase 1.
Sleep Deprivation
Calcineurin contributes to spatial memory impairment induced by rapid eye movement sleep deprivation.
Small Cell Lung Carcinoma
Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer.
Small Cell Lung Carcinoma
Key genes in lung cancer translational research: a meta-analysis.
Small Cell Lung Carcinoma
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
Small Cell Lung Carcinoma
Proto-oncogene Wip1, a member of a new family of proliferative genes in NSCLC and its clinical significance.
Small Cell Lung Carcinoma
[Expression and clinical significance of CIP2A in small cell lung cancer patients].
Smallpox
Overproduction, purification, and biochemical characterization of the dual specificity H1 protein phosphatase encoded by variola major virus.
Solitary Kidney
Patient and graft outcome in current era of immunosuppression: a single centre pilot study.
Spasm
Recent insights into the mechanisms, predisposing factors, and racial differences of coronary vasospasm.
Spinal Cord Injuries
Calcineurin-mediated BAD dephosphorylation activates the caspase-3 apoptotic cascade in traumatic spinal cord injury.
Spinal Cord Injuries
Critical role of regulator of calcineurin 1 in spinal cord injury.
Spinal Cord Injuries
FK506 treatment inhibits caspase-3 activation and promotes oligodendroglial survival following traumatic spinal cord injury.
Spinal Cord Injuries
PPP1CC is associated with astrocyte and microglia proliferation after traumatic spinal cord injury in rats.
Spinal Cord Injuries
The Emerging Roles of the Calcineurin-Nuclear Factor of Activated T-Lymphocytes Pathway in Nervous System Functions and Diseases.
Spinal Cord Ischemia
[The effects of calcineurin inhibitors on neurologic and histopathologic outcome after transient spinal cord ischemia in rabbits]
Spinocerebellar Ataxias
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Spinocerebellar Ataxias
Unusual cerebral white matter change in a Chinese family with Spinocerebellar ataxia type 12.
Spondylitis, Ankylosing
Autoantibodies against Protein Phosphatase Magnesium-Dependent 1A as a Biomarker for Predicting Radiographic Progression in Ankylosing Spondylitis Treated with Anti-Tumor Necrosis Factor Agents.
Spondylitis, Ankylosing
Role of Protein Phosphatase Magnesium-Dependent 1A and Anti-Protein Phosphatase Magnesium-Dependent 1A Autoantibodies in Ankylosing Spondylitis.
Spondylitis, Ankylosing
The intracellular protein phosphatase magnesium-dependent 1A negatively regulates osteoclast commitment.
Squamous Cell Carcinoma of Head and Neck
Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy.
Squamous Cell Carcinoma of Head and Neck
DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
DUSP1 phosphatase regulates the proinflammatory milieu in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Gene amplification and overexpression of protein phosphatase 1alpha in oral squamous cell carcinoma cell lines.
Squamous Cell Carcinoma of Head and Neck
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Squamous Cell Carcinoma of Head and Neck
Protein phosphatase-2A association with microtubules and its role in restricting the invasiveness of human head and neck squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Protein phosphatase-2A maintains focal adhesion complexes in keratinocytes and the loss of this regulation in squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Protein phosphatase-2A regulates endothelial cell motility and both the phosphorylation and the stability of focal adhesion complexes.
ST Elevation Myocardial Infarction
Evidence of increased platelet reactivity in the first six months after acute ST segment elevation myocardial infarction.
Staphylococcal Infections
Structure-Based Identification of a Potent Inhibitor Targeting Stp1-Mediated Virulence Regulation in Staphylococcus aureus.
Staphylococcal Infections
Tacrolimus impairs Kupffer cell capacity to control bacteremia: why transplant recipients are susceptible to infection.
Starvation
A calcium signalling network activates vacuolar K+ remobilization to enable plant adaptation to low-K environments.
Starvation
A yeast protein phosphatase related to the vaccinia virus VH1 phosphatase is induced by nitrogen starvation.
Starvation
Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response.
Starvation
Biochemical and molecular analysis of LePS2;1: a phosphate starvation induced protein phosphatase gene from tomato.
Starvation
Calcineurin Silencing in Dictyostelium discoideum Leads to Cellular Alterations Affecting Mitochondria, Gene Expression, and Oxidative Stress Response.
Starvation
Calcium channel regulator Mid1 links TORC2-mediated changes in mitochondrial respiration to autophagy.
Starvation
Cdc14 phosphatase downmodulates ESCRT-0 complex formation on vacuolar membranes and microautophagy after TORC1 inactivation.
Starvation
CNP-1 (ARRD-17), a Novel Substrate of Calcineurin, Is Critical for Modulation of Egg-Laying and Locomotion in Response to Food and Lysine Sensation in Caenorhabditis elegans.
Starvation
Cytoplasmic dynein undergoes intracellular redistribution concomitant with phosphorylation of the heavy chain in response to serum starvation and okadaic acid.
Starvation
Enzymatic and functional analysis of a protein phosphatase, Pph3, from Myxococcus xanthus.
Starvation
Global identification of genes related to nutrient deficiency in intervertebral disc cells in an experimental nutrient deprivation model.
Starvation
Inorganic phosphate as an important regulator of phosphatases.
Starvation
Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB.
Starvation
Molecular physiology of the neural circuit for calcineurin-dependent associative learning in Caenorhabditis elegans.
Starvation
New regulator for energy signaling pathway in plants highlights conservation among species.
Starvation
Protein phosphatase type-1 mRNA levels in response to starvation-refeeding and streptozotocin-diabetes.
Starvation
Specific phosphoantibodies reveal two phosphorylation sites in yeast Pma1 in response to glucose.
Starvation
The Crz1/Sp1 transcription factor of Cryptococcus neoformans is activated by calcineurin and regulates cell wall integrity.
Starvation
The dual-specificity protein phosphatase Yvh1p regulates sporulation, growth, and glycogen accumulation independently of catalytic activity in Saccharomyces cerevisiae via the cyclic AMP-dependent protein kinase cascade.
Starvation
The inhibitor-1 C terminus facilitates hormonal regulation of cellular protein phosphatase-1: functional implications for inhibitor-1 isoforms.
Starvation
The S. cerevisiae nitrogen starvation-induced Yvh1p and Ptp2p phosphatases play a role in control of sporulation.
Starvation
[CONTENT AND RESTORATION OF PHOSPHOPROTEIN PHOSPHOSERINE AND PHOSPHOPROTEIN PHOSPHATASE IN THE LIVER IN STARVATION AND SUBSEQUENT FEEDING OF ANIMALS.]
Status Epilepticus
A cellular mechanism for dendritic spine loss in the pilocarpine model of status epilepticus.
Status Epilepticus
A significant increase in both basal and maximal calcineurin activity in the rat pilocarpine model of status epilepticus.
Status Epilepticus
Effect of the calcineurin inhibitor FK506 on K(+)-Cl (-) cotransporter 2 expression in the mouse hippocampus after kainic acid-induced status epilepticus.
Status Epilepticus
Increased calcineurin expression after pilocarpine-induced status epilepticus is associated with brain focal edema and astrogliosis.
Status Epilepticus
Status epilepticus-induced changes in the subcellular distribution and activity of calcineurin in rat forebrain.
Status Epilepticus
The Calcineurin Inhibitor FK506 Prevents Cognitive Impairment by Inhibiting Reactive Astrogliosis in Pilocarpine-Induced Status Epilepticus Rats.
Status Epilepticus
The effects of calcineurin inhibitor FK506 on actin cytoskeleton, neuronal survival and glial reactions after pilocarpine-induced status epilepticus in mice.
Stevens-Johnson Syndrome
Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A record-based study.
Still's Disease, Adult-Onset
Calcineurin inhibitors for adult-onset Still's disease: a multicentre retrospective cohort study.
Stomach Neoplasms
Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines.
Stomach Neoplasms
Comprehensive analysis of vascular endothelial growth factor-C related factors in stomach cancer.
Stomach Neoplasms
Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis.
Stomach Neoplasms
DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer.
Stomach Neoplasms
Genetic variants in PPP2CA are associated with gastric cancer risk in a Chinese population.
Stomach Neoplasms
Genetically engineered drug rhCNB induces apoptosis and cell cycle arrest in both gastric cancer cells and hepatoma cells.
Stomach Neoplasms
Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.
Stomach Neoplasms
Inhibiting PP2Ac? Promotes the Malignant Phenotype of Gastric Cancer Cells through the ATM/METTL3 Axis.
Stomach Neoplasms
Loss of PPM1F expression predicts tumour recurrence and is negatively regulated by miR-590-3p in gastric cancer.
Stomach Neoplasms
MAEL contributes to gastric cancer progression by promoting ILKAP degradation.
Stomach Neoplasms
MicroRNA-27a contributes to the malignant behavior of gastric cancer cells by directly targeting PH domain and leucine-rich repeat protein phosphatase 2.
Stomach Neoplasms
microRNA-95 knockdown inhibits epithelial-mesenchymal transition and cancer stem cell phenotype in gastric cancer cells through MAPK pathway by upregulating DUSP5.
Stomach Neoplasms
MiR-125b promotes cell migration and invasion by targeting PPP1CA-Rb signal pathways in gastric cancer, resulting in a poor prognosis.
Stomach Neoplasms
Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance.
Stomach Neoplasms
Poor prognosis of phosphatase of regenerating liver 3 expression in gastric cancer: a meta-analysis.
Stomach Neoplasms
Prognostic value of PPM1D in 800 gastric cancer patients.
Stomach Neoplasms
Synergistic cytotoxic effect between serine-threonine phosphatase inhibitors and 5-fluorouracil: a novel concept for modulation of cytotoxic effect.
Stomach Neoplasms
[Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation]
Stomach Neoplasms
[The malignant phenotype of calcineurin B homologous protein 2 in gastric cancer and its clinical significance].
Stomatitis, Aphthous
Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.
Striatonigral Degeneration
Calcineurin immunoreactivity in striatonigral degeneration.
Striatonigral Degeneration
Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders.
Striatonigral Degeneration
Inhomogeneity of the putaminal lesion in striatonigral degeneration.
Striatonigral Degeneration
Subregional loss of putaminal efferents to the basal ganglia output nuclei may cause parkinsonism in striatonigral degeneration.
Stroke
Detailed in vitro pharmacological analysis of FK506-induced neuroprotection.
Stroke
Enhanced platelet-derived microparticle formation is associated with carotid atherosclerosis in convalescent stroke patients.
Stroke
Expression profile based gene clusters for ischemic stroke detection.
Stroke
High level calcineurin activity predisposes neuronal cells to apoptosis.
Stroke
Incidence, Risk Factors, and Outcomes of Stroke Following Cardiac Transplantation.
Stroke
Influence of dual-specificity protein phosphatase 5 on mechanical properties of rat cerebral and renal arterioles.
Stroke
Inpatient Neurologic Consultation in Solid Organ Transplant Patients.
Stroke
Mitochondrial Protein PGAM5 Regulates Mitophagic Protection against Cell Necroptosis.
Stroke
Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism.
Stroke
Over-expression of DSCR1 protects against post-ischemic neuronal injury.
Stroke
Tacrines for Alzheimer's disease therapy. III. The PyridoTacrines.
Stroke
[Kidney transplant: a mere stage of CKD?]
Subarachnoid Hemorrhage
Neuroprotective Effect of Protein Phosphatase 2A/Tristetraprolin Following Subarachnoid Hemorrhage in Rats.
Supranuclear Palsy, Progressive
Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci.
Surgical Wound Infection
Incidence and risk factors of incisional hernia formation following abdominal organ transplantation.
Syndactyly
Prevalence and associated phenotypes of DUSP6, IL17RD and SPRY4 variants in a large Chinese cohort with isolated hypogonadotropic hypogonadism.
Tachycardia, Ventricular
Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, EGb 761, in isolated ischemic/reperfused rat hearts.
Tachycardia, Ventricular
Heart block in mice overexpressing calcineurin but not NF-AT3.
Tauopathies
An okadaic acid-induced model of tauopathy and cognitive deficiency.
Tauopathies
Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.
Tauopathies
Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration.
Tauopathies
Memantine mediates astrocytic activity in response to excitotoxicity induced by PP2A inhibition.
Tauopathies
Methionine-Mediated Protein Phosphatase 2A Catalytic Subunit (PP2Ac) Methylation Ameliorates the Tauopathy Induced by Manganese in Cell and Animal Models.
Tauopathies
Screening of tau protein kinase inhibitors in a tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization.
Tauopathies
The protein phosphatase PP2A/B? binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: Implications for tauopathies.
Tauopathies
Transcriptome analyses of chronic traumatic encephalopathy show alterations in protein phosphatase expression associated with tauopathy.
TDP-43 Proteinopathies
The phosphatase calcineurin regulates pathological TDP-43 phosphorylation.
Telangiectasis
P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
Tension-Type Headache
Calcineurin inhibitor-induced headache: clinical characteristics and possible mechanisms.
Teratocarcinoma
Cloning and expression of a cDNA encoding a novel protein serine/threonine kinase predominantly expressed in hematopoietic cells.
Teratocarcinoma
Identification of a third alternatively spliced cDNA encoding the catalytic subunit of protein phosphatase 2B beta.
Teratocarcinoma
Inhibition of protein phosphatase PPM1D enhances retinoic acid-induced differentiation in human embryonic carcinoma cell line.
Teratocarcinoma
Mammalian protein serine/threonine phosphatase 2C: cDNA cloning and comparative analysis of amino acid sequences.
Teratocarcinoma
Protein phosphatase X has been highly conserved during mammalian evolution.
Teratoma
Fusion of the tumor-suppressor gene CHEK2 and the gene for the regulatory subunit B of protein phosphatase 2 PPP2R2A in childhood teratoma.
Tetanus
Enhanced spontaneous transmitter release at murine motor nerve terminals with cyclosporine.
Tetanus
Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients.
Tetanus
Protein kinase and phosphatase activity regulate the form of synaptic plasticity expressed.
Tetanus
Suppressive effect of preconditioning low-frequency stimulation on subsequent induction of long-term potentiation by high frequency stimulation in hippocampal CA3 neurons.
Tetany
Drug-induced alterations in Mg2+ homoeostasis.
Tetralogy of Fallot
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Thalassemia
The relation between mitogen activated protein kinase (MAPK) pathway and different genes expression in patients with beta Thalassemia.
Thrombasthenia
[Effect of the defect of integrin alpha II b beta 3 on the inside-out signal transduction in platelets]
Thrombocythemia, Essential
[The study of relationship between platelet function and thrombus in patients with essential thrombocythaemia]
Thrombocytopenia
Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
Thrombocytopenia
Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?
Thrombophilia
Deep vein thrombosis and pulmonary embolism after solid organ transplantation: an unresolved problem.
Thrombosis
Branched-Chain Amino Acid Catabolism Promotes Thrombosis Risk by Enhancing Tropomodulin-3 Propionylation in Platelets.
Thrombosis
Comparison of denovo sirolimus vs. Calcineurin inhibitor immunosuppression regarding incidence of deep venous thrombosis and pulmonary embolism following renal transplantation.
Thrombosis
Egyptian clinical practice guideline for kidney transplantation.
Thrombosis
Gene polymorphism of platelet glycoprotein I balpha in Chinese patients with large- and small-artery subtypes of ischemic stroke.
Thrombosis
Platelets and capillary injury in acute humoral rejection of renal allografts.
Thrombosis
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients.
Thrombosis
Safety of mTOR inhibitors in adult solid organ transplantation.
Thrombosis
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19.
Thrombosis
The catalytic subunit of protein phosphatase 1 gamma regulates thrombin-induced murine platelet alpha(IIb)beta(3) function.
Thrombosis
[Effects of sodium ozagrel in primary thrombocytosis combined with thrombosis.]
Thrombosis
[Identifying the specific causes of kidney allograft loss: A population-based study].
Thrombosis
[The study of relationship between platelet function and thrombus in patients with essential thrombocythaemia]
Thrombotic Microangiopathies
A case of thrombotic microangiopathy caused by oral contraceptives in a kidney transplant recipient.
Thrombotic Microangiopathies
Belatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report.
Thrombotic Microangiopathies
Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant.
Thrombotic Microangiopathies
Conversion from calcineurin inhibitors to sirolimus in transplant-associated thrombotic microangiopathy.
Thrombotic Microangiopathies
De novo post-transplant thrombotic microangiopathy localized only to the graft in autosomal dominant polycystic kidney disease with thrombophilia.
Thrombotic Microangiopathies
De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus.
Thrombotic Microangiopathies
De Novo Thrombotic Microangiopathy Immediately After Kidney Transplant in Patients Without Apparent Risk Factors.
Thrombotic Microangiopathies
De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection.
Thrombotic Microangiopathies
De Novo Thrombotic Microangiopathy in Renal Transplant Patients.
Thrombotic Microangiopathies
Diagnosis of de novo localized thrombotic microangiopathy by surveillance biopsy.
Thrombotic Microangiopathies
Everolimus worsening chronic proteinuria in patient with diabetic nephropathy post liver transplantation.
Thrombotic Microangiopathies
Glomerular mRNA expression of prothrombotic and antithrombotic factors in renal transplants with thrombotic microangiopathy.
Thrombotic Microangiopathies
Kidney Pathology after Hematologic Cell Transplantation-A Single-Center Observation Study of Indication Biopsies and Autopsies.
Thrombotic Microangiopathies
Living-Donor Kidney Transplant-Associated Thrombotic Microangiopathy Successfully Treated With Thymoglobulin: A Case Report.
Thrombotic Microangiopathies
No Relapse of Calcineurin Inhibitor-Associated Thrombotic Microangiopathy after Discontinuation of Eculizumab.
Thrombotic Microangiopathies
Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation.
Thrombotic Microangiopathies
Platelets and capillary injury in acute humoral rejection of renal allografts.
Thrombotic Microangiopathies
Rapamycin for refractory acute graft-versus-host disease.
Thrombotic Microangiopathies
Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
Thrombotic Microangiopathies
Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
Thrombotic Microangiopathies
Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids.
Thrombotic Microangiopathies
Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient.
Thrombotic Microangiopathies
Tacrolimus associated localized thrombotic microangiopathy developing in early stage after renal transplantation.
Thrombotic Microangiopathies
Tacrolimus-induced thrombotic microangiopathy: natural history of a severe, acute vasculopathy.
Thrombotic Microangiopathies
Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?
Thrombotic Microangiopathies
Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation.
Thrombotic Microangiopathies
Thrombotic microangiopathy associated with tacrolimus in lung transplantation.
Thrombotic Microangiopathies
Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient.
Thrombotic Microangiopathies
Transplant-associated thrombotic microangiopathy and immune haematological complications following intestine-containing organ transplantation: experience from over 100 consecutive cases.
Thrombotic Microangiopathies
Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus.
Thrombotic Microangiopathies
Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation.
Thrombotic Microangiopathies
Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post-Kidney Transplant: A Case Report.
Thrombotic Microangiopathies
[The Role of Laboratory Medicine in Hematopoietic Stem Cell Transplantation "Echocardiogram"].
Thymoma
Activation of messenger-independent protein kinases in wild-type and phorbol ester-resistant EL4 thymoma cells.
Thymus Neoplasms
Cloning, tissue distribution, subcellular localization and overexpression of murine histidine-rich Ca2+ binding protein.
Thyroid Cancer, Papillary
MicroRNA-145 inhibits human papillary cancer TPC1 cell proliferation by targeting DUSP6.
Thyroid Cancer, Papillary
MicroRNA-222 Promotes Invasion and Metastasis of Papillary Thyroid Cancer Through Targeting Protein Phosphatase 2 Regulatory Subunit B Alpha Expression.
Thyroid Cancer, Papillary
Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma.
Thyroid Carcinoma, Anaplastic
A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.
Thyroid Carcinoma, Anaplastic
miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA.
Thyroid Carcinoma, Anaplastic
NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26).
Thyroid Neoplasms
Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
Thyroid Neoplasms
Correction to: Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
Thyroid Neoplasms
DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
Thyroid Neoplasms
Long non-coding RNA HOTAIR/microRNA-761 sponge regulates PPME1 and further influences cell biological functions in thyroid carcinoma.
Thyroid Neoplasms
Regulator of calcineurin 1 modulates cancer cell migration in vitro.
Thyroid Neoplasms
Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma.
Tinea
Clinical and mycological analysis of twenty-one cases of tinea incognita in the aegean region of Turkey: a retrospective study.
Tinea
Genetic and Phenotypic analyses of Calcineurin A subunit in Arthroderma vanbreuseghemii.
Tinea
Psoriasis-like tinea incognita: a case report and literature review.
Tinea
Tinea corporis: an updated review.
Tinea
Tinea Incognita following the Use of an Antipsoriatic Gel.
Tinea
Tinea incognito due to Trichophyton mentagrophytes: case report.
Tinea
Tinea incognito in Korea and its risk factors: nine-year multicenter survey.
Tinea
[A tinea incognito case caused by Trichophyton rubrum with clinical and mycological cure and review of the literature]
Tremor
Completeness of reporting of adverse events in trials of maintenance immunosuppression in kidney transplantation: a systematic review.
Tremor
Health-related quality of life outcomes after kidney transplantation.
Tremor
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children: Analysis of Prognostic Factors.
Tremor
Neurologic complications after liver transplantation.
Tremor
Neurologic complications after solid organ transplantation.
Tremor
Neurologic complications in renal transplantation.
Tremor
Tacrolimus-Associated Psychotic Disorder: A Report of 2 Cases.
Tremor
Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy.
Tremor
Tremor induced by Calcineurin inhibitor immunosuppression: a single-centre observational study in kidney transplanted patients.
Tremor
Unusual cerebral white matter change in a Chinese family with Spinocerebellar ataxia type 12.
Tremor
[Neurological complications in renal transplant recipients]
Triple Negative Breast Neoplasms
Aurovertin B exerts potent antitumor activity against triple-negative breast cancer in vivo and in vitro via regulating ATP synthase activity and DUSP1 expression.
Triple Negative Breast Neoplasms
DUSP1 promoter methylation in peripheral blood leukocyte is associated with triple-negative breast cancer risk.
Triple Negative Breast Neoplasms
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Silencing of DUSP6 gene by RNAi-mediation inhibits proliferation and growth in MDA-MB-231 breast cancer cells: an in vitro study.
Triple Negative Breast Neoplasms
Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
Triple Negative Breast Neoplasms
The role of dual?specificity phosphatase 1 and protein phosphatase 1 in ?2?adrenergic receptor?mediated inhibition of extracellular signal regulated kinase 1/2 in triple negative breast cancer cell lines.
Tuberculosis
Abdominal tuberculosis in renal transplant recipient. Presentation of a case and literature review
Tuberculosis
An alternate conformation and a third metal in PstP/Ppp, the M. tuberculosis PP2C-Family Ser/Thr protein phosphatase.
Tuberculosis
Calcineurin Inhibitors and Variation in the Performance of Interferon-? Release Assays Used to Detect Tuberculosis Infection.
Tuberculosis
Egyptian clinical practice guideline for kidney transplantation.
Tuberculosis
Fever in a transplant recipient: think beyond infection.
Tuberculosis
First structural glimpse at a bacterial Ser/Thr protein phosphatase.
Tuberculosis
Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
Tuberculosis
Phosphoprotein phosphatase of Mycobacterium tuberculosis dephosphorylates serine-threonine kinases PknA and PknB.
Tuberculosis
Phosphorylation of Mycobacterium tuberculosis Ser/Thr Phosphatase by PknA and PknB.
Tuberculosis
PknB kinase activity is regulated by phosphorylation in two Thr residues and dephosphorylation by PstP, the cognate phospho-Ser/Thr phosphatase, in Mycobacterium tuberculosis.
Tuberculosis
Protein Phosphatase, Mg2+/Mn2+-dependent 1A controls the innate antiviral and antibacterial response of macrophages during HIV-1 and Mycobacterium tuberculosis infection.
Tuberculosis
Serine/Threonine Protein Phosphatase PstP of Mycobacterium tuberculosis Is Necessary for Accurate Cell Division and Survival of Pathogen.
Tuberculosis
Targeting the messengers: Serine/threonine protein kinases as potential targets for antimycobacterial drug development.
Tuberculosis
The condensing activities of the Mycobacterium tuberculosis type II fatty acid synthase are differentially regulated by phosphorylation.
Tuberculosis
Treatment of tuberculosis with rifabutin in a renal transplant recipient.
Tuberculosis
[Advances in the study of Mycobacterium tuberculosis protein phosphatase and its inhibitors].
Tuberous Sclerosis
Identification of proteins interacting with the catalytic subunit of PP2A by proteomics.
Tumor Virus Infections
Myxoma virus and Shope fibroma virus encode dual-specificity tyrosine/serine phosphatases which are essential for virus viability.
Unverricht-Lundborg Syndrome
Advances in the genetics of progressive myoclonus epilepsy.
Unverricht-Lundborg Syndrome
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
Uremia
Relationship between the expression levels of CD61, CD63, and PAC-1 on platelet surface in peripheral blood and the transplanted kidney function.
Uremia
Renal transplantation: basic concepts and evolution of therapy.
Uremia
[Complications in kidney transplantation]
Uremia
[The relationship between the peripheral blood of CD61, CD63, PAC-1 and the transplant kidney function]
Ureteral Obstruction
Norcantharidin inhibits renal interstitial fibrosis by downregulating PP2Ac expression.
Urinary Bladder Neck Obstruction
Calcineurin mediates bladder smooth muscle hypertrophy after bladder outlet obstruction.
Urinary Bladder Neck Obstruction
Calcineurin Mediates Bladder Wall Remodeling Secondary to Partial Outlet Obstruction.
Urinary Bladder Neoplasms
CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site.
Urinary Bladder Neoplasms
Deciphering the Roles of Thiazolidinediones and PPAR? in Bladder Cancer.
Urinary Bladder Neoplasms
Disruption of serine/threonine protein phosphatase 5 inhibits tumorigenesis of urinary bladder cancer cells.
Urinary Bladder Neoplasms
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
Urinary Bladder Neoplasms
miR-186 downregulates protein phosphatase PPM1B in bladder cancer and mediates G1-S phase transition.
Urinary Bladder Neoplasms
Oncogenic role of MIR516A in human bladder cancer was mediated by its attenuating PHLPP2 expression and BECN1-dependent autophagy.
Urinary Bladder Neoplasms
Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts.
Urinary Bladder Neoplasms
Targeting PPM1D by lentivirus-mediated RNA interference inhibits the tumorigenicity of bladder cancer cells.
Urinary Tract Infections
Calcineurin inhibitor Tacrolimus impairs host immune response against urinary tract infection.
Urinary Tract Infections
Recent advances in new-onset diabetes mellitus after kidney transplantation.
Urolithiasis
Egyptian clinical practice guideline for kidney transplantation.
Urolithiasis
Extracorporeal shock wave lithotripsy of impacted radiolucent stone at the right pyeloureteric junction and oral dissolution therapy in a patient with transplanted liver: a case report.
Urologic Diseases
[Identifying the specific causes of kidney allograft loss: A population-based study].
Urticaria
Calcineurin inhibitors in chronic urticaria.
Uterine Cervical Neoplasms
Human papillomavirus (HPV) oncoprotein E6 facilitates Calcineurin-Nuclear factor for activated T cells 2 (NFAT2) signaling to promote cellular proliferation in cervical cell carcinoma.
Uterine Cervical Neoplasms
Knockdown of Wip1 Enhances Sensitivity to Radiation in HeLa Cells Through Activation of p38 MAPK.
Uterine Cervical Neoplasms
Long non-coding RNA ARAP1-AS1 promotes the proliferation and migration in cervical cancer through epigenetic regulation of DUSP5.
Uterine Cervical Neoplasms
Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer.
Uterine Cervical Neoplasms
Production of DUSP1 protein using the baculovirus insect cell expression system and its in vitro effects on cancer cells.
Uterine Cervical Neoplasms
Synergistic cytotoxic effect between serine-threonine phosphatase inhibitors and 5-fluorouracil: a novel concept for modulation of cytotoxic effect.
Uterine Cervical Neoplasms
Volume-sensitive KCI cotransport associated with human cervical carcinogenesis.
Uterine Neoplasms
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Uveitis
A Review of the Course and Treatment of Non-Infectious Uveitis during Pregnancy.
Uveitis
Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis.
Uveitis
Pharmacogenetics of drugs used in the treatment of ocular inflammatory diseases.
Uveitis
The role of biologic agents in the management of non-infectious uveitis.
Uveitis
Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
Uveitis
[Systemic voclosporin for uveitis treatment]
Uveitis, Posterior
Mycophenolate mofetil use in the treatment of noninfectious uveitis.
Vaccinia
A protein phosphatase related to the vaccinia virus VH1 is encoded in the genomes of several orthopoxviruses and a baculovirus.
Vaccinia
A Tyr/Ser protein phosphatase encoded by vaccinia virus.
Vaccinia
A yeast protein phosphatase related to the vaccinia virus VH1 phosphatase is induced by nitrogen starvation.
Vaccinia
Bacterial and viral protein tyrosine phosphatases.
Vaccinia
Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR.
Vaccinia
Fluorogenic peptide substrates for serine and threonine phosphatases.
Vaccinia
Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection.
Vaccinia
Isolation and characterisation of a uniquely regulated threonine, tyrosine phosphatase (TYP 1) which inactivates ERK2 and p54jnk.
Vaccinia
Mutational and kinetic evaluation of conserved His-123 in dual specificity protein-tyrosine phosphatase vaccinia H1-related phosphatase: participation of Tyr-78 and Thr-73 residues in tuning the orientation of His-123.
Vaccinia
Myxoma virus and Shope fibroma virus encode dual-specificity tyrosine/serine phosphatases which are essential for virus viability.
Vaccinia
PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase.
Vaccinia
The dual-specificity phosphatase encoded by vaccinia virus, VH1, is essential for viral transcription in vivo and in vitro.
Vaccinia
Tyrosine phosphorylation of VHR phosphatase by ZAP-70.
Vaccinia
Vaccinia protein kinase 2: a second essential serine/threonine protein kinase encoded by vaccinia virus.
Vascular Diseases
Discovery and Characterization of Halogenated Xanthene Inhibitors of DUSP5 as Potential Photodynamic Therapeutics.
Vascular Diseases
Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation.
Vascular System Injuries
Cellular mechanisms of vascular injury mediated by calcineurin inhibitors.
Vascular System Injuries
Vascular injury mediated by calcineurin inhibitors: contribution of rheological factors?
Vascular System Injuries
Wild-type p53-induced phosphatase 1 promotes vascular smooth muscle cell proliferation and neointima hyperplasia after vascular injury via p-adenosine 5'-monophosphate-activated protein kinase/mammalian target of rapamycin complex 1 pathway.
Vasculitis
Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with antineutrophil cytoplasmic antibody-associated vasculitis and nephrosis.
Vasculitis
Gender differences in autoimmune diseases: estrogen increases calcineurin expression in systemic lupus erythematosus.
Venous Thrombosis
Comparison of denovo sirolimus vs. Calcineurin inhibitor immunosuppression regarding incidence of deep venous thrombosis and pulmonary embolism following renal transplantation.
Venous Thrombosis
Intraoperative placing of drains decreases the incidence of lymphocele and deep vein thrombosis after renal transplantation.
Ventricular Dysfunction
A preliminary study of platelet hyperactivity in the chronic indeterminate phase of Chagas' disease.
Ventricular Fibrillation
Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, EGb 761, in isolated ischemic/reperfused rat hearts.
Vesico-Ureteral Reflux
Clinicopathological Analysis of Medullary Ray Injury in 1-Year Protocol Paediatric Renal Allograft Biopsies.
Vesicular Stomatitis
PGAM5-MAVS interaction regulates TBK1/ IRF3 dependent antiviral responses.
Vesicular Stomatitis
PPP6C Negatively Regulates STING-Dependent Innate Immune Responses.
Viremia
A single-center experience of overseas kidney transplant for immunologically high-risk patients.
Viremia
Association of BK viremia with human leukocyte antigen mismatches and acute rejection, but not with type of calcineurin inhibitor.
Viremia
BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results.
Viremia
Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients.
Viremia
Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature.
Viremia
Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients.
Viremia
Hepatitis C infection in liver transplantation.
Viremia
Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction.
Viremia
Natural history of hepatitis C and outcomes following liver transplantation.
Viremia
Progression from Sustained BK Viruria to Sustained BK Viremia with Immunosuppression Reduction Is Not Associated with Changes in the Noncoding Control Region of the BK Virus Genome.
Viremia
Resurgence of BK virus following Covid-19 in kidney transplant recipients.
Viremia
[Treatment of recurrent HCV infection after liver transplantation]
Viremia
[Treatment of recurrent HCV infection after liver transplantation].
Viremia
[Treatment of recurrent hepatitis C infection after liver transplantation]
Virus Diseases
A case of thrombotic microangiopathy caused by oral contraceptives in a kidney transplant recipient.
Virus Diseases
Accompanying renal injuries did not impact graft survival in patients with transplant glomerulopathy.
Virus Diseases
Acute demyelinating polyneuropathy after lung transplantation: guillain-barré syndrome or tacrolimus toxicity?
Virus Diseases
An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome).
Virus Diseases
Anemia in solid organ transplantation.
Virus Diseases
Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha.
Virus Diseases
Cancer and mTOR inhibitors in Transplant Recipients.
Virus Diseases
Clinical-pathological correlations in post-transplant thrombotic microangiopathy.
Virus Diseases
Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant.
Virus Diseases
CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
Virus Diseases
Comparison of expression profiles induced by dust mite in airway epithelia reveals a common pathway.
Virus Diseases
Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?
Virus Diseases
Currently available useful immunohistochemical markers of renal pathology for the diagnosis of renal allograft rejection.
Virus Diseases
Diagnosis and prevention of chronic kidney allograft loss.
Virus Diseases
Dual Specificity Phosphatase 5 Is Essential for T Cell Survival.
Virus Diseases
DUSP1 regulates apoptosis and cell migration, but not the JIP1-protected cytokine response, during Respiratory Syncytial Virus and Sendai Virus infection.
Virus Diseases
Epigenome-wide effects of vitamin D on asthma bronchial epithelial cells.
Virus Diseases
Expression of calcineurin activity after lung transplantation: a 2-year follow-up.
Virus Diseases
Guillain-Barre syndrome: a typical paraneoplastic syndrome in a kidney transplant recipient with allograft renal cell carcinoma: a case report and review of the literature.
Virus Diseases
Hepatitis C virus-induced reduction in miR-181a impairs CD4(+) T-cell responses through overexpression of DUSP6.
Virus Diseases
Herpes viruses and tumours in kidney transplant recipients. The role of immunosuppression.
Virus Diseases
Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection.
Virus Diseases
Measles Virus Infection Inactivates Cellular Protein Phosphatase 5 with Consequent Suppression of Sp1 and c-Myc Activities.
Virus Diseases
New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.
Virus Diseases
Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation.
Virus Diseases
Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation.
Virus Diseases
PGAM5-MAVS interaction regulates TBK1/ IRF3 dependent antiviral responses.
Virus Diseases
PPM1D silencing by lentiviral-mediated RNA interference inhibits proliferation and invasion of human glioma cells.
Virus Diseases
Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor.
Virus Diseases
Renal thrombotic microangiopathy associated with chronic humoral graft versus host disease after hematopoietic stem cell transplantation.
Virus Diseases
Risk assessment and management of post-transplant diabetes mellitus.
Virus Diseases
Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report.
Virus Diseases
Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management.
Virus Diseases
The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen.
Virus Diseases
The multiple functions of protein phosphatase 6.
Virus Diseases
The pathogenesis and treatment of chronic allograft nephropathy.
Virus Diseases
The utility of cytodiagnostic urinalysis as a tool to diagnose kidney allograft dysfunction in the era lymphocyte-depleting induction therapy.
Virus Diseases
Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?
Virus Diseases
Thrombotic microangiopathy after kidney transplantation.
Virus Diseases
Vaccinia Virus Protein C6 Inhibits Type I IFN Signalling in the Nucleus and Binds to the Transactivation Domain of STAT2.
Virus Diseases
[Outcome of renal transplantation after tacrolimus switch to cyclosporine].
Vision Disorders
Posterior reversible encephalopathy syndrome in children with kidney disease.
Vitamin A Deficiency
Moderate maternal vitamin A deficiency alters myogenic regulatory protein expression and perinatal organ growth in the rat.
Vitamin D Deficiency
25-Hydroxy Vitamin D Deficiency Following Pediatric Hematopoietic Stem Cell Transplant.
Vitamin D Deficiency
CYP3A4 is a crosslink between vitamin D and calcineurin inhibitors in solid organ transplant recipients: implications for bone health.
Vitamin D Deficiency
New-Onset Diabetes after Kidney Transplantation.
Vitamin D Deficiency
Prevalence of vitamin D deficiency in post renal transplant patients.
Vitamin D Deficiency
The Association of 25-Hydroxyvitamin D Levels with Late Cytomegalovirus Infection in Kidney Transplant Recipients: the Wisconsin Allograft Recipient Database (WisARD).
Vitiligo
308nm excimer lamp monotherapy for lip vitiligo-a short case series.
Vitiligo
A multi-center, randomized, split face and/or neckcomparisonof 308-nm excimer laser and0·1%tacrolimus ointmentfor stable vitiligo, plus intramuscular slow releasing betamethasone for active vitiligo.
Vitiligo
A pilot study of 1% pimecrolimus cream for the treatment of childhood segmental vitiligo.
Vitiligo
A review of monochromatic excimer light in vitiligo.
Vitiligo
Are vitiligo treatments cost-effective? A systematic review.
Vitiligo
Childhood Vitiligo.
Vitiligo
Comparative efficacy of topical application of tacrolimus and clotrimazole in the treatment of pityriasis versicolor: A single blind, randomised clinical trial.
Vitiligo
Consensus on the treatment of vitiligo - Brazilian Society of Dermatology.
Vitiligo
Different Advanced Therapeutic Approaches to Treat Vitiligo.
Vitiligo
Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis.
Vitiligo
Effect of topical calcineurin inhibitors as monotherapy or combined with phototherapy for vitiligo treatment: a meta-analysis.
Vitiligo
Effectiveness of Topical Corticosteroid, Topical Calcineurin Inhibitors and Combination of Them in the Treatment of Vitiligo.
Vitiligo
Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study.
Vitiligo
Efficacy of the Topical Calcineurin Inhibitors Tacrolimus and Pimecrolimus in the Treatment of Vitiligo in Infants Under 2 Years of Age: A Randomized, Open-Label Pilot Study.
Vitiligo
Efficacy of topical calcineurin inhibitors in vitiligo.
Vitiligo
New treatment modalities for vitiligo: focus on topical immunomodulators.
Vitiligo
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Vitiligo
Pigmentation Disorders: Diagnosis and Management.
Vitiligo
Pimecrolimus increases the melanogenesis and migration of melanocytes in vitro.
Vitiligo
Potential new indications of topical calcineurin inhibitors.
Vitiligo
Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion.
Vitiligo
Successful Treatment of Vitiligo Associated with Vogt-Koyanagi-Harada Disease.
Vitiligo
The effectiveness of topical calcineurin inhibitors comparing with topical corticosteroids in the treatment of vitiligo: a systematic review and meta-analysis.
Vitiligo
The efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Vitiligo
The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial.
Vitiligo
The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo.
Vitiligo
The rationality involved in the popular use of coffee (Coffea sp) and sunflower seed (Helianthus annuus) for the treatment of vitiligo: a case report.
Vitiligo
Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo.
Vitiligo
Topical pimecrolimus for skin disease other than atopic dermatitis.
Vitiligo
Topical pimecrolimus in the treatment of vitiligo.
Vitiligo
Topical treatment and combination approaches for vitiligo: new insights, new developments.
Vitiligo
Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo: A Systematic Review and Meta-analysis.
Vitiligo
Update on childhood vitiligo.
Vitiligo
Update on skin repigmentation therapies in vitiligo.
Vitiligo
Vitiligo, From Physiopathology to Emerging Treatments: A Review.
Vitiligo
Vitiligo: an update on systemic treatments.
Vitiligo
Vitiligo: An Updated Narrative Review.
Vulvar Lichen Sclerosus
An arm-based network meta-analysis on treatments for vulvar lichen sclerosus and a call for development of core outcome sets: Treatment options for vulvar lichen sclerosus.
Vulvar Lichen Sclerosus
Calcineurin antagonists in vulvar lichen sclerosus.
Vulvar Lichen Sclerosus
[Topical treatment of vulvar lichen sclerosus with calcineurin inhibitors].
Vulvitis
Anti-inflammatory treatment.
Vulvitis
Successful treatment of plasma cell cheilitis with topical tacrolimus: Report of two cases.
Vulvitis
Therapeutic efficacy of topical calcineurin inhibitors in plasma cell balanitis: case series and review of the literature.
WAGR Syndrome
Unique Utilization of a Phosphoprotein Phosphatase Fold by a Mammalian Phosphodiesterase Associated with WAGR Syndrome.
Warts
Induction of Suicidal Erythrocyte Death by Cantharidin.
Warts
The natural anticancer agent cantharidin alters GPI-anchored protein sorting by targeting Cdc1-mediated remodeling in endoplasmic reticulum.
Whooping Cough
A novel role for protein phosphatase 2A in receptor-mediated regulation of the cardiac sarcolemmal Na+/H+ exchanger NHE1.
Whooping Cough
Angiotensin II type 2 receptor stimulation of neuronal delayed-rectifier potassium current involves phospholipase A2 and arachidonic acid.
Whooping Cough
Exposure of astrocytes to thrombin reduces levels of the metabotropic glutamate receptor mGluR5.
Whooping Cough
Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview.
Whooping Cough
Imidazoline NNC77-0074 stimulates insulin secretion and inhibits glucagon release by control of Ca(2+)-dependent exocytosis in pancreatic alpha- and beta-cells.
Whooping Cough
Modulation by angiotensin II of isoproterenol-induced cAMP production in preglomerular microvascular smooth muscle cells from normotensive and genetically hypertensive rats.
Whooping Cough
Pertussis toxin modification of PC12 cells inhibits a protein phosphatase 2A-like phosphatase.
Whooping Cough
Regulation of dopamine D-receptor activation in vivo by protein phosphatase 2B (calcineurin).
Whooping Cough
Signaling pathways involved in DNA synthesis and migration in response to lysophosphatidic acid and low-density lipoprotein in coronary artery smooth muscle cells.
Whooping Cough
Synthetic peptides based on the calmodulin-binding domain of myosin light chain kinase inhibit activation of other calmodulin-dependent enzymes.
Whooping Cough
The D(3) dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5.
Whooping Cough
The imidazoline NNC77-0020 affects glucose-dependent insulin, glucagon and somatostatin secretion in mouse pancreatic islets.
Whooping Cough
Tyrosine phosphorylation induced by cross-linking of Fc gamma-receptor type II in human neutrophils.
Williams Syndrome
Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway.
Wilms Tumor
m6A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells.
Wolfram Syndrome
Identification and characterization of wolframin, the product of the wolfram syndrome gene (WFS1), as a novel calmodulin-binding protein.
Wound Infection
Nosocomial infection in kidney transplant recipients: a retrospective analysis of a single-center experience.
Xeroderma Pigmentosum
Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition.
Zygomycosis
Emerging importance of infections due to zygomycetes in organ transplant recipients.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
show
top
